

CURRICULUM VITAE

PERSONAL DETAILS

Name: Richard Anthony **SCOLYER** AO

Address: Tissue Pathology & Diagnostic Oncology
Royal Prince Alfred Hospital
Missenden Road
Camperdown Sydney NSW 2050
AUSTRALIA

Telephone: +61 2 9515 7011 (Direct)
+61 2 9515 8405 (Fax)
+61 424208096 (Mobile)

Email: richard.scolyer@health.nsw.gov.au

EXECUTIVE SUMMARY

Professor Richard Scolyer AO, BMedSci, MBBS, MD, FRCPA, FRCPath, FAHMS is Senior Staff Specialist, Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney; Co- Medical Director, Melanoma Institute Australia; and Conjoint Professor, Sydney Medical School, Faculty of Medicine and Health, The University of Sydney. He provides a clinical consultation service for the diagnosis of difficult pigmented lesions and receives more than 2000 cases for opinion from Australasia and beyond annually. Richard effectively integrates his clinical practice with co-leading an award winning translational melanoma research laboratory. His record includes co-authoring more than 800 peer reviewed publications, books and/or book-chapters including in prestigious journals such as New England Journal of Medicine, Lancet, Nature, Cell, Nature Genetics, Lancet Oncology, Journal of Clinical Oncology, Journal of the National Cancer Institute and Cancer Discovery with >63,508 citations and a H-index of 120 ([Google Scholar](#) as at 3 August 2022). Richard has presented on more than 400 occasions at conferences throughout the world. In June 2021, he was appointed Officer of the Order of Australia (AO) for distinguished service to medicine, particularly in the field of melanoma and skin cancer, and to national and international professional organisations by The Governor-General of the Commonwealth of Australia. In 2020, he received the NSW Premier's Award for Outstanding Cancer Researcher of the Year, the Royal College of Pathologists of Australasia (RCPA) Distinguished Fellow Award 2020, The University of Sydney's 2020 Alumni Award for International Achievement and Clarivate Web of Science Group "Highly Cited Researcher in 2018, 2019, 2020 and 2021". He has received the NSW Premier's Award for Outstanding Cancer Research in 2009, 2012, 2013, 2014, 2016, 2017, 2018, 2020 and 2021, Thomson Reuters 2015 Citation Award in the Clinical Medicine category, the 2018 William O. Russell/Joanne Vandenberge Hill Award for Lifetime Achievement in Anatomical Pathology, MD Anderson Cancer Center, Research Australia's 2018 GSK Award for Research Excellence and the 2019 American Society of Dermatopathology's Elson B Helwig Award for excellence in dermatopathology. The 2021 University of Tasmania Distinguished Alumni Award and the 2021 University of Sydney's Vice-Chancellor Award for Outstanding Research. His publications have received most highly cited awards on 5 other occasions. Richard was recognised as a Clarivate Web of Science "Highly Cited Researcher 2019" and again in 2020. According to Thomson Reuters ISI Web of Knowledge, Richard is the highest ever published scientist in the world in the field of melanoma pathology and he also has the highest H index in this field. The Fame Report (2011) published by Medical Experts International (www.medexpert.com) ranked him the 6th leading melanoma expert in any field or discipline worldwide and the highest ranked melanoma pathologist worldwide. In June 2022, he was ranked the world's 6th leading melanoma expert in any field or discipline and the world's leading melanoma pathologist (<https://expertscape.com/ex/melanoma>). In September 2019, Richard was ranked as the leading Australian Pathologist in the entire field of Pathology (www.leagueofscholars.com).

Richard is an expert member of the World Health Organisation (WHO) Blue Books Editorial Board for the 5th edition of the WHO Classification of Skin Tumours series and was an editor of the 4th Edition of the World Health Organisation Classification of Tumours Skin Tumours volume in which he was the responsible editor for 3 of the 6 sections and authored/co-authored more than 30 chapters. He has also been an invited contributing author to 6 other volumes of the WHO Classification of Tumours including for Soft Tissue and Bone, Digestive System, Thoracic, Female Genital Tract and Paediatric tumours. He is also Vice Chair of the Melanoma Expert Panel of the American Joint Committee on Cancer (AJCC) for the 8th and 9th editions of AJCC Cancer Staging System, co-leads the Australian Melanoma Genome Project (part of the International Cancer Genome Consortium), was lead pathologist for the NIH funded The Cancer Genome Atlas (TCGA) Melanoma Project (Cell, 2015), chairs the Melanoma Expert Panel for the International Collaboration on Cancer Reporting, lead pathologist/member of the overseeing Management Committee, Multidisciplinary Working Party and Author for the Australian Melanoma Clinical Practice Guidelines and co-lead author of the College of American Pathologists Melanoma Reporting protocol. He is Editor-in-Chief of Pathology and is also an editorial board member of the American Journal of Surgical Pathology, Modern Pathology and Histopathology and several other international journals. Richard is a Past President of the Australasian Division of the International Academy of Pathology and is the current International Vice President representing Australasia on the International Academy of Pathology International Council. In 2019, Richard was the RCPA visiting Professor/Lecturer to Asia. Together with other MIA colleagues, Richard has been chief investigator on 3 consecutive 5 year NHMRC program grants (2006-2021) and has received multiple

personal Fellowships from the NHMRC and CINSW. He has also been an investigator/advisor on multiple phase 1, 2 and 3 clinical trials and a frequently sought-after advisor to industry.

ACADEMIC HISTORY

POSTGRADUATE

2006 University of Sydney
Doctor of Medicine (Thesis title: "The Pathology of Melanocytic Tumours: Diagnostic and Prognostic Features")

TERTIARY

1985 - 1990 University of Tasmania
Bachelor of Medical Science (1987)
Bachelor of Medicine and Bachelor of Surgery (1990)

SECONDARY

1983 - 1984 Launceston Community College
Higher School Certificate
1979 - 1982 Riverside High School
School Certificate

UNDERGRADUATE AWARDS & PRIZES

1982 Head Prefect
1982 Scott Kilvert Prize
1983 Best Year 11 Results
1984 Vice President, Student Council
1984 Academic Excellence

POSTGRADUATE EXAMINATIONS/QUALIFICATIONS

2007 Fellow of Royal College of Pathologists (United Kingdom)
2006 Doctor of Medicine (Thesis title: "The Pathology of Melanocytic Tumours: Diagnostic and Prognostic Features"), The University of Sydney
2000 Fellowship of Royal College of Pathologists of Australia
Royal College of Pathologists of Australasia
Part II Examination in Anatomical Pathology
1998 Royal College of Pathologists of Australasia
Part I Examination in Anatomical Pathology
1997 United States Medical Licensing Examination Step II
Educational Commission for Foreign Medical Graduates Certification granted 30th April 1997
1996 United States Medical Licensing Examination Step I
1995 Royal College of Pathologists of Australasia examination in Pathological Sciences
Royal College of Pathologists of Australasia General Pathology Haematology Practical Assessment

CURRENT ACADEMIC AND OTHER APPOINTMENTS

Current

1. Senior Staff Specialist in Anatomical Pathology & Cytopathology, Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, 2001-present
2. Conjoint Professor, Faculty of Medicine and Health, The University of Sydney, 2006-present
3. Co-Medical Director, Melanoma Institute Australia, 2017-present
4. Order of Australia, Department of the Prime Minister and Cabinet, Australian Government, June 2021-present
5. Invited Melanoma Expert Member for the National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium (CPTAC), 28/2/2022 - present.
6. Editorial Board and Expert member, World Health Organisation (WHO) Blue Books Editorial Board for the Skin Tumours volume, the 12th volume of the WHO Classification of Tumours 5th edition, Sept 2021-present.
7. Co-President, World Congress of International Academy of Pathology and Co-Chair of Organising Committee, Sydney 2022
8. Senior Staff Specialist in Anatomical Pathology & Cytopathology, Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, 2001-present
9. Consultant Pathologist, Melanoma Institute Australia (formerly the Sydney Melanoma Unit), 2001-present
10. Co-Director of Research, Melanoma Institute Australia, 2008-present
11. Australian Academy of Health and Medical Sciences (AAHMS) Fellowship, 2017-present
12. NHMRC Practitioner Fellow, 1/1/2013 –31/12/2022
13. Editor, 4th Edition of the World Health Organisation Classification of Tumours, Skin Tumours volume, 2016-present
14. Vice Chair, Melanoma Expert Panel, American Joint Committee on Cancer Staging System, eighth and ninth editions, 2013-present
15. Chair, Melanoma Expert Panel, International collaboration on Cancer reporting (on behalf of the College of American Pathologists, College of Canadian Pathologists, Royal College of Pathologists of the United Kingdom and Royal College of Pathologists of Australasia), appointed 2013-present.
16. Australian Clinical Practice Guidelines for Melanoma: Lead Pathologist, member of the Management Committee, Multidisciplinary Working Party and Author, 2015-present
17. Executive Committee Member, International Melanoma Pathology Study Group, 2010-present
18. Council member, International Sentinel Node Society, 2008-present

19. International Vice President, International Academy of Pathology, International Council (representative for Australasia) 2017-present (representing 132 countries/divisions world wide with membership of >100,000 pathologists)
20. Co-lead, Australian Melanoma Genome Project, 2013-present

Not-current

21. Visiting Medical Officer, Mater Hospital, North Sydney, 2006-2012
22. International Education Committee member, International Academy of Pathology (representative for Australasia), 2018-2020
23. Past-President, Australasian Division of the International Academy of Pathology, 2017-2019
24. President, Australasian Division of the International Academy of Pathology, 2015-2017
25. Lead pathologist and member of manuscript writing committee, clinical working group, analysis working group, disease working group of The Cancer Genome Atlas (TCGA) Melanoma Project, 2013-2015
26. President Elect, Australasian Division of the International Academy of Pathology, 2013-2015

POSTGRADUATE EMPLOYMENT

- | | |
|-------------------|--|
| 2001 - present | Senior Staff Specialist in Anatomical Pathology & Cytopathology
Tissue Pathology and Diagnostic Oncology
Royal Prince Alfred Hospital, Sydney NSW Australia |
| 2001 - 2003 | Inaugural Pathology Research Fellow (50% part time)
Melanoma and Skin Cancer Research Institute (MASCRI)
University of Sydney and Royal Prince Alfred Hospital
Sydney NSW Australia |
| Nov 1998 - 2001 | Pathology Registrar in Anatomical Pathology, Royal Prince Alfred Hospital, Sydney NSW Australia |
| 1996 - Oct 1998 | Pathology Registrar in Anatomical Pathology, The Canberra Hospital, Canberra ACT Australia |
| 1995 | Haematology Registrar, The Canberra Hospital, Canberra ACT Australia |
| 1994 – Sept - Oct | Medical Registrar, North Middlesex Hospital, London United Kingdom |
| - July - Aug | Senior House Officer (Cardiology), Papworth Hospital, Cambridge United Kingdom |
| - Jan - March | General Practitioner, Gateway Medical Centre, Gosford NSW Australia |
| 1993 | Senior Resident Medical Officer, Gosford District Hospital, Gosford NSW Australia |
| 1992 | Resident Medical Officer, Royal Adelaide Hospital, Adelaide SA Australia |
| 1991 | Intern, Royal Hobart Hospital, Hobart TAS Australia |

PAST APPOINTMENTS

1. RCPA Visiting Professor Lecture Tour Asia 2019.
2. Visiting Professor, Xiangya Hospital, Changsha, China (Honorary Title) June 2019
3. Visiting Scientist / Consultant Pathologist, Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst NSW, 1.10.2001 to 2008
4. Director of Pathology Research, Melanoma and Skin Cancer Research Institute, University of Sydney, 2003-2007
5. Fellow / Consultant Pathologist, Institute for Magnetic Resonance Research, University of Sydney, 2001-2006.
6. Visiting Scholar, Department of Pathology, University of Sydney, 1/8/2000 to 13/1/2001

PROFESSIONAL MEMBERSHIPS / CHAIRMANSHIP OF COMMITTEES

1. Invited to become a member of the Sydney Clinical Imaging Network (SCIN), 17.5.2022-current.
2. Invited participant in AJCC executive task for “Beyond TNM; What is the role of non-anatomic prognostic factors?” held virtually on Friday 18th December 2020
3. Member of the NSW Fellowship Election Selection Committee Aust Academy of Health & Medical Sciences, 2018
4. Chairman of review panel for abstracts and poster presentations, International Academy of Pathology, Australasian Division, Annual Scientific Meetings, 2009-2015
5. Invited Member, EORTC Melanoma Pathology Committee, 2008-2014
6. Member of the working party and advisor to the Clinical Practice Guidelines for the Management of Non-Melanoma Skin Cancer undertaken by the Australian Cancer Network, The Cancer Council of Australia and the Clinical Oncology Society of Australia in 2007 & 2008
7. Chairman of poster judging panel, International Academy of Pathology, Australasian Division, Annual Scientific Meeting, 2008-2015
8. Member of Abbott Molecular Scientific Advisory Board, Meeting on 30-31st October, 2007 New York
9. Member of Abstract Review Panel, Sentinel Node 2008, 6th International Sentinel Node Congress, Sydney, February 2008
10. Member of Organising Committee, Sentinel Node 2008, 6th International Sentinel Node Congress, Sydney, February 2008
11. Member of the subcommittee for chapter on “Lentigo maligna” for revision of the Clinical Practice Guidelines for the Management of Cutaneous Melanoma undertaken by the Australian Cancer Network, The Cancer Council of Australia and the Clinical Oncology Society of Australia in 2005
12. Invited member of NSW Melanoma Network Steering Committee Feb 2007
13. Member of International Melanoma Classification Workshop group 2006-2007 (meetings of a select group of key international authorities in San Francisco 27-28 January 2007 and Paris 16-17 March 2007)
14. Member of the Executive Advisory Group for Melanoma, Clinical Oncological Society of Australia, 2005-2008

15. Member of the subcommittee for chapter on “Treatment of lymph nodes” for revision of the Clinical Practice Guidelines for the Management of Cutaneous Melanoma undertaken by the Australian Cancer Network, The Cancer Council of Australia and the Clinical Oncology Society of Australia in 2005
16. Member of the subcommittee for chapter on “Biopsy of pigmented lesions” for revision of the Clinical Practice Guidelines for the Management of Cutaneous Melanoma undertaken by the Australian Cancer Network, The Cancer Council of Australia and the Clinical Oncology Society of Australia in 2005.
17. Member of the subcommittee for chapter on “Histopathological reporting of cutaneous melanoma” for revision of the Clinical Practice Guidelines for the Management of Cutaneous Melanoma undertaken by the Australian Cancer Network, The Cancer Council of Australia and the Clinical Oncology Society of Australia in 2005
18. Member of Abstract Review Panel, Sentinel Node 2004, 4th International Sentinel Node Congress, Los Angeles, USA, December 2004.
19. Member of Advisory Committee for RCPA Anatomical Pathology Quality Assurance Program (appointed 2004)
20. Member of Organising Committee, Sentinel Node 2004, 4th International Sentinel Node Congress, Los Angeles, USA, December 2004.
21. Guest Editor, Pathology, October 2004
22. Chairman of Abstract Review Panel, Melanocytic Pathology, 25th International Congress of the International Academy of Pathology, Brisbane 2004
23. Convenor of Melanocytic Pathology Scientific Program, 25th International Congress of the International Academy of Pathology, Brisbane 2004
24. Convenor of Soft Tissue Pathology Scientific Program, 25th International Congress of the International Academy of Pathology, Brisbane 2004
25. Member of Scientific Programme Committee 25th International Congress of the International Academy of Pathology, Brisbane 2004
26. Greater Metropolitan Transition Taskforce, NSW State Government Advisory Committee for Bone & Soft Tissue Tumour Services, 2002-2003
27. Editorial Board Member *Pathology* (appointed 2002)
28. Member of the RCPA Board of Education Australasian Soft Tissue Tumour Registry 2002-2022
29. Member of Organising Committee for Australasian Society of Dermatopathology Annual Scientific Meeting, Sydney 2002
30. Member of Anatomical Pathology Education Subcommittee, NSW Branch, Royal College of Pathologists of Australasia, 2001-present
31. Member of Central Sydney Area Health Service Cytology Quality Assurance Committee, 2001-2012
32. Chairman, Melanoma and Skin Cancer Research Institute Tumour Bank Committee, 2001-2008
33. Director, Executive Council and Board Member, Melanoma and Skin Cancer Research Institute, The University of Sydney/RPAH, 2001-2008.

OTHER PROFESSIONAL ACTIVITIES

1. 2019 College of American Pathologists (CAP) Skin Cancer Protocol Review Panel (CPRP) (annual)
2. Invited participant in Avant Melanoma Risk Modification Framework, Melbourne February 2008
3. Member of NSW Melanoma Network Steering Committee 2007
4. Member of Trial Monitoring Committee, Adjuvant Radiotherapy Trial for Regional Nodal Field Melanoma
5. Member of Trial Monitoring Committee, Whole Brain Radiotherapy Trial
6. Invited inaugural member of International Melanoma Pathology Group (international group of academic pathologists with commitment to the study of melanocytic lesions and melanoma). Affiliated with the Society for Melanoma Research. 2007. Inaugural meeting in New York City on 31st October 2007
7. Invited Member of International Melanoma Classification Workshops 2007 (meetings of a select group of key international authorities in San Francisco 27-28 January 2007 and Paris 16-17 March 2007)
8. Invited Member of International Melanoma Working Group (Chairman Prof J Kirkwood, USA)
9. Independent reviewer for National Health and Medical Research Council Biomedical (CJ Martin) Fellowship in 2006
10. Member of the Cancer Institute of NSW Melanoma Oncology Advisory Committee 2006
11. Member of the Cancer Institute of NSW Pathology Oncology Advisory Committee 2005-2006
12. Contributor to the revision of the Clinical Practice Guidelines for the Management of Cutaneous Melanoma undertaken by the Australian Cancer Network, The Cancer Council of Australia and the Clinical Oncology Society of Australia in 2005
13. Fellow, Institute for Magnetic Resonance Research (IMRR), University of Sydney, 2001-2004
14. Royal College of Pathologists of Australasia, Examiner in Pathological Sciences, 2004
15. Member of Advisory Committee for RCPA Anatomical Pathology Quality Assurance Program, 2004-2006
16. Royal College of Pathologists of Australasia, Examiner in Anatomical Pathology, 2004-2018
17. Contributor, Commonwealth Government of Australia, Support Scheme for Rural Specialists- Recent Advances in Pathology 2004. Televised live to various centres around Australia in 2004
18. Assessor for the Medical Testing Accreditation Advisory Committee of the National Association of Testing Authorities (NATA), 2003-2020
19. Contributor to National Cancer Control Institute document “Efficient and Effective Melanoma Diagnosis, 2003 on behalf of Commonwealth Government of Australia, Department of Health & Ageing and The Cancer Council of Australia
20. Nomination for Executive Council (Pathology Representative) of International Sentinel Node Society, 2002
21. Co-ordinating RCPA Visiting Professor 2002 Prof Cyril Fisher’s NSW Programme
22. Invigilator at RCPA examinations 2001

PROFESSIONAL AFFILIATIONS

- American Association for Cancer Research (AACR), active member, 2 August 2022 to present
- Order of Australia Association (lifetime appointment), July 2021 to present
- Sydney Cancer Partners (SCP), 2022 to present
- Sydney Catalyst Membership, 2020 to 2021

- Melanoma World Society (MWS), 2020 to present
- The Royal College of Pathologists (UK) – international membership, 2019 to present
- Australian Academy of Health and Medical Sciences (AAHMS) Fellowship, elected 2017 to present
- Executive Council Member of International Sentinel Node Society (ISNS), 2010 to present
- Executive Council Member of International Melanoma Pathology Study Group (IMPSG), 2009 to present
- Member Society for Melanoma Research (SMR), 2019 to present
- International Society of Bone and Soft Tissue Pathology (ISBSTP), 2014 to 2019
- International Society of Dermatopathology (ISDP), 2008 to present
- The American Society of Dermatopathology (ASDP) - Member (non-resident associate), 2004 to present
- Foundation member of International Sentinel Node Society (ISNS), 2003 to present
- Foundation Member of The International Society of Bone and Soft Tissue Pathology (ISBSTP), 2001 to present
- Member of the Australasian Dermatopathology Society (ADS), 2001 to present
- Member of the Medical Officers Association of Royal Prince Alfred Hospital (RPAH), 2001 to present
- Member of Australian Salaried Medical Officers Association, 2001 to present
- Member of Royal Prince Alfred Hospital (RPAH) Medical Board, 2001 to present
- Fellow of the Royal College of Pathologists of Australasia (RCPA), 2000 to present
- Member of Australasian Division of the International Academy of Pathology (IAP), 1998 to present
- Member of Australian Society of Cytology (ASC), 1996 to present
- United Medical Protection/Avant, 1990 to present

SERVICE TO STATE AND NATIONAL GOVERNMENTS

- Reviewer of a Medical Devices Fund Application for Health NSW Government (July 2022).
- National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium (CPTAC) - consortium is building a proteogenomic (proteomics + genomics) atlas of cancer – from March 2022.
- 2021: Cancer Institute NSW Research Advisory Expert Panel.
- Melanoma and Skin Cancer Trials Limited (MASC Trials) is Australia and New Zealand's collaborative trials group specialising in investigator-initiated melanoma and skin cancer research, supported by the Australian government via Cancer Australia. In the role of Expert of Scientific Advisory Committee – since 2019 (current).
- Review of pathology slides as part of quality audits for Health Departments in a number of State Governments in Australia.
- Co-Chair of Statewide Review of Melanoma Management in NSW, 2019-2020.
- 2006: Member of the Cancer Institute of NSW Melanoma Oncology Advisory Committee.
- 2006: Independent reviewer for National Health and Medical Research Council Biomedical (CJ Martin) Fellowship.
- 2005-2006: Member of the Cancer Institute of NSW Pathology Oncology Advisory Committee.
- Contributor to the revision of the Clinical Practice Guidelines for the Management of Cutaneous Melanoma undertaken by the Australian Cancer Network in 2005.
- 2004: Contributor, Commonwealth Government of Australia, Support Scheme for Rural Specialists- Recent Advances in Pathology Seminars 2004. Broadcast live to various centres throughout Australia in 2004.
- 2003: Contributor to National Cancer Control Institute document "Efficient and Effective Melanoma Diagnosis, on behalf of the Commonwealth Government of Australia, Department of Health & Ageing and The Cancer Council of Australia.
- 2003-present: Assessor for the Medical Testing and member of the Accreditation Advisory Committee of the National Association of Testing Authorities (NATA). NATA assesses pathology laboratories for adherence to Commonwealth Government set standards. NATA accreditation is required by pathology laboratories to be eligible for Medicare funding.
- 2002-2003: Member of Greater Metropolitan Transition Taskforce, NSW State Government Advisory Committee for Bone & Soft Tissue Tumour Services.

SERVICE TO PROFESSIONAL BODIES

- 2021: invited to sit on panel of judges for the GSK Award for Research Excellence.
- Invited Examiner, Doctorate of Science Degree (D.Sc) for The University of Sydney. Thesis title: The Genetic and Therapeutic Landscape of Cancer. (report completed March 2022).
- Invited Melanoma Expert Member for the National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium (CPTAC) (invited to join / accepted 28 February 2022).
- Expert Panel Member of Royal College of Pathologists of Australasia (RCPA) Structured Pathology Reporting of Cancer ([SPRC](#)) Project's Protocol 1st edition 2022 "Non-melanocytic skin cancer structured reporting protocol", Oct 2021 (as at 24.6.22 – available for public feedback – see [link](#)).
- Expert Panel Member of Royal College of Pathologists of Australasia (RCPA) Structured Pathology Reporting of Cancer ([SPRC](#)) Project's Protocol "Merkel cell carcinoma structured reporting protocol", Oct 2021 (in progress as at March 2022).
- Expert Panel Member of Royal College of Pathologists of Australasia (RCPA) Structured Pathology Reporting of Cancer ([SPRC](#)) Project's Protocol "Invasive melanoma (2nd edition) structured reporting protocol", Oct 2021 (in progress as at March 2022).
- Editor of the World Health Organisation (WHO) Classification of Tumours, 5th edition – Skin tumours – appointed Sept 2021.
- Expert member of the World Health Organisation (WHO) Blue Books Editorial Board for the Skin Tumours volume, the 12th volume in the 5th edition of the WHO Classification of Tumours series – Sept 2021.
- American Joint Committee on Cancer, (AJCC) Melanoma Expert Panel Vice Chairman – appointed 2013 (current).
- International Collaboration on Cancer Reporting (ICCR) – Expert Committee member for the 1st edition of the Dataset for Merkel Cell Reporting Protocol (published 2019) (see [link](#)) - 2018 – 2019.

- International collaboration on Cancer Reporting (ICCR) – Expert Committee “Domain Expert” for the 1st edition of the Histopathology Reporting Guide for Merkel Cell Carcinoma (published December 2019) (see [link](#)).
➤ Citation: Busam K, Bichakjian C, Coit D, Kutzner H, Requena L, Scolyer R, Stefanato C, Walsh N, Wood B (2019). *Merkel Cell Carcinoma, Histopathology Reporting Guide, 1st edition. International Collaboration on Cancer Reporting; Sydney, Australia. ISBN: 978-1-925687-33-0.*
- International collaboration on Cancer Reporting (ICCR) – Chair of Expert Committee Member for the 2nd edition of the Dataset for Invasive Melanoma (published October 2019) (see [link](#)).
- International collaboration on Cancer Reporting (ICCR) – Chair of Expert Committee for the 2nd edition of the Histopathology Reporting for Invasive Melanoma (published October 2019) (see [link](#)) – 2018 - 2019.
➤ Citation: Scolyer RA, Balamurgan T, Busam K, Elder D, Evans A, Gershenwald J, Frishberg DP, McMenamin M, Prieto VG, Shiau C, Swetter S, van den Oord J (2019). *Invasive Melanoma, Histopathology Reporting Guide, 2nd edition. International Collaboration on Cancer Reporting; Sydney, Australia. ISBN: 978-1-925687-32-3.*
- Contributor to [UK Mucosal Melanoma Guidelines](#) – 2018
- Executive Committee Member, The Cancer Research Advisory Committee, Cancer Institute NSW 2017 – 2020
- Fellowship of the Australian Academy of Health and Medical Sciences 2017 – present
- Editor, 4th Edition of the World Health Organisation (WHO) Classification of Tumours, Skin Tumours volume, appointed 2016
- Australian Clinical Practice Guidelines for Melanoma: member of the Management Committee, Multidisciplinary Working Party and Author, Australian Cancer Network (ANC) 2015 – present
- President, Australasian Division of the International Academy of Pathology, 2015-2017
- Lead pathologist and member of manuscript writing committee, clinical working group, analysis working group, disease working group of The [Cancer Genome Atlas \(TCGA\) Melanoma Project](#), 2013-2015
- Vice Chair, Melanoma Expert Panel, [American Joint Committee on Cancer Staging System](#), eighth and ninth editions, appointed 2013 - present
- International collaboration on Cancer Reporting (ICCR) – Chair, Melanoma Expert Panel and Expert Committee Member for the 1st edition of the Dataset for Invasive Melanoma (published November 2013) (see [link](#)), (on behalf of the College of American Pathologists, College of Canadian Pathologists, Royal College of Pathologists of the United Kingdom and Royal College of Pathologists of Australasia) – initial pilot project in 2011-2012.
- Executive Committee Member, International Melanoma Pathology Study Group (see [link](#)), 2010- present
- Invited Chairman “Skin & Adnexal”, Expert Panel Member of the [Royal College of Pathologists of Australasia \(RCPA\) Structured Pathology Reporting of Cancer \(SPRC\) Project](#) (goal is to promote internationally standardised evidence-based cancer reporting in Australasian for world-class patient care and to maintain highest-level patient outcomes), 2008.
- Convener, Poster Presentations and Awards, International Academy of Pathology of Australasia, Annual Scientific Meeting, Sydney, 2008
- Examiner, Masters of Biomedical Science Candidate, Monash University, Thesis title: “Melanoma histopathologic misdiagnosis: The impact of partial biopsy and associated factors”, 2007
- Executive Council Member, International Sentinel Node Society, appointed, 2006.
- Member of Arthur Purdy Stout Society of Surgical Pathologists. This prestigious worldwide society is composed of “pathologists dedicated to excellence in teaching research and practice of surgical pathology”, 2007
- Invited inaugural member of International Melanoma Pathology Study Group. “goals of the group will be to promote close working and collaborative relationships among the key melanoma pathologists around the world, coordinate research activities, better communication, development of consensus positions on many aspects of melanoma pathology, and to provide a platform for regular conferences and symposia, 2007
- Member of the Executive Advisory Group for Melanoma, Clinical Oncological Society of Australia, 2005 to present
- Independent reviewer for National Health and Medical Research Council Biomedical (CJ Martin) Fellowship, 2006
- Contributor to the revision of the Clinical Practice Guidelines for the Management of Cutaneous Melanoma undertaken by the Australian Cancer Network, 2005
- Member of Advisory Committee for Royal College of Pathologists of Australasia, Anatomical Pathology Quality Assurance Program, 2004 to 2010
- Lecturer in Royal Australasian College of Radiation Oncologists NSW Training Programme for Trainees (Skin pathology & soft tissue tumours)
- Royal College of Pathologists of Australasia, Examiner in Pathological Sciences, 2004 to 2016
- Royal College of Pathologists of Australasia, Examiner in Anatomical Pathology, 2004 to 2018
- Assessor for the Medical Testing Accreditation Advisory Committee of the National Association of Testing Authorities (NATA) for laboratory accreditation, 2003-2012.
- Member of the Royal College of Pathologists of Australasia Board of Education Australasian Soft Tissue Tumour Registry, 2002-2022.
- Lecturer in Royal Australasian College of Surgeons NSW Training Programme for General Surgical Trainees, 2002 to present
- Co-ordinator, Royal College of Pathologists of Australasia Visiting Professor 2002 Prof Cyril Fisher’s NSW Programme
- Member of Anatomical Pathology Education Subcommittee of NSW Branch of the Royal College of Pathologists of Australasia, 2001 to 2019.

EDITORIAL BOARDS/REVIEW PANELS

1. Pathology, Editor-in-Chief, 5.3.2022-current.
2. Editor of the World Health Organisation (WHO) Classification of Tumours, 5th edition – Skin tumours – appointed Sept 2021.
3. Expert member of the World Health Organisation Blue Books Editorial Board for the Skin Tumours volume, the 12th volume of the WHO Classification of Tumours 5th edition – Sept 2021.
4. Cancers, Editorial Board Member, from August 2020.
5. Modern Pathology, Board Member, from 1 January 2020.

6. Editor World Health Organisation Classification of Skin Tumours 4th Edition 2018.
7. Melanoma Research, Board Member, from 2018.
8. Pathology, Guest Editor, February 2016.
9. Melanoma Management, Editorial Board Member, from 2014.
10. Histopathology, International Editorial Advisory Board, from 2012.
11. American Journal of Surgical Pathology, from 2007.
12. Pathology, Guest Editor, October 2004.
13. Pathology, Senior Associate Editor, from 2002-2022.

Adhoc reviewer for numerous other journals including:

- *The Medical Journal of Australia*
- *Clinical Cancer Research*
- *Annals of Surgical Oncology*
- *Melanoma Research*
- *Annals of Surgical Oncology*
- *Journal of Clinical Pathology*
- *Annals of Oncology*
- *European Journal of Surgical Oncology*
- *Archives of Pathology and Laboratory Medicine*
- *World Journal of Surgical Oncology*
- *Australian & New Zealand Journal of Surgery*
- *Journal of Cellular and Molecular Medicine*
- *American Journal of Surgical Pathology*
- *Journal of Cutaneous Pathology*
- *Archives of Dermatology*
- *Lancet*
- *Many others*

Other Editorial Responsibilities

- Chairman of Abstract Review committee, Australasian Melanoma Conference, Sydney, 2016
- Chairman of Abstract Review committee, Annual Scientific Meeting of Australasian Division of the International Academy of Pathology, 2008-2015
- Member of Abstract Review Panel, Sentinel Node 2004, 4th International Sentinel Node Congress, Los Angeles, USA, 2004.
- Chairman of Abstract Review Panel, Melanocytic Pathology, 25th International Congress of the International Academy of Pathology, Brisbane, 2004
- Chairman of Abstract Review Panel, Soft Tissue Pathology, 25th International Congress of the International Academy of Pathology, Brisbane, 2004
- Abstracts (poster presentations) at the Annual Scientific Meeting of Australasian Division of the International Academy of Pathology, 2003
- Abstracts (poster presentations) at the Annual Scientific Meeting of Australasian Division of the International Academy of Pathology, 2002
- Abstracts (poster presentations) at the Annual Scientific Meeting of Australasian Division of the International Academy of Pathology, 2001

AWARDS

1. *{as at 6.6.22 finalist}* **NSW Health Pathology Awards 2022:** RAS together with Dr Robert Rawson presented “Research Improving Melanoma Patient Outcomes” as part of the NSW Health Pathology State-wide Education Series Multi-disciplinary Team which is a finalist in the 2022 NSW Health Pathology Awards in the “People and Culture” category for its Scientific & Technical Statewide Education Series.
2. **Sydney Local Health District/Sydney Research 2022 Research Excellence Award**, awarded to Professor Richard Scolyer, Associate Professor Alexander Menzies and Professor Georgina Long in recognition of the best publication in a high impact journal for “Menzies, A.M., Amaria, R.N., Rozeman, E.A. et al. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). *Nat Med* 27, 301–309 (2021). <https://doi.org/10.1038/s41591-020-01188-3>”.
3. **RPAH Medical Officers Association President's Prize for diagnostic and laboratory-based research**, Andrew Li’s submission was selected as one of the five finalists to present on one of his PhD projects - “Clinicopathologic characterisation of cutaneous Head and neck melanoma” -**Andrew Li**, Jessie Xu, Tyler Blah, Serigne Lo, Kerwin Shannon, Robyn Saw, Angela Hong, Alex Varey, Kevin London, Pascale Guitera, Matt Carlino, Alex Menzies, Georgina Long, John Thompson*, Richard Scolyer*, Sydney Ch’ng* (*joint co-supervisors). Presentation took place virtually on Friday 10 December 2021.
4. **2021 NSW Premier’s Award for Outstanding Cancer Research: Wildfire Award**, recognises a NSW researcher, or team of researchers, who has made a significant difference to cancer care or research practice, for a highly cited publication. Long GV, Atkinson V, Lo S, Guminski AS, Sandhu S, Brown MP, Edwards J, Gonzalez M, **Scolyer RA**, Menzies AM, McArthur GA. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. *Lancet Oncol*. 2018 May;19(5):672-681. doi: 10.1016/S1470-2045(18)30139-6. Epub 2018 Mar 27. PMID 29602646
5. **The University of Sydney’s 2021 Vice-Chancellor’s Award for Outstanding Research:** awarded to Professors. **Richard A. Scolyer** and Georgina V. Long, Faculty of Medicine & Health (Melanoma Institute Australia) – announced 18 November 2021.

6. **Clarivate Web of Science Group: Highly Cited Researcher 2021.** *In recognition of exceptional research performance demonstrated by production of multiple highly cited papers that rank in the top 1% for field and year in "Clinical Medicine". Certificate dated 16 Nov 2021.*
7. **ExpertScape's** PubMed-based algorithms placed RAS in the top 0.1% of scholars writing about Neuroendocrine Tumors over the past 10 years, a level they label as "World Expert". Announced by ExpertScape in their "Daily Experts" announcement on 10 November 2021.
8. **2021 University of Tasmania Distinguished Alumni Award.** *The award recognises distinguished community and or professional service and achievement by University of Tasmania graduates. The award highlights the diversity and quality of the contributions our graduates make to the enrichment of our society and is typically made to senior alumni at or near the peak of their careers. Notified of this award on Mon 4.10.21.*
9. **Top 10 percent of articles published:** "Your paper in *The Journal of Clinical Endocrinology and Metabolism*, "Tsang VHM, McGrath RT, Clifton-Bligh RJ, Scolyer RA, Jakrot V, Guminski AD, Long GV, Menzies AM. Checkpoint inhibitor associated autoimmune diabetes (CIADM) is distinct from type 1 diabetes.. *Clin Endocrinol Metab.* 2019 Jul 2. pii: jc.2019-00423" was one of the top 10 percent of articles published in the journal in 2019-2020 as assessed by rate of citation" – as per email from Journal of Clinical Endocrinology & Metabolism on 19th June 2021.
10. **Order of Australia** on 13th June 2021 RAS was appointed Officer of the Order of Australia (AO) for distinguished service to medicine, particularly in the field of melanoma and skin cancer, and to national and international professional organisations by The Governor-General of the Commonwealth of Australia. *In the Australian honours system appointments to the Order of Australia confer the highest recognition for outstanding achievement and service.*
11. **International Academy of Pathology: Certificate of Appreciation** "for meritorious service and participation in the mission of the IAP Education Committee" awarded on 3 December 2020.
12. **2020 NSW Premier's Award for Outstanding Cancer Research: Wildfire Award**, recognises a NSW researcher, or team of researchers, who has made a significant difference to cancer care or research practice, for a highly cited publication. Hayward NK, Wilmott JS, Waddell N, Johansson PA, Field MA, Nones K, Patch A-M, Kakavand H, Alexandrov LB, Burke H, Jakrot V, Kazakoff S, Holmes O, Leonard C, Sabarinathan R, Mularoni L, Wood S, Xu Q, Waddell N, Tembe V, Pupo GM, de Paoli-Iseppi R, Vilain RE, Shang P, Lau LMS, Dagg RA, Schramm S-J, Pritchard A, Grimmond SM, Pickett HA, Yang JY, Stretch JR, Behren A, Kefford RF, Hersey P, Long GV, Cebon J, Shackleton M, Spillane AJ, Saw RPM, Lopez-Bigas N, Pearson JV, Thompson JF, **Scolyer RA**, Mann GJ. Whole-genome landscapes of major melanoma subtypes. *Nature.* 2017 May 11;545(7653):175-180. doi: 10.1038/nature22071.
13. **2020 NSW Premier's Award for Outstanding Cancer Research: Outstanding Cancer Researcher of the Year**, recognises outstanding researchers whose commitment and talent has had a significant impact on cancer treatment, clinical trials, prevention, and research across NSW.
14. **The Royal College of Pathologists of Australasia (RCPA): Distinguished Fellow Award 2020** – November 2020. *The award, the highest that the College has to bestow, is made in recognition of your eminent position as one of Australia's most distinguished medical researchers. Amongst your many achievements, nominators commented on your extensive contribution of published work on melanomas, your far-reaching consultative practice for melanomas and skin cancers and improvement in diagnoses and treatment of these. Also noted were your membership and contributions on international committees and their respect for you as noted in a support letter from Memorial Sloan Kettering Cancer Centre "outstanding scientific contributions, academic leadership, clinical excellence, and mentoring of young colleagues."*
15. **Clarivate Web of Science Group: Highly Cited Researcher 2020.** *In recognition of exceptional research performance demonstrated by production of multiple highly cited papers that rank in the top 1% for field and year in "Cross-Field". Certificate dated 18 Nov 2020.*
16. **The Pathologist's 2020 Power List within the "Big Breakthroughs" category**, which celebrates trailblazers working at the cutting edge and driving forward the future of the field. Link: <https://thepathologist.com/power-list/2020>.
17. **The University of Sydney: 2020 Alumni Award for International Achievement** (link to award ceremony: https://www.youtube.com/watch?v=wU_mWMbWYHM).
18. Nominee for Australian of the Year 2019.
19. **Clarivate Web of Science Group: Highly Cited Researcher 2019.** *In recognition of exceptional research performance demonstrated by production of multiple highly cited papers that rank in the top 1% for field and year in Cross-Field. Issued 19 November 2019.*
20. **The American Society of Dermatopathology: Elson B. Helwig Memorial award** in "recognition of excellence in the realm of diagnostic dermatopathology and for significant contribution to the dermatopathology literature and the education of fellows and colleagues". Awarded at the ASDP 56th Annual Meeting in San Diego, California on 18 October 2019.
21. **Highly cited publication in Annals of Surgical Oncology** "Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond."
22. **The Pathologist's 2019: "Trailblazers" Power List** – a power list of top 100 Pathologists worldwide with RS listed in top 10 and the only Australian in the top 100.
23. ExpertScape DailyExperts – 29/5/2019: Richard Scolyer recognised as an ExpertScape World Expert in Melanoma (top 0.1%) (see www.expertscape.com/ex/melanoma, in June 2022, Richard ranked 6th leading melanoma expert in any field or discipline and world's leading melanoma pathologist)..
24. WBRT trial listed in the "Ten Practice Changes That I Will Make After Attending ASCO 2019".
25. 2019 Phase 3 international trial of adjuvant whole brain radiotherapy (WBRT) or observation (Obs) following local treatment of 1-3 melanoma brain metastases (MBMs) This abstract was hand-selected to be included in the 2019 Best of ASCO® program.
26. **2018 NSW Premier's Award for Outstanding Cancer Research: Professor Rob Sutherland AO Make a Difference Award.**
27. **Research Australia: 2018 GSK Award for Research Excellence** co-awarded to Professor **Richard Scolyer** and Professor Georgina Long.
28. **2018 International Academy of Pathology Commendation 1 Award for Pathologist category.** Paper: C. Quek, P. Shang, R. Rawson, P. Ferguson, R. Saw, G. Long, G. Mann, **R. Scolyer** and J. Wilmott "Recurrent hotspot SF3B1 mutations in mucosal melanoma: frequency and impact on survival"
29. **2018 International Academy of Pathology Best Poster/Abstract for the Pathologist category.** Paper: TN Gide, BM Allanson, Peter Ferguson, AM Menzies, RPM Saw, JF Thompson, GV Long, **RA Scolyer** and JS Wilmott. "Analysis of indoleamine 2,3-dioxygenase expression in longitudinal primary, nodal and distant metastatic melanoma specimens"

30. **MD Anderson Cancer Centre: 2018 William O. Russell Lectureship and Joanne Vandenberg Hill Award for Lifetime Achievement in Anatomical Pathology.**
31. **2017 NSW Premier's Award for Outstanding Cancer Research: Wildfire Award**, recognises a NSW researcher, or team of researchers, who has made a significant difference to cancer care or research practice, for a highly cited publication. Rizos H, Menzies AM, Pupo GM, Carlino MS, Fung C, Hyman J, Haydu LE, Mijatov B, Becker TM, Boyd SC, Howle J, Saw R, Thompson JF, Kefford RF, **Scolyer RA**, Long GV. BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact. Clin Cancer Res. 2014 Apr 1;20(7):1965-77.
32. **2017 NSW Premier's Award for Outstanding Cancer Research: Excellence in Translational Cancer Research Award.** Co-awardees Professors Richard Scolyer and Georgina V. Long and the Melanoma Institute Australia Translational Team.
33. **Sydney Catalyst International Cancer Research Symposium 2017: Top poster presentation** - "CD103+ tumour-resident CD8+ T cells are associated with improved survival in immunotherapy naive melanoma patients and respond to anti-PD-1 immunotherapy". Jarem Edwards, James S. Wilmott, Jason Madore, Tuba Nur Gide, Camelia Quek, Jinbiao Chen, Rehana Hewavisenti, Peter Hersey, Thomas Gebhardt, Wolfgang Weninger, Warwick J. Britton, Robyn P. M. Saw, John F. Thompson, Alexander M. Menzies, Georgina V. Long, **Richard A. Scolyer**, Umamainthan Palendira.
34. Annual Scientific Meeting of the Australasian Division of the International Academy of Pathology: **2017 Commendation Award** (second prize) - Pathologist/Scientist category for the best abstract. "Biomarkers of Response and Resistance to Combined Anti-CTLA-4 and Anti-PD-1 Immunotherapy in Melanoma Patients Utilising Multiplex Immunofluorescence" Nur Gide T, Quek C, Madore J, Menzies AM, Dent R, Carlino M, Guminski A, Saw R, Thompson J, **Scolyer RA**, Long GV, Wilmott J.
35. **Royal Prince Alfred Hospital: 2016 Foundation Research Medal and Prize.**
36. **2016 NSW Premier's Award for Outstanding Cancer Research: Wildfire Award**, recognises a NSW researcher, or team of researchers, who has made a significant difference to cancer care or research practice, for a highly cited publication. Long GV, Wilmott JS, Capper D, Preusser M, Zhang YE, Thompson JF, Kefford RF, von Deimling A, **Scolyer RA**. Am J Surg Pathol 2013.
37. **Thomson Reuters Citation and Innovation Award: 2015 Outstanding Research Team** for research in BRAF-mutated melanoma. Co-winners with Professor Georgina Long, Professor Richard Kefford, Professor Grant McArthur.
38. **2014 NSW Premier's Award for Outstanding Cancer Research: Wildfire Award**, recognises a NSW researcher, or team of researchers, who has made a significant difference to cancer care or research practice, for a highly cited publication between 1 January 2011– 31 December 2011. Long GV, Menzies AM, Nagrial AM, Haydu L, Hamilton AL, Mann GJ, Hughes TM, Thompson JF, **Scolyer RA**, Kefford RF. "Prognostic and clinico-pathologic associations of oncogenic BRAF in metastatic melanoma." J Clin Onc 2011.
39. **2013 NSW Premier's Awards for Outstanding Cancer Research: Wildfire Award** recognises a NSW researcher, or team of researchers, who has made a significant difference to cancer care or research practice, for a highly cited publication between 1 January 2010– 31 December 2010. Guitera P, Pellacani G, Crotty KA, **Scolyer RA**, Li L-XL, Bassoli S, Vinceti M, Rabinovitz H, Longo C, Menzies SW. 'The Impact of In Vivo Reflectance Confocal Microscopy on the Diagnostic Accuracy of Lentigo Maligna and Equivocal Pigmented and Nonpigmented Macules of the Face.' J Invest Dermatol 2010.
40. **Asian Society for Pigment Cell Research/Australasian Society for Dermatology Research meeting: Best clinical research presentation by a student** (Tori Mar) for "BRAF/NRAS wild-type melanomas have a high mutation load correlating with histological and molecular signatures of UV damage." Mar VJ, Wong SQ, Li J, **Scolyer RA**, McLean C, Papenfuss AT, Tothill RW, Kakavand H, Mann GJ, Thompson JF, Behren A, Cebon JS, Wolfe R, Kelly JW, Dobrovic A, McArthur GA. Clin Cancer Res, 2013.
41. **2012 NSW Premier's Award for Outstanding Cancer Research: Outstanding Cancer Research Fellow.**
42. **2009 NSW Premier's Award for Outstanding Cancer Research: Excellence in Translational Research:** Sydney Melanoma Unit (CINSW Translational Program Grant CIs: Mann, Thompson, Kefford, **Scolyer**, Hersey, Menzies, Christopherson).
43. **2009 NSW Premier's Award for Outstanding Cancer Research: Outstanding Cancer Research Fellow.**
44. **Commendation (2nd prize) for poster presentation** (scientist/pathologist): Zhuang L, Lee CS, **Scolyer RA**, McCarthy SW, Zhang X, Thompson JF, Bron LP, Hersey P. Involvement of Tumour Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) and Its Death Receptors (DR4 and DR5) in Human Melanoma. Annual Scientific Meeting of Australasian Division of the IAP, Sydney, 2005.
45. **1st prize for poster presentations** at Annual Meeting of the Swiss Society of Gynaecologists and Obstetricians, Lugano, Switzerland. Heinzlmann-Schwarz VA, Gardiner-Garden M, Henshall SM, Scurry J, **Scolyer RA**, Fink D, Sutherland RL, Hacker NF, O'Brien PM. Galectin 4 and Meprin A are new candidate diagnostic markers for mucinous ovarian cancer, 2005.
46. **2nd Prize for Poster presentations** at Annual Scientific Meeting of the Australasian Division of the International Academy of Pathology. Heinzlmann-Schwarz V, Gardiner-Garden M, Henshall S, Gish K, Scurry J, **Scolyer R**, Hacker N, O'Brien P, Sutherland R. Interstudy validation of gene expression profiles identifies candidate biomarkers of epithelial ovarian cancer, 2003.
47. **Sentinel Node Congress: 2002 Young Investigators Award International.** Yokohama Japan, 2002.

INVITED LECTURES / PRESENTATIONS

1. "Pathology as the Gold Standard for Melanoma Diagnosis - How much does it glitter?" invited to give plenary lecture (virtual) at the World Congress of Cancers of the Skin (WCCS) 2022 being held as a hybrid event in Argentina, 26-29 October 2022 (hybrid).
2. "Pitfalls in the Diagnosis of Pigmented Lesions" invited to talk (virtual) during the "Skin Cancer Pathology Symposium" at the World Congress of Cancers of the Skin (WCCS) 2022 being held as a hybrid event in Argentina, 26-29 October 2022 (hybrid).
3. "Research Improving Melanoma Patient Outcomes", together with Dr Robert Rawson (invited speakers), at the NSW Health Pathology 'Early Career Research Education Series' on Wednesday 22 June 2022 (virtual).
4. "BAP1-inactivated melanocytic lesions" and "Nevoid melanoma" during Pitfalls and challenges in melanocytic dermatopathology session at International Society of Dermatopathology (ISDP) 2022 Virtual Meeting, 16-17 May 2022 (virtual).
5. Case presentations x 3 at The Pathology of melanoma: an international course, Institut Curie, Paris, France, 21-22 April 2022 (virtual).
6. "Predictive biomarkers for targeted and checkpoint inhibitor therapies" at The pathology of melanoma: an international course, Institut Curie, Paris, France, 21-22 April 2022 (virtual).
7. "Acral melanocytic nevi and melanoma" at The pathology of melanoma: an international course, Institut Curie, Paris, France, 21-22 April 2022 (virtual).
8. "Oral and genital melanocytic lesions" at The pathology of melanoma: an international course, Institut Curie, Paris, France, 21-22 April 2022 (virtual).

9. "AJCC 8th edition guidelines" at The pathology of melanoma: an international course, Institut Curie, Paris, France, 21-22 April 2022 (virtual).
10. Presentation – RAS together with Dr Alison Potter, of 2 difficult to diagnose cases at the PathPresenter's "Learning from the Experience of Experts" on-line Teaching Conference in Pathology 2022 (9-10 April 2022) with over 1,500 attendee registrations from around the world.
11. "Recent Advances in the Diagnosis and Treatment of Melanoma" (clinical presentation) – invited to present "Grand Rounds Visiting Professor Lecturer, Richard Scolyer AO" at Yale Dermatology on Wednesday 2nd March 2022 (virtual).
12. "Biomarkers are critical for Personalised Immunotherapy" (scientific presentation) – invited to present "Grand Rounds Visiting Professor Lecturer, Richard Scolyer AO" at Yale Dermatology on Wednesday 2nd March 2022 (virtual).
13. "Zero Deaths from Melanoma: Progress to Date and Future Prospects" – invited to present the Martin C. Mihm Lecture, part of the Cutaneous Oncology Program for Massachusetts General Hospital on Wed 2 February 2022 (virtual) (EST Wed 2 Feb).
14. "Zero Deaths from Melanoma" – lecture objectives: (i) understand the melanoma pathways defined in the WHO classification and their implications for diagnosis and management, (ii) understand the concept of borderline melanocytic tumors and how they have been incorporated into the WHO classification and (iii) recognize the pitfalls in the diagnosis of melanocytic tumors and know strategies on how to avoid them. Invited lecture at Wake Forest Baptist Health Department of Dermatology's Virtual Quarterly Meeting on Wednesday 1 December 2021 (EST Tues 30 November EST).
15. "Refining pathological response assessment in neoadjuvant therapy for melanoma" – invited to present at Immunotherapy Bridge 2021 (part of broader session "Neoadjuvant Immunotherapy across Cancers") on 2 December 2021 (Italy – virtual)
16. RAS co-chaired various sessions at the Australasian Melanoma Conference (AMC) 2021 (virtual), hosted by Melanoma Institute Australia, namely:-
 - i. Welcome/Opening Address – Day 1 (with Prof. Georgina Long);
 - ii. Session 1.3.1 Keynote 1 (with Prof. Georgina Long);
 - iii. Session 1.5.1 Debate 1 (with Prof. Georgina Long) "To shave or not to shave when biopsying melanoma";
 - iv. Session 1.5.1 Debate 2 (with Prof. Georgina Long) "The role of sentinel node biopsy is overstated in melanoma";
 - v. Welcome/Opening Address – Day 2 (with Prof. Georgina Long);
 - vi. Session 2.3.1 – Multi Disciplinary Care Session (Three Cases Studies plus panel) (with Assoc Prof. Alexander Menzies); and
 - vii. AMC Closing (with Prof. Georgina Long).
17. "A lens into the future of the melanoma MDT in 2025" – as an invited panel member at the Breakfast Symposium (sponsored by MSD) at the Australasian Melanoma Conference (AMC) 2021 on Saturday 20th November 2021 (virtual)
18. "Pathology: Rare Cancers of the Skin - updates on Merkel Cell Carcinomas and other lethal lesions" – invited to present at GAC-SC 2021 (Global Advances and Controversies in Skin Cancer Conference) on Saturday 6th November (virtual).
19. RAS invited to Chair Session "8C - Rare Melanoma Subtypes" at SMR Virtual Congress 2021 on Sunday 31st October 2021 (virtual).
20. "Melanoma Risk Prediction Tools" – invited to present at International Melanoma Pathology Group (IMPG) Symposium on Friday 29 October (Syd time) 2021 (virtual).
21. "Predictive Biomarkers for Immunotherapies" – invited to present at International Melanoma Working Group Fall Meeting on Sunday 3 October 2021 (virtual).
22. "Zero Deaths from Melanoma - progress to date and prospects for the future" – invited to present (with Prof. Georgina Long) at the monthly Sydney Research Council Meeting on Tues 28 September (virtual).
23. "Applying Patient disease characteristics to Inform Treatment in Melanoma" – Educational module presented in conjunction with Novartis as a pre-recorded presentation as part of the Satellite Symposium at European Society for Medical Oncology (ESMO) 2021 – virtual (20 September 2021)
24. "Pitfalls in the Diagnosis of Melanocytic Tumours and How to Avoid Them" – invited to present lecture at the Harvard CME course Dermatopathology Update on Friday 10 September 2021 (AEST) – live/virtual (9-11 September 2021)
25. Microscope Sessions A&B "Challenging Pigmented Lesions", together with Dr Elizabeth Paver at the Harvard CME course Dermatopathology Update on Friday 10 September 2021 (AEST) – live/virtual (9-11 September 2021).
26. "Concepts & Strategies for Diagnosing Challenging Melanocytic Tumours" - invited to deliver (virtually) on Sat 21 August 2021, the Geoffrey Hunter Oration at the 41st Australasian Dermatology Society (ADS) Annual Scientific Meeting (20-22 August).
27. "Approach to Melanocytic Cutaneous Neoplasms" – virtual presentation, with Dr Elizabeth Paver at the PathPresenter's Masterclass in Pathology 2021 (13-15 August 2021) with 7,100 attendee registrations from around the world.
28. "Zero Deaths from Melanoma" virtual-live presentation by RAS of the inaugural "Eva Raik Memorial Oration" by RAS on Saturday 3rd July 2021 at the Royal College of Pathologists of Australasia's 2021 Path Update (2-4 July 2021)
29. "Pathological Response in Neoadjuvant Therapy in Melanoma" virtual presentation by RAS on Wednesday 9th June 2021 at International Neoadjuvant Melanoma Consortium (INMC) Symposium ASCO June 2021.
30. "Genomic Landscape of Melanoma Subtypes" virtual presentation by RAS on Thursday 19th May 2021 at American Academy of Cancer Research (AACR) Annual Meeting 17-21 May 2021.
31. "Highlights from 10th World Congress of Melanoma: Primary Tumour Management Impacts Treatment at All Stages" presented by RAS at Cancer Institute NSW's "Cancer Conversations" on-line event on Tuesday 18th May 2021.
32. "Merkel Cell Carcinoma and Other Skin Cancers: State of the Art Tips & Tricks for Diagnosis" on Fri 23rd April 2021 - Masterclass: Merkel Cell Carcinoma and Non-Melanoma Skin Cancer at The 45th IAP Annual Scientific Meeting (Virtual) – 22-24 April 2021.
33. "Summary of Symposium SY56 – Melanoma pathology – genomics and morphology" during the 10th World Congress of Melanoma on 15-17 April 2021 (virtual).
34. "Integrative risk modeling to predict sentinel node positivity – do gene expression profiles do it best?" presented by RAS (Symposium SY10 – Advances in melanoma staging and prognosis: AJCC V8, integrative risk modelling, and beyond) during the 10th World Congress of Melanoma on 15-17 April 2021 (virtual)
35. "Melanoma Institute Australia in Sydney" presented by RAS (Symposium session SY44 – Interdisciplinary skin cancer centers: how they dealt with the Corona pandemic in different counties) during the 10th World Congress of Melanoma on 15-17 April 2021 (virtual)
36. "Concepts & Strategies for Diagnosing Challenging Melanocytic Tumours" on Thursday 18th March 2021 - Short Course at USCAP 2021 (virtual) – 13-18 March 2021. Course directors: Richard A. Scolyer, Marty Mihm, David Elder and Adriana Piris
37. "Melanocytic Lesion Workshop" presented by Dr Peter Ferguson and Dr Robert Rawson and chaired by RAS at RCPA PASS Workshop (live) on Wednesday 24 February 2021.

38. "Why and how should research training be integrated into residency?" presented by RAS at a Special Session: Education strategies in pathology for the next decade during the virtual 32nd Congress of the European Society of Pathology and XXXIII International Congress of the International Academy of Pathology Congress and Exhibition on Monday 7 December 2020.
39. 2020 Merkel Cell Carcinoma Masterclass: Maximising patient benefit with multidisciplinary management. The identification and pathology of MCC as well as participating in case study presentations and panel discussions during the Masterclass. Webinar held on 26 October 2020.
40. Workshop recording – Dermpedia Org – (virtual) with Dr's Zembowicz and Scolyer on Conditional Probability For Dermatopathologists: Theoretical Principles of Using Ancillary Tests In Evaluation Of Challenging Melanocytic Tumors. It Is All About The H&E, Stupid! – recorded Fri 11 September 2020 – available 15 September 2020.
41. "Towards Zero Deaths from Melanoma" – Grand Round Meeting 2020 at Royal Hobart Hospital (virtual) – 11 September 2020.
42. "Melanoma Near Misses: Clues to Diagnosis" - 10th London Dermatopathology Symposium 2020 (virtual) – September 2020.
43. "Epidermal/Keratinocytic Skin Tumours: Highlights from the New WHO Classification" – 10th London Dermatopathology Symposium 2020 (virtual) – September 2020.
44. "Highlights from the new WHO Classification of Skin Tumours" – live stream lecture for Pathcast on Wednesday 5 August 2020 (link: <https://www.youtube.com/watch?v=91cY2JEdrTg>).
45. "Fireside chat" on dysplastic naevi with Dr Artur Zembowicz from Harvard, May 2020.
46. "Diagnosis of melanocytic tumours: the crucial role of histopathology in the molecular era" Short Course at USCAP 2020, Los Angeles, USA 29 February – 5 March 2020. Course directors: Richard Scolyer, Marty Mihm, David Elder and Adirion Piris.
47. Pigmented Lesions & Other Hot Topics in Dermatopathology Course, Sydney Australia, 14-15 February 2020:-
 - i. Chairperson;
 - ii. "Combined naevi including deep penetrating naevi and BAP1 inactivated naevi";
 - iii. "Borderline melanocytic tumours";
 - iv. "Sentinel node biopsy pathology";
 - v. "Naevoid melanoma";
 - vi. "Melanoma prognosis, staging & pathology reporting" and
 - vii. "Pigmented Pagets disease".
48. Case presentations x 3 at The Pathology of melanoma: an international course, Institut Curie, Paris, France, 16-17 January 2020.
49. "Predictive biomarkers for targeted and checkpoint inhibitor therapies" at The pathology of melanoma: an international course, Institut Curie, Paris, France, 16-17 January 2020.
50. "Acral melanocytic nevi and melanoma" at The pathology of melanoma: an international course, Institut Curie, Paris, France, 16-17 January 2020.
51. "Oral and genital melanocytic lesions" at The pathology of melanoma: an international course, Institut Curie, Paris, France, 16-17 January 2020.
52. "AJCC 8th edition guidelines" at The pathology of melanoma: an international course, Institut Curie, Paris, France, 16-17 January 2020.
53. "Atypical Spitz Borderline Melanocytic tumours." International Melanoma Pathology Study Group Workshop at Huntsman Cancer Clinic, University of Salt Lake City Hospital – 19 November 2019.
54. "Melanoma and the Immune System – Highlights on pathologic assessment and translational research" Plenary Session presented by **Richard A Scolyer** & Michael Tetzlaff at the 16th International Congress of the Society for Melanoma Research (SMR), Salt Lake City, Utah, USA on 20–23 November 2019.
55. "Mucosal melanoma" at the 12th International Melanoma Pathology Symposium in Salt Lake City, Utah, USA. Hosted by International Melanoma Pathology Study Group (IMPSG). 20 November 2019
56. "Zero Deaths from Melanoma: The Critical Role Pathologists will Play to Achieve this Goal", Elson B. Helwig Memorial Lecture at ASDP 56th Annual Meeting (San Diego, USA) 17-20 October 2019.
57. "The New AJCC Classification of Melanoma" - Special Topics: Update on Pathology of Melanocytic Tumors at the ASDP 56th Annual Meeting in San Diego, USA on 17-20 October 2019.
58. "Molecular pathology of melanoma" at RCPA: Introductory Short Course in Genomic & Molecular Pathology Short course in Melbourne on 13 October 2019.
59. "Contemporary issues in melanoma pathology" at MD Anderson RPAH Pathwest Surgical Pathology Conference in Margaret River, WA in September 2019 (invited speaker).
60. "Zero deaths from Melanoma; latest data from early diagnosis and advanced disease", a joint presentation Prof. G. Long and Prof **R.A. Scolyer**. BMS – Visiting Speaker Tour in Zurich and Vienna, September 2019.
61. "Predicting clinical outcomes in Melanoma patients." BMS: Visiting Speaker Tour in Switzerland, August 2019.
62. "Zero Deaths from Melanoma" - Alan Cooper Epiderm Lecture in Brisbane on the 9 August 2019.
63. "Is Pathology the Gold Standard for Diagnosis of Melanoma Tumours?" a Plenary Lecture at combined RCPA/Singapore Society of Pathology event. RCPA: Visiting Lectureship to Overseas (Singapore) July 2019.
64. "Pathologic Aspects of Melanoma Staging" at RCPA: Visiting Lectureship to Overseas (Singapore) July 2019.
65. "Hot Topics in Melanocytic Pathology", Plenary Lecture at combined RCPA/ Academy of Medicine event (Singapore) July 2019.
66. "Melanoma Near Misses" at RCPA: Visiting Lectureship to Overseas (Singapore) July 2019.
67. "Hot topics in melanocytic pathology" at RCPA: Visiting Lectureship to Overseas (Hong Kong) July 2019.
68. "Morphological and genomic analyses of melanoma" at RCPA: Visiting Lectureship to Overseas (Hong Kong) July 2019.
69. "Evolving Concepts and Hot Topics in Melanoma" at RCPA: Visiting Lectureship to Overseas (Kuching Sarawak Malaysia) July 2019.
70. "Melanoma vs. Naevus: Strategies for Difficult Decision" at RCPA: Visiting Lectureship to Overseas (Kuching Sarawak Malaysia) July 2019.
71. "Challenges in Diagnosis of Pigmented Lesions" Plenary session at RCPA: Visiting Lectureship to Overseas (Kuching Sarawak Malaysia) July 2019.
72. "Genetics and microenvironment of mucosal melanoma" at the 6th Frontiers of International Melanoma Forum in Changsha (Invited Speaker) 15-16 June 2019.
73. "Principles and Controversies in Classification of Melanocytic Tumors" a Faculty - Moderated Plenary discussion at Dermpedia, Orlando (Editorial Board/Program Committee) April 2019.
74. "Keratinocytic/Epidermal Tumors" at Dermpedia, Orlando (Editorial Board/Program Committee) April 2019.

75. "Melanoma on Skin with Low Cumulative Solar Damage (Superficial Spreading Melanoma)" at Dermpedia, Orlando (Editorial Board/Program Committee) April 2019.
76. "Overview - Melanocytomas and Spitz Tumors" at Dermpedia, Orlando (Editorial Board/Program Committee) April 2019.
77. "Desmoplastic Melanoma" at Dermpedia, Orlando (Editorial Board/Program Committee) April 2019.
78. "Melanocytic Tumors" at Dermpedia, Orlando (Editorial Board/Program Committee) April 2019.
79. "Is pathology the gold standard for melanoma diagnosis?" at the Melanoma Screening Summit ASSC, Brisbane Australia (Invited Speaker) March 2019.
80. "The Impact of Novel Molecular Findings on the Spitzoid Proliferation, Update Adjuvant Therapy in Melanoma or Findings of the Cancer Genome Studies" at the Department of Dermatology at Brigham and Women's hospital, Boston Massachusetts March 2019 (Invited Speakers Series).
81. "Something Borrowed (Melanocytoma)" at USCAP, Washington March 2019.
82. "See Something, Say Something? What is Important (And What Isn't) In Reporting Melanoma and its Variants" at USCAP, Washington March 2019.
83. "Diagnosis of Melanocytic Tumors: The Crucial Role of Histopathology in the Molecular Era" Short Course 50 at USCAP, Washington March 2019.
84. "Cancer Risk - Melanoma, Lifestyle & Inherited Risk Profiles" at Global Adolescent and Young Adult Cancer Congress, Sydney, Australia, December 2018.
85. "Insights into melanoma data management" Breakout session at EADO Barcelona, Spain, November 2018.
86. "Data management at a dedicated melanoma centre: Melanoma Institute Australia" at EADO Barcelona, Spain, November 2018.
87. "Melanoma biology and genetics" Chair at EADO Barcelona, Spain, November 2018.
88. "Melanoma genomics" at EADO Barcelona, Spain, November 2018.
89. "Genomic Classification of mucosal melanoma" at the 2018 Beijing International Melanoma Congress, China, August 2018.
90. "Prevention and Diagnosis" Plenary Chair at Australasian Melanoma Conference Melbourne, Australia, October 2018.
91. "Borderline Lesions: histological and management challenges" at the Australasian Melanoma Conference Melbourne, Australia, October 2018.
92. "Predicting patient outcomes" Plenary Session at Australasian Melanoma Conference, Melbourne, Australia, October 2018.
93. "Staging" at the World Congress on Cancers of the Skin Sydney, Australia, August 2018.
94. "Current Melanoma Standard of Care" at the World Congress on Cancers of the Skin in Sydney, Australia, August 2018.
95. "Melanoma Near Misses" at the World Congress on Cancers of the Skin Sydney, Australia, August 2018.
96. "Hot Topics and Evolving Concepts in Melanoma Pathology" Chair at the World Congress on Cancers of the Skin Sydney, Australia, August 2018.
97. "Management of High Risk Early Stage Melanoma" at World Congress on Cancers of the Skin Sydney August 2018.
98. Fighting Australia's National Cancer, 1850 Society Cocktail Reception, The University of Sydney June 2018.
99. "Launch of the Clinical Guidelines Australia for Melanoma" at the Australian Skin Cancer Conference, Broadbeach Queensland, Australia, May 2018.
100. "What should be in the melanoma pathology report and what does it mean for the patient" at the Australian Skin Cancer Conference Broadbeach Queensland, Australia, May 2018.
101. "AJCC 8th edition guidelines" at International Course on Melanoma Pathology Paris, France, April 2018.
102. "Oral and genital melanocytic lesion" at International Course on Melanoma Pathology Paris, France, April 2018.
103. "Acral melanocytic nevi and melanoma" at International Course on Melanoma Pathology Paris, France, April 2018.
104. "Predictive biomarkers for targeted and checkpoint inhibitor therapies" at International Course on Melanoma Pathology, Paris, France, April 2018.
105. Case presentations x 2 - International Course on Melanoma Pathology Paris, France, April 2018.
106. "Pitfalls of Dermatopathology: When Things are NOT What They SEEM to Be" at USCAP Vancouver, Canada, March 2018.
107. "Melanocytic Lesions: A Practical Approach to Diagnosis, Adjunctive Molecular and Appropriate Therapy/Management" at USCAP Vancouver, Canada, March 2018.
108. "Pathologists can transform understanding of disease pathogenesis and revolutionise treatment: experience from the Australian melanoma genome project" at RCPA Pathology Update 2018, A Bridge to the Future, Sydney, Australia, March 2018.
109. "The Ultimate Melanoma Masterclass" Chair/Lecturer at Melanoma Institute Australia, Sydney, Australia, February 2018.
110. "Morphologic and Genomic Analysis of Melanoma: Leading a Revolution in Understanding Disease Pathogenesis and Treating Cancer Patients" a William O Russell Lectureship at MD Anderson, Houston, USA, February 2018.
111. "New World Order: 8th Edition of AJCC Staging" at the 12th Annual UNC Melanoma Conference, North Carolina, USA, February 2018.
112. Poster Chair for the category "Melanoma" ESMO Asia Congress Singapore, November 2017.
113. "Genomics and microenvironment of mucosal and acral melanoma. Is it different from cutaneous melanoma?" at ESMO Asia Congress Singapore, November 2017.
114. "Predictive markers of response and resistance to immunotherapies in melanoma and NSCLC" at COSA Sydney, Australia, November 2017.
115. "Histopathology – TILs, PD-L1" at Clinical Oncology Society of Australia Annual Scientific Meeting November 2017.
116. "SCC of the Skin – Classification and Clinically Relevant" at the Contemporary Management of Complex Skin Cancers CME conference, New York, November 2017.
117. "Lentigo Maligna Melanoma Pathology" at the Contemporary Management of Complex Skin Cancers CME conference, New York, November 2017.
118. "AJCC 8th Edition Melanoma Staging Updates and Melanoma Genetics" at the Contemporary Management of Complex Skin Cancers CME conference, New York, November 2017.
119. "Problems Interpreting Sentinel Node Biopsies including Tumour Burden" at the International Melanoma Pathology Study Group, Brisbane, Australia, October 2017.
120. "Pathological Assessment Following Neoadjuvant Therapy in Melanoma: Challenges, Opportunities & Consensus Recommendations" at the World Melanoma / Society of Melanoma Research Joint Congress Neoadjuvant Therapy Symposium Brisbane October 2017.
121. "Pathological aspects of melanoma staging: a guide to the AJCC 8th edition World Congress Melanoma", Brisbane Australia October 2017.

122. "Neurotropic melanoma" at the 10th International Melanoma Pathology Symposium Brisbane, Australia October 2017.
123. "Deep Penetrating and Combined Nevi" at the Northwestern Course On Cutaneous Lymphoma and Melanoma, Chicago, September 2017.
124. "Blue nevi and Blue Nevus-Like Melanoma" at the Northwestern Course On Cutaneous Lymphoma and Melanoma, Chicago, September 2017.
125. "Nodal Nevi" at the Northwestern Course On Cutaneous Lymphoma And Melanoma, Chicago, September 2017.
126. "Pathology of Acral Nevi and Melanomas" at the Northwestern Course On Cutaneous Lymphoma and Melanoma, Chicago, September 2017.
127. "Updates in Staging and Reporting of Melanoma" at the Northwestern Course On Cutaneous Lymphoma And Melanoma, Chicago, September 2017.
128. "Pathology of Lentigo Maligna" at the Northwestern Course On Cutaneous Lymphoma And Melanoma, Chicago, September 2017.
129. "Mutational Analysis of Melanoma" at the Northwestern Course On Cutaneous Lymphoma And Melanoma, Chicago, September 2017.
130. "Genomics of Melanoma: Things are not Always as they Seem" at Charles Perkins Centre Bio-Domain Group Leader Seminar, The University of Sydney, August 2017.
131. "Nicotinamide for skin cancer chemoprevention. Effects on tumour cell infiltrates and melanoma biology", a joint presentation by Minocha R, Martin AJ, Chen AC, **Scoflyer RA**, Lyons G, McKenzie CA, Madore J, Halliday GM, Damian DL at the 50th Australasian College of Dermatology, Annual Scientific Meeting, Sydney in May 2017.
132. "Nicotinamide for Skin Cancer Chemoprevention: effects on Tumour Immune Cell Infiltrates and Melanoma Biology", a joint presentation by Minocha R, Martin A, Chen A, **Scoflyer RA**, Lyons G, McKenzie C, Madore J, Halliday G, Damian D at The Molecular and Experimental Pathology Society Conference. Melbourne, November 2016.
133. "Is pathology the gold standard for diagnosing melanocytic tumors: Does it always glitter?" at 13th Congress of EADO, Athens, Greece, May 2017.
134. "Whole genome sequencing of major melanoma subtypes and its relevance for patient care" at 13th Congress of EADO, Athens, Greece, May 2017.
135. "Acral, Mucosal, and Cutaneous Melanoma: Whole Genomic Sequencing" at International Melanoma Working Group (IMWG) meeting, Athens, Greece, May 2017.
136. "The Genomic Revolution and Melanoma: Implications for Skin Cancer Doctors" at 2017 Skin Cancer College of Australasia Plenary Lecture. Surfer's Paradise, Queensland, May 2017.
137. "Combined and deep penetrating/plexiform nevi, nodules in nevi" at The pathology of melanoma: an international course, Institut Curie, Paris, France, April 2017.
138. "Acral (including subungual) melanocytic lesions, nevi, and melanoma" at The pathology of melanoma: an international course, Institut Curie, Paris, France, April 2017.
139. "AJCC 8th edition guidelines for cutaneous melanoma staging" at The pathology of melanoma: an international course, Institut Curie, Paris, France, April 2017.
140. "Predictive biomarkers for targeted and in checkpoint inhibitor therapies" at The pathology of melanoma: an international course, Institut Curie, Paris, France, April 2017.
141. "Melanocytic lesions: a practical approach to diagnosis, adjunctive molecular studies and appropriate therapy/management" at 2017 Annual Meeting USCAP, March 2017.
142. "Hot Topics in Pathology –Dermatopathology" at 2017 Annual Meeting USCAP, March 2017.
143. "Plenary session. Genomic studies in cutaneous melanoma and comparison with ocular melanomas" at World Ophthalmology Conference in March 2017.
144. "Desmoplastic melanoma, naevoid melanoma and deep penetrating naevus" at United States and Canadian Association of pathologists annual scientific meeting San Antonio Texas March 2017 (presented a course with Prof Martin Mihm from Harvard Medical School).
145. HOTT presentation: "BRAF and PDL1 testing in melanoma and their implications for patient management", March 2017
146. RPAH tissue pathology ground rounds: new staging system in melanoma, March 2017.
147. "MIA journal club: update on the eighth edition AJCC melanoma staging system" at MIA in March 2017.
148. "Melanocytic Lesions: A practical approach to diagnosis, adjunctive molecular studies and appropriate therapy/management" at USCAP Annual Meeting, San Antonio, March 2017.
149. 9th Annual MRA Scientific Retreat, Washington, February 2017.
150. Review and Recent Advances in Pathology Lecture series in conjunction with the Too Hard Slide Show 2017
151. "Genomics and immunobiology of acral and mucosal melanoma" at ESMO Asia 2016, Singapore, December 2016.
152. "Monitoring response and resistance in melanoma, Biomarkers for immune checkpoint therapies" at Special Symposium, ESMO Asia 2016 in December 2016.
153. "The New AJCC Melanoma Staging System" at Society of Melanoma Research, Annual Scientific Meeting, Boston November 2016.
154. "Neoadjuvant Therapy Symposium: Pathology Issues Panel discussion" at the Society of Melanoma Research, Annual Scientific Meeting, Boston, November 2016.
155. "Melanoma Medicine: The Next 50 Years, Dermatopathology Session" at Massachusetts General Hospital Pigmented Lesion Clinic 50th Anniversary Mini-Symposium. Boston USA November 2016.
156. "Dysplastic naevi" at Hammersmith on the Harbour Conference, Sydney November 2016.
157. "Update on the Australian Melanoma Genome Project" at Royal Prince Alfred Hospital, November 2016.
158. "Genomic Studies in Melanoma" at the Australasian Melanoma Conference, Sydney October 2016.
159. "Is pathology the gold standard for the diagnosis of melanocytic tumours: does it glitter?" at the Australasian Melanoma Conference, Sydney October 2016.
160. "Nicotinamide for Skin Cancer Chemoprevention: effects on Tumour Immune Cell Infiltrates and Melanoma Biology" a joint presentation by Minocha R, Martin A, Chen A, **Scoflyer RA**, Lyons G, McKenzie C, Madore J, Halliday G, Damian D at The Australasian Melanoma Conference. Sydney, October 2016.
161. "The Australian Melanoma Genome Project" at the 3rd Beijing International Melanoma Congress, Beijing China, 22-23 October 2016.
162. "The Australasian Bid to host the World Congress of the International Academy of Pathology in Sydney in 2022", World Congress of the International Academy of Pathology Cologne Germany September 2016.
163. "Fighting Australia's National Cancer: Progress to Date and Prospects for the Future" at RPAH Foundation Medal Winner's Grand Rounds Presentation, September 2016.

164. "Measuring the Melanoma Immune Response" at Locoregional Melanoma Conference, Melbourne August 2016.
165. "Melanoma Predictive Biomarkers in the era of effective immune therapies" at Immunotherapy: From Bench to Bedside. Sydney August 2016.
166. "Melanoma biomarkers in the Era of Effective Immunotherapies" at Oncoimmunology Symposium, Sydney July 2016.
167. "Mutation Analysis" at Memorial Sloan Kettering Cancer Centre Pathology of Melanocytic Tumours Course, New York, USA, 9-10 May 2016.
168. "Prognostic Factors – How to Assess and What to Report" at Memorial Sloan Kettering Cancer Centre Pathology of Melanocytic Tumours Course, New York, USA, 9-10 May 2016.
169. "Pathology of Acral Nevi and Melanomas" at Memorial Sloan Kettering Cancer Centre Pathology of Melanocytic Tumours Course, New York, USA, 9-10 May 2016.
170. "Deep Penetrating and Combined Nevi" at Memorial Sloan Kettering Cancer Centre Pathology of Melanocytic Tumours Course, New York, USA, 9-10 May 2016.
171. "Nodal Nevi" at Memorial Sloan Kettering Cancer Centre Pathology of Melanocytic Tumours Course, New York, USA, 9-10 May 2016.
172. "Blue Nevus-Like Melanoma: at Memorial Sloan Kettering Cancer Centre Pathology of Melanocytic Tumours Course, New York, USA, 9-10 May 2016.
173. "Cases 6-10" at Memorial Sloan Kettering Cancer Centre Pathology of Melanocytic Tumours Course, New York, USA, 9-10 May 2016.
174. US and Canadian Academy of Pathologists Annual Scientific Meeting. Pigmented lesion course with Dr Martin Mihm and Dr Daniela Massi: a. Naevoid melanoma; b. Desmoplastic melanoma; c. Deep penetrating naevus, Seattle USA, 12-18 March, 2016.
175. "Melanoma pathology reporting and staging (including sentinel node biopsy)" at Recent Advances in Pathology in Sydney, February 2016.
176. "Australian Melanoma Genome Project", Society for Melanoma Research Conference, San Francisco USA, 19-22 November 2015.
177. International Melanoma Pathology Study group workshop: Convenor and facilitator: Pathology terms, definitions and guidelines for AJCC staging, UCSF, San Francisco USA, 18 November 2015.
178. "Melanoma Round up: Melanoma Pathology Update for Clinicians" at Melanoma Institute Australia, Sydney Australia, 12 November 2015.
179. "Update on Melanoma Pathology". Global Advances and Controversies in Skin Cancer, Brisbane, Australia, October 2015.
180. "Interpreting the Difficult Skin Cancer" Speaker and Chair at Global Advances and Controversies in Skin Cancer, Brisbane, Australia, October 2015.
181. "Biospecimen Banking at MIA" at MIA Research Retreat, August 2015.
182. "Melanoma biomarkers in the molecular era" at Centenary Institute, Sydney June 2015.
183. "Biggest Pitfalls in the Melanocytic Pathology" at Perth Surgical Pathology Conference, Keynote speaker, Perth November 2014.
184. "Evaluating melanocytic lesions in the molecular era" at Perth Surgical Pathology Conference, Keynote speaker, Perth November 2014.
185. "Seven case presentations" at Perth Surgical Pathology Conference, Keynote speaker, Perth November 2014.
186. "Melanoma Biomarkers in the Molecular Era: A story of mixed fortunes with practical implications for patient care" at 2nd National Melanoma Conference, Perth, October 2014.
187. "Dysplastic naevi and related entities". Hammersmith on the Harbour. Sydney, October 2014.
188. "New Techniques for Evaluating Melanocytic Lesions" at Harvard Medical School Dermatopathology Update, Boston, USA, September 2014.
189. "Dysplastic Naevi & Melanocytic Lesions in Chronic Sun-damaged Skin. Why such controversy?" at Harvard Medical School Dermatopathology Update, Boston, USA, September 2014.
190. "Academy Awards for Big Bloopers in Melanocytic Lesions (with tips on how to avoid them)" at Harvard Medical School Dermatopathology Update, Boston, USA, September 2014.
191. "Melanoma in the Molecular Era" at Cancer Institute NSW, The Forum, Sydney, March 2014.
192. "Academy Awards for the Biggest Pitfalls in Melanocytic Pathology (and tips on how to avoid them)" at MD Anderson Cancer Center/PathWest/RPAH Surgical Pathology Symposium. Controversies and Evolving Concepts, Sydney, February 2014.
193. "Merkel cell carcinoma and tumour thickness: is the Breslow index also relevant for non-melanoma skin cancer?" at Global Controversies and Advanced Skin Cancer (incorporating the Australian National Melanoma Conference), Brisbane, November 2013.
194. "On-going Controversy: Apropos sentinel lymph node biopsy." Session Chairperson at Global Controversies and Advanced Skin Cancer (incorporating the Australian National Melanoma Conference), Brisbane, November 2013.
195. "Workshop on Pathology of Melanocytic Proliferations" Convenor and lecturer at Global Controversies and Advanced Skin Cancer (incorporating the Australian National Melanoma Conference), Brisbane, November 2013.
196. "Molecular testing and updates from pathology" at Melanoma Institute Australia's World Round-Up, Sydney October 2013.
197. "Predictors of sentinel node metastasis in melanoma" at XXXIV Congress of the International Society of Dermatopathology. Florence Italy, September 2013.
198. "BRAF mutant melanoma and effects of treatment on biopsies" at 8th World Congress on Melanoma, Hamburg, Germany, July 2013.
199. "Histological detection of sentinel lymph node metastases" at 8th World Congress on Melanoma, Hamburg, Germany, July 2013.
200. "Melanoma mutation testing: a practical guide for clinicians" at 8th World Congress on Melanoma, Hamburg, Germany, July 2013.
201. "What tools really work for melanoma secondary prevention" at 8th World Congress on Melanoma, Hamburg, Germany, July 2013.
202. "Atypical Spitzoid tumours: benign or malignant?" Session chairperson at 8th World Congress on Melanoma, Hamburg, Germany, July 2013.
203. "Mutation screening for melanoma: how should it be done?" Session chairperson at 8th World Congress on Melanoma, Hamburg, Germany, July 2013.
204. "Melanoma in sun-protected sites" at Edinburgh Dermatopathology Course, Edinburgh, Scotland, June 2013.
205. "Sentinel lymph node biopsy in melanoma patients: important issues for pathologists" at Edinburgh Dermatopathology Course, Edinburgh, Scotland, June 2013.
206. "Blue naevi and related entities" at Edinburgh Dermatopathology Course, Edinburgh, Scotland, June 2013.
207. "Fighting Australia's national cancer: progress to date and future prospects" at Vincent McGovern Memorial lecture, International Academy of Pathology June 2013. Sydney.
208. "CD34 positive soft tissue tumours" at Dermpedia Comprehensive Course on Soft Tissue Tumors, Scottsdale Arizona, April 2013.
209. "Unusual vascular tumours" at Dermpedia Comprehensive Course on Soft Tissue Tumors, Scottsdale Arizona, April 2013.

210. "Distinguishing primary from metastatic melanoma" at Dermpedia Comprehensive Course on Soft Tissue Tumors, Scottsdale Arizona, April 2013.
211. "Melanoma diagnosis, classification & treatment: progress to date and future prospects" at Dermpedia Comprehensive Course on Soft Tissue Tumors, Scottsdale Arizona, April 2013.
212. "Melanoma pathology reporting and staging (including sentinel node evaluation)" at Dermpedia Comprehensive Course on Soft Tissue Tumors, Scottsdale Arizona, April 2013.
213. "Problematic melanocytic tumours" at Dermpedia Comprehensive Course on Soft Tissue Tumors, Scottsdale Arizona, April 2013.
214. "Dermatopathology Update" at RPAH Diagnostic Pathology Course. 14th¹ February 2013, Sydney.
215. "BRAF mutant melanoma and treatment effects on biopsies" at Society of Melanoma Research. Los Angeles, November 2012.
216. "Dysplastic naevi- what is their significance?" at Hammersmith on the Harbour, Sydney October 2012.
217. "Atypical fibroxanthoma revisited" at World Congress of the International Academy of Pathology, Cape Town, South Africa, 1 October 2012.
218. "The melanoma pathology report" at World Congress of the International Academy of Pathology, Cape Town, South Africa, 2 October 2012.
219. "Staging of melanoma: practical guidelines" at World Congress of the International Academy of Pathology, Cape Town, South Africa, 2 October 2012.
220. "Desmoplastic melanoma" at World Congress of the International Academy of Pathology, Cape Town, South Africa, 1 October 2012.
221. "Pigmented epithelioid melanocytoma" at World Congress of the International Academy of Pathology, Cape Town, South Africa, 1 October 2012.
222. "A crucial review of melanoma staging including the role of sentinel lymph node biopsy" at Australasian Dermatopathology Conference, Melbourne, September 2012.
223. "Biospecimen Banking at MIA." MIA Research Retreat, 24 August 2012.
224. "Melanoma and Tumour Infiltrating Lymphocytes." MIA Research retreat, 24 August 2012.
225. "Melanoma Classification and Mutation Testing in the Molecular Era." Brazilian Oncology Meeting. 24 June 2012.
226. Panel member: "Education session on Recent Advances in Melanoma" - Sydney June 2012.
227. "Histopathology for dermoscopists" at World Congress on Dermatology. Brisbane, Queensland, 20 May 2012.
228. "The gold standard of dermatopathology: does it always glitter." Key note lecture. Plenary session. World Congress on Dermatology. Brisbane, Queensland, 19 May 2012.
229. "Tissue is the Issue." Tumour Banking Forum, Australian Melanoma Consumer Alliance, Melbourne, 8 May 2012.
230. "Cutaneous Ewings sarcoma" at British Division of the International Academy of Pathology, Oxford, United Kingdom, 14 April 2012.
231. "Pitfalls and important issues in the pathological diagnosis and reporting of melanocytic tumours" at British Division of the International Academy of Pathology, Oxford, United Kingdom, 13 April 2012.
232. Chair, Dermatopathology Masters Class, RCPA Pathology Update, 12 March 2012.
233. Chair person, Plenary Session, RCPA Pathology Update, 12 March 2012.
234. "Evolving concepts in the classification of melanocytic tumours and its importance and relevance for multidisciplinary patient care." Key note lecture. United Kingdom Melanoma Group meeting, London, UK, 27 January 2012.
235. "Staining and research opportunities in anatomical pathology" at NSW Anatomical Pathology Trainee Induction Course 2012. 24 January 2012.
236. "Tumour infiltrating lymphocyte grade is an independent predictor of outcome in melanoma" at Harvard Medical School Melanoma Symposium, Boston, USA, 13 November 2011.
237. "The pathologic reporting of melanoma: the development of consensus guidelines." at International Melanoma Pathology Working Group symposium, Tampa, Florida, USA. 10 November 2011.
238. "Melanoma classification in the molecular era." Joint Session of The Interdisciplinary Melanoma/Skin Cancer Centres and Melanoma Update for Primary Care Physicians, Surgeons, Oncologists and Dermatologists Tampa, Florida USA, 9 November 2011.
239. "Tissue is the issue: biospecimen banking." Joint Session of The Society of Melanoma Research and The Interdisciplinary Melanoma/Skin Cancer Centre Tampa, Florida, USA, 8 November 2011.
240. "Contemporary issues in melanocytic pathology." MD Anderson Cancer Center/PathWest/RPAH Pathology Symposium: New and Evolving Concepts and Contemporary Issues in Surgical Pathology, September 2011.
241. "Skin pathology." NSW Surgical Trainees Education program. Sydney. 6 September 2011.
242. "Melanoma in Australia." Brazilian Melanoma Congress. Rio de Janeiro, Brazil, 18 August 2011.
243. "Melanoma pathology for clinicians." Key note address. Brazilian Melanoma Congress. Rio de Janeiro, Brazil, 17 August 2011.
244. "The melanoma pathology report: what should be included and what does it mean for the patient." Brazilian Melanoma Congress. Rio de Janeiro, Brazil, 17 August 2011.
245. "Evolving concepts in melanoma classification." Brazilian Melanoma Congress. Rio de Janeiro, Brazil, 17 August 2011.
246. "Sentinel node biopsy in melanoma." Brazilian Melanoma Congress. Rio de Janeiro, Brazil, 17 August 2011.
247. "An approach to the diagnosis of problematic melanocytic tumours." Brazilian Melanoma Congress. Rio de Janeiro, Brazil, 17 August 2011.
248. "Melanocytic tumour pathology: what a dermatologist must know." Taiwanese Dermatological Society Meeting. Taipei, Taiwan. 25 May 2011.
249. "Melanoma pathology in the molecular era." Asia Pacific International Academy of Pathology Biennial Scientific Meeting. Taipei, Taiwan. 24 May 2011.
250. "Melanoma Research at Melanoma Institute Australia". Harvard Medical School Melanoma Retreat 26 March 2011.
251. "The melanoma pathology report and prognostic factors." Dermpedia Comprehensive Course of Melanocytic Proliferations, Scottsdale Arizona, USA. 17 March 2011.
252. "Blue naevi including unusual variants. Dermpedia Comprehensive Course of Melanocytic Proliferations." Scottsdale Arizona, USA. 17 March 2011.
253. "Cutaneous spindle cell neoplasms including desmoplastic melanoma, atypical fibroxanthoma and sarcomatoid carcinomas." Dermpedia Comprehensive Course of Melanocytic Proliferations, Scottsdale Arizona, USA. 16 March 2011.
254. "The role of molecular pathology in the multidisciplinary care of patients with melanocytic tumours". Dermpedia Comprehensive Course of Melanocytic Proliferations, Scottsdale Arizona, USA. 16 March 2011.

255. "Epidermotropic metastatic melanoma and primary dermal melanoma: when and how can they be distinguished?" *Dermpedia Comprehensive Course of Melanocytic Proliferations*, Scottsdale Arizona, USA. 16 March 2011.
256. "Sentinel node biopsy in melanoma: A practical guide for pathologists. *Dermpedia Comprehensive Course of Melanocytic Proliferations*." Scottsdale Arizona, USA. 16 March 2011.
257. "The role of molecular pathology in the multidisciplinary care of patients with melanocytic tumours. *Dermpedia Comprehensive Course of Melanocytic Proliferations*". Scottsdale Arizona, USA. 15 March 2011.
258. "Subungual melanocytic tumours. *Dermpedia Comprehensive Course of Melanocytic Proliferations*". Scottsdale Arizona, USA. 15 March 2011.
259. "Cutaneous small blue cell tumours. *Dermpedia Comprehensive Course of Melanocytic Proliferations*". Scottsdale Arizona, USA. 15 March 2011.
260. "Evolving concepts in melanoma classification and their importance relevance to multidisciplinary patient care". *RCPA Pathology Update* 5 March 2011.
261. "Dermatopathology Slide Seminar and Symposium." at RPAH Diagnostic Pathology Course. February 2011, Sydney.
262. Piet Grobler Memorial Lecture: "Pathology is a critical aspect in the multidisciplinary care of melanoma patients". 2011 Johannesburg Dermatopathology Symposium, Johannesburg, South Africa, January 2011.
263. "The melanoma pathology report: what should be included and what does it mean for the patient". 2011 Johannesburg Dermatopathology Symposium, Johannesburg, South Africa, January 2011.
264. "Sentinel node biopsy in melanoma". 2011 Johannesburg Dermatopathology Symposium, Johannesburg, South Africa, January 2011.
265. "Interesting case presentations." 2011 Johannesburg Dermatopathology Symposium, Johannesburg, South Africa, January 2011.
266. "Sectioning and Staining in Pathology". RCPA Trainee Induction Seminar, Sydney, January 2011.
267. "Opportunities for Research in Pathology". RCPA Trainee Induction Seminar, Sydney, January 2011.
268. "Melanoma Pathology for Primary Care Physicians." at International Melanoma Centres Meeting, Sydney November 2010.
269. Panel participant: "Interesting Melanoma Cases". At Symposium, International Melanoma Centres Meeting, November 2010.
270. Chairman and Convenor, Melanoma Pathology Symposium, 5th International Symposium of the International Melanoma Pathology Working Group, Sydney, November 2010.
271. "The RCPA Structured Pathology Reporting Protocol." Melanoma Pathology Symposium, 5th International Symposium of the International Melanoma Pathology Working Group, Sydney, November 2010.
272. Chairman and Convenor, Session Title "Melanoma Pathology in the Multidisciplinary Care of Melanoma Patients in the Molecular Era", Melanoma 2010, Annual Meeting of Society for Melanoma Research and Melanoma Centres Meeting, Sydney, November 2010.
273. Chairman session: "Pathology and Molecular Oncology" at International Sentinel Node Congress, Yokohama, Japan, 18 November 2010.
274. Plenary session: "Predicting non-sentinel node positivity and clinical outcome in sentinel node positive melanoma patients." International Sentinel Node Congress, Yokohama, Japan, 17 November 2010.
275. "Pathological Diagnosis of Blue naevi and Related Tumours". World Congress of the International Academy of Pathology, Sao Paulo, Brazil, 14th October 2010.
276. "Approach and tips to the RCPA specialist anatomical pathology examinations". New Zealand Annual Scientific Meeting, Royal College of Pathologists of Australasia, Rotorua, New Zealand, September 2010.
277. "Cutaneous soft tissue tumours". New Zealand Annual Scientific Meeting, Royal College of Pathologists of Australasia, Rotorua, New Zealand, September 2010.
278. "Problematic melanocytic tumours". New Zealand Annual Scientific Meeting, Royal College of Pathologists of Australasia, Rotorua, New Zealand, September 2010.
279. "The critical role of pathology in the multidisciplinary care of melanoma patients." Key note lecture at Australasian Division of the International Academy of Pathology Annual Scientific Meeting, Sydney, 4 June 2010.
280. "Not every tumour is melanoma - even when it is S100 positive!" Dermatopathology Companion Meeting. Australasian Division of the International Academy of Pathology Annual Scientific Meeting, Sydney, 4 June 2010.
281. "Skin Pathology for Radiation Oncologists." Sydney, 25 May 2010.
282. "Update For Surgeons At Melanoma Institute Australia." Essential Melanoma Pathology for Surgeons. 27 March 2010.
283. MIA: New Horizons and Future Directions in Melanoma Research & Therapeutics: Genetic and morphological classification of melanoma. 26 March 2010.
284. "Melanoma Prognostic Factors". Moffitt Cancer Centre, Tampa, Florida 2 March 2010.
285. Lecturer at Dermatopathology Self-Assessment Course, International Dermatopathology Society Meeting Miami 2010.
286. "Soft Tissue and Bone Pathology Slide Seminar and Symposium." RPAH Diagnostic Pathology Course. 2 February 2010, Sydney.
287. "Dermatopathology Slide Seminar and Symposium." RPAH Diagnostic Pathology Course. 1 February 2010, Sydney.
288. "Melanocytic Tumours Slide Seminar. Diagnosis of Melanocytic Lesions: Common Problems for the Practising Pathologist 2009". Paris. 29 November 2009.
289. "Pathology Reporting of Melanoma. Diagnosis of Melanocytic Lesions: Common Problems for the Practising Pathologist 2009". Paris 28 November 2009.
290. "Melanoma Prognostic Factors in 2009" Society of Melanoma Research, Annual Scientific Meeting, Boston, November 2009.
291. "Research and Clinical Trials" at the Sydney Melanoma Unit (co-presentation with Prof's G Mann, R Kefford and J Thompson). Advances in Melanoma Care 2009, Sydney, 16 May 2009.
292. "Biopsy and Histopathology of Melanoma: What the pathologist needs in order to accurately diagnose melanoma. What should be included in the melanoma Pathology Report and What it means for your Patient." Advances in Melanoma Care 2009, Sydney, 15 May 2009.
293. Chairperson for session: "Free Communication 21: Histopathology", World Congress on Melanoma, Vienna, 15 May 2009.
294. "Tumour infiltrating lymphocytes in melanoma" World Congress on Melanoma, Vienna, 15 May 2009.
295. "Tumour infiltrating lymphocytes in melanoma". RPAH Scientific Meeting. 6 May 2009.
296. "Tissue Microarrays and other special techniques" Melanoma Institute Australia, Research Retreat, Sydney, 24 April 2009.
297. "Histologically ambiguous melanocytic tumours" Melanoma Institute Australia, Research Retreat, Sydney, 24 April 2009.
298. RCPA Postgraduate Diagnostic Surgical Pathology Course – Soft Tissue and Bone Pathology, Sydney, 3 April 2009.
299. "Mimics and Pitfalls in the Diagnosis of Melanoma: RCPA Recent Advances in Pathology, Sydney, 1 April 2009.

300. "Skin Pathology for Plastic Surgeons" Royal Australian College of Surgeons, NSW Training Programme in Plastic Surgery, Sydney. 31 March 2009.
301. "Melanocytic Pathology" Westmead Institute for Cancer Research, March 26th 2009.
302. "Contemporary Issues in Melanocytic Pathology" MD Anderson Cancer Center, Houston, Texas, USA, 19 March 2009.
303. "Melanocytic Tumour Slide Seminar" MD Anderson Cancer Center, Houston, Texas, USA, 19 March 2009.
304. "Pigmented Lesions Slide seminar" McGill University, Montreal, March 17 2009.
305. "Combined naevi and related entities." International Melanoma Pathology Working Group, Nomenclature Meeting, San Francisco, USA. 3 March 2009.
306. "Interobserver reproducibility of the assessment of micromorphometric features of sentinel lymph nodes containing metastatic melanoma." Murali R, Cochran AJ, Cook MG, Karim RZ, Starz H, Moncrieff M, Thompson JF, **Scoflyer RA**. British Association of Plastic, Reconstructive and Aesthetic Surgeons. Winter Meeting, London, United Kingdom, 3-5 December 2008.
307. "Pigmented epithelioid melanocytoma." Lim C, Murali R, McCarthy SW, **Scoflyer RA**. Trends in Surgical Pathology, Sydney, Australia, 12 November 2008.
308. "Melanoma ins-situ: a patterns-of-care study in New South Wales." Madronio C, Armstrong B, Thompson J, Beard J, Curtin A, Redman S, **Scoflyer RA**, Karim R, Morton R, Holt, P, Mann G, Barton M, Kearney P. Clinical Oncology Society of Australia, Annual Scientific Meeting, Sydney November 2008.
309. "Quality benchmarks for regional lymph node dissections in melanoma." Spillane AJ, Cheung B, Stretch JR, **Scoflyer RA**. Thompson JF. Clinical Oncology Society of Australia, Annual Scientific Meeting, Sydney. November 2008.
310. "Lactate dehydrogenase 5 (LDH5) expression in human melanoma relates to its progression." Zhuang L, **Scoflyer RA**, McCarthy SW, Zhang XD, Lee CS, Thompson JF, Hersey P. Clinical Oncology Society of Australia, Annual Scientific Meeting, Sydney November 2008.
311. "Endocrine mucin producing sweat gland carcinoma". Karim R, Scoflyer RA. International Academy of Pathologists, Australasian Division 2008 Conference, Darling Harbour Sydney. November 2008.
312. "Mimics of Melanoma" in Mimics of Malignancy Symposium, XVIIth World Congress of International Academy of Pathology, Athens, Greece, October 2008.
313. "Deep penetrating naevus and related entities", XVIIth World Congress of International Academy of Pathology, Athens, Greece, October 2008.
314. "Skin Tumours: Pathology for Clinicians" Radiation Oncology Registrar Training Course. 24 October 2008.
315. "A Career in Pathology" Final Year University of Sydney Medical Students 10 October 2008
316. "Subungual Melanoma". Australasian Dermatopathology Society, Annual Scientific Meeting, Melbourne, 3 Aug 2008.
317. "Subungual Melanocytic Tumours". RPAH Scientific Meeting. 30 July 2008.
318. "Diagnosis of melanoma by 4-colour FISH". Morey AL, McCarthy SW, **Scoflyer RA**. Australasian Society for Dermatology Research Conference May 2008 Sydney.
319. "Pathological examination of sentinel nodes". RPAH Scientific Meeting. 21 May 2008.
320. "Pathological Reporting of Melanoma- What should be included in the pathology report and what does it mean for the patient?" Recent Advances in Pathology, Sydney, April 2008.
321. "Interobserver reproducibility of micromorphometric features of sentinel lymph nodes containing metastatic melanoma". Murali R, Cochran A, Cook M, Karim R, Starz H, Moncrieff M, Thompson JF, **Scoflyer RA**. 6th Biennial International Sentinel Node Society Meeting Sydney February 2008.
322. "Sentinel lymph node biopsy in paediatric and adolescent melanoma patients". Howman-Giles R, Shaw H, Uren R, Scoflyer RA., Thompson J. 6th Biennial International Sentinel Node Society Meeting Sydney February 2008.
323. "Efficiency of different models predicting sentinel node status in 1,104 melanoma patients". Rossi CR, Pasquali S, Mocellin S, Pilati PL, Nitti D, Saw RP, **Scoflyer RA**, Stretch JR, Thompson JF. 6th Biennial International Sentinel Node Society Meeting Sydney February 2008.
324. "Controversies in the Pathological Examination of Sentinel Lymph Nodes" Richard **Scoflyer** (Australia) versus Martin Cook (UK). 6th Biennial International Sentinel Node Society Meeting Sydney February 2008.
325. "Consensus conference: Sentinel lymph node biopsy: recommended histological examination". Alistair Cochran (USA), Martin Cook (UK), Richard **Scoflyer** (Australia), Alain Spatz (France), Hans Starz (Germany), Giuseppi Viale (Italy). 6th Biennial International Sentinel Node Society Meeting Sydney February 2008.
326. Co-chairman Melanoma Proffered papers session. 6th Biennial International Sentinel Node Society Meeting Sydney February 2008.
327. Co-chairman Melanoma Proffered papers session. 6th Biennial International Sentinel Node Society Meeting Sydney February 2008.
328. "Metastatic epithelioid haemangiopericytoma to the skin." Presented by Cooper C, **Scoflyer RA** at RCPA Trends in Surgical Pathology, November 2007.
329. "Histopathologic reporting of primary cutaneous melanoma: a Sydney perspective." International Melanoma Congress, 1 November 2007 in New York, NY, 1-4 November, 2007.
330. "Subungual melanoma: clues to diagnosis of early lesions and recommendations for histopathologic reporting." International Melanoma Congress, November 1, 2007 in New York, NY, November 1-4, 2007.
331. "A Career in Pathology", Presentation at Conference Week 2007 to Final Year University of Sydney Medical Students: 5 October 2007.
332. "Getting the most out of routine cancer pathology." RPAH Medical officers Association 73rd Annual Reunion Programme, 26 September 2007.
333. "Masters Class: Melanocytic Tumours." Australasian Division of the International Academy of Pathology Annual Scientific Meeting, Sydney, 4 June 2007.
334. "Digital Papillary Adenocarcinoma." Australasian Division of the International Academy of Pathology Annual Scientific Meeting, Sydney, 2 June 2007.
335. "Long-Term Protective Effect of Mature DC-LAMP+ Dendritic Cell Accumulation in Sentinel Lymph Nodes Containing Micrometastatic Melanoma." Presented by **Scoflyer RA**, Elliott B, Suci S, Lebecque S, Rimoldi D, Gugerli O, Musat E, Sharma RN, Lienard D, Keilholz U, Testori A, Eggermont A, Mackie R, Robert C, Cook M, Thompson JF, Angevin E, Spatz A; on behalf of the European Organization for Research and Treatment of Cancer Melanoma Group at the American Society of Clinical Oncology, Chicago on 2 June 2007 (presented by Alain Spatz on my behalf).
336. "Fine needle biopsy in melanoma patients: an analysis of 2204 cases with implications for patient management." Clinical Oncological Society of Australia Annual Scientific Meeting and Australian Health and Medical Research Congress, Melbourne, 1st December 2006.

337. "Meet the Professors- Pathology" Breakfast Session. 5th Biennial International Sentinel Node Society Meeting, Rome, Italy, 1-4 November 2006.
338. "Intraoperative evaluation of sentinel nodes from melanoma patients". Plenary Session. 5th Biennial International Sentinel Node Society Meeting, Rome, Italy, 1-4 November 2006.
339. Chairman, Plenary Session "Nodal Pathology and Clinical Implications". Plenary Session. 5th Biennial International Sentinel Node Society Meeting, Rome, Italy, 1-4 November 2006.
340. "Comparison of the Microstaging Approaches for melanoma- Associated Sentinel Node". 5th Biennial International Sentinel Node Society Meeting, Rome, Italy, 1-4 November 2006.
341. "Pigmented Dermatofibrosarcoma Protuberans (Bednar tumor)." Presented by Murali R, **Scolyer RA** at Harvard Medical School & Massachusetts General Hospital Dermatopathology Update With Mini-symposium On Soft Tissue Tumors - "Hands On" Slide Seminar On Pigmented Lesions. Boston, Massachusetts, USA, 19 -21 October 2006.
342. "Atypical deep penetrating nevus." Presented by **Scolyer RA**, Murali R, McCarthy SW at Harvard Medical School & Massachusetts General Hospital Dermatopathology Update With Mini-symposium On Soft Tissue Tumors - "Hands On" Slide Seminar On Pigmented Lesions. Boston, Massachusetts, USA, 19-21 October 2006.
343. "Diagnosis of metastatic melanoma by fine needle biopsy: clinicopathologic analysis of 2204 cases." Presented by Murali R, Doubrovsky A, Watson GF, McKenzie PR, Lee CS, McLeod DJ, Uren RF, Stretch JR, Saw RP, Thompson JF, **Scolyer RA** at the 32nd European Congress of Cytology. Venice, Italy, 1-4 October 2006.
344. "Diagnostic accuracy of fine needle biopsy for metastatic melanoma: analysis of 2204 cases." Presented by Murali R, Doubrovsky A, Watson GF, McKenzie PR, Lee CS, McLeod DJ, Uren RF, Stretch JR, Saw RP, Thompson JF, **Scolyer RA** at The University of Sydney Cancer Research Network, Inaugural Meeting. Sydney, Australia, 12 September 2006.
345. "Challenges in Melanocytic Pathology". Australasian Dermatopathology Society Annual Scientific Meeting, Sydney, August 12th 2006.
346. "Fine needle biopsy for metastatic melanoma: analysis of 2204 cases." Presented by Murali R, Doubrovsky A, Watson GF, McKenzie PR, Lee CS, McLeod DJ, Uren RF, Stretch JR, Saw RP, Thompson JF, **Scolyer RA** at the Royal Prince Alfred Hospital Medical Officers Association 72nd Reunion. Sydney, Australia, 30 June 2006.
347. "Melanocytic lesions of uncertain malignant potential". Melanoma Diagnosis and Treatment CME Course, Sydney, 16th June 2006.
348. "The evolution of the classification of tumours with a haemangiopericytomatous growth pattern." Australasian Division of the International Academy of Pathology Annual Scientific Meeting, Sydney, 2 June 2006.
349. "Sarcomas showing fibroblastic differentiation: a concept in evolution. Australasia Sarcoma Group Annual Scientific Meeting, Sydney 1-2 October 2005.
350. "Biopsying low grade fatty tumours" Australasia Sarcoma Group Annual Scientific Meeting, Sydney (joint presentation with Dr Paul Stalley) 1-2 October 2005.
351. "Cooperation between pathologists and clinicians: a key element in the multidisciplinary care of melanoma patients." Memorial Sloan Kettering Cancer Center, New York, USA, 23 September 2005.
352. "Recurring Problems in the Diagnosis of Melanocytic Tumours." Pathology Grand Rounds. Memorial Sloan Kettering Cancer Center, New York, USA, 22 September 2005.
353. "Clues to the Diagnosis of Melanocytic Tumours" Slide Seminar. Memorial Sloan Kettering Cancer Center, New York, USA, 22 September 2005.
354. "Nipple Adenoma". Slide Seminar on Skin Adnexal Tumours. Harvard Medical School Dermatopathology CME Course, Boston, USA. 17 September 2005.
355. "Digital Papillary Adenocarcinoma". Slide Seminar on Skin Adnexal Tumours. Harvard Medical School Dermatopathology CME Course, Boston, USA. 17 September 2005.
356. "Melanocytic Pathology: Diagnostic Problems and Important Issues", Harvard Medical School Dermatopathology CME Course, Boston, USA. 16 September 2005.
357. "Blue Naevus and its Variants (including so-called "Malignant Blue Naevus)." Harvard Medical School Dermatopathology CME Course, Boston, USA. 16 September 2005.
358. "Spitzoid Melanocytic Tumours" Interactive slide seminar. Harvard Medical School Dermatopathology CME Course, Boston, USA. 16 September 2005.
359. "Difficult Problems in Melanocytic Lesions" Slide Seminar. Mayo Clinic, Rochester, Minnesota, USA, (in conjunction with Dr Stan McCarthy) 13 September 2005.
360. "Desmoplastic Melanoma" Interactive slide seminar. Harvard Medical School Dermatopathology CME Course, Boston, USA. 15 September 2005.
361. "Pitfalls and Important Issues in the Diagnosis of Melanocytic Tumours", Mayo Clinic, Rochester, Minnesota, USA, 12 September 2005
362. "Pathological features of Naevi Occurring in Unusual Sites." 6th World Melanoma Conference, Vancouver, Canada, September 2005.
363. "Sentinel Node Biopsy: How Much Sampling is Enough?" 6th World Melanoma Conference, Vancouver, Canada. September 2005.
364. "Problems in the Diagnosis of Melanocytic Tumours- Issues for Histotechnology." Australasian Institute of Medical Scientists 2005 National Scientific Meeting,. Sydney, 6^h July 2005.
365. "Fibrosarcomas: Past and Present Concepts", Australasian Division of the International Academy of Pathology Annual Scientific Meeting, Sydney, 3 June 2005.
366. "Desmoplastic melanoma and sentinel node biopsy." Presented at the Royal Australasian College of Surgeons Annual Scientific Meeting, Perth, Australia, by **Scolyer, R**, Thompson JF, Quinn MJ. May, 2005
367. Difficult Melanocytic Skin Tumours. Plenary Panel Session (with Dr Stan McCarthy and Dr Geoff Strutton). Royal College of Pathologists of Australasia Annual Scientific Meeting, Sydney. March 2005.
368. Moderator and Chairman in "Pathology Symposium: How Much Sampling of the Sentinel Node is Enough?", Sentinel Node 2004, 4th International Sentinel Node Congress, Los Angeles, USA, December 2004.
369. "Meet the Professor Breakfasts: Pathology- **Richard Scolyer**", Sentinel Node 2004, 4th International Sentinel Node Congress, Los Angeles, USA, December 2004.
370. "Sentinel node biopsy assists in determining malignancy in patients with histologically ambiguous atypical Spitzoid tumours." Sentinel Node 2004, 4th International Sentinel Node Congress, Los Angeles, USA, December 2004.
371. "Deep-penetrating Naevus", Difficult Problems in Melanocytic Pathology Slide Seminar, 25th International Congress of International Academy of Pathology, Brisbane, October 2004.

372. Chairman, Difficult Problems in Melanocytic Pathology Seminar, 25th International World Congress of the International Academy of Pathology, Brisbane, October 2004.
373. "Blue naevus and blue naevus variants", Frontiers in Melanocytic Pathology, Long Course, 25th International Congress of International Academy of Pathology, Brisbane, October 2004.
374. Chairman, Evolving Concepts in Soft Tissue Pathology Symposium, 25th International World Congress of the International Academy of Pathology, Brisbane, October 2004.
375. "Fibrosarcomas: Past and Present Concepts", Evolving Concepts in Soft Tissue Pathology Symposium, 25th International Congress of International Academy of Pathology, Brisbane, October 2004.
376. Chairman, "A Mistake I Made and What I Learned From It" Soft Tissue Pathology Seminar, 25th International World Congress of the International Academy of Pathology, Brisbane, October 2004.
377. "Lipofibromatosis", "A Mistake I Made and What I Learned From It" Soft Tissue Pathology Slide Seminar, 25th International Congress of International Academy of Pathology, Brisbane, October 2004.
378. "Pathology of Melanocytic Skin Tumours", Skin Cancer Doctors Symposium 2004, Sydney, September 2004.
379. "Melanoma Pathology- What the Radiation Oncologist Needs to Know", Royal Australasian College of Radiation Oncologists NSW Training Programme, July 2004.
380. "Soft Tissue Pathology- What the Radiation Oncologist Needs to Know", Royal Australasian College of Radiation Oncologists NSW Training Programme, July 2004.
381. "Myopericytoma" RCPA Trends in Surgical Pathology 2003 Slide Seminar, November 2003.
382. "Histopathology of Melanoma- What Your Pathologist Should be Telling You in 2003". World Congress of International Society of Plastic, Reconstructive and Aesthetic Surgeons, Sydney, NSW, 11 August 2003.
383. "Cellular Neurothekeoma" Australasian Division of the International Academy of Pathology Annual Scientific Meeting, Sydney, 30 May 2003.
384. "Chordoma Periphericum" Australasian Division of the International Academy of Pathology Annual Scientific Meeting, Sydney, 30 May 2003.
385. "Polymorphous Low-grade Adenocarcinoma of the Lung" Australasian Division of the International Academy of Pathology Annual Scientific Meeting, Sydney, 30 May 2003.
386. Chairman of Gynaecological Pathology Test and Teach Session, Australasian Division of the International Academy of Pathology Annual Scientific Meeting, Sydney, 30 May 2003.
387. RCPA Postgraduate Diagnostic Surgical Pathology Course – Melanocytic Pathology, Sydney (with Dr Stan McCarthy & Dr Allan Palmer). May 2003.
388. "Is Mitotic Rate a Predictor of Prognosis in Melanoma Patients?" Sydney Cancer Institute Seminar, May 2003.
389. RCPA Postgraduate Diagnostic Surgical Pathology Course – Soft Tissue and Orthopaedic Pathology, Sydney (with Dr Andrew Kedziora). April 2003.
390. "Difficulties and Controversies in Melanocytic Pathology" Royal College of Pathologists of Australasia, Pathology Update, Sydney, March 2003.
391. "Mitotic rate is a powerful predictor of prognosis in primary cutaneous melanoma." Clinical Oncological Society of Australia Annual Scientific Meeting, Sydney, November 2002.
392. "Excision margin affects local recurrence rates for melanomas- analysis of 2681 patients with melanomas <2.0mm thick." Clinical Oncological Society of Australia Annual Scientific Meeting, Sydney, November 2002.
393. "Can pathological features of positive sentinel lymph nodes predict further nodal involvement in regional node fields of melanoma patients?" Sentinel Node 2002, Yokohama, Japan November 2002.
394. "Pathological review of negative sentinel lymph nodes in melanoma patients with regional recurrence: a clinicopathological study of 1152 patients undergoing sentinel lymph node biopsy. Sentinel Node 2002, Yokohama, Japan November 2002 .
395. "Lipofibromatosis" RCPA Trends in Surgical Pathology 2002 Slide Seminar.
396. "Should Pathologists Count Mitoses in Melanomas?" Australasian Society of Dermatopathology Annual Scientific Meeting, Sydney, September 2002.
397. "Heavily Pigmented Melanocytic Lesions. Are They All Malignant?" Australasian Society of Dermatopathology Annual Scientific Meeting, Sydney, September 2002.
398. "Pathology of Skin Tumours." The Royal Australasian College of Surgeons NSW Training Programme, Sydney, June 2002.
399. "Pulmonary Follicular Dendritic Cell Sarcoma" Australasian Division of the International Academy of Pathology Annual Scientific Meeting, Sydney, May 2002.
400. "Spitz Naevus versus Spitzoid Melanoma: When and How Can They Be Distinguished?" Australasian Division of the International Academy of Pathology Annual Scientific Meeting, Sydney, May 2002.
401. Royal College of Pathologists of Australasia Pathology Week lecture "Pathology of Tomorrow". University of New South Wales, March 2002.
402. RCPA Postgraduate Diagnostic Surgical Pathology Course – Soft Tissue Pathology, Sydney, February 2002 (with Dr Andrew Kedziora).
403. "Inflammatory Myxohyaline Tumour." RCPA Trends in Surgical Pathology 2001 Slide Seminar.
404. "Clinical and Pathological Features and Diagnosis of Creutzfeldt-Jacob Disease, Variant CJD and Bovine Spongiform Encephalopathy or Other Prion Diseases." Joint Scientific Conference of Australasian Institute of Medical Scientists, Australasian Association of Clinical Chemistry, Australian Society of Microbiology and Histotechnology Group, Jamberoo, NSW, July 2001.
405. "Primary Pleural Synovial Sarcoma" Australasian Division of the International Academy of Pathology Annual Scientific Meeting, Sydney, June 2001.
406. "Subungual Malignant Melanoma." (with Dr Stan McCarthy) Australasian Division of the International Academy of Pathology Annual Scientific Meeting, Sydney, June 2001.
407. "Extranodal Rosai-Dorfman Disease" Australasian Division of the International Academy of Pathology Annual Scientific Meeting, Sydney, June 2001.
408. RCPA Postgraduate Diagnostic Surgical Pathology Course – Soft Tissue Pathology, Sydney, May 2001 (with Dr Andrew Kedziora).
409. RCPA Postgraduate Diagnostic Surgical Pathology Course – Orthopaedic Pathology, Sydney (with Drs Stan McCarthy & Fiona Bonar) May 2001.
410. "Subungual Melanoma." 5th World Melanoma Conference, Venice Italy, March 2001. (with Dr Stan McCarthy).

411. "Parachordoma." RCPA Trends in Surgical Pathology 2000 Slide Seminar.
412. "Can phyllodes tumours of the breast be distinguished from fibroadenomas by fine needle aspiration cytology?" RCPA Annual Scientific Meeting, Canberra ACT, November 2000.
413. Is it possible to diagnose unusual breast tumours by fine needle aspiration cytology? A study of 8 phyllodes tumours. University of Sydney College of Health Sciences and The Medical Foundation Research Conference: From Cell to Society 2. Leura NSW, November 2000.
414. "Complications of an elective berry aneurysm repair- vasospasm or venous infarction?", North-West Neurological Society Meeting, Hunter Valley NSW, October 2000.
415. "Recent Advances in Cervical Cytology Screening", University of Tasmania Medical Class of 1990's 10 Year Reunion Conference, Hobart Tas, October 2000.
416. "Hyalinizing Spindle Cell Tumour with Giant Rosettes." RCPA Trends in Surgical Pathology, 1999 Slide Seminar.
417. "Churg-Strauss Syndrome – a clinicopathological case conference." Grand Rounds at The Canberra Hospital (whilst working at RPAH). November 1998.
418. "Genes, Errors and Disease" to ACT Society of Pharmacists at The Canberra Hospital, September 1997.

CONFERENCE PARTICIPATIONS

1. The International Academy of Pathology (IAP) World Congress 9-14 October 2022, Sydney, Australia in the capacity of Co-Program Chair IAP 2022 of the Organising Committee.
2. International Melanoma Congress "The pathology of melanoma: an international course" at Institut Curie, Paris, France, in the capacity of Director, held on 21-22 April 2022.
3. PathPresenter's "Learning from the Experience of Experts" on-line Teaching Conference in Pathology 2022 in the capacity as Faculty Member, held virtually on 9-10 April 2022.
4. Australian Melanoma Conference (AMC) 2021 – Co-Conference Chair, Co-Chair of Scientific Organising Committee and Co-Chair of Organising Committee – event held 19-20 November 2021 (virtual)
5. Australasian Division of the International Academy of Pathology Annual Scientific Meeting, 2021.
6. 10th World Congress of Melanoma, 14-17 April 2021, Rome Italy (Congress Faculty member).
7. Australasian Division of the International Academy of Pathology Annual Scientific Meeting, 2020 (postponed due to COVID).
8. International Melanoma Congress, Institut Curie, Paris April 2020.
9. Pigmented Lesions & Other Hot Topics in Dermatopathology Course, 14-15 February 2020, Sydney Australia.
10. Australasian Division of the International Academy of Pathology Annual Scientific Meeting, 2019.
11. Australasian Division of the International Academy of Pathology Annual Scientific Meeting, 2018.
12. Australasian Division of the International Academy of Pathology Annual Scientific Meeting, 2017.
13. 9th World Congress of Melanoma and 14th International Congress of the Society for Melanoma Research, 18-21 October 2017, Brisbane Australia.
14. International Melanoma Congress, Institut Curie, Paris April 2017.
15. 9th International Melanoma Pathology Symposium, 5 November 2016, Boston USA.
16. The Australasian Melanoma & AMGP Conference, 28-29 October 2016, Sydney Australia.
17. Australasian Division of the International Academy of Pathology Annual Scientific Meeting, 2016, Brisbane Australia.
18. Melanoma Symposium, Memorial Sloan Kettering Cancer Center, New York, May 2016.
19. Asia Pacific Meeting of the International Academy of Pathology, 4-7 June 2015, Brisbane Australia.
20. Australasian Division of the International Academy of Pathology Annual Scientific Meeting, 2014, Brisbane Australia.
21. Australasian Division of the International Academy of Pathology Annual Scientific Meeting, 2013, Sydney Australia.
22. 8th World Congress of Melanoma 17-20 July 2013, Hamburg, Germany, member of Organizing Committee.
23. Australasian Division of the International Academy of Pathology Annual Scientific Meeting, 2012, Sydney Australia.
24. 7th International Melanoma Research Congress and 4th Melanoma and Skin Cancer Centres Meeting, 4-7 November 2010, Sydney Australia.
25. Annual RPAH Diagnostic Surgical Pathology Course 2010-2015.
26. Member of Organising Committee, Sentinel Node 2008, 6th International Sentinel Node Congress, Sydney, February 2008.
27. Invited Guest Faculty Member, Harvard Medical School Dermatopathology Update 2005 Boston USA.
28. Member of Organising Committee, Sentinel Node 2004, 4th International Sentinel Node Congress, Los Angeles, USA, December 2004.
29. "A Mistake I Made and What I Learned From It", Soft Tissue Pathology Slide Seminar (with Andrew Folpe), 25th International Congress of International Academy of Pathology, Brisbane, October 2004.
30. "Evolving Concepts in Soft Tissue Pathology", Soft Tissue Pathology Symposium (with Dr Andrew Folpe), 25th International Congress of International Academy of Pathology, Brisbane, October 2004.
31. Free Papers Session in Melanocytic Pathology, (with Dr Stan McCarthy), 25th International Congress of International Academy of Pathology, Brisbane, October 2004.
32. Free Papers Session in Soft Tissue Pathology, (with Andrew Folpe), 25th International Congress of International Academy of Pathology, Brisbane, October 2004.
33. "Frontiers in Melanocytic Pathology", Long Course (with Dr Stan McCarthy & Dr David Elder), 25th International Congress of International Academy of Pathology, Brisbane, October 2004.
34. "Difficult Problems in Melanocytic Pathology" Slide Seminar (with Dr Stan McCarthy & Dr David Elder), 25th International Congress of International Academy of Pathology, Brisbane, October 2004.
35. I am a co-author of the interactive on-line "Pigmented Skin Lesion Course" written for University of Sydney Medical students (with Dr Scott Menzies, Dr Jonathan Stretch, Prof William McCarthy, Prof John Thompson) (www.skincancer.med.usyd.edu.au). It was initially trialled as a compulsory course in community medicine rotation for University of Sydney year 4 medical students in 2003. Subsequently it was taken up formally by the University of Sydney and University of Connecticut in 2004. The Australian National University medical program plans to use the course and it is also currently being trialled for general practice training in Ireland.
36. Member of Organising Committee of Australasian Society of Dermatopathology Annual Scientific Meeting Sydney 2002.
37. RCPA Recent Advances in Pathology lecture series 2001-2016 (co-convenor).

CONFERENCE ABSTRACTS

1. Rebecca C. Simpson, Erin R. Shanahan, Marcel Batten, Ines P. Silva, Irene L. M. Reijers, Judith M. Versluis, Alexander M. Menzies, Robyn P. M. Saw, Maria Gonzalez, Kerwin F. Shannon, Andrew J. Spillane, Christian U. Blank, **Richard A. Scolyer**, Georgina V. Long. Longitudinal analysis of circulating immune cell subsets in melanoma patients treated with immune checkpoint inhibitor immunotherapy. Submitted to ASI 2022 – 50th Annual Scientific Meeting of The Australian and New Zealand Society for Immunology, Melbourne, Australia, 29 November – 2 December 2022.
2. Kazi J Nahar, Felix Marsh-Wakefield, Annie Tasker, **Richard A. Scolyer**, Georgina V. Long, Alexander M. Menzies, Umamainthan Palendira. Lessons from immunotherapy-induced immune related adverse events. Submitted to ASI 2022 – 50th Annual Scientific Meeting of The Australian and New Zealand Society for Immunology, Melbourne, Australia, 29 November – 2 December 2022.
3. Camelia Quek, Xinyu Bai, Ines Silva, Alex Menzies, Georgina V. Long, **Richard A. Scolyer** and James S. Wilmott. Single-cell spatial architecture of tumour microenvironment in patients with in-transit melanoma (ITM). To be submitted to ESMO Asia Congress 2022 – Singapore – 2-4 December 2022.
4. Felicity Newell*, Peter A. Johansson*, James S. Wilmott, Katia Nones, Vanessa Lakis, Antonia L. Pritchard, Serigne N. Lo, Robert V. Rawson, Stephen H. Kazakoff, Andrew J. Colebatch, Lambros T. Koufariotis, Peter M. Ferguson, Scott Wood, Conrad Leonard, Matthew H. Law, Kelly Brooks, Natasa Broit, Jane M. Palmer, Kasey L. Coutts, Ismael A. Vergara, Georgina V. Long, Andrew P. Barbour, Omgo E. Nieweg, Brindha Shivalingam, William A. Robinson, Jonathan R. Stretch, Andrew J. Spillane, Robyn P. M. Saw, Kerwin F. Shannon, John F. Thompson, Graham J. Mann, John V. Pearson, **Richard A. Scolyer**#, Nicola Waddell#, Nicholas K. Hayward# (*These authors contributed equally. # These authors jointly supervised this work). Genomics of melanoma subtypes: whole-genome sequencing of 570 tumours. Abstract to be submitted to 20th Australasian Genomic Technologies Association (AGTA) conference, Sunshine Coast, 30 October – 2 November 2022.
5. {Authors TBC} Marianne Berwick, Richard A. Scolyer. Mutational profiles are differently prognostic in scalp/neck and face melanomas. Submitted to 2022 Society for Melanoma Research (SMR) Congress, Edinburgh, Scotland on 17-20 October 2022.
6. Jordan W. Conway , Serigne N.Lo, Ismael A. Vergara, Tuba N. Gide, Jorja Braden, Matteo S. Carlino, Robyn P.M. Saw, John F. Thompson, Andrew J. Spillane, Kerwin F. Shannon, Brindha Shivalingam, Alexander M. Menzies, James S. Wilmott, Georgina V. Long, **Richard A. Scolyer**, Inês Pires da Silva. The hypoxic microenvironment at different sites of melanoma metastasis. Submitted to 2022 Society for Melanoma Research (SMR) Congress, Edinburgh, Scotland on 17-20 October 2022.
7. Su Yin Lim, Yinxing Lin, Bernadette Pedersen, Ashleigh Stewart, Jean YH Yang, Jenny Lee, **Richard A Scolyer**, Georgina V Long, Helen Rizos. Single cell profiling of tumor biopsies reveals molecular heterogeneity of response. Submitted to 2022 Society for Melanoma Research (SMR) Congress, Edinburgh, Scotland on 17-20 October 2022.
8. Xinyu Bai, Camelia Quek, Ines Silva, Alex Menzies, Georgina V. Long, **Richard A. Scolyer** and James S. Wilmott. Spatial analysis characterises cellular immunotypes of in-transit melanoma associated with response to checkpoint inhibitor immunotherapy. Submitted to 2022 Society for Melanoma Research (SMR) Congress, Edinburgh, Scotland on 17-20 October 2022.
9. T. N. Gide, E. Paver, Z. Yaseen, A. M. Menzies, J.S. Wilmott*, **R.A. Scolyer***, and G.V. Long* (*contributed equally to this work). LAG-3 Expression and Outcome of Metastatic Melanoma Patients Treated with Combination Anti-LAG-3 + Anti-PD-1 Immunotherapies. Submitted to 2022 Society for Melanoma Research (SMR) Congress, Edinburgh, Scotland on 17-20 October 2022.
10. Ines Pires da Silva, Ismael Vergara, Isabel Li, Serigne Lo, Matt Carlino, Alex Menzies, **Richard A. Scolyer**, Georgina V. Long. Time-dependent prediction of development of melanoma brain metastases (MBM) from the start of BRAF/MEK inhibitors (BRAF/MEKi) or anti-Pd-1(PD1-based immunotherapy (IO). Submitted to 2022 Society for Melanoma Research (SMR) Congress, Edinburgh, Scotland on 17-20 October 2022.
11. C. Quek*, A. Pratapa*, I. Silva*, G. Al-Eryani*, A. Mayer*, N. Bartonicek, K. Harvey, C. Buckley, O. Braubach, R. Saw, J. Stretch, K. Shannon, A. Menzies, **R. Scolyer***, G. Long*, A. Swarbrick*, J. Wilmott* (*contributed equally). Spatially Resolved Single-Cell Features Reveal Distinct Cellular Maps In The Tumour Microenvironment Of Melanoma Patients With Primary And Acquired Resistance To Immunotherapies. Abstract submitted (and accepted for oral presentation) to International Academy of Pathology (IAP) 2022 - Sydney - Bridge to a Cure in Sydney/Virtual on 11-15 October 2022.
12. James S. Wilmott+, Alexander M. Menzies+, Ismael A. Vergara*, Serigne N. Lo, Naoyuki Maeda, Kumiko Koyama, Ines Pires da Silva, Georgina V. Long, **Richard A. Scolyer**, Eva R. Shteinman* (*/+These authors contributed equally to this work). Molecular and clinical correlates of HER3 expression in melanoma. Abstract submitted to International Academy of Pathology (IAP) 2022 - Sydney - Bridge to a Cure in Sydney/Virtual on 11-15 October 2022.
13. J. Braden, A. Potter, E. Paver, R. Rawson, A. Menzies, M. Carlino, G. Au-Yeung, R. Saw, A. Spillane, J. Stretch, K. Shannon, T. Pennington, S. Ch'ng, D. Gyorki, J. Howle, D. Daneshvar, J. Wilmott, S. Lo, I. Silva, **R. Scolyer**, & G. Long. Neotrio Trial - Optimal Neoadjuvant Sequencing Of Anti-PD1 and BRAF Targeting Therapy In Resectable BRAF Mutant Stage IIIB/C/D Melanoma: Results Of Histopathological Analysis. Abstract submitted to International Academy of Pathology (IAP) 2022 - Sydney - Bridge to a Cure in Sydney/Virtual on 11-15 October 2022.
14. T. N. Gide, E. Paver, Z. Yaseen, A. M. Menzies, M. S. Carlino1, R. P.M. Saw, J.F. Thompson, J.S. Wilmott*, **R.A. Scolyer***, and G.V. Long* (*contributed equally to this work). Analysis Of Lag3 Expression In Metastatic Melanoma Patients Treated With Combination Anti-Lag3 + Anti-Pd-1-Based Immunotherapies. Abstract to be submitted to International Academy of Pathology (IAP) 2022 - Sydney - Bridge to a Cure in Sydney/Virtual on 11-15 October 2022.
15. I.A. Vergara*, K. Aivazian*, M.S. Carlino, A.D. Guminski, K.F. Shannon, S. Ch'ng, R.P.M. Saw, G.V. Long, J.S. Wilmott and **R.A. Scolyer** (* These authors contributed equally to this work). Genomic Profiling Of Metastatic Basal Cell Carcinoma Reveals Candidate Drivers Of Disease And Therapeutic Targets. Abstract to be submitted to International Academy of Pathology (IAP) 2022 - Sydney - Bridge to a Cure in Sydney/Virtual on 11-15 October 2022.
16. J.S. Wilmott, A. Vergara, T.N. Gide, P. Shan, J.F. Thompson, I.P. Da Silva, M.S. Carlino, A.M. Menzies, A.J. Potter, G.V. Long, **R.A. Scolyer**. Accuracy of large tumour mutation burden panels in FFPE melanoma samples and associations with responses to Immunotherapies. Abstract to be submitted to International Academy of Pathology (IAP) 2022 - Sydney - Bridge to a Cure in Sydney/Virtual on 11-15 October 2022.

17. Ismael A. Vergara, Serigne N. Lo, Alexander M. Menzies, Matteo S. Carlino, **Richard A. Scolyer**, Georgina V. Long and Inês Pires da Silva. Differential Impact Of Braf/mek And Ici Therapies On The Pattern Of Progression Of Stage Iv Melanoma Patients. Abstract submitted to (and accepted for oral presentation at) NSW Cancer Conference, Sydney on 15th September 2022.
18. Georgina V. Long, Andrew Spillane, Thomas Pennington, Kerwin Shannon, Jonathan Stretch, Maria Gonzalez, Robyn P.M. Saw, Serigne Lo, **Richard A. Scolyer**, Alexander M. Menzies. NeoPeLe: A Phase 2 Trial of Neoadjuvant (NAT) Pembrolizumab (Pembro) Combined with Lenvatinib (Lenva) In Resectable Stage III Melanoma. Abstract submitted to and accepted as poster presentation at ESMO Congress 2022 in Paris, France on 9-13 September 2022.
19. Alexander HR Varey, Mary-Ann El-Sharouni, Julie Simon, Jeffrey E Gershenwald, Georgina V Long, Richard A Scolyer, John F Thompson, Serigne N Lo. Predicting recurrence free survival for stage II melanoma patients – a validated tool to guide adjuvant systemic therapy. Abstract submitted to and accepted as poster presentation at ESMO Congress 2022 in Paris, France on 9-13 September 2022.
20. Amelia M Taylor, Claire Galea, Kerwin Shannon, Sydney Ch'ng, Robyn Saw, Thomas Pennington, Jonathan Stretch, Andrew Spillane, Alexander C J van Akkooi, Alexander HR Varey, Ines P da Silva, Matteo S Carlino, **Richard A Scolyer**, Georgina V Long, Serigne Lo, Alexander M Menzies. A dynamic recurrence risk prediction tool for adjuvant therapy in stage III melanoma. Abstract submitted to ESMO Congress 2022 in Paris, France on 9-13 September 2022.
21. Judith M. Versluis, Robert Elens, Irene L.M. Reijers, Alexander M. Menzies, Astrid A.M. van der Veldt, Ellen Kapiteijn, Elisa A. Rozeman, Martin C. Klop, Winan J. van Houdt, Robyn P.M. Saw, Charlotte L. Zuur, Thomas E. Pennington, Bart A. van de Wiel, **Richard A. Scolyer**, Annegien Broeks, Alexander van Akkooi, Georgina V. Long, Christian U. Blank. Clinical and tumor characteristics of patients (pts) with recurrence after pathologic response upon neoadjuvant ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma. 28.4.22: Abstract submitted to and accepted for mini oral presentation at ESMO Congress 2022 in Paris, France on 9-13 September 2022.
22. ILM Reijers, P Dimitriadis, RPM Saw, JM Versluis, TE Pennington, E Kapiteijn, AAM van der Veldt, KPM Suijkerbuijk, GAP Hospers, W van Houdt, WMC Klop, K Sikorska, A Broeks, A Spillane, BA van de Wiel, **RA Scolyer**, AM Menzies, ACJ van Akkooi and GV Long and CU Blank. Survival data of the PRADO trial stratified according to the interferon-gamma (IFN-γ) signature and tumor mutational burden (TMB). Abstract submitted to ESMO Congress 2022 in Paris, France on 9-13 September 2022.
23. ILM Reijers, AM Menzies, JM Versluis, P Dimitriadis, MW Wouters, RPM Saw, WMC Klop, TE Pennington, WJ van Houdt, LJW Bosch, S Cornelissen, M Lopez-Yurda, LG Grijpink-Ongering, RV Rawson, AJ Spillane, **RA Scolyer**, BA van de Wiel, ACJ van Akkooi, GV Long and CU Blank. Relapse-free survival (RFS) update and first translational analyses of DONIMI, a study testing personalized neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in stage III melanoma patients (pts) based on the interferon-gamma signature (IFN-γ sign) algorithm. Abstract submitted to ESMO Congress 2022 in Paris, France on 9-13 September 2022.
24. M.W. Lucas, J. Lijnsvelt, S. Pulleman, **R.A. Scolyer**, A.M. Menzies, A.C.J. van Akkooi, W.J. van Houdt, K. Shannon, T.E. Pennington, E.W. Kapiteijn, K.P.M. Suijkerbuijk, S. Sandhu, G.A.P. Hospers, A.A.M. van der Veldt, M. Stevense, M.S. Carlino, J.W.B. de Groot, P. Rutkowski, G.V. Long and C.U. Blank. The NADINA trial: A multicenter, randomised phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma. Abstract submitted to ESMO Congress 2022 in Paris, France on 9-13 September 2022.
25. Jorja Braden, Alison J. Potter, Elizabeth Paver, Robert Rawson, Alexander M. Menzies, Matteo S. Carlino, George Au-Yeung, Robyn P.M. Saw, Andrew J. Spillane, Kerwin F. Shannon, Thomas E. Pennington, Sydney Ch'ng, David E. Gyorki, Julie Howle, Dariush Daneshvar, James S. Wilmott, Serigne Lo, Ines P. Silva, **Richard A. Scolyer** & Georgina V. Long. Neotrio - Optimal Neoadjuvant (NAT) Sequencing of Anti-PD1 and BRAF Targeting Therapy (TT) In BRAF Mutant Stage III Melanoma: Results Of Histopathological Analysis. 29.4.22: Abstract to be submitted to ESMO Congress 2022 in Paris, France on 9-13 September 2022.
26. Rebecca C. Simpson, Marcel Batten, Erin R. Shanahan, Ines P. Silva, Irene L. M. Reijers, Judith M. Versluis, Alexander M. Menzies, Robyn P. M. Saw, Maria Gonzalez, Kerwin F. Shannon, Andrew J. Spillane, Christian U. Blank, **Richard A. Scolyer**, Georgina V. Long. Longitudinal analysis of circulating immune cell subsets in melanoma patients (pts) treated with neo-adjuvant ipilimumab (ipi) & nivolumab (nivo). Abstract submitted to ESMO Congress 2022 in Paris, France on 9-13 September 2022.
27. Nicholas Allen, Elizabeth Paver, **Richard A. Scolyer**, Fergal J. Moloney. A sheep in wolf's clothing: Agminated blue naevi masquerading as in-transit melanoma metastases. Abstract to be submitted to Australasian Dermatopathology Society (ADS) 42nd Annual Meeting 2022 (virtual) on 9-11 September 2022.
28. (authors tbc) Nigel Maher and **Richard A. Scolyer**. A BAP-1 inactivated melanocytic tumour with adverse behaviour. Abstract to be submitted to Australasian Dermatopathology Society (ADS) 42nd Annual Meeting 2022 (virtual) on 9-11 September 2022.
29. Moncrieff MD, Lo SN, **Scolyer RA**, Heaton MJ, Nobes JP, Snelling AP, Carr MJ, Nessim C, Wade R, Peach AH, Kisyoova R, Mason J, Wilson ED, Nolan G, Jones RP, Sondak VK, Thompson JF, Zager JS. ASO Visual Abstract: Evaluation of Indications for Sentinel Node Biopsy in Early-Stage Melanoma with the Advent of Adjuvant Systemic Therapy: An International Multicenter Study. Abstract submitted to 2022 ASCO Annual Meeting in Chicago/Virtual on 3-7 June 2022. Ann Surg Oncol. 2022 May 25. doi: 10.1245/s10434-022-11822-8. Online ahead of print. PMID: 35612683
30. Alexander HR Varey, Georgina V Long, **Richard A Scolyer**, John F Thompson, Serigne N Lo. A Tool to Predict Survival Outcomes for Patients with Stage II Melanoma. Abstract submitted to 2022 ASCO Annual Meeting in Chicago/Virtual on 3-7 June 2022.
31. Alexander HR Varey, Mary-Ann El-Sharouni, Julie Simon, Jeffrey E Gershenwald, Georgina V. Long, **Richard A Scolyer**, John F Thompson, Serigne N. Lo. Predicting recurrence free survival for stage II melanoma patients – a validated tool to guide adjuvant systemic therapy. Abstract submitted to 2022 ASCO Annual Meeting in Chicago/Virtual on 3-7 June 2022.
32. Georgina V. Long, Matteo S. Carlino, George Au-Yeung, Andrew Spillane, Kerwin Shannon, David E. Gyorki, Julie Howle, Sydney Ch'ng, Maria Gonzalez, Robyn P.M. Saw, Thomas Pennington, Serigne Lo, **Richard A. Scolyer**, Alexander M. Menzies. NeoTrio: Randomized Trial of Neoadjuvant (NAT) Pembrolizumab (Pembro) ALONE, in Sequence (SEQ) Or Concurrent (CON) With Dabrafenib + Trametinib (D+T) In Resectable BRAF-Mutant Stage III Melanoma To Determine Optimal Combination of Therapy. Abstract submitted (as at 2.4.22 – accepted for oral presentation) - 2022 ASCO Annual Meeting in Chicago/Virtual on 3-7 June 2022.
33. Alexander M Menzies, Robyn P M Saw, Serigne Lo, Maria Gonzalez, Sydney Ch'ng, Omgo E Nieweg, Kerwin F Shannon, Peter M Ferguson, Jenny Lee, Helen Rizos, Robert V Rawson, Jonathan R Stretch, John F Thompson, Louise Emmett, Rony Kapoor, Andrew J Spillane, **Richard A Scolyer**, Georgina V Long. Neoadjuvant dabrafenib and trametinib (D+T) for stage III melanoma: Long-term results from the NeoCombi trial. 15.2.22: abstract submitted to (2.4.22 accepted for poster presentation at) the 2022 ASCO Annual Meeting in Chicago/Virtual on 3-7 June 2022.

34. J.M. Versluis, K. Sikorska, E.A. Rozeman, A.M. Menzies, H. Eriksson, W.M.C. Klop, R.P.M. Saw, B.A. van de Wiel, **R.A. Scolyer**, J.V. van Thienen, H. Mallo, M. Gonzalez, A. Torres Acosta, L.G. Grijpink-Ongering, A. van der Wal, J.B.A.G. Haanen, A.C.J. van Akkooi, G.V. Long, C.U. Blank. Survival update of neoadjuvant ipilimumab + nivolumab in macroscopic stage III melanoma – the OpACIN and OpACIN-neo trials. Abstract submitted/accepted (and selected for a poster presentation) to the 2022 ASCO Annual Meeting in Chicago/Virtual on 3-7 June 2022.
35. Ines Pires da Silva, Serigne Lo, Jordan Conway, **Richard A. Scolyer**, Matteo Carlino, Alexander Menzies, Georgina Long. VEGF inhibitors (VEGFi) activity in liver metastases (mets) regardless of primary cancer type: meta-analysis and systematic review. 14.2.22: Abstract submitted to (4.422: selected for poster presentation at) the 2022 ASCO Annual Meeting in Chicago/Virtual on 3-7 June 2022.
36. ILM Reijers, P Dimitriadis, EA Rozeman, O Krijgsman, S Cornelissen, LJW Bosch, A Broeks, AM Menzies, BA van de Wiel, **RA Scolyer**, GV Long and CU Blank. The interferon-gamma (IFN- γ) signature from baseline tumor material predicts pathologic response after neoadjuvant ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma. 15.2.22: Abstract submitted to (5.422: abstract accepted for poster presentation at) the 2022 ASCO Annual Meeting in Chicago/Virtual on 3-7 June 2022.
37. {Authors tbc} James S. Wilmott, Ismael A. Vergara, Hansol Lee, Peter A. Johansson, Peter M Ferguson, Shivalingam, Brindha, **Richard A. Scolyer**, Georgina V. Long. Post hoc analysis of COMBI-MB trial of dabrafenib and trametinib in patients with BRAF-mutant melanoma brain metastases. Abstract to be submitted to the 2022 ASCO Annual Meeting in Chicago/Virtual on 3-7 June 2022.
38. Ismael A. Vergara, Serigne N. Lo, Alexander M. Menzies, Matteo S. Carlino, **Richard A. Scolyer**, Georgina V. Long and Inês Pires da Silva. Differential impact of BRAF/MEK and immune checkpoint inhibitors on the pattern of progression of stage IV melanoma patients. 14.2.22: abstract submitted to the 2022 ASCO Annual Meeting in Chicago/Virtual on 3-7 June 2022.
39. Maria Gonzalez, Alexander M. Menzies, Matteo S. Carlino, Shahneen Sandhu, Robyn P.M. Saw, Serigne N. Lo, James Wilmott, Sydney Ch'ng, Kerwin F. Shannon, Thomas Pennington, Gregory Gard, Selvan Pather, Alison Brand, Muzib A. Razak, Monica Osorio, Russell Hogg, **Richard A. Scolyer**, Georgina V. Long. A multicentre, open label, phase II study to determine the response to neoadjuvant pembrolizumab and lenvatinib (NeoMucMel). Abstract to be submitted to the 2022 ASCO Annual Meeting in Chicago/Virtual on 3-7 June 2022.
40. Serigne N. Lo, Tuba N. Gide, Maria Gonzalez, Ines P. da Silva, Alexander Menzies, Matteo S. Carlino, **Richard A. Scolyer**, Stephane Heritier, James S. Wilmott, Georgina V. Long. A biomarker guided Bayesian response-adaptive phase II trial for metastatic melanoma: The Personalized Immunotherapy Platform (PIP)-Trial design. 15.2.22: abstract submitted to (and selected for poster presentation at) the 2022 ASCO Annual Meeting in Chicago/Virtual on 3-7 June 2022.
41. Amelia M Taylor, Claire Galea, Kerwin Shannon, Sydney Ch'ng, Robyn P M Saw, Thomas Pennington, Jonathan Stretch, Andrew Spillane, Alexander C J van Akkooi, Alex Varey, Ines P da Silva, Matteo S Carlino, **Richard Scolyer**, Georgina V Long, Serigne Lo, Alexander M Menzies. A dynamic recurrence risk prediction tool for adjuvant therapy in stage III melanoma. 14.2.22: Abstract submitted (but later withdrawn) to the 2022 ASCO Annual Meeting in Chicago/Virtual on 3-7 June 2022.
42. M.W. Lucas, J.M. Lijnsvelt, S.M. Pulleman, **R.A. Scolyer**, A.M. Menzies, A.C.J. van Akkooi, W.J. van Houdt, K. Shannon, T.E. Pennington, K.P.M. Suijkerbuijk, E.W. Kapiteijn, A.A.M. van der Veldt, M.S. Carlino, S. Sandhu, M. Gonzalez, C.L. Zuur, W.M.C. Klop, G.V. Long and C.U. Blank. The NADINA trial: A multicenter, randomised phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma. 15.2.22: submitted (and accepted) at 2022 ASCO Annual Meeting in Chicago/Virtual on 3-7 June 2022.
43. M. Gibson, **R.A. Scolyer**, H.P. Soyer, P. Ferguson, K. McGeechan, L. Irwig, K.J.L. Bell. Estimating the potential impact of interventions to reduce over-calling and under-calling of melanoma. Submitted to The Australasian College of Dermatologists (ASD) 54th Annual Scientific Meeting on 30 April – 3 May 2022
44. Rodrigo J. Schwartz, Genevieve Ho, **Richard A. Scolyer**, Elizabeth Paver, Bruna Gouveia, Linda Martin, Pascale Guitera. Confocal microscopy guided “punch scoring”: a useful technique to mark a focal area of change in pigmented lesion to facilitate histopathological diagnosis of early melanoma. Submitted to The Australasian College of Dermatologists (ASD) 54th Annual Scientific Meeting on 30 April – 3 May 2022.
45. Canan Güvenç, Asier Antoranz, Madhavi Dipak Andhari, Anna Szumera-Ciećkiewicz, Pawel P. Teterycz, Piotr R. Rutkowski, Robert V. Rawson, **Richard A. Scolyer**, John F. Thompson, Julia Newton-Bishop, Marguerite Stas, Veerle Boecxstaens, Oliver Bechter, Jurgen Vercauteren, Marjan Garmyn, Joost van den Oord, and Francesca Maria Bosisio. Metastasizing and Non-Metastasizing Thick Melanomas: Molecular profiling and in situ validation through MILAN multiplexing. Abstract submitted to (and accepted for poster presentation at) the 18th European Association of Dermato-Oncology (EADO) Congress in Seville, Spain on 21-23 April 2022.
46. Grace H. Attrill, Teresa A. Bailey, Trina Lum, Georgina V. Long, James S. Wilmott, **Richard A. Scolyer**. Molecular analysis finds excision margin length predictive of recurrence in acral melanoma. Submitted to (and accepted for a poster at) American Association for Cancer Research (AACR) Annual Meeting 2022, New Orleans, Louisiana (8-13 April 2022).
47. Asmi Chakraborty, Mariana Perez, Norhan B. B. Mohammed, Aristotelis Antonopoulos, Liettel Ortega, Michael Wells, Jordan D. Carroll, Caleb Staudinger, Anthony Griswold, Zasha Pou, Ramon Jimenez, James S. Wilmott, John F. Thompson, Wei Wang, **Richard A. Scolyer**, George F. Murphy, Stuart M. Haslam, and Charles J. Dimitroff. Hypoxia controls the glycolytic signature and related pro-tumorigenic properties of metastatic melanomas. Submitted to Glycobiology Annual Meeting in April 2022 by Asmi Chakraborty.
48. Leila Moayed-Alaei, Stephen Mann, Elizabeth C. Paver, **Richard A. Scolyer**. The utility of molecular testing in the diagnosis of undifferentiated metastatic melanoma in a patient with multiple primaries. Abstract submitted (accepted as a poster) to The Royal College of Pathologists of Australasia's Pathology Update 2022 “In Our Hands” (4-6 March 2022) (Sydney)
49. E Paver, A Potter, K Dempsey, R Morton, **R Scolyer**. Types of biopsy performed and clinical information provided for pathological evaluation of suspected melanomas at a tertiary referral centre. Accepted abstract at Australasian Melanoma Conference (AMC) 2021 (19-20 November 2021) (Sydney-hybrid)
50. AJ Potter, E Paver, A Colebatch, P Ferguson, R Rawson, S Ch'ng, RPM Saw, K Shannon, TE Pennington, J Stretch, O Nieweg, A Spillane, M Carlino, A Menzies, GV Long, **RA Scolyer**. Pathologist-initiated “reflex” BRAF mutation testing in metastatic melanoma at a tertiary referral centre. Accepted abstract at Australasian Melanoma Conference (AMC) 2021 (19-20 November 2021) (Sydney-hybrid)
51. Colebatch AJ*, Paver EC*, Vergara I, John F. Thompson, Georgina V. Long, Wilmott JS, **Scolyer RA** (*contributed equally). Elevated non-coding promoter mutations are associated with malignant transformation of melanocytic naevi to melanoma. Accepted abstract at Australasian Melanoma Conference (AMC) 2021 (19-20 November 2021) (Sydney-hybrid)

52. Serigne N. Lo, Gabrielle J. Williams, Anne Cust, David W. Ollila, **Richard A. Scolyer**, John F. Thompson. Long-Term Incidence of death due to melanoma and from other causes in patients with thin (T1) cutaneous melanomas: A population-based competing-risk analysis confirms 0.8mm Breslow thickness as a risk classification cut-point. Accepted abstract and oral presentation at Australasian Melanoma Conference (AMC) 2021 (19-20 November 2021) (Sydney-hybrid)
53. Rodrigo J Schwartz, Genevieve Ho, Annika Smith, Helena Collgros, Amanda Regio Pereira, Georgina V. Long, Alexander M. Menzies, Alison J Potter, Elizabeth Paver, **Richard A. Scolyer**, Linda K Martin. Successful treatment of Eruptive Keratoacanthomas with actitretin for patients on Checkpoint Inhibitor Immunotherapy. Accepted abstract at Australasian Melanoma Conference (AMC) 2021 (19-20 November 2021) (Sydney-hybrid)
54. David Coker, Thomas Pennington, Serigne N. Lo, **Richard A Scolyer**, Sydney Ch'ng, Omgo Nieweg, Kerwin Shannon, Andrew Spillane, Jonathan Stretch, John F. Thompson, Robyn P.M. Saw. Extent of Disease Burden in Lymph Node Dissections for Clinically Detected Melanoma Metastasis. Accepted abstract at Australasian Melanoma Conference (AMC) 2021 (19-20 November 2021) (Sydney-hybrid)
55. Tuba N. Gide, Serigne Lo, Camelia Quek, Ismael Vergara, Ines P. da Silva, Ping Shang, Eva Shteinman, Zarwa Yaseen, Elizabeth Paver, Alexander M. Menzies, Matteo S. Carlino, Robyn P.M. Saw, John F. Thompson, **Richard A. Scolyer***, Georgina V. Long*, and James S. Wilmott* (*contributed equally). PIP: Personalised Immunotherapy Platform as a Predictive Tool for Immunotherapy Response in a Prospective Cohort of Patients with Metastatic Melanoma. Accepted abstract at Australasian Melanoma Conference (AMC) 2021 (19-20 November 2021) (Sydney-hybrid)
56. Zarwa Yaseen, Tuba N. Gide, Jordan W. Conway, Georgina V. Long, **Richard A. Scolyer**, and James S. Wilmott. Validation Of An Accurate Automated Multiplex Immunofluorescence Method For Immunoprofiling Melanoma. Accepted abstract at Australasian Melanoma Conference (AMC) 2021 (19-20 November 2021) (Sydney-hybrid)
57. Serigne N. Lo, Gabrielle J. Williams, Anne Cust, David W. Ollila, **Richard A. Scolyer**, John F. Thompson . Long-Term Crude Incidence of death due to melanoma and from other causes in patients with thin (T1) cutaneous melanomas: A population-based competing risk analysis confirms 0.8mm Breslow thickness as a risk classification cut-point. Accepted abstract at Australasian Melanoma Conference (AMC) 2021 (19-20 November 2021) (Sydney-hybrid)
58. Grace H. Attrill, Hansol Lee, Annie T. Tasker, Eva Shteinman, Angela L. Ferguson, Ismael A. Vergara, Umaimainthan Palendira, Georgina V. Long, James S. Wilmott, Peter M. Ferguson, **Richard A. Scolyer**. Immunophenotyping of primary melanoma to predict patient outcomes. Accepted abstract at Australasian Melanoma Conference (AMC) 2021 (19-20 November 2021) (Sydney-hybrid)
59. Jorja Braden, Elizabeth Paver, Alison Potter, Alexander Menzies, Matteo Carlino, George Au-Yeung, R.P.M. Saw, Andrew J. Spillane, Jonathan F. Stretch, Kerwin Shannon, Tom E. Pennington, Sydney. Ch'ng, David Gyorki, Julia Howle, Dariush Daneshvar, Ines Pires Da Silva, **Richard A. Scolyer**, James S. Wilmott, Georgina V. Long. Translational Investigation into the Optimal Neoadjuvant Sequencing of Anti-PD1 and BRAF targeting therapy in Resectable BRAF Mutant stage IIIB/C/D Melanoma: Results of Translational Investigations. Accepted abstract to Australasian Melanoma Conference (AMC) 2021 (19-20 November 2021) (Sydney-hybrid)
60. Andrew Li, Sydney Ch'ng, **Richard A Scolyer**, John F Thompson, Serigne N. Lo, Alexander HR Varey. External Validation of the EORTC-DeCOG Nomogram Predicting Recurrence, Distant Metastasis and Overall Mortality in Melanoma Patients with Positive Sentinel Lymph Nodes in an Australian Population. Accepted abstract to Australasian Melanoma Conference (AMC) 2021 (19-20 November 2021) (Sydney-hybrid)
61. Ismael A. Vergara, Serigne N. Lo, Alexander M. Menzies, Matteo S. Carlino, **Richard A. Scolyer**, Georgina V. Long, Inês Pires da Silva. A graph-based approach unveils complex patterns of melanoma distant metastases. Accepted abstract to Australasian Melanoma Conference (AMC) 2021 (19-20 November 2021) (Sydney-hybrid)
62. Ismael A. Vergara*, Karina Aivazian*, Ping Sheng, Matteo S. Carlino, Alexander D. Guminski, Georgina V. Long, James S. Wilmott and **Richard A. Scolyer** (*Authors contributed equally). Molecular features of metastatic basal cell carcinoma. Accepted abstract to Australasian Melanoma Conference (AMC) 2021 (19-20 November 2021) (Sydney-hybrid)
63. Genevieve Ho; Rodrigo Jorge Schwartz Aldea; Amanda Regio Pereira; Florentia Dimitrou; Catriona McKenzie; Robyn P.M. Saw; **Richard A Scolyer**; Georgina V Long; Pascale Guitera. Reflectance confocal microscopy for assessment of treatment response to anti-PD1 based immunotherapy in synchronous Stage III primary scalp melanoma. Accepted abstract to Australasian Melanoma Conference (AMC) 2021 (19-20 November 2021) (Sydney-hybrid)
64. Su Yin Lim, Jenny H. Lee, Bernadette Pedersen, Ashleigh Stewart, Zizhen Ming, Malama Irvine, Elena Shklovskaya, Alexander M. Menzies, Matteo S. Carlino, **Richard A. Scolyer**, Georgina V. Long and Helen Rizos. The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma. Accepted abstract to Australasian Melanoma Conference (AMC) 2021 (19-20 November 2021) (Sydney-hybrid)
65. Rebecca C. Simpson, Erin R. Shanahan, Marcel Batten, Irene L. M. Reijers, Mark Read, Ines P. Silva, Judith Versluis, Rosilene Ribeiro, Alexandra S. Angelatos, Jian Tan, Chandra Adhikari, Alexander M. Menzies, Robyn P. Saw, Maria Gonzalez, Kerwin F. Shannon, Andrew J. Spillane, Rebecca Velickovic, Laurence Macia, Andrew J. Holmes, James S. Wilmott, Christian U. Blank, **Richard A. Scolyer**, Georgina V. Long. Enterotypes underlie gut microbial associations with clinical outcomes during anti-PD1/anti-CTLA4 immunotherapy. Accepted abstract to Australasian Melanoma Conference (AMC) 2021 (19-20 November 2021) (Sydney-hybrid)
66. Georgina V. Long, Reinhard Dummer, Anna C. Pavlick, Michael A. Postow, Antoni Ribas, Caroline Robert, **Richard A. Scolyer**, Janis M. Taube, Michael Tetzlaff, Shu-Chih Su, Rohini Singh, Scott J. Diede, Hussein Abdul-Hassan Tawbi. KEYMAKER-U02: Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Melanoma. Accepted as an e-poster to Clinical Oncology Society of Australia (COSA) Annual Scientific Meeting (16-18 November 2021)
67. Jorja Braden, Elizabeth Paver, Alison Potter, Alexander Menzies, Matteo Carlino, George Au-Yeung, R.P.M. Saw, Andrew J. Spillane, Jonathan F. Stretch, Kerwin Shannon, Tom E. Pennington, Sydney. Ch'ng, David Gyorki, Julia Howle, Dariush Daneshvar, Ines Pires Da Silva, **Richard A. Scolyer**, James S. Wilmott, Georgina V. Long. Translational Investigation into the Optimal Neoadjuvant Sequencing of Anti-PD1 and BRAF targeting therapy in Resectable BRAF Mutant stage IIIB/C/D Melanoma: Results of Translational Investigations. Accepted for poster presentation at Clinical Oncology Society of Australia (COSA) Annual Scientific Meeting (16-18 November 2021)
68. A.J. Potter, E Paver, PF Ferguson, R Rawson, A Colebatch, R Gupta, S O'Toole, W Cooper, G.V. Long, **R.A. Scolyer**. Pathologist-initiated "reflex" BRAF mutation testing in metastatic melanoma at a tertiary referral centre. Submitted to NSW Health Pathology Research Forum 2021 (virtual) (10-11 November 2021)
69. AJ Potter, AT Li, JF Thompson, GV Long, S Ch'ng, **RA Scolyer**. Driver mutation status of cutaneous scalp melanoma. Submitted and accepted for a Rapid-Fire presentation at NSW Health Pathology (NSWHP) Research Forum 2021 (virtual) (10-11 November 2021). **NB: Dr Alison Potter awarded the People's Choice – presentation, poster, and best Early Career Researcher (ECR) presentation at NSW Health Pathology's Inaugural Research Forum for 2021"**

70. Russell J. Diefenbach, Jenny H. Lee, Ashleigh Stewart, Alexander M. Menzies, Matteo S. Carlino, Georgina V. Long, Robyn P. M. Saw, Jonathan R. Stretch, **Richard A. Scolyer**, and Helen Rizos. Anchored multiplex PCR custom melanoma next generation sequencing panel for analysis of circulating tumor DNA. *Submitted to SMR Congress 2021 (28-31 October 2021) (hybrid)*
71. Rebecca C. Simpson, Erin R. Shanahan, Marcel Batten, Irene L. M. Reijers, Mark Read, Ines P. Silva, Judith Versluis, Rosilene Ribeiro, Alexandra S. Angelatos, Jian Tan, Chandra Adhikari, Alexander M. Menzies, Robyn P. Saw, Maria Gonzalez, Kerwin F. Shannon, Andrew J. Spillane, Rebecca Velickovic, Laurence Macia, Andrew J. Holmes, James S. Wilmott, Christian U. Blank, **Richard A. Scolyer**, Georgina V. Long. Enterotypes underlie gut microbial associations with response and toxicity in neo-adjuvant immunotherapy. *Submitted and accepted as oral presentation at SMR Congress 2021 (28-31 October 2021) (hybrid)*
72. Ismael A. Vergara, Serigne N. Lo, Alexander M. Menzies, Matteo S. Carlino, **Richard A. Scolyer**, Georgina V. Long, Inês Pires da Silva. A graph-based approach unveils complex patterns of melanoma distant metastases. *Submitted to SMR Congress 2021 (28-31 October 2021) (hybrid)*
73. Camelia Quek*, Xinya Bai*, Ping Shang, Grace H. Attrill, Tuba Nur Gide, Peter M Ferguson, Kazi Nahar, Umaimainthan Palendira, Georgina V. Long*, **Richard A Scolyer***, James S. Wilmott* (*contributed equally). Identifying and targeting novel immunosuppressive mechanisms in adolescent and young adult (AYA) melanoma patients. *Submitted and accepted as oral presentation at SMR Congress 2021 (28-31 October 2021) (hybrid)*
74. Tuba N. Gide, Serigne Lo, Camelia Quek, Ismael A. Vergara, Ines P. da Silva, Ping Shang, Eva Shteinman, Zarwa Yaseen, Elizabeth Paver, Andrew J. Spillane, Jonathan R. Stretch, Kerwin F. Shannon, Alexander M. Menzies, Matteo S. Carlino, Robyn P.M. Saw, John F. Thompson, **Richard A. Scolyer***, Georgina V. Long*, and James S. Wilmott* (*contributed equally to this work). Implementation of the Personalised Immunotherapy Platform in a Pilot Study to Predict Immunotherapy Response in Metastatic Melanoma. *Submitted to SMR Congress 2021 (28-31 October 2021) (hybrid)*
75. R.V Rawson#, E. R Shteinman#, S. Ansar, G.V Long, **R.A Scolyer**, J.S Wilmott. Diagnostic utility of PRAME, p53 and 5-hmC in melanoma, neurofibroma, scar and begin nevi. *Submitted to SMR Congress 2021 (28-31 October 2021) (hybrid)*
76. Zarwa Yaseen, Tuba N. Gide, Jordan W. Conway, Georgina V. Long, **Richard A. Scolyer**, and James S. Wilmott. Validation of an accurate immunoprofiling melanoma method using automated multiplex immunofluorescence. *Submitted to SMR Congress 2021 (28-31 October 2021) (hybrid)*
77. Grace H. Attrill, Hansol Lee, Annie T. Tasker, Eva Shteinman, Angela L. Ferguson, Ismael A. Vergara, Umaimainthan Palendira, Georgina V. Long, Peter M. Ferguson, **Richard A. Scolyer**, James S. Wilmott. Immunophenotyping of primary melanoma to predict patient outcomes. *Submitted to and accepted as an oral presentation at SMR Congress 2021 (28-31 October 2021) (hybrid)*
78. AJ Potter, IA Vergara, AJ Colebatch, JS Wilmott, JF Thompson, GV Long, **RA Scolyer**. In search of an origin: defining the molecular signature of isolated pulmonary melanoma. *Submitted to The American Society of Dermatopathology (ASDP) 58th Virtual Annual Meeting (20-24 October 2021) (virtual)*
79. AJ Potter, AT Li, JF Thompson, GV Long, S Ch'ng, **RA Scolyer**. Driver mutation status of cutaneous scalp melanoma. *Submitted and accepted as poster to The American Society of Dermatopathology (ASDP) 58th Virtual Annual Meeting (20-24 October 2021) (virtual). NB: Dr Alison Potter awarded the Physician-in-Training Award for the Best Resident/Fellow Poster Abstract Presentation for abstract titled: 'Driver Mutation Status of Cutaneous Scalp Melanoma'*
80. Mathias Seviiri, **Richard A. Scolyer**, John F. Thompson, D. Tim Bishop, Mark M. Iles, Georgina V. Long, Stuart MacGregor, and Matthew H. Law. A large genome-wide association study for melanoma-specific survival reveals two novel loci linked to PSEN2, and ADCK3 genes. *American Society of Human Genetics (ASHG) Conference 2021 (accepted for a poster presentation) (18-22 October 2021) (virtual).*
81. Kenneth Onimus, Adrian Wells, Courtney Herman, Ahmed Tawashi, Georgina Long, Richard Scolyer, Rebecca Velickovic, Madan Jagasia, Arvind Natarajan, Anand Veerapathran. Successful Manufacturing of Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy from Cryopreserved Melanoma Tumors Shipped from Australia. *Submitted to 8th Annual ASTCT Fall Clinical Education Virtual Conference (23-25 September 2021)*
82. Jason J. Luke; Piotr Rutkowski; Paola Quierolo; Michele Del Vecchio; Jacek Mackiewicz; Vanna Chiarion-Sileni; Luis de la Cruz Merino; Muhammad A Khattak; Dirk Schadendorf; Georgina Long, Paolo A Ascierto; Mario Mandala; Federica De Galitiis; Andrew Haydon; Reinhard Dummer; Jean-Jacques Grob; Caroline Robert; Vernon Sondak; Richard Scolyer; John M. Kirkwood; Ke Chen; Scott Diede; Sama Ahsan; Nageatte Ibrahim; and Alexander M. M. Eggermont on behalf of the KEYNOTE-716 Investigators* (*A complete list of investigators who participated in the KEYNOTE-716 study is provided in Table 1 of the Supplementary Appendix, available at NEJM.org). Adjuvant Pembrolizumab in Resected High-risk Stage II Melanoma. *Submitted to European Society for Medical Oncology (ESMO) 2021 (16-21 Sept) - virtual*
83. Jason J. Luke; Piotr Rutkowski; Paola Quierolo; Michele Del Vecchio; Jacek Mackiewicz; Vanna Chiarion-Sileni; Luis de la Cruz Merino; Muhammad A Khattak; Dirk Schadendorf; Georgina V. Long, Paolo A Ascierto; Mario Mandala; Federica De Galitiis; Vernon Sondak; **Richard A. Scolyer**; John M. Kirkwood; Ke Chen; Nageatte Ibrahim; Sama Ahsan; Alexander M. M. Eggermont. Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase 3 trial. *Submitted to European Society for Medical Oncology (ESMO) 2021 (16-21 Sept) - virtual*
84. Reinhard Dummer, Georgina V. Long, Anna C. Pavlick, Michael A. Postow, Antoni Ribas, Caroline Robert, **Richard A. Scolyer**, Janis M. Taube, Michael Tetzlaff, Shu-Chih Su, Rohini Singh, Scott J. Diede, Hussein Abdul-Hassan Tawbi. Investigational (Inv) Agents With or Without Pembrolizumab (pembro) or Pembro Alone in Melanoma (mel): KEYMAKER-U02. *Accepted abstract as an e-poster presentation at ESMO 2021 (16-21 Sept) - virtual.*
85. Noëlle M.J. van den Heuvel, Irene L.M. Reijers, Judith M. Versluis, Alexander M. Menzies, Jacobien M. Kieffer, Nikoletta Kapsali, Michel W.J.M. Wouters, Robyn P.M. Saw, Willem M.C. Klop, Thomas E. Pennington, Mary-Jane Gregorio, Andrew J. Colebatch, Andrew Spillane, Bart. A. van de Wiel, **Richard A. Scolyer**, Alexander C.J. van Akkooi, Lonneke V. van de Poll-Franse, Georgina V. Long, Christian U. Blank, Annelies H. Boekhout. Health-Related Quality of Life in Melanoma patients treated with Neoadjuvant Nivolumab and Domatinostat: preliminary results. *Accepted as poster presentation at the ESMO Congress 2021 (16-21 Sept) virtual.*
86. ILM Reijers, JM Versluis, AM Menzies, P Dimitriadis, MW Wouters, RPM Saw, WMC Klop, TE Pennington, LJW Bosch, S Cornelissen, LG Grijpink-Ongering, MJ Gregorio, M Lopez-Yurda, RV Rawson, AJ Spillane, BA van de Wiel, **RA Scolyer**, ACJ van Akkooi, GV Long and CU Blank. Personalized combination of neoadjuvant domatinostat (DOM), nivolumab (NIVO) and ipilimumab (IPI) in stage IIIB-D melanoma patients (pts) stratified according to the interferon-gamma signature (IFN- γ sign): the DONIMI study. *Accepted as poster presentation and as a mini oral presentation at the ESMO Congress 2021 (16-21 Sept).*

87. Kazi J Nahar*, Felix Marsh-Wakefield*, Robert V Rawson, Tuba N Gide, Angela Ferguson, Ruth Olivia, Camelia Quek, Stephen Tattersal, Christopher J Kiely, Neomal Sandanayake, Matteo S Carlino, James Wilmott, **Richard A Scolyer**, Georgina V Long*, Alexander M Menzies*, Umaimainthan Palendira* (*contributed equally). Systemic myeloid cells and local T cells propel immunotherapy induced colitis. (accepted) Sydney Cancer Conference (9-10 September 2021).
88. Camelia Quek*, Catherine Bai*, Ping Shang, Grace H. Attrill1, Tuba Nur Gide, Peter M. Ferguson, Kazi Nahar, Umaimainthan Palendira, Georgina V. Long*, **Richard A. Scolyer*** and James S. Wilmott* (*contributed equally). Identifying and targeting novel immunosuppressive driver mechanisms in young melanoma patients. Submitted to Sydney Cancer Conference (9-10 September 2021).
89. Zarwa Yaseen, Tuba N. Gide, Jordan W. Conway, Georgina V. Long, **Richard A. Scolyer**, James S. Wilmott. Validation Of An Accurate Automated Multiplex Immunofluorescence Method For Immunoprofiling Melanoma. Sydney Cancer Conference 9-10 Sept 2021.
90. Alexander HR Varey, Clare Galea, Tasnia Ahmed, Richard A. Scolyer, John F. Thompson, Serigne N. Lo. A Dynamic Tool to Predict the Competing Risks of Melanoma-Specific or Non-Melanoma Death. 2021 Westmead Hospital week – 25-27 August 2021.
91. Stephen Law, Anne Cust, Amelia Smit, Kathy Dempsey, Victoria Mar, **Richard A. Scolyer**, Rachael L. Morton. Patterns of healthcare use and costs of diagnostic skin biopsies in the primary health care setting: Analysis of linked administrative data in the Australian Genomics Managing Your Risk randomised controlled trial. International Health Economics Association (IHEA) Conference 2021 (virtual) 12-15 July 2021.
92. Ong J-S, Seviiri M, Dusingize JC, Gharahkhani P, Han X, Neale RE, Olsen CM, Landi MT, Iles MM on behalf of GenoMEL, **Scolyer RA**, Long GV on behalf of MIA, Whiteman DE, MacGregor S, Law MH. Evaluating the complex relationship between balding and skin cancer in men through multivariable Mendelian randomization analyses. GeneMappers Conference 2021 (virtual) 23-25 June 2021.
93. Camelia Quek*, Catherine Bai*, Ping Shang, Grace H. Attrill1, Tuba Nur Gide, Peter M. Ferguson, Kazi Nahar, Umaimainthan Palendira, Georgina V. Long*, **Richard A. Scolyer*** and James S. Wilmott* (*contributed equally). Immunosuppressive-driven mechanisms impede response to checkpoint-based immunotherapies in adolescent and young adult melanoma patients. Sydney Catalyst Research Showcase, 16 June 2021.
94. Georgina V. Long, Victoria Atkinson, Serigne N. Lo, Alexander Guminski, Shahneen Sandhu, Michael Brown, Maria Gonzalez, **Richard A. Scolyer**, Louise Emmett, Alexander M. Menzies, Grant A. McArthur. 5-Year Overall Survival from the Anti-PD1 Brain Collaboration (ABC Study); Randomized Ph 2 Study of Nivolumab (nivo) or Nivo+Ipilimumab (ipi) in Patients (pts) with Melanoma Brain Metastases (mets). American Society of Clinical Oncology (ASCO) 2021 (virtual) 4-6 June 2021 (accepted – oral presentation).
95. Jason J. Luke, Piotr Rutkowski, Paolo Pronzato, Michele Del Vecchio, Jacek Mackiewicz, Vanna Chiarion-Sileni, Luis De La Cruz Merino Sr., Muhammad Adnan Khattak, Dirk Schadendorf, Georgina V. Long, Paolo Antonio Ascierto, Mario Mandalà, Federica De Galitiis, Vernon K. Sondak, **Richard A. Scolyer**, John M. Kirkwood, Ke Chen, Nageatte Ibrahim, Sama Ahsan, Alexander M. Eggermont, Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the Keynote 716 double-blinded phase III trial. American Society of Clinical Oncology (ASCO) 2021 (virtual) 4-6 June 2021
96. Camelia Quek*, Ines P Silva*, Ghamdan Al-Eryani*, Aron Mayer*, Nenad Bartonicek, Kate Harvey, Chi Buckley, Oliver Braubach, Robyn P M Saw, Jonathan Stretch, Kerwin Shannon, Alex M Menzies, **Richard A Scolyer***, Georgina V Long*, Alexander Swarbrick*, James Wilmott* (*contributed equally). Spatially resolved single-cell sequencing reveals unfavourable immune diversity and intratumoural vessels in resistance melanoma patients treated with checkpoint inhibitor immunotherapy. Abstract submitted-accepted to European Association for Cancer Research (EACR) Bioinformatics in Cancer Conference (virtual) 18-19 May 2021.
97. Mathias Seviiri, Georgina V. Long, Catherine M. Olsen, David C. Whiteman, **Richard A. Scolyer**, Stuart MacGregor, and Matthew H. Law. Higher genetic risk for melanoma is associated with improved survival from melanoma. Australian Polygenic Risk Symposium (APRS) 2021, 20-22 April 2021.
98. David J. Coker, Anna Lawless, Serigne Lo, Tasnia Ahmed, **Richard A. Scolyer**, Sydney Ch'ng, Omgo E. Nieweg, Kerwin F. Shannon, Andrew J. Spillane, Jonathan Stretch, John F Thompson, Robyn PM. Saw. Outcomes following surgical resection of in-transit melanoma metastases. World Congress of Melanoma-EADO 2021 (virtual) – 15-17 April 2021.
99. Reinhard Dummer, Georgina V. Long, Anna C. Pavlick, Michael A. Postow, Antoni Ribas, Caroline Robert, **Richard A. Scolyer**, Janis M. Taube, Michael Tetzlaff, Shu-Chih Su, Rohini Singh, Scott J. Dieder, Hussein Abdul-Hassan Tawbi. KEYMAKER-U02: Phase I/II study of investigational agents with or without pembrolizumab or pembrolizumab alone in patients with melanoma. World Congress of Melanoma-EADO 2021 (virtual) – 15-17 April 2021 – **poster presentation**.
100. Christopher G. Harris, Serigne N. Lo, Tasnia Ahmed, **Richard A. Scolyer**, Peter M. Ferguson, Rooshdiya Z. Karim, Tai Khoa Lam, Kenneth K Lee, Kerwin F. Shannon, Andrew J. Spillane, Jonathan R. Stretch, John F. Thompson and Robyn PM Saw. Primary dermal melanoma: prognosis and treatment implications. World Congress of Melanoma-EADO 2021 (virtual) – 15-17 April 2021.
101. C. Güvenç, Asier Antoranz, M. Stas, V. Boecxstaens, O. Bechter, M. Garmyn, J. J. van den Oord, A. Szumera-Ciećkiewicz, R.V. Rawson, **R.A. Scolyer**, Francesca Bosisio. Road to metastatisation: the TWEAK pathway as a discriminant between metastasizing and non-metastasizing thick melanomas. 10th World Congress of Melanoma 14-17 April 2021 (virtual).
102. Jordan W. Conway, Robert V. Rawson, James S. Wilmott, Georgina V. Long, **Richard A. Scolyer**, Inês Pires da Silva. Spatial distribution and immune cell infiltration at different sites of melanoma metastases (mets). AACR Annual Meeting 2021 (virtual) 9-14 April 2021.
103. Camelia Quek*, Ines P Silva*, Ghamdan Al-Eryani*, Aaron Mayer, Nenad Bartonicek, Kate Harvey, Chi Buckley, Oliver Braubach, Robyn PM Saw, Jonathan Stretch, Kerwin Shannon, Alexander M Menzies, **Richard A Scolyer***, Georgina V Long*, Alexander Swarbrick*, James Wilmott* (*contributed equally). CODEX multiplex image mapping to scRNAseq immunotherapy treated melanoma. American Association for Cancer Research (AACR) Annual Meeting 2021 (virtual) 9-14 April 2021.
104. Asmi Chakraborty, Mariana Perez, Norhan B. B. Mohammed, Michael Wells, James S. Wilmott, John F. Thompson, Stuart M. Haslam, Wei Wang, **Richard A. Scolyer**, George F. Murphy and Charles J. Dimitroff. Hypoxia-mediated downregulation of GCNT2/I-antigen in metastatic melanoma accelerates disease progression and mortality. American Association for Cancer Research (AACR) Annual Meeting 2021 (virtual) 9-14 April Hawaii Dermatopathology Conference 2021.
105. Matthew Gibson, **Richard Scolyer**, Peter Soyer, Peter Ferguson, Les Irwig, Kevin Mcgeechn, Katy JL Bell. Estimating the potential impact of interventions to reduce over-calling and under-calling of melanoma. The Australasian College of Dermatologists (ACD) Annual Scientific Meeting (virtual) 9-11 April 2021.
106. Moncrieff, Marc D.; Lo, Serigne; **Scolyer, Richard**; Nobes, Jenny; Heaton, Martin; Snelling, Andrew; Carr, Michael J.; Zager, Jonathan S.; Kisyova, Rumi; Mason, Jennifer; Wilson, Ewan; Wade, Ryckie; Peach, Howard; Nessim, Carolyn; Nolan, Grant; Pritchard-Jones, Rowan; Olofsson Bagge, Roger; Johansson, Iva; Wright, Lucie; Patel, Nakul; Sondak, Vernon K.; Thompson, John F. A Quest for the Lost Tribe: Surgical Management of AJCC IB Melanoma with the Advent of Adjuvant Systemic Therapy. Accepted to SSO 2021 (Society of Surgical Oncology) – International Conference on Surgical Cancer Care (virtual) 18-20 March 2021.

107. Reinhard Dummer, Georgina V. Long, Anna Pavlick, Michael Postow, Antoni Ribas, Caroline Robert, **Richard A. Scolyer**, Janis M. Taube, Michael Tetzlaff, Shu-Chih Su, Sama Ahsan, Scott J. Diede, Hussein A. Tawbi. Investigational agents with or without pembrolizumab versus pembrolizumab alone in patients with melanoma: the phase 1/2 Keymaker-U02 (MK-3475-U02) study. Abstract accepted for virtual presentation by Reinhard Dummer on Feb 23 2021 at Melanoma Research Alliance (MRA) 2021 (virtual) 22-24 February, 2021.
108. Karina Aivazian, Serigne N. Lo, **Richard A. Scolyer**. Regression in primary cutaneous melanoma: impact on sentinel lymph node status and survival. ASDP 57th Annual Meeting (virtual), Nov 2020.
109. Matthias Braun, Ashmitha Sundarajan, Dillon Corvino, Kimberly Stannard, Michael Hölzel, Elizabeth Ahern, Brett Hughes, James S. Wilmott, Georgina V. Long, **Richard A. Scolyer**, Martin D. Batstone, Jennifer Landsberg, Dima Dietrich, Lukas Flatz, Andre Veillette, Sandra Nicholson, Robert Johnston, Ludovic Martinet, Mark J. Smyth, Tobias Bald. CD155 on tumor cells drives resistance to immunotherapy by inducing the degradation of the activating receptor CD226 in CD8⁺ T cells. Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting 2020 (virtual) 9-14 November 2020.
110. Reinhard Dummer, Georgina V. Long, Anna Pavlick, Michael Postow, Antoni Ribas, Caroline Robert, **Richard A. Scolyer**, Janis M. Taube, Michael Tetzlaff, Jason Liao, Sama Ahsan, Scott J. Diede, Hussein A. Tawbi. MK-3475-U02: Phase 1/2 study of investigational agents with or without pembrolizumab versus pembrolizumab monotherapy in melanoma. Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting 2020 (virtual) 9-14 November 2020.
111. Asmi Chakraborty, Norhan BB Mohammed, Frances Clemente Erickson, Michael Wells, James S. Wilmott, John F. Thompson, Wei Wang, **Richard A. Scolyer**, George F. Murphy and Charles J. Dimitroff. GCNT2 suppression in metastatic melanoma is potentiated by hypoxia and correlates with aggressive disease progression. Annual Society of Glycobiology, November 2020.
112. Jordan W. Conway, Robert V. Rawson, James S. Wilmott, Georgina V. Long, **Richard A. Scolyer**, Inês Pires da Silva. The tumour immune microenvironment (TIME) at different sites of melanoma metastases (mets). Cancer Research Network Postgraduate and Early career Researcher Symposium 2020 – presented by Jordan Conway on 10th November 2020.
113. Grace H. Attrill*, Carina Owen*, Tasnia Ahmed, Serigne Lo, Andrew Colebatch, Jordan W. Conway, Inês Pires da Silva, Matteo S. Carlino, Alexander M. Menzies, Mainthan Palendira, **Richard A. Scolyer**, Georgina V. Long, James S. Wilmott (*contributed equally). Tumour specific, tumour resident, cytotoxic T cells are associated with reduced recurrence in adjuvant PD-1 treatment stage III melanoma. Cancer Research Network Postgraduate and Early career Researcher Symposium 2020 – presented by Grace Attrill on 10th November 2020.
114. Rebecca Simpson, Marcel Batten, Erin Shanahan, Mark Read, Ines Silva, Alexandra Aangelatos, Jian Tan, Rosilene Ribeiro, Chandra Adhikari, Jordan Conway, Alex Menzies, Robin Saw, Jonathan Stretch, Omgo Nieweg, Andrew Spillane, Laurence Macia, Maria Gonzales, Kerwin Shannon, Rebecca Velickovic, Christian Blank, Andrew Holmes, James Wilmott, **Richard A. Scolyer**, Georgina V. Long. Gut microbiota predicts response and adverse events during anti-PD1/anti-CTLA4 neoadjuvant immunotherapy. Event: Sydney Catalyst Postgraduate and Early Career Researcher Symposium 2020 – Friday 30th October 2020, Sydney (oral presentation by Rebecca Simpson).
115. Donya Tohidi Esfahani, Karina Aivazian, **Richard A. Scolyer**. Utility of next generation sequencing for differentiating malignant PEComa from melanoma metastasis. Sydney Catalyst Postgraduate and Early Career Researcher Symposium 2020 – Friday 30 October 2020, Sydney
116. T. N. Gide*, I. P. Silva*, C. Quek, P.M. Ferguson, M. Batten, P. Shang, T. Ahmed, A.M. Menzies, M.S. Carlino, R P.M. Saw, J.F. Thompson, J.S. Wilmott*, **R.A. Scolyer*** and G. V. Long* (*contributed equally to this work). Genomic and Clinical Profiles of Patients with Innate Resistance to Anti-PD-1 Based Immunotherapies in Melanoma. Event: Sydney Catalyst Postgraduate and Early Career Researcher Symposium 2020 – Friday 30 October 2020, Sydney (oral presentation).
117. Catherine Bai, Camelia Quek, Ping Shang, Umamainthan Palendira, Grace Attrill, Tuba Nur Gide, Georgina V. Long, **Richard A. Scolyer** and James S. Wilmott. Immunogenetic features of adolescent and young adult (AYA) melanoma and their implications for response to checkpoint-based immunotherapies. Selected for oral presentation at Kids Cancer Alliance ECR Symposium 17-18 September 2020.
118. T. N. Gide*, I. P. Silva*, C. Quek, PM Ferguson, M. Batten, P. Shang, T. Ahmed, A.M. Menzies, M.S. Carlino, R.P.M. Saw, J.F. Thompson, J.S. Wilmott*, **R.A. Scolyer***, G.V. Long* (*contributed equally to this work). Analysis Of Clinical And Molecular Profiles Of Patients With Innate Resistance To Anti-Pd-1 +/- Anti-Ctla-4 Immunotherapy In Metastatic Melanoma. Abstract - IAP Conference (May 2020).
119. Maria Gonzalez, Alexander M. Menzies, Thomas Pennington, Robyn Saw, Andrew J. Spillane, Jonathan Stretch, Kerwin F. Shannon, Sydney Ch'ng, Omgo E. Nieweg, Maria Cruzado, Monica Osorio, Robert Rawson, Peter Ferguson, Helen Rizos, Serigne Lo, **Richard A. Scolyer**, Georgina V. Long. A phase II study of neoadjuvant pembrolizumab and lenvatinib for resectable stage III melanoma: the neopele study. Abstract - ASCO 2020 (virtual) June 2020.
120. Serigne Lo, Mary-Ann El Sharouni, Karijn Suijkerbuijk, Tasnia Ahmed, Witkamp Arjen, Anne E. Cust, Vigfús Sigurdsson, Paul J. van Diest, **Richard A. Scolyer**, Carla Van Gils, John F. Thompson. Quantifying the additional prognostic value of sentinel lymph node status over established clinicopathologic primary tumor features for predicting survival outcomes in melanoma patients. ASCO 2020 June (Accepted to be published on line).
121. Ines Pires da Silva, Tasnia Ahmed, Serigne Lo, M Carlino, Richard A Scolyer, Alex Menzies, Georgina V. Long. Clinical models that predict site of first and subsequent melanoma metastases (MM) in 6031 patients (pts). ASCO 2020 June.
122. John J. Park, Russell J. Diefenbach, Natalie Byrne, Richard Kefford, Georgina V. Long, Richard A. Scolyer, Elin Gray, Matteo S. Carlino, Helen Rizos. Circulating tumor DNA (ctDNA) in patients (pts) with metastatic uveal melanoma (UM) treated with protein kinase C inhibitor (PKCi). Abstract – ASCO 2020.
123. Mary-Ann El Sharouni, Karijn PM Suijkerbuijk, Arjen J Witkamp, Vigfús Sigurdsson, Paul J van Diest, Carla H van Gils, Matthew Stodell, Serigne N Lo, John F Thompson, Anne Cust, Tasnia Ahmed, Richard A Scolyer. The incremental value of sentinel lymph node status to predict clinical outcomes in melanoma patients. 10/2/2020 draft circulated. Abstract - ASCO 2020.
124. Jenny H Lee, Matteo S Carlino, Alexander M Menzies, **Richard A Scolyer**, Georgina V Long, Helen Rizos. Plasma next generation sequencing (NGS) to analyse clonal evolution in metastatic melanoma (MM) patients (pts) with early acquired resistance to immune checkpoint inhibitors (ICI). Abstract ASCO 2020.
125. Noëlle Milena Jane Van den Heuvel, Irene L.M. Reijers, Elisa A. Rozeman, Judith M. Versluis, Katarzyna Józwiak, Andrew Spillane, **Richard A. Scolyer**, Thomas Pennington, Robyn Saw, Maria Gonzalez, Winan J. van Houdt, Willem M.C. Klop, Michel W.J.M. Wouters, Alexander M. Menzies, Alexander Christopher Jonathan Van Akkooi, Lonneke V van de Poll-Franse, Georgina V. Long, Christian U.

- Blank, Annelies H. Boekhout. Health-related quality of life in stage III melanoma patients treated with neoadjuvant ipilimumab and nivolumab followed by index lymph node excision only, compared to therapeutic lymph node dissection: First results of the PRADO trial. Abstract – ASCO 2020.
126. CU Blank, ILM Reijers, JM Versluis, EA Rozeman, K Sikorska, L Grijpink, M Gonzalez, R Zucker, A Spillane, JA van der Hage, DJ Grünhagen, **RA Scolyer**, B van de Wiel, AM Menzies, ACJ van Akkooi, GAP Hospers, KPM Suijkerbuijk, AM van der Veldt, HW Kapiteijn and GV Long. Preliminary results of PRADO: a study to test personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in high risk resectable stage III melanoma. Abstract – ASCO 2020 (accepted).
 127. Elisa A. Rozeman, Irene L.M. Reijers, Esmée P Hoefsmit, Karolina Sikorska, Oscar Krijgsman, Bart A. Van De Wiel, Petros Dimitriadis, Hanna Eriksson, Maria Gonzalez, Lindsay G Grijpink-Ongering, Ron M. Kerkhoven, Annegien Broeks, Willem M.C. Klop, Andrew Spillane, Robyn Saw, Alexander Christopher Jonathan Van Akkooi, **Richard A. Scolyer**, Alexander M. Menzies, Georgina V. Long, Christian U. Blank. 24-months RFS and updated toxicity data from OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant Ipilimumab (IPI) and Nivolumab (NIVO) in stage III melanoma. Abstract – virtual ASCO 2020 (accepted as poster discussion).
 128. Jenny HJ Lee, Matteo S. Carlino, Alexander M. Menzies, Justin Iver Odegaard, Martina Lefterova, **Richard A. Scolyer**, Georgina V. Long, Helen Rizos. Circulating tumor DNA (ctDNA) using Guardant360 to predict response in BRAF V600 WT metastatic melanoma (MM) patients (pts) receiving immune checkpoint inhibitors (ICI). Abstract – ASCO 2020.
 129. Serigne N Lo, Jiawen Ma, **Richard A Scolyer**, Lauren E Haydu, Jonathan R Stretch, Robyn PM Saw, Omgo E Nieweg, Kerwin F Shannon, Andrew J Spillane, Sydney Ch'ng, Graham J Mann, Jeffrey E Gershenwald, John F Thompson, Alexander HR Varey. An improved risk-prediction calculator for sentinel node positivity in melanoma patients: the MIA nomogram. Abstract - Submitted to the International Sentinel Node Society's Biennial Meeting, ISNS 2020 in Houston.
 130. Watts CG, Thompson JF, Smith AL, Robinson S, Chang C, Schmid H, Kelly JW, Hong AM, **Scolyer RA**, Long GV, Spillane AJ, Henderson M, Gyorki DE, Mar VJ, Morton RL, Saw RPM, Varey AH, Mann GJ, Cust AE. Exploring reasons why some Australian general practitioners (family physicians) do not refer eligible patients with invasive melanomas for a discussion about sentinel node biopsy. Abstract - International Sentinel Node Society Meeting in Houston in May 2020.
 131. Mary-Ann El Sharouni, Serigne N Lo, Alexander HR Varey, Arjen J Witkamp, Vigfús Sigurdsson, Paul J van Diest, **Richard A Scolyer**, Carla H van Gils, John F Thompson. External validation of a risk-prediction calculator for sentinel node positivity in melanoma patients (the MIA nomogram) using a large European , population-based cohort. Abstract – submitted to the International Sentinel Node Society's Biennial Meeting, ISNS 2020 in Houston.
 132. Andrew J Colebatch, Chandra Adharki, Helen Rizos, Robert V Rawson, Peter M Ferguson, Stanley W McCarthy, John F Thompson, James S Wilmott, Georgina V Long, **Richard A Scolyer**. Abstract - Roche Scientific Poster Display, Anatomical Pathology – RCPAQAP Pathology Update 2020.
 133. Simpson R, Batten M, Shanahan ER, Read M, Silva IP, A. Aangelatos, J. Tan, Adhikari C, Conway J, Menzies AM, Saw RPM, Stretch J, Nieweg OE, Spillane AJ, Macia L, Gonzales M, Shannon KF, Velickovic R, Blank CU, Holmes AJ, Wilmott, JS, **Scolyer RA**, Long GV. Intestinal microbiota predict response and toxicities during Anti-PD-1/Anti-CTLA-4 Immunotherapy. Pathology Update 2020 (accepted).
 134. Karina Aivazian, Louise Jackett, Serigne Lo, Robert V Rawson, James S Wilmott, Peter M Ferguson, John F Thompson, Georgina V Long, **Richard A Scolyer**. Prognostic Role of Regression in Primary Cutaneous Melanoma. Abstract - submitted to Roche Scientific Poster Display, Anatomical Pathology – RCPAQAP Pathology Update 2020.
 135. Karina Aivazian, Annabelle Mahar, Louise Jackett, Diane Payton, **Richard A Scolyer**. GLI Activated Nested Malignant Epithelioid Cell Tumour. Abstract - submitted to Roche Scientific Poster Display, Anatomical Pathology – RCPAQAP Pathology Update 2020.
 136. Karina Aivazian, Robert V Rawson, James S Wilmott, Peter M Ferguson, John F Thompson, Georgina V Long, **Richard A Scolyer**. Mutational Analysis of Undifferentiated Melanoma. Abstract - submitted to Roche Scientific Poster Display, Anatomical Pathology – RCPAQAP Pathology Update 2020.
 137. Karina Aivazian, James S Wilmott, Alexander Guminski, Robert V Rawson, Peter M Ferguson, John F Thompson, Georgina V Long, **Richard A Scolyer**. Genomic Alterations in Metastatic Basal Cell Carcinoma. Abstract - Roche Scientific Poster Display, Anatomical Pathology at RCPAQAP Pathology Update 2020.
 138. Jordan W. Conway, Robert V. Rawson, James S. Wilmott , Georgina V. Long, **Richard A. Scolyer**, Inês Pires da Silva. Understanding the tumour immune microenvironment (TIME) at different sites of melanoma metastases (mets). Abstract - submitted to RCPAQAP - Pathology Update 2020
 139. Christian U Blank, Judith M Versluis, Elisa A Rozeman, Alexander M Menzies, Irene LM Reijers, Oscar Krijgsman, Esmée P Hoefsmit, Bart A van de Wiel, Karolina Sikorska, Carolien Bierman, Petros Dimitriadis, Maria Gonzalez, Annegien Broeks, Ron Kerkhoven, Andrew J Spillane, John Haanen, Winan van Houdt, Robyn PM Saw, Hanna Eriksson, Alexander CJ van Akkooi, **Richard A Scolyer**, Ton NM Schumacher and Georgina V Long. 36-months and 18-months relapse-free survival after (neo)adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma patients – update of the OpACIN and OpACIN-neo trials. Abstract – submitted to AACR 2020.
 140. Jarem Edwards*, Inês Pires da Silva*, Angela Ferguson, Jordan Conway, Grace Attrill, Robyn P. M. Saw, John F. Thompson, Alexander M. Menzies, Umaimainthan Palendira* and James S. Wilmott*, Georgina V. Long*, **Richard A. Scolyer*** and James S. Wilmott. Defining melanoma patients unresponsive to single agent anti-PD-1 therapy but responsive to combination anti-PD-1 + anti-CTLA-4 therapy. Abstract – submitted to AACR 2020.
 141. ILM Reijers, EA Rozeman, P Dimitriadis, O Krijgsman, L Bosch, S Cornelissen, J Bouwman, JM Versluis, D Rao, B van de Wiel, A Spillane, **R Scolyer**, AM Menzies, ACJ van Akkooi, GV Long and CU Blank. Personalized combination of neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in macroscopic stage III melanoma patients stratified according to interferon-gamma (IFN-γ) signature – the DONIMI trial. Abstract – submitted to ITOC 2020 congress.
 142. J. Versluis, E. Rozeman, A. Menzies, I. Reijers, O. Krijgsman, E. Hoefsmit, B. van de Wiel, K. Sikorska, C. Bierman, P. Dimitriadis, M. Gonzalez, A. Broeks, R. Kerkhoven, A. Spillane, J. Haanen, W. van Houdt, R. Saw, H. Eriksson, A. van Akkooi, **R. Scolyer**, T. Schumacher, G. Long and C. Blank. Update of the OpACIN and OpACIN-neo trials: 36-months and 18-months relapse-free survival after (neo)adjuvant ipilimumab + nivolumab in macroscopic stage III melanoma patients. Abstract - submitted to ITOC 2020 Congress.
 143. Jen G. Cheung, Helen Rizos , Helmut Schaidt, Michael Brown, Nick Hayward, Georgina Long, **Richard A Scolyer**, Graham Mann, Mark Shackleton. AXMAP – the Australian pdX Melanoma Project. Abstract - Lorne Cancer Conference 2020 and The Joint Baker Institute – La Trobe Research Symposium 2020.

144. Dr Andreanne Wadell, Giuliana Carlos, Bruna Malhovense, Christoph Sinz, Tasnia Ahmed, Serigne Lo, Robert Rawson, **Richard Scolyer**, Pascale Guitera. Can in vivo reflectance confocal microscopy detect invasion in pigmented macule suspected to be lentigo maligna or lentigo maligna melanoma? *Submitting as abstract for national conference as at 31/10/2019*.
145. Grace H Attrill*, Carina Owen* (*co authors), Tasnia Ahmed, Serigne Lo, Andrew Colebatch, Jordan W Conway, Inês Pires da Silva, Matteo S Carlino, Alexander M Menzies, Mainthan Palendira, **Richard A Scolyer**, Georgina V Long, James S Wilmott. CD103+CD39+PD-1+ CD8+ T cells are associated with a reduced risk of recurrence in adjuvant PD-1 treated-stage III melanoma patients. *SMR Nov 2019*.
146. Barnhill R, Vermeulen P, van Dam P, Daelemans S Busam K, Lazar A, **Scolyer R**, Lugassy C. Analysis of Histopathological Growth Patterns in Hepatic Metastases from Cutaneous Melanoma. Liver Metastasis Research Network meeting, Valencia June 2019.
147. Ipenburg N et. al. External validation of a prognostic model to predict survival of sentinel node-negative melanoma patients. *European Dermatology conference (EADV) 2019*.
148. Lim SY, Lee JH, Gide TN, Menzies AM, Guminski A, Carlino MS, Shazanfar S, Strbenac D, Yang J, Kefford RF, **Scolyer RA**, Long GV, Rizos H. Dynamic changes in transcriptome and cytokine expression in melanoma patients treated with combination PD-1 and CTLA-4 inhibitors. *CIMT 2019*.
149. Hauschild A, Ascierto PA, Carlino MS, Eggermont AMM, Gershenwald JE, Grob JJ, Kirkwood JM, JJ, Mohr P, Robert C, Ross MI, **Scolyer RA**, Sondak VK, Yoon CH, Poklepovic AS, Rutkowski P, Anderson JR, Ahsan S, Ibrahim N, Long GV. Phase 3 KEYNOTE-716: Adjuvant Pembrolizumab (pembro) Versus Placebo, With Crossover or Rechallenge, in Resected High-Risk Stage II Melanoma. *ESMO 2019*.
150. Nahar K, Rawson R, Sandanayake N, Tattersall S, Carlino MS, Palendira M, **Scolyer RA**, Long GV, Menzies AM. Clinico- pathological characteristics of immune colitis in melanoma patients treated with combination ipilimumab and anti-PD1 (IPI+PD1) and PD1 monotherapy. *ESMO 2019*.
151. Haydu LE, Lo S, McQuade JL, Glitza IC, Tawbi H, Carlino MS, Menzies AM, Long GV, Lazar A, Tetzlaff M, **Scolyer RA**, Gershenwald JE, Thompson JF, Davies MA. Prediction of Risk of Central Nervous System Metastasis for AJCC 8th Edition Stage III Melanoma Patients. *SNO 2019*.
152. Ray FR, Cooper WA, **Scolyer RA**, Griffin S, Lim PIT, Strasser SI, Kench J, McKenzie CA. The many faces of colonic malakoplakia: A case series and review of the literature. *IAP 2019*.
153. Ipenburg NA, Nieweg OE, Ahmed T, van Doorn R, **Scolyer RA**, Long GV, Thompson JF, Lo S. External validation of a prognostic model to predict survival of sentinel node-negative melanoma patients. *EADV congress 2019*.
154. Lepletier A, Madore J, O'Donnell J, Johnston R, McDonald E, Massi D, Merelli B, Mandala M, Dougall B, Teng MWL, Waddell N, Long GV, **Scolyer RA**, Smyth MJ. Tumor-intrinsic CD155 expression limits sensitivity to anti-PD-1 therapy in advanced metastatic melanoma. *Brisbane Immunotherapy 2019*.
155. Lee JHJ, Menzies AM, Carlino MS, Kefford R, **Scolyer RA**, Long GV, Rizos H. Circulating tumor DNA (ctDNA) in metastatic melanoma (MM) patients (pts) with brain metastases (mets). *ASCO 2019*.
156. Fogarty GB, Dolven-Jacobsen K, Morton RL, Hruby G, Nowak AK, Vardy JL, Drummond KJ, Dhillon HM, Mandel C, **Scolyer RA**, Shivalingam B, Middleton MR, Burmeister BH, Lo SN, Reisse CH, Paton EJ, Steel V, Williams NC, Thompson JF, Hong AM. Phase 3 international trial of adjuvant whole brain radiotherapy or observation following local treatment in 1 to 3 melanoma brain metastases. *ASCO 2019 & ASTRO 2019*.
157. Menzies AM, Rozeman EA, Amaria RN, Huang ACC, **Scolyer RA**, Tetzlaff MT, Van De Wiel BA, Lo S, Tarhini AA, Abdul-Hassan Tawbi H, Burton EM, Karakousis G, Ascierto PA, Spillane A, Davies MA, Van Akkooi ACJ, Mitchell TC, Long GV, Wargo JA, Blank CU. Pathological response and survival with neoadjuvant therapy in melanoma: A pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). *ASCO 2019*.
158. Rozeman EA, Menzies AM, Kriggsman O, Van De Wiel BA, Van TM, Sirorska K, Eriksson H, Hoefsmit EP, Valenti M, Gonzalez M, Jakrot V, Broeks A, Kerkhoven RM, Spillane A, Saw R, **Scolyer RA**, Van Akkooi ACJ, Hansson J, Long GV, Blank CU. OpACIN-neo: A multicenter phase 2 study to identify the optimal neoadjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO)—Updated RFS results and biomarker analysis. *ASCO 2019*.
159. Phase 3 KEYNOTE-716 Study: Adjuvant Therapy With Pembrolizumab versus Placebo in Resected High-Risk Stage II Melanoma USA ePoster World Congress of Dermatology (WCD) 2019 congress June 10-15, 2019 in Milan, Italy.
160. Phase 3 KEYNOTE-716 Study: Adjuvant Therapy With Pembrolizumab versus Placebo in Resected High-Risk Stage II Melanoma Poster presentation at ASCO-SITC 2019 Clinical Immuno-Oncology Symposium 28 – March 2, 2019 San Francisco, CA.
161. Luke J, Ascierto P, Carlino M, Eggermont A, Grob J, Hauschild A, Kirkwood J, Long G, Mohr P, Robert C, Gershenwald J, Poklepovic A, Ross M, **Scolyer R**, Yoon C, Anderson J, Ahsan S, Ibrahim N, Sondak V. Phase III KEYNOTE-716 study: Adjuvant therapy with pembrolizumab versus placebo in resected high-risk stage II melanoma. *ASCO-SITC Clinical Immuno-Oncology Symposium March 2, 2019*.
162. PA Ascierto, MS Carlino, J-J Grob, A Hauschild, JM Kirkwood, JJ Luke, GV Long, P Mohr, C Robert, VK Sondak, JE Gershenwald, A Poklepovic, M Ross, **RA Scolyer**, J Anderson, S Ahsan, N Ibrahim, AMM Eggermont. Phase 3 KEYNOTE-716 Study: Adjuvant Therapy With Pembrolizumab versus Placebo in Resected High-Risk Stage II Melanoma. *World Congress of Dermatology (WCD) 2019*.
163. Silva I, Ahmed T, Rai R, Park J, McQuade J, Johnson D, Guminski A, Lo S, **Scolyer R**, Long G, Menzies A. Haematologic predictors of response and toxicity (tox) in metastatic melanoma (MM) patients (pts) treated with anti-PD-1 alone (PD1) or combined with ipilimumab (IPI+PD1). *Society for Melanoma Research Congress 2018 Manchester*.
164. Silva I, Tasker A, Quek C, Lim E, Wang K, Ahmed T, Lo S, Yang J, Rizos H, Wilmott J, **Scolyer R**, Menzies A, Long G. Melanoma liver metastases (mets) are immunosuppressive and have distinct clinical and genetic profile. *Society for Melanoma Research Congress 2018 Manchester*.
165. Batten M, Shanahan ER, Silva IP, Adhikari C, Conway J, Tasker A, Menzies AM, Wilmott JS, Saw RPM, Spillane AJ, Shannon KF, Blank CU, Homes AJ, **Scolyer RA**, Long GV. Low intestinal microbial diversity is associated with severe immune-related adverse events and lack of response to neoadjuvant combination antiPD1/anti-CTLA4 immunotherapy. *AACR Annual Meeting Chicago, Illinois, USA 2018*.
166. Barnet MB, Jackson K.J.L, Gao B, Nagrial A, Boyer M, Cooper W, Hui R, Linton A, Tattersall M, Gibson G, Cebon J, Long GV, Menzies AM, **Scolyer RA**, Lacaze P, Brink R, Peters T, Cowley M, Gayevskiy V, Thomas D, Pinese M, Blinman P, Kao S, Goodnow C. Exploring the germ-line contribution to exceptional response to PD-1/PD-L1 inhibition in lung cancer patients by whole genome sequencing. *AACR Annual Meeting 2018 Chicago US*.

167. A Nomogram To Predict The Risk Of Sentinel Lymph Node Positivity In An Australian Melanoma Population. World Congress on Cancers of the Skin 2018.
168. Economides A, Paton E, Star P, Fogarty GB, Hong A, Stretch JR, **Scoflyer RA**, Guitera P. Clinical management of lentigo maligna, a review via the ANZMTG 02.12 RADICAL trial. The Australasian College of Dermatologists' Annual Scientific Meeting (ASM) May 2018 Gold Coast, Australia.
169. Star P, Goodwin A, Kapoor R, Conway M, Long GV, **Scoflyer R**, Guitera P. Appropriate cancer surveillance plan for the BAP1 positive patient: A proposed interdisciplinary consensus strategy. The Australasian College of Dermatologists' Annual Scientific Meeting (ASM) May 2018 Gold Coast, Australia.
170. McCarthy R, **Scoflyer R**, Jackett L. A rare case of a giant heterogenous plaque-type blue naevus. The Australasian College of Dermatologists' Annual Scientific Meeting (ASM) May 2018 Gold Coast, Australia.
171. Gonzalez M, Menzies A, Saw R, Spillane AJ, Nieweg O, Shannon K, Thompson JF, Howle JR, Ch'ng S, Stretch J, Osorio M, Emmett L, Rizos H, Guminski A, Carlino M, **Scoflyer RA**, Long GV. Determining optimal sequencing of anti-PD-1 and BRAF-targeted therapy: A Phase II Randomised Study of Neoadjuvant Pembrolizumab with/without Dabrafenib and Trametinib (D+T) in BRAF V600 Mutant Resectable Stage IIIB/C/D Melanoma (NeoTrio Trial). ASCO Chicago June 2018.
172. Gide T, Quek C, Menzies A, Madore J, Velickovic R, Wongchenko M, Yan Y, Carlino M, Guminski A, Saw R, Silva I, Palendira U, Thompson J, **Scoflyer RA**, Long GV, Wilmott J. Transcriptomic and immunophenotypic profiles of melanoma tissue from patients (pts) treated with anti-PD-1 +/- ipilimumab to define mechanisms of response and resistance. ASCO Chicago June 2018.
173. Jakrot V, Peranec M, Blayden S, Dent R, De Silva C, Ordonez P, Whitbourne K, Lewis-Conway J, Tembe V, GV Long GV, **Scoflyer RA**. Prospective blood collections from clinical cohorts – an MIA experience. Australasian Biospecimen Network Association Conference (ABNA) Brisbane Oct 2017.
174. Long GV, Atkinson V, Lo S, Guminski A, Sandhu S, Brown M, Gonzalez M, **Scoflyer RA**, Emmett L, Menzies AM, McArthur GA. Randomized Ph 2 Study of Nivolumab (nivo) or Nivo+Ipilimumab (ipi) in Patients (pts) with Melanoma Brain Metastases (mets): Anti-PD1 Brain Collaboration (ABC). World Congress of Melanoma/ Society for Melanoma Research Congress Brisbane October 2017.
175. Cru Cruzado M, Sun Y, Emmett E, Dalton J, Lane S, Thompson J, Saw R, Hong A, **Scoflyer R**, Guminski A, Long GV, Gonzalez M, Menzies A. Clinical trial recruitment and management of melanoma patients who live a long-distance from a tertiary referral centre. World Congress Melanoma October 2017.
176. Lee H, Quek C, Edwards J, Gide TN, Madore J, Menzies A, Dent R, Wongchenko M, Yan Y, Carlino M, Guminski A, Saw R, Thompson J, Long GV, **Scoflyer RA**, Wilmot J. Immune phenotypic analysis of NK cells in predicting response to anti-PD-1 therapy. SMR October 2017.
177. Lim S, Menzies A, Welsh S, Lee J, Breen E, Kefford R, **Scoflyer RA**, Long GV, Rizos H. MAPK pathway inhibition in melanoma induces differential effects on immune activity. SMR October 2017.
178. Alexander, M. Menzies, E A. Rozeman, R N Amaria, **R A. Scoflyer**, M T. Tetzlaff, A Guminski, M A. Davies, C U. Blank, J A. Wargo, G V. Long. Preliminary Results from the International Neoadjuvant Melanoma Consortium (INMC) ASCO Annual Meeting, June 2017, Chicago, Illinois, USA.
179. Long GV, Atkinson V, Menzies AM, Lo S, Guminski A, Brown MP, Gonzalez M, Diamante K, Sandhu S, **Scoflyer RA**, Emmett L, McArthur GA. A Randomized Phase 2 Study of Nivolumab or Nivolumab combined with Ipilimumab in Patients with Melanoma Brain Metastases: The Anti-PD1 Brain Collaboration (ABC). ASCO Chicago USA, June 2017.
180. T.N. Gide, C. Quek, J. Madore, A.M. Menzies, R. Dent, M.S. Carlino, A. Guminski, R.P.M. Saw, J.F. Thompson, **R.A. Scoflyer**, G.V. Long, J.S. Wilmott. Biomarkers of response and resistance to combined anti-ctla-4 and anti-pd-1 immunotherapy in melanoma patients utilising multiplex immunofluorescence. 41st Annual Scientific Meeting of the Australasian Division of the IAP Sydney Australia, June 2017.
181. Siwen Hu-Lieskovan, Zeynep Eroglu, Jesse Zaretsky, Dae Won Kim, Alain Algazi, Douglas Johnson, Elizabeth Liniker, Ben Kong, Rodrigo Munhoz, Suthae Rapisuwon, Bartosz Chmielowski, Jeffrey A. Sosman, **Richard A. Scoflyer**, Richard Joseph, Michael A. Postow, Matteo S Carlino, Wen-Jen Hwu, Georgina Long, Antoni Ribas. Analysis of mutational burden and adaptive immune response in desmoplastic melanomas (DM) treated with anti-PD-1/L1. ASCO Annual Meeting, Chicago, USA, June 2017.
182. Rozeman EA, Van Akkooi ACJ, Routier E, Menzies AM, Eriksson H, Smith M, **Scoflyer RA**, Hoeller C, Hansson J, Robert C, Larkin JMG, Long GV, Blank CU. Multicenter phase 2 study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO) (OpACIN-neo). ASCO Annual Meeting, Chicago, USA, June 2017.
183. Rozeman EA, Van Akkooi ACJ, Routier E, Menzies AM, Eriksson H, Smith M, **Scoflyer RA**, Hoeller C, Hansson J, Robert C, Larkin JM, Long GV, Blank CU. Multicenter phase 2 study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO) (OpACIN-neo). ASCO May 2017.
184. Menzies AM, Rozeman EA, Amaria RN, **Scoflyer RA**, Tetzlaff MT, Guminski A, Davies MA, Blank CU, Wargo JA, Long GV. Preliminary Results from the International Neoadjuvant Melanoma Consortium (INMC). ASCO Chicago USA, June 2017.
185. Da Silva IEDP, Wang KYX, Wilmott JS, Holst J, Park J, Quek C, Wongchenko M, Yan Y, Mann GJ, Carlino MS, Kefford R, **Scoflyer RA**, Yang J, Long GV, Rizos H, Menzies AM. Distinct gene expression, mutational profile and clinical outcomes of V600E and V600K/R BRAF-mutant metastatic melanoma (MM). ASCO May 2017.
186. Long GV, Atkinson V, Menzies AM, Lo S, Guminski AD, Brown MP, Gonzalez MM, Diamante K, Sandhu SKS, **Scoflyer RA**, Emmett L, McArthur GA. A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): The Anti-PD1 Brain Collaboration (ABC). ASCO May 2017.
187. Menzies AM, Rozeman EA, Amaria RN, **Scoflyer RA**, Tetzlaff MT, Guminski A, Davies MA, Blank CU, Wargo JA, Long GV. Preliminary results from the international neoadjuvant melanoma consortium (INMC). ASCO May 2017.
188. Hu-Lieskovan S, Eroglu Z, Zaretsky JM, Kim DW, Algazi AP, Johnson DB, Liniker E, Kong B, Munhoz R, Rapisuwon S, Chmielowski B, Sosman JA, **Scoflyer RA**, Joseph RW, Postow MA, Carlino MS, Hwu WJ, Long GV, Ribas A. Analysis of mutational burden and adaptive immune response in desmoplastic melanomas treated with PD-1/L1 inhibitors. ASCO May 2017.
189. Distinct gene expression, mutational profile and clinical outcomes of V600E and V600K/R BRAF-mutant metastatic melanoma (MM).
190. Minocha R, Martin AJ, Chen AC, **Scoflyer R.A**, Lyons G, McKenzie CA, Madore J, Halliday GM, Damian DL. Nicotinamide for skin cancer chemoprevention: effects on tumour immune infiltrates and melanoma biology. Australasian College of Dermatology Meeting, Sydney, Australia, May 2017.

191. Star P, Rawson R, **Scoflyer R.A**, Guitera P. Defining lentigo maligna(LM) and its margins and identifying predictors for recurrence: Correlation of clinical, dermatoscopic(DS), confocal microscopy (RCM) and histopathological data. 50th Annual Scientific Meeting, Sydney, Australia, 6-9 May 2017.
192. Collgros H, Uribe P, Ardigo M, **Scoflyer R.A**, Guitera P. In vivo Reflectance confocal microscopy on the lip: From normal to sun damaged skin and non-melanocytic skin cancer. 50th Annual Scientific Meeting, Sydney, Australia 6-9 May 2017.
193. Star P, Rawson R, **Scoflyer RA**, Lee K, Stretch J, Guitera P. The application of the SMART scoring technique to the mapping of lentigo maligna prior to surgery: Case Series of Five Patients. Australasian Melanoma Conference, Sydney, Australia, 28-29 October 2016.
194. Star P, Jackett L, **Scoflyer R.A**, Cheung K, Guitera P, Long GV, Martin L. Multiple recurring squamoproliferative lesions in patients receiving immunotherapy for metastatic melanoma: a clinicopathological study of two cases. 37th Australasian Dermatopathology Society Annual Meeting,, Auckland, New Zealand, 9 – 11 September 2016.
195. Martin AJ, Chen A, Choy B, Fernandez Penas P, Halliday G, Dalziel R, McKenzie C, **Scoflyer R.A**, Dhillon HM, Vardy JL, St George G, Chinniah N, Damian D. Oral nicotinamide to reduce actinic cancer: A phase 3 double-blind randomized controlled trial. ASCO. J Clin Oncol 33, 2015 (suppl; abstr 9000).
196. Minocha R, Chen A, **Scoflyer R.A**, Lyons G, Madore J, Choy B, Fernandez Penas P, Halliday G, Dalziel R, McKenzie C, Halliday G, Damian D. Nicotinamide chemoprevention and immunomodulation in melanoma and non-melanoma skin cancer. Australas J Dermatol 57(Suppl 1), p64, 2016.
197. Damian D, Chen A, Martin A, Choy B, Fernandez Penas P, Dalziel R, McKenzie C, **Scoflyer RA**, Dhillon H, Vardy J, Halliday G. Oral nicotinamide reduces transepidermal water loss: a randomised controlled trial. Australas J Dermatol 57(Suppl 1), p31, 2016.
198. Damian D, Chen A, Martin A, Choy B, Fernandez Penas P, Dalziel R, McKenzie C, **Scoflyer RA**, Dhillon H, Vardy J, Halliday G. Oral nicotinamide for skin cancer chemoprevention: the ONTRAC study and clinical practice. Australas J Dermatol 57(Suppl 1), p22, 2016.
199. Saw RPM, Menzies AM, Guminski A, Nieweg OE, Shannon KF, Gonzalez M, Ch'ng S, Kefford RF, Thompson JF, Stretch J, Spillane AJ, **Scoflyer RA**, Long GV. Phase 2 study of neoadjuvant dabrafenib + trametinib (D+T) for resectable stage iiib/c BRAF-V600 mutation positive melanoma. ASCO Annual Meeting, Chicago, USA, 3-7 June 2016.
200. Long GV, Atkinson V, Menzies AM, Guminski A, Sandhu S, Brown MP, Liaw TYE, Gonzalez M, Davison J, **Scoflyer RA**, Emmett L, McArthur G. A Randomized Phase 2 Study of Nivolumab and Nivolumab Combined With Ipilimumab in Patients (Pts) With Melanoma Brain Metastases: The Anti-PD1 Brain Collaboration (ABC Study). ASCO Annual Meeting, Chicago, USA, 3-7 June 2016.
201. Chen AC, Martin AJ, Choy B, Fernández-Peñas P, Dalziel R, McKenzie CA, **Scoflyer RA**, Dhillon HM, Vardy JL, Kricker A, St George G, Chinniah N, Halliday GM, Damian DL. Oral nicotinamide for non-melanoma skin cancer chemoprevention. Taiwanese Dermatological Association Spring Meeting, Kaohsiung, Taiwan, Apr - 1 May 2016.
202. Welsh SJ, Boyd S, McGuire H, Gonzales M, Menzies AM, Kakavand H, James E, Smith E, Fazekas B, Guminski A, Kefford RF, **Scoflyer RA**, Long GV, Rizos H. In depth profiling of the response of melanoma to MAPK inhibition. Oral presentation, AACR Annual Meeting, New Orleans, USA, 16-20 April 2016.
203. Murali R, van de Nes J, Gessi M, Sucker A, Moeller I, Stiller M, Horn S, Scholz S, Pischler C, Stadler N, Schilling B, Zimmer L, Hillen U, **Scoflyer RA**, Buckland M, Lauriola L, Pietsch T, Waha A, Schadendorf D, Griewank K. Targeted Next Generation Sequencing Reveals Unique Mutation Profile of Primary Melanocytic Tumors of the Central Nervous System. United States & Canadian Academy of Pathology (USCAP) Meeting, Washington, USA, 12-18 March 2016.
204. Satgunaseelan L, Villain RE, Madore J, Chia N, Lum T, Boyer M, **Scoflyer RA**, Clark J, Gupta R. Programmed Cell Death-Ligand 1 (PD-L1) expression in Oral Cavity Squamous Cell Carcinoma (OSCC). United States & Canadian Academy of Pathology (USCAP) Meeting, Washington, USA, 12-18 March 2016.
205. Henderson MA, Fisher R, Di Iulio J, Gyorki D, Spillane J, Speakman D, Burmeister B, Ainslie J, Smithers M, Hong A, Shannon K, **Scoflyer RA**, Carruthers S, Coventry B, Babbington S, Duprat J, Hoekstra H, Thompson JF. Long Term Prospective Assessment of Quality of Life and Lymphoedema after Inguinal or Inguinal and Pelvic Lymphadenectomy for Recurrent Melanoma in the Groin. Society of Surgical Oncology, Boston, USA, 2-5 March 2016.
206. Chen A, Martin A, Choy B, Fernández-Peñas P, Dalziel R, McKenzie C, **Scoflyer RA**, Dhillon H, Vardy J, Kricker A, St George G, Chinniah N, Halliday G, Damian D. 'Oral nicotinamide for non-melanoma skin cancer chemoprevention.' Asia and Oceania Conference on Photobiology, Taipei, Taiwan, 15-18 November 2015.
207. Foote M, Smithers M, Thompson JF, Hong A, Fogarty G, **Scoflyer RA**, Henderson M, Estall V, Potter A, Paton E, Lucas A, Barker C, Lian M, Burmeister B. ANZMTG 01.09 TROG 08.09 An International Randomised Trial of Post-operative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck. 2nd Global Advances and Controversies in Skin Cancer Conference (GAC-SC), Brisbane, Australia 29–31 October, 2015.
208. Boyd SC, Welsh SJ, Kakavand H, Guminski G, Kefford RF, Menzies AM, **Scoflyer RA**, Long GV, Rizos H. Circulating Tumour DNA to Monitor Treatment Response in Early Stage Melanoma Patients. ASMR 2015.
209. McKenzie C, Chen AC, Martin AJ, Dalziel R, **Scoflyer RA**, Dhillon HM, Vardy JL, Halliday GM, Damian DL. Oral nicotinamide to reduce nonmelanoma skin cancer in renal transplant recipients: a Phase 2 randomized controlled trial. Banff-CST Joint Scientific Meeting to be held in Vancouver, BC from 5-10 October, 2015.
210. Lee JL, Vilain RE, **Scoflyer RA**, Mihm MC, Lian CG. 5-Hydroxymethylcytosine Immunoreactivity in Pigmented Epithelioid Melanocytomas Supports Their Uncertain Biological Potential. American Society of Dermatopathology 2015 Meeting, Vancouver, Canada, 8 June, 2015.
211. Kakavand H, Lum T, Wilmott JS, Smith E, O'Toole S, Long GV, **Scoflyer RA**. BRAF (V600E) and NRAS (Q61R/Q61L) mutation analysis using immunohistochemistry: implications for routine mutation testing of melanoma samples. Asia Pacific International Anatomical Pathology conference, Brisbane, Australia, 4-7 June, 2015.
212. Wargo JA, Amaria RN, Ross MI, Saw RPM, Gershenwald JE, Hwu P, Patel SP, Glitza IC, Diab A, Kefford RF, **Scoflyer RA**, Rizos H, Thompson JF, Shannon K, Spillane A, Carlino MS, Guminski A, Simpson L, Davies MA, Long GV. 'Neoadjuvant BRAF (dabrafenib) and MEK (trametinib) inhibition for high-risk resectable stage III and IV melanoma.' 2015 ASCO Annual Meeting, Chicago, USA, 29 May-2 June 2015.
213. Eroglu Z, Kim DW, Johnson DB, Algazi AP, Munhoz RR, Liniker E, Kong B, Khurana N, Chmielowski B, Sosman JA, **Scoflyer RA**, Carlino MS, Postow MA, Hwu W-J, Long GV, Ribas A. 'Response to anti-PD1/PDL1 therapy in patients with metastatic desmoplastic melanoma.' 2015 ASCO Annual Meeting, Chicago, USA, 29 May-2 June 2015.
214. Johnson DB, Menzies AM, Zimmer L, Eroglu Z, Ye F, Zhao S, Sucker A, Rizos H, Hugo W, Gutzmer R, Kefford RF, Gogas H, Kong X, **Scoflyer RA**, Garraway LA, Sosman JA, Ribas A, Lo RS, Long GV, Schadendorf D. BRAF inhibitor acquired resistance: A

- multicenter meta-analysis of the spectrum and clinical implications of resistance mechanisms. 2015 ASCO Annual Meeting, Chicago, USA, 29 May-2 June 2015.
215. Martin AJ, Chen A, Choy B, Penas PF, Halliday G, Dalziel R, McKenzie C, **Scoflyer RA**, Dhillon HM, Vardy JL, St George G, Chinniah N, Damian D. Oral nicotinamide to reduce actinic cancer: A phase 3 double-blind randomized controlled trial. ASCO Chicago, USA, 29 May-2 June, 2015.
 216. Long GV, Fung C, Menzies AM, Pupo G, Carlino MS, Hyman J, Shahheydari H, Tembe V, Thompson J, Saw R, Howle J, Hayward N, Johansson P, **Scoflyer RA**, Kefford RF, Rizos H. Predominance of MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF mutant metastatic melanoma. 2014 Society for Melanoma Research International Congress, Zurich, Switzerland, 13-16 November, 2014. Published in: *Pigment Cell & Melanoma Research*, 27:1223, 2014 (poster presentation).
 217. Madore J, Menzies AM, Kakavand H, Wilmott JS, Hyman J, Horak CE, Simon JP, Cogswell JP, Inzunza HD, Kefford RF, Thompson J, Long GV, Hersey P, **Scoflyer RA**. Inpatient heterogeneity of tumoural PD-L1 expression in immunotherapy-naïve metastatic melanoma. 2014 Society for Melanoma Research International Congress, Zurich, Switzerland, 13-16 November, 2014. Published in: *Pigment Cell & Melanoma Research*, 27:1208, 2014 (poster presentation).
 218. Kakavand H, Wilmott JS, Menzies AM, Vilain R, Haydu LE, Yearly J, Thompson J, Kefford R, Hersey P, Long GV, **Scoflyer RA**. PDL1 expression and tumor infiltrating lymphocytes define different subsets of MAPK inhibitor treated melanoma patients. 2014 Society for Melanoma Research International Congress, Zurich, Switzerland, 13-16 November, 2014. Published in: *Pigment Cell & Melanoma Research*, 27:1201, 2014 (poster presentation).
 219. Chen A, Martin A, Choy B, Fernández-Peñas P, Dalziel R, McKenzie C, **Scoflyer RA**, Dhillon H, Vardy J, Krick A, St George G, Chinniah N, Halliday G, Damian D. Oral nicotinamide for skin cancer chemoprevention. 11th EADO Congress & 8th World Meeting of Interdisciplinary Melanoma/Skin Cancer Centres, Marseille, France, 28-31 October, 2015.
 220. Ziman M, Gray E, Rizos H, Reid A, Boyd S, Lo J, Tembe V, Freeman J, Lee J, **Scoflyer RA**, Siew K, Cooper A, Khattak M, Long GV, Carlino M, Millward M. Circulating tumour DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. 11th EADO Congress & 8th World Meeting of Interdisciplinary Melanoma/Skin Cancer Centres, Marseille, France, 28-31 October, 2015.
 221. Dutton-Regester K, Gartner JJ, Emmanuel R, Qutob N, Davies M, Gershenwald J, Robinson W, Robinson S, Rosenberg S, **Scoflyer RA**, Mann G, Thompson J, Hayward N, Samuels Y. Highly recurrent RPS27 5'UTR mutations in melanoma. 2014 Society for Melanoma Research International Congress, Zurich, Switzerland, 13-16 November, 2014. Published in: *Pigment Cell & Melanoma Research*, 27:1192, 2014 (poster presentation).
 222. Cooper A, Carlino MS, Saunders C, Pupo GM, Menzies AM, Thompson JF, **Scoflyer RA**, Long GV, Kefford RF, Rizos H. Tumour glucose metabolism is maintained on withdrawal of BRAF and MEK inhibition in acquired BRAF/MEK inhibitor resistance. 2014 Society for Melanoma Research International Congress, Zurich, Switzerland, 13-16 November, 2014. Published in: *Pigment Cell & Melanoma Research*, 27:1182, 2014 (poster presentation).
 223. Jakrot V, Smith E, Long GV, **Scoflyer RA**, Mann G. Managing Tumour Requirements for Mutation Testing and Clinical Trial Entry. 2nd National Melanoma Conference, Perth, Australia, October 2014.
 224. Valey A, Hong A, Mann G, Stretch J, Saw R, Spillane A, Shannon K, Lee K, Thompson JF, **Scoflyer RA**. Neurotropic melanomas: Clinical behaviour and radiotherapy responsiveness. 2nd National Melanoma Conference, Perth, Australia, 10-11 October, 2014 (poster presentation).
 225. Davies MA, Tawbi H, Ouellet D, Lazar AJF, Weinberg JS, Butterfield LH, Hamilton RL, Amankulor N, Engh JA, Shivalingham B, Kefford RF, **Scoflyer RA**, Mahmood S, Richards-Peterson LE, Swann S, Arbushites MC, Long GV, Kirkwood JM. Pharmacokinetic and pharmacodynamic analysis of preoperative therapy with dabrafenib alone and in combination with trametinib in patients with BRAF mutation-positive melanoma with metastases to the brain (BRV116521). ASCO Meeting Abstracts, Chicago, USA, May-June, 2014.
 226. Carlino MS, Fung C, Shahheydari H, Todd JR, **Scoflyer RA**, Kefford RF, Long GV, Rizos H. Correlation between pre-existing MEK1P124 mutations and clinical and invitro response to BRAF inhibitors in metastatic melanoma. ASCO Meeting Abstracts, Chicago, USA, May-June, 2014.

CONFERENCE POSTERS

1. James S. Wilmott+, Alexander M. Menzies+, Ismael A. Vergara*, Serigne N. Lo, Naoyuki Maeda, Kumiko Koyama, Ines Pires da Silva, Georgina V. Long, **Richard A. Scoflyer**, Eva R. Shteinman* (*/+These authors contributed equally to this work). Molecular and clinical correlates of HER3 expression in melanoma. Abstract accepted as a poster presentation to International Academy of Pathology (IAP) 2022 - Sydney - Bridge to a Cure in Sydney/Virtual on 11-15 October 2022.
2. ILM Reijers, AM Menzies, JM Versluis, P Dimitriadis, MW Wouters, RPM Saw, WMC Klop, TE Pennington, WJ van Houdt, LJW Bosch, S Cornelissen, M Lopez-Yurda, LG Griepink-Ongering, RV Rawson, AJ Spillane, **RA Scoflyer**, BA van de Wiel, ACJ van Akkooi, GV Long and CU Blank. Relapse-free survival (RFS) update and first translational analyses of DONIMI, a study testing personalized neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in stage III melanoma patients (pts) based on the interferon-gamma signature (IFN- γ sign) algorithm. Abstract submitted to and accepted for post presentation at ESMO Congress 2022 in Paris, France on 9-13 September 2022.
3. Georgina V. Long, Andrew Spillane, Thomas Pennington, Kerwin Shannon, Jonathan Stretch, Maria Gonzalez, Robyn P.M. Saw, Serigne Lo, **Richard A. Scoflyer**, Alexander M. Menzies. NeoPeLe: A Phase 2 Trial of Neoadjuvant (NAT) Pembrolizumab (Pembro) Combined with Lenvatinib (Lenva) In Resectable Stage III Melanoma. Abstract submitted to and accepted as poster presentation at ESMO Congress 2022 in Paris, France on 9-13 September 2022.
4. Alexander HR Valey, Mary-Ann El-Sharouni, Julie Simon, Jeffrey E Gershenwald, Georgina V Long, Richard A Scoflyer, John F Thompson, Serigne N Lo. Predicting recurrence free survival for stage II melanoma patients – a validated tool to guide adjuvant systemic therapy. 2.5.22: Abstract submitted to and accepted as poster presentation at ESMO Congress 2022 in Paris, France on 9-13 September 2022.
5. JM Versluis, K Sikorska, EA Rozeman, AM Menzies, H Eriksson, WMC Klop, RPM Saw, BA van de Wiel, RA Scoflyer, JV van Thienen, H Mallo, A Torres Acosta, M Gonzalez, LG Griepink-Ongering, A van der Wal, JBAG Haanen, ACJ van Akkooi, GV Long and CU Blank. Survival update of neoadjuvant ipilimumab + nivolumab in macroscopic stage III melanoma – the OpACIN and OpACIN-neo trials. Selected for poster presentation at 2022 ASCO Annual Meeting in Chicago/Virtual on 3-7 June 2022.

6. M.W. Lucas, J.M. Lijnsvelt, S.M. Pulleman, **R.A. Scolyer**, A.M. Menzies, A.C.J. van Akkooi, W.J. van Houdt, K. Shannon, T.E. Pennington, K.P.M. Suijkerbuijk, E.W. Kapiteijn, A.A.M. van der Veldt, M.S. Carlino, S. Sandhu, M. Gonzalez, C.L. Zuur, W.M.C. Klop, G.V. Long and C.U. Blank. The NADINA trial: A multicenter, randomised phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma. Selected for poster presentation at 2022 ASCO Annual Meeting in Chicago/Virtual on 3-7 June 2022.
7. ILM Reijers, P Dimitriadis, EA Rozeman, O Krijgsman, S Cornelissen, LJW Bosch, A Broeks, AM Menzies, BA van de Wiel, **RA Scolyer**, GV Long and CU Blank. The interferon-gamma (IFN- γ) signature from baseline tumor material predicts pathologic response after neoadjuvant ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma. Selected for poster presentation at 2022 ASCO Annual Meeting in Chicago/Virtual on 3-7 June 2022.
8. Serigne N. Lo, Tuba N. Gide, Maria Gonzalez, Ines P. da Silva, Alexander Menzies, Matteo S. Carlino, **Richard A. Scolyer**, Stephane Heritier, James S. Wilmott, Georgina V. Long. A biomarker guided Bayesian response-adaptive phase II trial for metastatic melanoma: The Personalized Immunotherapy Platform (PIP)-Trial design. Selected for poster presentation at 2022 ASCO Annual Meeting in Chicago/Virtual on 3-7 June 2022.
9. Alexander M Menzies, Robyn P M Saw, Serigne Lo, Maria Gonzalez, Sydney Ch'ng, Omgo E Nieweg, Kerwin F Shannon, Peter M Ferguson, Jenny Lee, Helen Rizos, Robert V Rawson, Jonathan R Stretch, John F Thompson, Louise Emmett, Rony Kapoor, Andrew J Spillane, **Richard A Scolyer**, Georgina V Long. Neoadjuvant dabrafenib and trametinib (D+T) for stage III melanoma – long-term results from the NeoCombi trial. Selected for poster presentation at 2022 ASCO Annual Meeting in Chicago/Virtual on 3-7 June 2022.
10. Ines Pires da Silva, Serigne Lo, Jordan Conway, **Richard A. Scolyer**, Matteo Carlino, Alexander Menzies, Georgina Long. VEGF inhibitors (VEGFi) activity in liver metastases (mets) regardless of primary cancer type: meta-analysis and systematic review. Selected for poster presentation at 2022 ASCO Annual Meeting in Chicago/Virtual on 3-7 June 2022.
11. Canan Güvenç, Asier Antoranz, Madhavi Dipak Andhari, Anna Szumera-Cie'ckiewicz, Pawel P. Teterycz, Piotr R. Rutkowski, Robert V. Rawson, **Richard A. Scolyer**, John F. Thompson, Julia Newton-Bishop, Marguerite Stas, Veerle Boecxstaens, Oliver Bechter, Jurgen Vercauteren, Marjan Garmyn, Joost van den Oord, and Francesca Maria Bosisio. Metastasizing and Non-Metastasizing Thick Melanomas: Molecular profiling and in situ validation through MILAN multiplexing. Selected for poster presentation at the 18th European Association of Dermato-Oncology (EADO) Congress in Seville, Spain on 21-23 April 2022.
12. Grace H. Attrill, Teresa A. Bailey, Trina Lum, Jordan W. Conway, Georgina V. Long, James S. Wilmott, **Richard A. Scolyer**. Molecular analysis finds excision margin width predictive of recurrence in acral melanoma. Selected as a poster at American Association for Cancer Research (AACR) Annual Meeting 2022, New Orleans, Louisiana (8-13 April 2022).
13. Leila Moayed-Alaei, Stephen Mann, Elizabeth C. Paver, **Richard A. Scolyer**. The utility of molecular testing in the diagnosis of undifferentiated metastatic melanoma in a patient with multiple primaries. Accepted as a poster at The Royal College of Pathologists of Australasia's Pathology Update 2022 "In Our Hands" (4-6 March 2022) (Sydney)
14. Kenneth Onimus, Adrian Wells, Courtney Herman, Ahmed Tawashi, Georgina V. Long, **Richard A. Scolyer**, Rebecca Velickovic, Robyn P M Saw, Thomas E Pennington, Alexander M. Menzies, Madan Jagasia, Arvind Natarajan, Anand Veerapathran. Successful Manufacturing of Tumor-infiltrating Lymphocyte (TIL) Cell Therapy from Cryopreserved Melanoma Tumors Shipped from Australia. Accepted as a poster presentation at the 2022 Tandem Meetings, Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR are the combined annual meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) in Salt Lake City on the 2-6 February 2022.
15. Sandhu S, Spain L, Chua M, Pattison D, Guminski, A, Roach P, Hruby G, Wyld D, Lin C, Chua B, Xu W., Law P, Foote M, Meniawy T, Francis R, Dass J, Brown M, Kirkwood I, Gorayski P, Yap M, Vargas S, Cumming S, Gonzales L, Tothill R, Neeson P, Pope K, Poulsen M, Atkinson V, Lo S, Gill A, Scolyer R, Fogarty G, Hicks R. GoTHAM A phase IB/II study of combination avelumab with peptide receptor radionuclide therapy or conventional fractionated radiotherapy in patients with metastatic Merkel cell carcinoma. Poster presented at Australasian Melanoma Conference (AMC) 2021 (19-20 November 2021) (Sydney-hybrid)
16. E Paver, A Potter, K Dempsey, R Morton, **R Scolyer**. Types of biopsy performed and clinical information provided for pathological evaluation of suspected melanomas at a tertiary referral centre. Poster presented at Australasian Melanoma Conference (AMC) 2021 (19-20 November 2021) (Sydney-hybrid)
17. Colebatch AJ*, Paver EC*, Vergara I, John F. Thompson, Georgina V. Long, Wilmott JS, **Scolyer RA** (*contributed equally). Elevated non-coding promoter mutations are associated with malignant transformation of melanocytic naevi to melanoma. Poster presented at Australasian Melanoma Conference (AMC) 2021 (19-20 November 2021) (Sydney-hybrid)
18. Genevieve Ho; Rodrigo J Schwartz; Amanda Regio Pereira; Florentia Dimitrou; Elizabeth Paver, Catriona McKenzie, Robyn P.M. Saw, **Richard A Scolyer**, Georgina V Long, Pascale Guitera. Reflectance confocal microscopy for assessment of treatment response to anti-PD1 based immunotherapy in synchronous Stage III primary scalp melanoma. Poster presented at Australasian Melanoma Conference (AMC) 2021 (19-20 November 2021) (Sydney-virtual).
19. Jorja Braden, Elizabeth Paver, Alison Potter, Alexander Menzies, Matteo Carlino, George Au-Yeung, R.P.M. Saw, Andrew J. Spillane, Jonathan F. Stretch, Kerwin Shannon, Tom E. Pennington, Sydney. Ch'ng, David Gyorki, Julia Howle, Dariush Daneshvar, Ines Pires Da Silva, **Richard A. Scolyer**, James S. Wilmott, Georgina V. Long. Translational Investigation into the Optimal Neoadjuvant Sequencing of Anti-PD1 and BRAF targeting therapy in Resectable BRAF Mutant stage IIIB/C/D Melanoma: Results of Translational Investigations. Accepted for poster presentation at Clinical Oncology Society of Australia (COSA) Annual Scientific Meeting (16-18 November 2021).
20. Georgina V. Long, Reinhard Dummer, Anna C. Pavlick, Michael A. Postow, Antoni Ribas, Caroline Robert, **Richard A. Scolyer**, Janis M. Taube, Michael Tetzlaff, Shu-Chih Su, Rohini Singh, Scott J. Dieder, Hussein Abdul-Hassan Tawbi. KEYMAKER-U02: Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Melanoma. Accepted as an e-poster to Clinical Oncology Society of Australia (COSA) Annual Scientific Meeting (16-18 November 2021)
21. AJ Potter, AT Li, JF Thompson, GV Long, S Ch'ng, **RA Scolyer**. Driver mutation status of cutaneous scalp melanoma. Submitted and accepted as a poster presentation at The American Society of Dermatopathology (ASDP) 58th Virtual Annual Meeting (20-24 October 2021) (virtual)
22. Mathias Seviiri, **Richard A. Scolyer**, John F. Thompson, D. Tim Bishop, Mark M. Iles, Georgina V. Long, Stuart MacGregor, and Matthew H. Law. A large genome-wide association study for melanoma-specific survival reveals two novel loci linked to PSEN2, and ADCK3 genes. American Society of Human Genetics (ASHG) Conference 2021 (accepted for a poster presentation) (18-22 October 2021) (virtual).
23. Noëlle M.J. van den Heuvel, Irene L.M. Reijers, Judith M. Versluis, Alexander M. Menzies, Jacobien M. Kieffer, Nikoleta Kapsali, Michel W.J.M. Wouters, Robyn P.M. Saw, Willem M.C. Klop, Thomas E. Pennington, Mary-Jane Gregorio, Andrew J. Colebatch,

- Andrew Spillane, Bart. A. van de Wiel, **Richard A. Scolyer**, Alexander C.J. van Akkooi, Lonneke V. van de Poll-Franse, Georgina V. Long, Christian U. Blank, Annelies H. Boekhout. Health-Related Quality of Life in Melanoma patients treated with Neoadjuvant Nivolumab and Domatinostat: preliminary results. Poster at ESMO Congress 2021 (16-21 Sept) virtual
24. Christopher G. Harris, Serigne N. Lo, Tasnia Ahmed, **Richard A. Scolyer**, Peter M. Ferguson, Rooshdiya Karim, Tai Khoa Lam, Kenneth K Lee, Kerwin F. Shannon, Andrew J. Spillane, Jonathan R. Stretch, John F. Thompson and Robyn PM Saw. Poster presentation at Primary dermal melanoma: prognosis and treatment implications. World Congress of Melanoma-EADO 2021 (virtual) – 15-17 April 2021.
 25. David Coker, Annal Lawless, Serigne Lo, Tasnia Ahmed, **Richard A. Scolyer**, Sydney Ch'ng, Omgo Nieweg, Kerwin Shannon, Andrew Spillane, Jonathan Stretch, John F Thompson, Robyn Saw. Outcomes following surgical resection of in-transit melanoma metastases. Poster presentation at World Congress of Melanoma-EADO 2021 (virtual) – 15-17 April 2021.
 26. Camelia Quek* , Ines P Silva*, Ghamdan Al-Eryani*, Aron Mayer, Nenad Bartonicek, Kate Harvey, Chi Buckley, Oliver Braubach, Robyn P M Saw, Jonathan Stretch, Kerwin Shannon, Alex M Menzies, **Richard A Scolyer***, Georgina V. Long*, Alexander Swarbrick*, James S Wilmott* (*contributed equally). CODEX multiplex image mapping to CITEseq datasets in immunotherapy treated melanoma. Poster presentation at AACR Annual Meeting 2021 (virtual) 9-14 April 2021.
 27. Jordan W. Conway, Robert V. Rawson, James S. Wilmott, Georgina V. Long, **Richard A. Scolyer**, Inês Pires da Silva. Spatial distribution and immune cell infiltration at different sites of melanoma metastases (mets). Poster presentation at AACR Annual Meeting 2021 (virtual) 9-14 April 2021.
 28. R. Dummer, G. V. Long, A. C. Pavlick, M. A. Postow, A. Ribas, C. Robert, **R. A. Scolyer**, J. M. Taube, M. Tetzlaff, S-C. Su, R. Singh, Scott J. Diede, H. A-H. Tawbi. KEYMAKER-U02: Phase 1/2 study of investigational agents with or without pembrolizumab or pembrolizumab alone in patients with melanoma. Accepted as e-poster at World Congress of Melanoma-EADO 2021 (virtual) – 15-17 April 2021.
 29. Matthew Gibson, , **Richard Scolyer** Peter Soyer, Peter Ferguson, Les Irwig, Kevin Mcgeechn, Katy JL Bell. Estimating the potential impact of interventions to reduce over-calling and under-calling of melanoma. Accepted as poster presentation at The Australasian College of Dermatologists (ACD) ASM 2021 – virtual 9-11 April 2021. Accepted for poster presentation.
 30. R Dummer; GV Long; M Postow; A Ribas; C Robert; **RA Scolyer**; JM Taube; M Tetzlaff; SC Su; S Ahsan, SJ Diede; HA Tawbi. KEYMAKER-U02: Phase 1/2 Study of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Monotherapy in Melanoma. E-poster presented at SITC 2020 (virtual) 11-14 November 2020.
 31. Donya Tohidi-Esfahani, Karina Aivazian, Andrew J. Spillane, James S. Wilmott, **Richard A. Scolyer**. Utility of next generation sequencing for differentiating malignant PEComa from melanoma metastasis. Event: Sydney Catalyst Postgraduate and Early Career Researcher Symposium 2020 – Friday 30th October 2020, Sydney.
 32. Reinhard Dummer, Georgina V. Long, Anna Pavlick, Michael Postow, Antoni Ribas, Caroline Robert, **Richard A. Scolyer**, Janis M. Taube, Michael Tetzlaff, Jason Liao, Sama Ahsan, Scott J. Diede, Hussein A. Tawbi. MK-3475-U02: Phase 1/2 study of investigational agents with or without pembrolizumab versus pembrolizumab monotherapy in melanoma. Congress: 6.10.2020 – accepted as a poster to the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2020– 9-14 November 2020 (virtual).
 33. M Gonzalez, AM Menzies, T. Pennington, RPM Saw, AJ Spillane, JR Stretch, KF Shannon, S Ch'ng, OE Nieweg, M Cruzado, M Osorio, RV Rawson, PM Ferguson, H Rizos, S Lo, **RA Scolyer**, GV Long. A phase II study of neoadjuvant pembrolizumab and lenvatinib for resectable stage III melanoma: The neopele study. Poster presented ASCO 2020 (virtual) poster presentation.
 34. Elisa A. Rozeman, Irene L.M. Reijers, Esmée P Hoefsmit, Karolina Sikorska, Oscar Krijgsman, Bart A. Van De Wiel, Petros Dimitriadis, Hanna Eriksson, Maria Gonzalez, Lindsay G Grijpink-Ongering, Ron M. Kerkhoven, Annegien Broeks, Willem M.C. Klop, Andrew Spillane, Robyn Saw, Alexander Christopher Jonathan Van Akkooi, **Richard A. Scolyer**, Alexander M. Menzies, Georgina V. Long, Christian U. Blank. 24-months RFS and updated toxicity data from OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant Ipilimumab (IPI) and Nivolumab (NIVO) in stage III melanoma. Abstract – virtual ASCO 2020 (accepted as poster discussion).
 35. NMJ Van den Heuvel, IRM Reijers, EA Rozeman, JM Versluis, K Józwiak, AJ Spillane, **RAScolyer**, TE Pennington, RPM Saw, M Gonzalez, WJ van Houdt, WMC Klop, MWJM Wouters, AM Menzies, ACJ Van Akkooi, LV van de Poll-Franse, GV Long, CU Blank, AH Boekhout. Health-related quality of life in stage III melanoma patients treated with neoadjuvant ipilimumab and nivolumab followed by index lymph node excision only, compared to therapeutic lymph node dissection: First results of the PRADO trial. Poster presented at virtual ASCO 2020.
 36. Karina Aivazian, Annabelle Mahar, **Richard A. Scolyer**. GLI Activated Paraganglioma-like Malignant Epithelioid Cell Tumour. Poster - Roche Scientific Poster Display, Anatomical Pathology – RCPAQAP Pathology Update 2020 (March 2020).
 37. Rossello F, Posner A, Raleigh J, Hatzimihalis A, Sandhu S, Neeson P, Para S.Q, Becker J.C, De Ieso P, Johnston M, Chua M, McArthur G, Gill A.J, **Scolyer R.A**, Hicks R, Godfrey D.I and Tohill R.W. Exploring Gamma Delta T Cells in Merkel Cell Carcinoma. Poster @ 41st Annual Lorne Genome Conference 2020 (16-18 Feb 2020).
 38. Asmi Chakraborty, Norhan Mohammed, Michael Wells, James S. Wilmott, John F. Thompson, Stuart R. Haslam, Wei Wang, **Richard A. Scolyer**, George F. Murphy and Charles J. Dimitroff. Melanoma metastasis-related GCNT2 suppression is induced by hypoxia. Poster - NIH/NCI Alliance of Glycobiologists Tumor Glycobiological Laboratories U01 meeting in Washington DC. Feb 2020.
 39. J. J. Luke; P. A. Ascierto; M. S. Carlino; J. E. Gershenwald; J.-J. Grob; A. Hauschild; J. Kirkwood; G.V. Long; P. Mohr; C. Robert; M. Ross; **R.A. Scolyer**; C. H. Yoon; A. S. Poklepovic; P. Rutkowski; J. R. Anderson; S. Ahsan; N. Ibrahim; A.M.M. Eggermont. Adjuvant Pembrolizumab in Patients With Resected High-Risk Stage II Melanoma: Phase 3 KEYNOTE-716 With Crossover or Rechallenge SMR, Salt Lake City. Nov. 2019.
 40. Hauschild, A, Ascierto P, Matteo C, Eggermont A, Gershenwald J, Grob JJ, Kirkwood, J, Luke J, Mohr P, Robert C, Merrick R, **Scolyer R**, Yoon C, Poklepovic A, Rutkowski P, Anderson J, Ahsan S, Ibrahim N, Long, G. Adjuvant Pembrolizumab (pembro) in Patients (pts) With Resected High-Risk Stage II Melanoma: Phase 3 KEYNOTE-716 With Crossover or Rechallenge. SMR 2019
 41. Grace H. Attrill*, Carina Owen* (*Co-authors), Tasnia Ahmed, Serigne Lo, Andrew Colebatch, Jordan W. Conway, Inês Pires da Silva, Matteo S. Carlino, Alexander M. Menzies, Maintho Palendira, **Richard A. Scolyer**, Georgina V. Long, James S. Wilmott. CD103+CD39+PD-1+ CD8+ T cells are associated with a reduced risk of recurrence in adjuvant PD-1 treated-stage III melanoma patients. SMR 2019.
 42. Tuba N. Gide, Ines P. Silva, Camelia Quek, Tasnia Ahmed, Alexander M. Menzies, Matteo S. Carlino, Robyn P.M. Saw, John F. Thompson, Marcel Batten, Georgina V. Long, **Richard A. Scolyer**, James S. Wilmott. 'Close Proximity of Immune and Tumor Cells Underlies Response to Anti-PD-1 Based Therapies in Metastatic Melanoma Patients.' SMR 2019.

43. Ines Pires da Silva, Tasnia Ahmed, Serigne Lo, Matteo S. Carlino, **Richard A. Scolyer**, Alexander M. Menzies, Georgina V. Long. Clinical factors and overall survival (OS) associated with patterns of metastases (mets) in melanoma patients (pts). ESMO Sept 27th – Oct 1, 2019, Barcelona, Spain.
44. Kazi Nahar, Robert V Rawson, Nemes Sandanayake, Stephen Tattersal, Matteo S Carlino, Umaimainthan Palendira, **Richard A Scolyer**, Georgina V Long, Alexander M Menzies. Clinico-pathologic characteristics of immune colitis in melanoma patients treated with combination ipilimumab and anti-PD1(IPI+PD1) and PD1 monotherapy. ESMO Sept 27th – Oct 1, 2019, Barcelona, Spain.
45. JM Versluis, ILM Reijers, EA Rozeman, AM Menzies, ACJ van Akkooi, WJ van Houdt, C Bierman, **RA Scolyer**, BA van de Wiel, GV Long, CU Blank. Comparable responses of melanoma at primary site and synchronous lymph node metastases upon neoadjuvant ipilimumab (IPI) and nivolumab (NIVO). ESMO Sept 27th – Oct 1, 2019, Barcelona, Spain.
46. ILM Reijers, EA Rozeman, AM Menzies, JM Versluis, BA van de Wiel, K Sikorska, H Eriksson, K Shannon, C Bierman, H van Tinteren, M Gonzalez, AJ Spillane, RPM Saw, ACJ van Akkooi, **RA Scolyer**, J Hansson, GV Long and CU Blank. Continental differences in pathologic response to neoadjuvant ipilimumab (IPI) plus nivolumab (NIVO) in patients with macroscopic stage III melanoma in the phase 2 OpACIN-neo trial. ESMO Sept 27th – Oct 1, 2019, Barcelona, Spain.
47. EA Rozeman, AM Menzies, O Krijgsman, EP Hoefsmit, BA van de Wiel, K Sikorska, TM Van, H Eriksson, C Bierman, M Gonzalez, K Shannon, A Broeks, AJ Spillane, RPM Saw, ACJ van Akkooi, **RA Scolyer**, J Hansson, GV Long and CU Blank. 18-months relapse-free survival (RFS) and biomarker analyses of OpACIN-neo: a study to identify the optimal dosing schedule of neoadjuvant Ipilimumab (IPI) + Nivolumab (NIVO) in stage III melanoma. ESMO 2019
48. Grob1 JJ, Ascierto PA, Carlino MS, Gershenwald JE, Hauschild A, Kirkwood JM, Long GV, Luke JJ, Mohr P, Poklepovic AS, Robert C, Ross MI, Rutkowski1P, **Scolyer RA**, Sondak VK, Yoon CH, Anderson JR, Ahsan S, Ibrahim N, Eggermont AMM. KEYNOTE-716: phase 3 study of adjuvant pembrolizumab (pembro) vs placebo (PBO) in resected high-risk stage II melanoma. EADO 2019
49. Silva I, Menzies AM, Newell F, Wilmott JS, Carlino MS, Ferguson P, Edwards J, Spillane A, Shannon K, Saw R, Thompson J, Rizos H, Mann G, Johansson PA, Hayward NK, **Scolyer RA**, Waddell, N, Long GV. Comprehensive molecular profiling of metastatic melanoma to predict response to monotherapy and combination immunotherapy. ASCO 2019
50. Silva I, Ahmed T, Lo S, Rai R, Smith JL, Park JJ, Nabhan C, **Scolyer RA**, Carlino MS, McQuade JL, Johnson DB, Long GV, Menzies AM. Clinical models to predict response and survival in metastatic melanoma (MM) patients (pts) treated with anti-PD-1 alone (PD1) or combined with ipilimumab (IPI+PD1). ASCO 2019
51. Carlino MS, Ascierto PA, Eggermont AMM, Gershenwald JE, Grob JJ, Hauschild A, Kirkwood JM, Long GV, Mohr P, Robert C, Ross MI, **Scolyer RA**, Sondak VK, Yoon C, Poklepovic AS, Rutkowski P, Anderson JR, Ahsan S, Ibrahim N, Luke JJ. Pembrolizumab versus placebo as adjuvant therapy in resected high-risk stage II melanoma: Phase 3 KEYNOTE-716 study. ASCO 2019
52. Fiona R Ray, Wendy A Cooper, **Richard A Scolyer**, Sean Griffin, Peter IT Lim5 Simone I Strasser, James Kench, Catriona A McKenzie. The many faces of colonic malakoplakia: A case series and review of the Literature. IAP 2019
53. Phase 3 KEYNOTE-716 Study: Adjuvant Therapy With Pembrolizumab versus Placebo in Resected High-Risk Stage II Melanoma Poster presentation at ASCO-SITC 2019 Clinical Immuno-Oncology Symposium 28 – March 2, 2019 San Francisco, CA
54. Phase 3 KEYNOTE-716 Study: Adjuvant Therapy With Pembrolizumab versus Placebo in Resected High-Risk Stage II Melanoma. USA ePoster World Congress of Dermatology (WCD) 2019 congress June 10-15, 2019 in Milan, Italy
55. J.J. Luke, P.A. Ascierto, M.S. Carlino, A.M. Eggermont, J.-J. Grob, A. Hauschild, J.M. Kirkwood, G.V. Long, P. Mohr, C. Robert, J. E. Gershenwald, A. Poklepovic, Merrick Ross, **R.A. Scolyer**, J.R. Anderson, S. Ahsan, N. Ibrahim, V.K. Sondak “Phase 3 KEYNOTE-716 Study: Adjuvant Therapy With Pembrolizumab Versus Placebo in Resected High-Risk Stage II Melanoma 33rd Annual Meeting of the Society for Immunotherapy of Cancer Washington DC November 7-11, 2018
56. Shklovskaya E, Lee J, Lim S, Alavi S, Thompson J, Saw R, Carlino M, **Scolyer R**, Menzies A, Long G, Kefford R, Rizos H Flow cytometric analysis of immune responses in the melanoma tissue biopsies before or during anti-PD1 immunotherapy 4th International Cancer Immunotherapy, Cancer Immunology Research 2019
57. “Biospecimen Banking In The Neo-adjuvant Setting” Society for Melanoma Research 15th International Congress Manchester England October 2018
58. Quek C, Shang P, Rawson R, Ferguson P, Saw R, Long G, Mann G, **Scolyer RA**, Wilmott J. “Recurrent Hotspot SF3B1 mutations in mucosal melanoma: Frequency and impact on survival” International Academy of Pathology Sydney 2018
59. Guitera P, Fogarty G, Hong A, Stretch J, **Scolyer R**, Paton E, Economides A “Clinical Management of Lentigo Maligna, a Review via the ANZMTG 02.12 RADICAL Trial” Aust. College of Dermatologists May 2018
60. Gonzalez M, Menzies AM, Saw RPM, Thompson JF, Spillane AJ, Howle J, Nieweg O, K. Shannon K, Ch'ng S, Stretch JF, Carlino MS, Guminski A, Emmett L, Rizos H, **Scolyer RA**, Long GV “A Phase II, Randomised, Open Label Study of Neoadjuvant Pembrolizumab with/without Dabrafenib and Trametinib (D+T) in BRAF V600 Mutant Resectable Stage IIIB/C/D Melanoma (NeoTrio Trial)” ESMO Congress 2017
61. Lo S, **Scolyer RA**, Thompson J “Long-term survival outcome of patients with thin (T1) cutaneous melanomas: a naturally-occurring, biologically-relevant Breslow thickness cutpoint of 0.8mm separates higher risk from lower risk tumors” World Congress Melanoma, Brisbane Australia October 2017
62. Cru Cruzado M, Sun Y, Emmett E, Dalton J, Lane S, Thompson J, Saw R, Hong A, **Scolyer R**, Guminski A, Long GV, Gonzalez M, Menzies A. “Clinical trial recruitment and management of melanoma patients who live a long-distance from a tertiary referral centre” World Congress Melanoma October 2017
63. Silva I, Wang K, Wilmott JS, Holst J, Park J, Quek C, Wongchenko M, Yan Y, Mann G, Carlino MS, Kefford RF, **Scolyer RA**, Yang J, Long GV, Rizos H, Menzies AM. Distinct gene expression, mutational profile and clinical outcomes of V600E and V600K/R BRAF-mutant metastatic melanoma (MM), ASCO Annual Meeting 2017, June 2017, Illinois, USA
64. Rozeman EA, van Akkooi ACJ, Routier E, Menzies AM, Smith M, **Scolyer RA**, Hoeller C, Hansson J, Robert C, Larkin J, Long GV, Blank CU. Multicenter phase 2 study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO) (OpACIN-neo), ASCO Annual Meeting 2017, June 2017, Illinois, USA
65. Economides A, Paton E, Fogarty G, Hong A, Stretch J, **Scolyer R** “Clinical Management of Lentigo Maligna, a Review via the ANZMTG 02.12 RADICAL Trial” Australasian College of Dermatologists May 2018
66. Helena Collgros, Pablo Uribe, Marco Ardigo, **Richard Scolyer**, Pascale Guitera. In vivo reflectance confocal microscopy on the lip: from normal to sun damaged skin and non-melanocytic skin cancer, 50th Annual Scientific meeting of the Australasian College of Dermatologist, May 2017, Sydney

67. EA Rozeman, AM Menzies, **R Scolyer**, B van de Wiel, C Lei, L Pronk, L Grippink-Ongerink, M Gonzales, JBAG Haanen, JV van Thienen, A Spillane, WM Klop R Saw, ACJ van Akkooi, GV Long, and CU Blank “OpACIN-neo – A Multicenter Phase 2 Study to identify the Optimal neo-Adjuvant Combination scheme of Ipilimumab (IPI) and Nivolumab (NIVO). ESMO 2018
68. C Krisp, J.F Thompson, R Parker, D Pascovici, J Wilmott, N Hayward, M Molloy, G Mann, **RA. Scolyer**. SWATH proteome phenotyping of melanoma identifies biomarkers of MEK response and post biopsy survival. 65th ASMS Conference, June 2017, Indianapolis, USA
69. F Saletta, RE Vilain, AK Gupta, S Nagabushan, A Yuksel, D Catchpoole1, **R Scolyer**, JA Byrne, G McCowage. PD-L1 expression and association with patient outcome in a large paediatric cohort. 28th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium November 2016. Munich, Germany.
70. McKenzie C, Chen AC, Martin AM, Dalziel R, **Scolyer RA**, Dhillon HM, Vardy JL, Halliday GM, Damian DL. Oral nicotinamide to reduce nonmelanoma skin cancer in renal transplant recipients: a pilot Phase 2 randomized controlled trial. Banff Transplant Meeting, 2015, Vancouver, Canada.
71. Dunshee I, Filho S, Drummond M, Thompson JF, Masako Ferreira L, **Scolyer RA**. Comparison of clinicopathological features and clinical outcomes of invasive amelanotic and pigmented melanomas. Annual HEMONC TODAY Melanoma and Cutaneous Malignancies Meeting, New York, USA, March 18-19 2016.
72. Murali R, van de Nes J, Gessi M, Sucker A, Moeller I, Stiller M, Horn S, Scholz S, Pischler C, Stadler N, Schilling B, Zimmer L, Hillen U, **Scolyer RA**, Buckland M, Lauriola L, Pietsch T, Waha A, Schadendorf D, Griewank K. Targeted next-generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous system. USCAP 2016 Annual Meeting, Seattle, USA, March 12-18 2016.
73. Ge L, Vilain RE, Lo S, Aivazian K, **Scolyer RA**, Thompson JF. Breslow thickness measurements of melanomas around AJCC staging cut-off points: imprecision and terminal digit bias have important implications for staging and patient management. SSO's 69th Annual Cancer Symposium, Boston, USA, March 2-5 2016.
74. Madore J, Vilain RE, Menzies AM, Strbenac D, Yang Y, Thompson JF, Long GV, Mann GJ, **Scolyer RA**, Wilmott JS. Low somatic mutation burden is associated with PD-L1 negative status, weaker expression of T-cell & macrophage-related genes, & worse survival in stage-III melanoma: implications for PD-1 checkpoint inhibitor therapies. Society for Melanoma Research 2015 International Congress, San Francisco, USA, November 18–21 2015 .
75. Satgunaseelan L, Villain RE, Madore J, Chia N, Lum T, Boyer M, **Scolyer RA**, Clark J, Gupta R. ‘Programmed Cell Death-Ligand 1 (PD-L1) expression in Oral Cavity Squamous Cell Carcinoma (OSCC).’ Lifehouse symposium, Chris O'Brien Lifehouse, Sydney, Australia, 18 September 2015.
76. Wargo JA, Amaria RN, Ross MI, Saw RPM, Gershenwald JE, Hwu P, Patel SP, Glitza IC, Diab A, Kefford RF, **Scolyer RA**, Rizos H, Thompson JF, Shannon K, Spillane A, Carlino MS, Guminski A, Simpson L, Davies MA, Long GV. Neoadjuvant BRAF (dabrafenib) and MEK (trametinib) inhibition for high-risk resectable stage III and IV melanoma. American Society of Clinical Oncology AGM, Chicago, USA, 29 May-2 June 2015.
77. Varey AH, Hong AM, Stretch JR, Spillane AJ, Saw RPM, Shannon K, Lee K, Thompson JF, **Scolyer RA**. Neurotropic melanomas: clinical behaviour and radiotherapy responsiveness. Society of Surgical Oncology 68th Annual Cancer Symposium, Houston, USA, 25-28 March, 2015 (poster presentation).
78. Haydu LE, **Scolyer RA**, Mann G, Saw RPM, Stretch JR, Spillane AJ, Thompson JF. Prognostic factors vary after conditional survival in a large cohort of Stage III melanoma patients (n=4856). Society of Surgical Oncology 68th Annual Cancer Symposium, Houston, USA, 25-28 March, 2015 (poster presentation).
79. Holtkamp LH, Wang S, Wilmott JS, Madore J, Vilain R, Thompson JF, Nieweg OE, **Scolyer RA**. Patient outcome and detailed pathologic examination of negative completion lymph node dissection specimens in melanoma patients with minimal (<0.1mm) sentinel node metastases. Society of Surgical Oncology 68th Annual Cancer Symposium, Houston, USA, 25-28 March, 2015 (poster presentation).
80. Holtkamp LHJ, Wang S, Wilmott JS, Madore J, Vilain R, Thompson JF, Nieweg OE, **Scolyer RA**. Detailed pathologic examination of negative completion lymph node dissection specimens and clinical outcome in melanoma patients with minimal (<0.1mm) sentinel node metastasis. Royal College of Pathologists of Australasia – Pathology Update 2015, Melbourne, Australia, 27 February – 3 March 2015 (poster presentation).
81. Wilmott JS, Johansson P, Field MA, Jakrot V, Pearson JV, Waddell N, Shang CA, Gilbert A, Cebon J, Shackleton M, Grimmond SM, Fitzgerald A, Thompson JF, Hayward NK, **Scolyer RA**, Mann GJ. Australian Genome Project. 10th International Cancer Genome Consortium Scientific Workshop, Verona, Italy, 15-17 February 2015 (poster presentation).
82. Martin AJ, Chen A, Choy B, Fernandez Penas P, Halliday G, Dalziel R, McKenzie C, **Scolyer RA**, Dhillon HM, Vardy JL, St George G, Chinniah N, Damian D. ‘Oral nicotinamide to reduce actinic cancer: A phase 3 double-blind randomized controlled trial.’ 2015 ASCO Annual Meeting, Chicago, USA, 29 May-2 June 2015.
83. Holtkamp LH, Wang S, Wilmott JS, Madore J, Vilain R, Thompson JF, Nieweg OE, **Scolyer RA**. Patient Outcome and Detailed Pathologic Examination of Negative Completion Lymph Node Dissection Specimens in Melanoma Patients with Minimal (<0.1mm) Sentinel Node Metastases. Society of Surgical Oncology, Houston, Texas, USA, 25-28 March 2015.
84. Haydu LE, **Scolyer RA**, Mann G, Saw RP, Stretch JR, Spillane AJ, Thompson JF. Prognostic Factors Vary after Conditional Survival in a Large Cohort of Stage III Melanoma Patients (n=4586). Society of Surgical Oncology, Houston, Texas, USA, 25-28 March 2015.
85. Varey AH, Hong AM, Stretch JR, Spillane AJ, Saw RP, Shannon K, Lee K, Thompson JF, **Scolyer RA**. Neurotropic Melanomas: Clinical Behavior and Radiotherapy Responsiveness. Society of Surgical Oncology, Houston, Texas, USA, 25-28 March 2015.
86. Cheng HM, Menzies S, **Scolyer RA**, Guitera P. Assessment of the Optimal Interval for Digital Dermoscopy Monitoring for the Evaluation of Pigmented Nail Lesions. The Australasian College of Dermatologists 48th Annual Scientific Meeting, Adelaide, Australia, 16-19 May 2015.
87. Wilmott JS, Johansson P, Field MA, Jakrot V, Pearson JV, Waddell N, Shang CA, Gilbert A, Cebon J, Shackleton M, Grimmond SM, Fitzgerald A, Thompson JF, Hayward NK, **Scolyer RA**, Mann GJ. Australian Genome Project. 10th International Cancer Genome Consortium Scientific Workshop, Verona, Italy, 15-17 February 2015.
88. Erratum (change to order of authors) Claire Lugassy, Richard Scolyer, Georgina Long, Alexander Menzies, Paul Mischel and Raymond L. Barnhill. PDGFR expression in anti-BRAF resistant melanoma: are angiotropic melanoma cells a source of BRAF resistance and disease progression? J Cutan Pathol 2014; 41: 159–160. DOI: 10.1111/cup.12355. 50th Annual Meeting of the American Society of Dermatopathology

89. Raymond Barnhill, Claire Lugassy, Richard Scolyer, Georgina Long, Alexander Menzies, Paul Mischel. PDGFBR expression in anti-BRAF resistant melanoma: are angiotropic melanoma cells a source of BRAF resistance and disease progression? J Cutan Pathol 2014; 41: 159–160. 50th Annual Meeting of the American Society of Dermatopathology
90. Wevers KP, Murali R, Bastiaannet E, **Scolyer RA**, Suurmeijer AJ, Thompson JF, Hoekstra HJ. Assessment of a new predictive score for non-sentinel node positivity in melanoma. Society of Surgical Oncology, 65th Annual Cancer Symposium, Orlando, Florida, USA, 21–24 March 2012.
91. Murali R, Riedel ER, Busam KJ, Cooper WA, Garrido-Ruiz M, Karim RZ, Leecy T, Pulitzer MP, **Scolyer RA**. Inter-observer agreement of assessment of desmoplasia and neurotropism in melanoma. United States and Canadian Academy of Pathology, 2012 Annual Meeting, Vancouver, Canada, 17–23 March 2012.
92. Murali R, Haydu LE, Long GV, Quinn MJ, Saw RP, Shannon K, Spillane AJ, Stretch JR, Kefford RF, Thompson JF, **Scolyer RA**. Clinico-pathologic factors associated with distant metastasis and survival in patients with thin primary cutaneous melanoma. International Melanoma Congress 2011, Tampa, Florida, USA, 9–13 November 2011.
93. Murali R, deSilva C, McCarthy SW, Thompson JF, **Scolyer RA**. Sentinel lymph nodes containing very small (<0.1mm) deposits of metastatic melanoma cannot be safely regarded tumor-negative. International Melanoma Congress 2011, Tampa, Florida, USA, 9–13 November 2011.
94. Takei Y, Lam S, Chong KK, Murali R, **Scolyer RA**, Kuo C, Morton DL, Hoon DSB. Molecular upstaging and profiling of sentinel lymph Nodes in paediatric cutaneous melanoma patients. 7th International Sentinel Node Society Meeting, Yokohama, Japan, 18–20 November 2010. Murali R, Morey AL, Desilva C, McCarthy SW, **Scolyer RA**. Fluorescence in situ hybridization in the evaluation of melanocytic tumors. 7th Annual International Melanoma Congress, Sydney, Australia, 4–7 November 2010.
95. Carter C, De Silva C, Synnott M, Thompson JF, Stretch JR, Spillane A, Quinn MJ, Saw RP, Shannon K, Murali R, Kefford R, Hersey P, Shivalingam B, Hughes M, Howle J, Long G, Mann GJ, **Scolyer RA**. Bio-specimen Banking: Melanoma Institute Australia. 7th Annual International Melanoma Congress, Sydney, Australia, 4–7 November 2010.
96. Bonenkamp J, In't Hout F, Haydu L, Murali R, Thompson JF, **Scolyer RA**. Prognostic importance of the extent of ulceration of clinically localized cutaneous melanoma. 15th Congress of the European Society of Surgical Oncology, Bordeaux, France, 15–17 September 2010.
97. Murali R, Haydu L, Long GV, Thompson JF, **Scolyer RA**. Factors predictive of clinical outcomes in patients with thin cutaneous melanoma. International Academy of Pathology (Australasian Division), 35th Annual Scientific Meeting, Sydney, Australia, 4–6 June 2010.
98. Murali R, Moncrieff MD, Hong J, Cooper CL, Shingde M, Samuel DG, Thompson JF, **Scolyer RA**. The prognostic value of mitotic rate in recurrent melanoma. International Academy of Pathology (Australasian Division), 35th Annual Scientific Meeting, Sydney, Australia, 4–6 June 2010.
99. Verwer N, Murali R, Cooper WA, **Scolyer RA**, Thompson JF. Lymphoma arising in patients with cutaneous melanoma. International Academy of Pathology (Australasian Division), 35th Annual Scientific Meeting, Sydney, Australia, 4–6 June 2010.
100. Murali R, Goumas C, **Scolyer RA**, Armstrong BK for the GEM Study Group. Comparison of pathological features of multiple primary cutaneous melanomas. International Academy of Pathology (Australasian Division), 35th Annual Scientific Meeting, Sydney, Australia, 4–6 June 2010.
101. Azimi F, **Scolyer RA**, Murali R, Moncrieff M, Saw RP, Thompson JF. The prognostic importance of tumour-infiltrating lymphocyte grade in patients with primary cutaneous melanoma. International Academy of Pathology (Australasian Division), 35th Annual Scientific Meeting, Sydney, Australia, 4–6 June 2010.
102. Murali R, Zannino D, Synnott M, McCarthy SW, Thompson JF, **Scolyer RA**. Pathological features of metastases from primary cutaneous desmoplastic melanoma. International Academy of Pathology (Australasian Division), 35th Annual Scientific Meeting, Sydney, Australia, 4–6 June 2010.
103. In't Hout F, Murali R, Haydu L, Thompson JF, Bonenkamp J, **Scolyer RA**. Prognostic importance of the extent of ulceration of clinically localised cutaneous melanoma. International Academy of Pathology (Australasian Division), 35th Annual Scientific Meeting, Sydney, Australia, 4–6 June 2010.
104. Murali R, Haydu L, Thompson JF, **Scolyer RA**. Sentinel lymph node biopsy in patients with thin melanoma. International Academy of Pathology (Australasian Division), 35th Annual Scientific Meeting, Sydney, Australia, 4–6 June 2010.
105. Murali R, Desilva C, Thompson JF, **Scolyer RA**. Association of histological features of metastatic melanoma in sentinel lymph nodes with lymph node recurrence, distant metastasis and survival. International Academy of Pathology (Australasian Division), 35th Annual Scientific Meeting, Sydney, Australia, 4–6 June 2010.
106. Murali R, Desilva C, Thompson JF, **Scolyer RA**. SNORE (non-Sentinel Node risk score): a system for accurately stratifying risk of non-sentinel node positivity in cutaneous melanoma patients with positive sentinel lymph nodes. International Academy of Pathology (Australasian Division), 35th Annual Scientific Meeting, Sydney, Australia, 4–6 June 2010.
107. Murali R, Moncrieff MD, Hong J, Cooper CL, Shingde M, Samuel DG, Thompson JF, **Scolyer RA**. The prognostic value of mitotic rate in recurrent melanoma. 3rd World Meeting of International Melanoma/Skin Cancer Centers, Berlin, Germany
108. Goto Y, Arigami T, Murali R, **Scolyer RA**, Tanemura A, Uehara T, Turner RR, Nguyen L, Nguyen T, Morton DL, Ferrone S, Hoon DSB. Expression of human high molecular weight? melanoma-associated antigen (HMW-MAA) in desmoplastic melanoma: an immunohistochemical and qRT-PCR study. 3rd World Meeting of International Melanoma/Skin Cancer Centers, Berlin, Germany
109. Verwer N, Murali R, Cooper WA, **Scolyer RA**, Thompson JF. Lymphoma arising in patients with cutaneous melanoma. 3rd World Meeting of International Melanoma/Skin Cancer Centers, Berlin, Germany
110. Murali R, Goumas C, **Scolyer RA**, Armstrong BK for the GEM Study Group. Comparison of pathological features of multiple primary cutaneous melanomas: a study of 1168 patients. 3rd World Meeting of International Melanoma/Skin Cancer Centers, Berlin, Germany
111. Svobodová S, Browning J, MacGregor D, **Scolyer RA**, Murali R, Thompson JF, Pollara G, Deb S, Azad A, Davis ID, Cebon JS. Prognostic impact of cancer-testis antigen expression in primary cutaneous melanoma. Control of Cancer Immunosuppression: The Challenge for Cancer Vaccine Development. 17th Annual International Cancer Immunotherapy Symposium, New York, USA
112. Deb S, Azad A, Chionh F, Browning J, Sewell J, **Scolyer RA**, Murali R, Thompson JF, Svobodová S, Davis ID, Cebon JS. Expression of cancer-testis antigens in late stage melanoma is associated with high Fox-P3 expression in tumor-infiltrating lymphocytes in early stage disease. Control of Cancer Immunosuppression: The Challenge for Cancer Vaccine Development. 17th Annual International Cancer Immunotherapy Symposium, New York, USA

113. Deb S, Azad A, Chionh F, Browning J, Sewell J, **Scolyer RA**, Murali R, Thompson JF, Svobodová S, Davis ID, Cebon JS. Expression of cancer-testis antigens in late stage melanoma is associated with high Fox-P3 expression in tumor-infiltrating lymphocytes in early stage disease. 30th Annual Conference, Australasian Dermatopathology Society, Auckland, New Zealand (oral)
114. Cebon JS, Svobodová S, Browning J, Davis ID, **Scolyer RA**, Murali R, Thompson JF, Deb S, Azad A, MacGregor D. Prognostic impact of Cancer-Testis antigen expression in primary cutaneous melanoma. American Society of Clinical Oncology, 2009 Annual Meeting, Orlando USA (oral)
115. Zhuang L, **Scolyer RA**, McCarthy SW, Murali R, Zhang XD, Thompson JF, Hersey P. Lactate dehydrogenase 5 (LDH-5) expression and its relationship to Bcl-2 anti-apoptotic protein expression in human melanoma. 7th World Congress on Melanoma and 5th Congress of the European Association of Dermato-Oncology, Vienna, Austria
116. Murali R, Shaw HM, Lai K, McCarthy SW, Thompson JF, Stretch JR, Quinn MJ, **Scolyer RA**. Sentinel lymph node biopsy in patients with cutaneous desmoplastic melanoma: a clinicopathological study. 7th World Congress on Melanoma and 5th Congress of the European Association of Dermato-Oncology, Vienna, Austria
117. Karim RZ, Gerega SK, Yang YH et al. Increased expression of proteins from the G1/S transition of the cell cycle are important in progression in mammary phyllodes tumours. Accepted for presentation at the Match 2009 Pathology Update Meeting (Annual RCPA college conference)
118. Karim RZ, Gerega SK, Yang YH et al. Proteins from the Wnt pathway are involved in the pathogenesis and progression of mammary phyllodes tumours. Accepted for presentation at the Match 2009 Pathology Update Meeting (Annual RCPA college conference)
119. Mandal RV, Murali R, Lundqvist KF, Ragsdale BD, Heenan P, Mihm MJ, **Scolyer RA**, Zembowicz A. Long term follow-up in patients with pigmented epithelioid melanocytoma. United States and Canadian Academy of Pathology, 2009 Annual Meeting, Boston, USA, 7-13 March 2009
120. Suzanne Svobodova, Judy Browning, Duncan MacGregor, **Richard A Scolyer**, Rajmohan Murali, John Thompson, Siddhartha Deb, Arun Azad, Ian D. Davis and Jonathan Cebon. Cancer-Testis Antigen Expression In Cutaneous Primary Melanoma Has Independent Impact On Prognosis. Lorne Cancer Conference 2009.
121. Karim RZ, Gerega SK, Yang YH et al. Phyllodes tumours of the breast – a clinico-pathological analysis of 65 cases. Presented at the Sept 2008 Leura Breast Conference; Darling Harbour Sydney
122. Haydu L, Holt P, **Scolyer R**, Karim R, Madronio C, Thompson J, Armstrong B. Quality of histopathological reporting on melanoma in NSW. Clinical Oncology Society of Australia, Annual Scientific Meeting, Sydney November 2008.
123. Murali R, Hughes TM, Thompson JF, **Scolyer RA**. Pathological staging of primary cutaneous melanoma is affected by interobserver variation in the histopathological reporting of key prognostic parameters. World Congress of the International Academy of Pathology, Athens Greece October 2008.
124. Gzell C., Carrol S., Suchowska N., Beith J., Tan K., **Scolyer R.**, Radiation Recall Dermatitis after pre-sensitisation with pegylated liposomal doxorubicin. RANZCR 59th Annual Scientific Meeting, 2008.
125. Murali R, Loughman NT, McKenzie PR, Watson GF, Thompson JF, **Scolyer RA**. Cytological features of melanoma in fluid specimens. World Congress of the International Academy of Pathology, Athens Greece October 2008.
126. Liqing Zhuang, C Soon Lee, **Richard A Scolyer**, Stanley W McCarthy, Xu Dong Zhang, John F Thompson and Peter Hersey. "Increased expression of Mcl-1 and Bcl-XL and decreased expression of Bcl-2 is associated with melanoma progression and transcription factors". Perspectives in Melanoma X and the Third Annual International Melanoma Research Congress, Noordwijk Aan Zee, The Netherlands, 14-16 September 2008.
127. Liqing Zhuang, C Soon Lee, **Richard A Scolyer**, Stanley W McCarthy, Wendy A Cooper, Xu Dong Zhang, John F Thompson and Peter Hersey. "The glucose-regulated stress protein GRP78 is upregulated during progression of melanoma". XXth International Pigment Cell Conference IPCC 2008 conjoined with Vth International Melanoma Research Congress IMRC 2008, Sapporo, Japan, May 7-12, 2008.
128. Tan KL, Gzell CE, Carroll SL, Suchowska N, Beith J, **Scolyer RA**. Radiation recall dermatitis (RRD) after pre-sensitisation with pegylated liposomal doxorubicin (PLD): a case report. Annual Scientific Meeting of Australasian Division of the IAP, Sydney, June 2008.
129. Salim AA, Stanford D, McCaughan B, Cooper WA, **Scolyer RA**. Localised malignant mesothelioma. Annual Scientific Meeting of Australasian Division of the IAP, Sydney, June 2008.
130. AR Shipman1, ALC Agero, I Cook, **RA Scolyer**, P Craig, HH Pas, F Wojnarowska, DF Murrell. Classical Epidermolysis Bullosa Acquisita Requiring Multiple Esophageal Dilatations. American Academy of Dermatology, San Antoni, Feb 2008.
131. Tan K-B, **Scolyer R**, McCarthy S, Schatz J, Nabarro M, Lee K, Rusli J, Banu B, Bonar F. Tumoral calcium pyrophosphate dihydrate crystal deposition disease (tophaceous pseudogout) of the hand: a report of two cases including one with a heretofore unreported associated florid reactive myofibroblastic proliferation. Hong Kong International Academy of Pathology ASM October 2007.
132. Madronio C, Armstrong B, Thompson J, Beard J, Curtin A, Redman S, **Scolyer R**, Karim R, Morton R, Holt P, Mann G, Barton M, Frommer M, Kearey. Melanoma Patterns of Care. 29th Annual Meeting of the International Association of Cancer Registries, Ljubljana, Slovenia September 2007
133. **Scolyer RA**, Elliott B, Suci S, Eggermont AMM, MacKie R, Robert C, Cook MG, Thompson JF, Angevin E, Spatz A; on behalf of the EORTC Melanoma Group. Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma. American Society of Clinical Oncology Annual Scientific Meeting 2007.
134. Murali R, Sharma RN, Thompson JF, Stretch JR, Lee CS, McCarthy SW, **Scolyer RA**. Sentinel lymph node biopsy aids in the management of so-called "atypical Spitzoid tumours". Annual Scientific Meeting of Australasian Division of the IAP, Sydney, June 2007.
135. Murali R, Loughman NT, Shaw HM, McKenzie PR, Watson GF, Thompson JF, **Scolyer RA**. Cytological features of metastatic/recurrent lesions in patients with histologically-confirmed primary cutaneous desmoplastic melanoma. Annual Scientific Meeting of Australasian Division of the IAP, Sydney, June 2007
136. Tan K-B, Moncrieff M, Thompson JF, McCarthy SW, Shaw HM, Quinn MJ, Li L-XL, Crotty KA, Stretch JR, **Scolyer RA**. Subungual melanoma: A clinicopathological analysis of 124 cases and comparison with acral naevi. Annual Scientific Meeting of Australasian Division of the IAP, Sydney, June 2007
137. Murali R, Karim RZ, Cochran AJ, Cook MG, Starz H, Abrishami P, Thompson JF, **Scolyer RA**. Interobserver reproducibility of histomorphologic parameters in sentinel lymph nodes containing metastatic melanoma – preliminary findings. Sentinel Node 2006 – New Boundaries. Rome, Italy, 1-4 November 2006.
138. Karim RZ, **Scolyer RA**, Li Wei, Yee VSK, McKinnon JG, Li L-X, Uren RF, Lam S, Hoon DSB, Thompson JF. A Retrospective Analysis of RT-PCR in Clinically False Negative Sentinel Lymph Node Biopsies in Melanoma. Sentinel Node 2006 – New Boundaries. Rome, Italy, 1-4 November 2006.

139. O'Brien P, Heinzelmann-Schwarz V, **Scolyer R**, Scurry J, Smith A, Gardiner-Garden M, Biankin A, Baron-Hay S, Scott C, Ward R, Hacker N, Sutherland R. Expression of the metalloproteinase meprin alpha differentiates primary and secondary mucinous carcinomas of the ovary. Familial cancer: Research and Practice. A combined meeting of kConFab, Australian Ovarian Cancer Study, and the Family Cancer Clinics of Australia. 16-19 August 2006, Couran Cove, Qld.
140. O'Brien P, Davies M, Scurry J, Smith A, Henderson M, Barton C, Saunders D, Henshall S, Quinn D, **Scolyer R**, Scurr L, deFazio A, Clancy J, Watts C, Hacker N, Sutherland R. High expression of EDD is an adverse prognostic factor for disease recurrence in serous epithelial ovarian cancer and is associated with cisplatin resistance. Familial cancer: Research and Practice. A combined meeting of kConFab, Australian Ovarian Cancer Study, and the Family Cancer Clinics of Australia. 16-19 August 2006, Couran Cove, Qld.
141. Zhuang L, Lee CS, **Scolyer RA**, McCarthy SW, Palmer AA, Zhang X, Hersey P. Progression of melanoma is associated with increased expression of mcl-1 and bcl-xl but decreased expression of bcl-2. Annual Scientific Meeting of Australasian Division of the IAP, Sydney, June 2006.
142. Wang H, Martin RCW, **Scolyer RA**, Thompson JF. Malignant blue naevi- clinical features and prognosis. 6th World Congress on Melanoma, Vancouver, Canada, September 6-10, 2005.
143. Zhuang L, Lee CS, **Scolyer RA**, McCarthy SW, Zhang X, Thompson JF, Bron LP, Hersey P. Involvement of Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) and Its Death Receptors (DR4 and DR5) in Human Melanoma. 6th World Congress on Melanoma, Vancouver, Canada, September 6-10, 2005.
144. Mooney E, **Scolyer RA**, Thompson JF, Colman MH, Palmer AA, McCarthy SW. Nevroid melanoma. 6th World Congress on Melanoma, Vancouver, Canada, September 6-10, 2005.
145. Akland K, Coleman M, Shaw H, Soong S-J, Chen D-T, **Scolyer R**, Thompson J. Total number of positive nodes and primary melanoma mitotic rate as major prognostic factors in positive sentinel nodes. 6th World Congress on Melanoma, Vancouver, Canada, September 6-10, 2005.
146. Bourne R, Stanwell P, King S, **Scolyer R**, Stretch J, Thompson J, Lean C, Mountford C. 3T MR microimaging of primary cutaneous melanoma. International Society for Magnetic Resonance in Medicine, 2005 Meeting.
147. Zhuang L, Lee CS, **Scolyer RA**, McCarthy SW, Zhang X, Thompson JF, Bron LP, Hersey P. Involvement of Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) and Its Death Receptors (DR4 and DR5) in Human Melanoma. Annual Scientific Meeting of Australasian Division of the IAP, Sydney, June 2005.
148. Heinzelmann-Schwarz VA, Henshall SM, Gardiner-Garden M, **Scolyer RA**, Leung K-C, Scurry J, Smith A, Hacker NF, O'Brien PM, Sutherland RL. Reduced expression of SOC3 predicts poor outcome in epithelial ovarian cancer. Ovarian Cancer Forum, Washington DC, USA, 4-8 April 2005.
149. M. Dom, S. Fredericks, C. S. Lee, B. Rose, K. Gao, G. Smith, **R.A. Scolyer**, A. Hong, M. Wong, C. O'Brien. Differences in expression of cell cycling proteins in pleomorphic adenoma and carcinoma ex pleomorphic adenoma of the parotid gland may assist surgical management. Australian & New Zealand Head and Neck Society, Annual Scientific Meeting 2004.
150. Rose BR, Li W, Tran N, Shiyab S, Liu J, **Scolyer RA**, Lee CS, Wong M, Hong A, O'Brien CJ. Mechanisms of HPV 16 induced tonsillar cancer differ from those in cervical cancer. Australian & New Zealand Head and Neck Society, Annual Scientific Meeting 2004.
151. Beavis A, Dawson M, Doble P, Li LL, **Scolyer RA**, Uren RF, De Silva C, Thompson JF. Confirming the identity of sentinel nodes by analysis of antimony in fine needle aspirates using ICP-MS. 4th Annual International Sentinel Node Congress, Los Angeles USA, December 2004.
152. Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, **Scolyer RA**, Leung K-C, Scurry J, Smith A, Sutherland R, O'Brien P, Hacker N. Reduced expression of SOC3 is an independent predictor of poor outcome in epithelial ovarian cancer. 10th Biennial Meeting of the "International Gynecologic Cancer Society", Edinburgh, Scotland, 2004.
153. Heinzelmann-Schwarz V, **Scolyer R**, Scurry J, Gardiner-Garden M, Smith A, Hacker N, Sutherland R, O'Brien P. Galectin4 and Meprin alpha are biomarkers for mucinous ovarian tumors. International Academy of Pathology, World Congress, Brisbane, October 2004.
154. Zhuang L, Lee CS, **Scolyer RA**, McCarthy SW, Palmer AA, Zhang X, Hersey P. Expression of extracellular-signal related kinase (ERK) and its activation (phosphorylated ERK) in malignant melanoma. International Academy of Pathology, World Congress, Brisbane, October 2004.
155. Zhuang L, Lee CS, **Scolyer RA**, McCarthy SW, Palmer AA, Zhang X, Hersey P. Immunohistochemical detection of Akt kinase and activation of Akt (phosphorylated Akt Ser473) in melanoma. International Academy of Pathology, World Congress, Brisbane, October 2004.
156. Karim RZ, Wills EJ, McCarthy SW, **Scolyer RA**. Myxoid Adrenocortical Carcinoma- An Unusual Variant. International Academy of Pathology, World Congress, Brisbane, October 2004.
157. Karim RZ, Rose B, Wills EJ, **Scolyer RA**. Condyloma Acuminata of the Urinary Bladder with PCR Confirmed HPV 11. International Academy of Pathology, World Congress, Brisbane, October 2004.
158. Heinzelmann-Schwarz V, **Scolyer RA**, Gardiner-Garden M, Leung K, Scurry J, Smith A, Henshall S, Hacker N, Sutherland R, O'Brien P. Reduced expression of SOC3 is an independent predictor of poor outcome in epithelial ovarian cancer. 43rd Australian Society for Medical Research National Scientific Conference. Sydney, 7th June 2004.
159. Heinzelmann-Schwarz V, **Scolyer RA**, Scurry J, Gardiner-Garden M, Smith A, Hacker N, Sutherland R, O'Brien P. Galectin4 and Meprin alpha expression differentiates the mucinous phenotype from other subtypes of epithelial ovarian tumors. Australasian Society of Gynaecological Oncologists Annual Scientific Meeting, Singapore, May 2004.
160. Hsiao E, Bourne R, Thompson J, **Scolyer RA**, Stretch J, Lean C. Use of proton MRS to differentiate melanoma from benign lesions in skin biopsies. International Society of Magnetic Resonance in Medicine Annual Scientific Meeting 2004.
161. Heinzelmann-Schwarz V, Gardiner-Garden M, Henshall S, Scurry J, **Scolyer RA**, Gish K, Hacker N, O'Brien P, Sutherland R. Over expression of genes involved in cellular adhesion (DDR1, claudin 3 and Ep-CAM) is an early event in the development of epithelial ovarian cancer. American Association for Cancer Research, Annual Scientific Meeting, Orlando, USA, April 2004.
162. Doubrovsky A, de Wilt JHW, **Scolyer RA**, McCarthy WH, Thompson JF. Sentinel node biopsy is more accurate than elective lymph node dissection in determining the regional node status of patients with cutaneous melanoma. Society of Surgical Oncology Cancer Symposium, New York, United States of America, March 18-21, 2004.
163. Schwarz V, Gardiner-Garden M, Henshall S, Scurry J, **Scolyer RA**, Hacker N, O'Brien P, Sutherland R. Interstudy comparison of gene expression profiles identifies tumour markers of epithelial ovarian cancer. 42nd Australian Society for Medical Research National Scientific Conference, Adelaide, 22-25. Nov. 2003.

164. Li W, Thompson CH, Xin D, Cossart YE, O'Brien CJ, McNeil EB, Gao K, **Scolyer RA**, Rose BR. Comparison of squamous cell carcinomas of the tonsil from Chinese and Australian patients. 9th International Congress on Oral Cancer in association with the 5th Annual Scientific Meeting of the Australian and New Zealand Head and Neck Society, Melbourne, Victoria, Australia, November 2003.
165. Schwarz V, Gardiner-Garden M, Henshall S, Scurry J, **Scolyer RA**, Hacker N, O'Brien P, Sutherland R. Interstudy comparison of gene expression profiles identifies tumour markers of epithelial ovarian cancer. 13th St Vincents & Mater Health Sydney, Research Symposium, Garvan Institute, 12th Sept. 2003.
166. Zhuang L, Ooi T, Halliday G, Barnetson R, **Scolyer R**. Inflammatory reaction in actinic keratosis- an immunohistochemical analysis. Annual Scientific Meeting of Australasian Division of the IAP, Sydney, June 2003.
167. Beavis AD, Dawson M, Doble PA, Li LL, Soper R, **Scolyer RA**, Uren RF, Thompson JF. Detection of antimony in tissue sections as a marker for sentinel lymph nodes. Annual Scientific Meeting of Australasian Division of the IAP, Sydney, June 2003.
168. **Scolyer RA**, Shaw HM, McCarthy SW, Thompson JF. Can pathological features of the primary cutaneous lesions in melanoma patients predict the frequency of non-sentinel lymph node metastases? Annual Scientific Meeting of Australasian Division of the IAP, Sydney, June 2003.
169. **Scolyer RA**, Lawrence L-XL, Soper R, Dawson M, Doble P, Beavis A, Uren RF, McCarthy SW, Thompson JF. Antimony quantitation in nodal tissue can validate the sentinel lymph node biopsy technique. A quality assurance tool? Annual Scientific Meeting of Australasian Division of the IAP, Sydney, June 2003.
170. Heinzelmann-Schwarz V, Gardiner-Garden M, Henshall S, Gish K, Scurry J, **Scolyer R**, Hacker N, O'Brien P, Sutherland R. Interstudy validation of gene expression profiles identifies candidate biomarkers of epithelial ovarian cancer. Annual Scientific Meeting of Australasian Division of the IAP, Sydney, June 2003.
171. Li W, Thompson CH, O'Brien CJ, McNeil EB, **Scolyer RA**, Cossart YE, Veness MJ, Walker DM, Morgan GJ, Rose BR. Human papillomavirus as a prognostic marker for squamous cell carcinoma of the tonsil. 4th Annual Scientific Meeting of the Australian and New Zealand Head and Neck Society, Sydney, NSW, Australia, November 2002.
172. **Scolyer RA**, Li LL-X, Soper R, Dawson M, Doble PA, Beavis AD, Uren RF, McCarthy SW, Thompson JF. Antimony quantitation in nodal tissue can validate the sentinel lymph node biopsy technique. A quality assurance tool? Sentinel Node 2002, Yokohama, Japan 2002.
173. **Scolyer RA**, Shaw HM, McCarthy SW, Thompson JF. Can pathological features of the primary cutaneous lesions in melanoma patients predict the frequency of non-sentinel lymph node metastases. Sentinel Node 2002, Yokohama, Japan 2002.
174. Dawson M, Beavis A, Doble P, Li L, Soper R, **Scolyer RA**, Uren RF, Thompson JF. Sentinel Node 2002, Yokohama, Japan 2002.
175. Starrit E, Uren RF, **Scolyer R**, Thompson JF. Ultrasound detection of melanoma metastases in sentinel nodes. Sentinel Node 2002, Yokohama, Japan 2002.
176. Li W, Thompson C, O'Brien C, McNeil E, **Scolyer R**, Cossart Y, Veness M, Walker M, Morgan G, Rose B. Human papilloma virus as a prognostic marker for carcinoma of the tonsil. Royal College of Surgeons of Australasia Annual Scientific Meeting Sydney Nov 2002.
177. Wong AY, Trebeck C, **Scolyer RA**, Greenberg M. Two unusual cases of malignant mesothelioma. Australian Society of Cytology Annual Scientific Meeting, Sydney, October 2002.
178. KD Nicoll, SW McCarthy, AA Palmer, SF Bonar, GB Taylor, JF Scurry, B Wood, **RA Scolyer**. Inflammatory Myxohyaline Tumour: a report of 6 cases. Annual Scientific Meeting of Australasian Division of the IAP, Sydney, June 2002
179. L Li, KA Crotty, AA Palmer, JJ Kril, **RA Scolyer**, JF Thompson, SW McCarthy. Melanin can be effectively bleached for argyrophilic staining of nucleolar organizer regions (AgNORs) of pigmented lesions: a morphometric evaluation. Annual Scientific Meeting of Australasian Division of the IAP, Sydney, June 2002
180. L Li, **RA Scolyer**, V Ka, G McKinnon, SW McCarthy, JF Thompson. Pathological review of negative sentinel lymph nodes (SLNs) in patients with regional recurrence of malignant melanoma: a clinicopathological review of 1400 cutaneous melanoma patients with SLN biopsies. Annual Scientific Meeting of Australasian Division of the IAP, Sydney, June 2002
181. L Zhuang, SW McCarthy, AA Palmer, **RA Scolyer**. Combined naevi- benign lesions frequently misdiagnosed clinically and pathologically as melanomas. Clinicopathological review of 182 cases. Annual Scientific Meeting of Australasian Division of the IAP, Sydney, June 2002
182. RZ Karim, J Ma Wyatt, **RA Scolyer**. Myoid Angioendothelioma of the spleen. Annual Scientific Meeting of Australasian Division of the IAP, Sydney, June 2002
183. M Sarris, **R Scolyer**, M Konopka, J Thompson, CG Harper, CS Lee. Nm23 cytoplasmic expression is reduced in primary cutaneous melanomas with cerebral metastases. Annual Scientific Meeting of Australasian Division of the IAP, Sydney, June 2002
184. R Bourne, C DeSilva, L Li, **R Scolyer**, J Thompson, C Lean, C Mountford. Proton MRS Detects Metastatic Melanoma in Lymph Nodes. Proceedings of the International Society for Magnetic Resonance in Medicine, 2002.
185. Li W, Rose BR, Thompson CH, Cossart YE, **Scolyer RA**, McNeil EB, O'Brien CJ. Presence of human papillomavirus and expression of cell cycle regulators in tonsillar squamous cell carcinoma. 1st Australian Virology Group Meeting, Frazer Island, Queensland, Australia, December 2001.
186. Nicoll KD, **Scolyer RA**. Giant cell tumour of tendon sheath diagnosed by fine needle aspiration cytology. Australian Society of Cytology Annual Scientific Meeting, Adelaide, October 2001.
187. **Scolyer RA**, McKenzie PR, Achmed D, Lee CS. Is breast fine needle aspiration cytology useful in distinguishing phyllodes tumours from fibroadenomas? Australian Society of Cytology Annual Scientific Meeting, Adelaide, October 2001.
188. **Scolyer RA**, McKenzie PR, Achmed D, Lee CS. Can phyllodes tumours be distinguished from fibroadenomas using fine needle aspiration cytology? Annual Scientific Meeting of Australasian Division of the IAP, Sydney, June 2001
189. Cooper WA, Nicoll KD, Wills EJ, McKenzie PR, **Scolyer RA**. Extrapleural solitary fibrous tumours- a report of two cases. Annual Scientific Meeting of Australasian Division of the IAP, Sydney, June 2001
190. Buckland M, Davies S, **Scolyer R**, Harper C. Expression of the oligodendrocyte-specific antigen CNPase in human gliomas. Annual Scientific Meeting of Australasian Division of the IAP, Sydney, June 2001
191. Li W, Rose BR, Thompson CH, Cossart YE, **Scolyer RA**, McNeil EB, O'Brien CJ. Molecular analysis of early stage tonsil cancer. 2th Annual Scientific Meeting of the Australian and New Zealand Head and Neck Society, Gold Coast, Queensland, Australia, November 2000.
192. Li W, Rose B, Thompson C, **Scolyer R**, Cossart Y, McNeil E, Tattersall M, O'Brien C. Molecular analysis of early stage tonsil cancers. College of Health Sciences and The Medical Foundation Research Conference: From Cell to Society 2. Leura NSW, November 2000

193. **Scolyer RA**, McKenzie PR, Achmed D, Lee CS. Is it possible to diagnose unusual breast tumours by fine needle aspiration cytology? A study of 8 phyllodes tumours. College of Health Sciences and The Medical Foundation Research Conference: From Cell to Society 2. Leura NSW, November 2000
194. **Scolyer RA**, McCarthy SW, Wills EJ, Palmer AA. Low-grade Fibrosarcoma with Palisaded Granuloma-like Bodies (Giant Rosettes). Annual Scientific Meeting of Australasian Division of the IAP, Sydney, June 2000
195. **Scolyer RA**, Rose B, Painter DM. Inverted Duct Papilloma of Minor Salivary Gland Origin. Annual Scientific Meeting of The Royal College of Pathologists of Australasia, Melbourne, October 1999
196. **Scolyer RA**, Painter DM, Harper CG, Lee CS. Diagnosis of Hepatocellular Carcinoma Metastasizing to the Orbit by Fine Needle Aspiration Cytology. Annual Scientific Meeting of Australasian Division of the IAP, Sydney, June 1999

CONFERENCE ABSTRACTS SELECTED FOR ORAL PRESENTATION

1. C. Quek*, A. Pratapa*, I. Silva*, G. Al-Eryani*, A. Mayer*, N. Bartonicek, K. Harvey, C. Buckley, O. Braubach, R. Saw, J. Stretch, K. Shannon, A. Menzies, **R. Scolyer***, G. Long*, A. Swarbrick*, J. Wilmott* (*contributed equally). Spatially Resolved Single-Cell Features Reveal Distinct Cellular Maps In The Tumour Microenvironment Of Melanoma Patients With Primary And Acquired Resistance To Immunotherapies. Abstract accepted for oral presentation at International Academy of Pathology (IAP) 2022 - Sydney - Bridge to a Cure in Sydney/Virtual on 11-15 October 2022.
2. Ismael A. Vergara, Serigne N. Lo, Alexander M. Menzies, Matteo S. Carlino, **Richard A. Scolyer**, Georgina V. Long and Inês Pires da Silva. Differential Impact Of Braf/mek And Ici Therapies On The Pattern Of Progression Of Stage Iv Melanoma Patients. Abstract submitted to (and accepted for oral presentation at) NSW Cancer Conference, Sydney on 15th September 2022.
3. Georgina V. Long, Matteo S. Carlino, George Au-Yeung, Andrew Spillane, Kerwin Shannon, David E. Gyorki, Julie Howle, Sydney Ch'ng, Maria Gonzalez, Robyn P.M. Saw, Thomas Pennington, Serigne Lo, **Richard A. Scolyer**, Alexander M. Menzies. NeoTrio: Randomized Trial of Neoadjuvant (NAT) Pembrolizumab (Pembro) ALONE, in Sequence (SEQ) Or Concurrent (CON) With Dabrafenib + Trametinib (D+T) In Resectable BRAF-Mutant Stage III Melanoma To Determine Optimal Combination of Therapy. Abstract accepted for oral presentation at 2022 ASCO Annual Meeting in Chicago/Virtual on 3-7 June 2022.
4. Gibson M, **Scolyer RA**, Soyer PH, Ferguson P, McGeechan K, Irwig L, Bell K. Estimating the potential impact of interventions to reduce over-calling and under-calling of melanoma. Accepted for an oral presentation at The Australasian College of Dermatologists Annual Scientific Meeting 2022 (ACD ASM) in Adelaide on 30 April – 3 May 2022.
5. Serigne N. Lo, Gabrielle J. Williams, Anne Cust, David W. Ollila, **Richard A. Scolyer**, John F. Thompson. Long-Term Incidence of death due to melanoma and from other causes in patients with thin (T1) cutaneous melanomas: A population-based competing-risk analysis confirms 0.8mm Breslow thickness as a risk classification cut-point. Accepted abstract and oral presentation at Australasian Melanoma Conference (AMC) 2021 (19-20 November 2021) (Sydney-hybrid)
6. AJ Potter, AT Li, JF Thompson, GV Long, S Ch'ng, **RA Scolyer**. Driver mutation status of cutaneous scalp melanoma. Accepted for a Rapid-Fire presentation at NSW Health Pathology (NSWHP) Research Forum 2021 (virtual) (10-11 November 2021)
7. Rebecca C. Simpson, Erin R. Shanahan, Marcel Batten, Irene L. M. Reijers, Mark Read, Ines P. Silva, Judith Versluis, Rosilene Ribeiro, Alexandra S. Angelatos, Jian Tan, Chandra Adhikari, Alexander M. Menzies, Robyn P. Saw, Maria Gonzalez, Kerwin F. Shannon, Andrew J. Spillane, Rebecca Velickovic, Laurence Macia, Andrew J. Holmes, James S. Wilmott, Christian U. Blank, **Richard A. Scolyer**, Georgina V. Long. Enterotypes underlie gut microbial associations with response and toxicity in neo-adjuvant immunotherapy. *Submitted and accepted as oral presentation at SMR Congress 2021 (28-31 October 2021) (hybrid)*
8. Camelia Quek*, Xinya Bai*, Ping Shang, Grace H. Attrill, Tuba Nur Gide, Peter M Ferguson, Kazi Nahar, Umaimainthan Palendira, Georgina V. Long*, **Richard A Scolyer***, James S. Wilmott* (*contributed equally). Identifying and targeting novel immunosuppressive mechanisms in adolescent and young adult (AYA) melanoma patients. *Submitted and accepted as oral presentation at SMR Congress 2021 (28-31 October 2021) (hybrid)*
9. Grace H. Attrill, Hansol Lee, Annie T. Tasker, Eva Shteinman, Angela L. Ferguson, Ismael A. Vergara, Umaimainthan Palendira, Georgina V. Long, Peter M. Ferguson, **Richard A. Scolyer**, James S. Wilmott. Immunophenotyping of primary melanoma to predict patient outcomes. Submitted to and accepted as an oral presentation at SMR Congress 2021 (28-31 October 2021) (hybrid)
10. Jason J. Luke; Piotr Rutkowski; Paola Quierolo; Michele Del Vecchio; Jacek Mackiewicz; Vanna Chiarion-Sileni; Luis de la Cruz Merino; Muhammad A Khattak; Dirk Schadendorf; Georgina V. Long, Paolo A Ascierto; Mario Mandalà; Federica De Galitiis; Vernon Sondak; **Richard A. Scolyer**; John M. Kirkwood; Ke Chen; Nageatte Ibrahim; Sama Ahsan; Alexander M. M. Eggermont. Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase 3 trial. Selected for oral presentation at European Society for Medical Oncology (ESMO) 2021 (16-21 Sept) - virtual
11. ILM Reijers, JM Versluis, AM Menzies, P Dimitriadis, MW Wouters, RPM Saw, WMC Klop, TE Pennington, WJ v Houdt, LJW Bosch, S Cornelissen, LG Grijpink-Ongering, MJ Gregorio, M Lopez Yurda, RV Rawson, AJ Spillane, BA van de Wiel, RA Scolyer, ACJ van Akkooi, GV Long and CU Blank. DONIMI study: Personalized combinations of neoadjuvant Domatinostat, Nivolumab and Ipilimumab in macroscopic stage III melanoma based on the IFN-gamma signature. Accepted as poster presentation and as a mini oral presentation at the ESMO Congress 2021 (16-21 Sept).
12. Camelia Quek*, Catherine Bai*, Ping Shang, Grace H. Attrill, Tuba Nur Gide, Peter M. Ferguson, Kazi Nahar, Umaimainthan Palendira, Georgina V. Long*, **Richard A. Scolyer*** and James S. Wilmott* (*contributed equally). Identifying and targeting novel immunosuppressive driver mechanisms in young melanoma patients. Accepted for oral presentation at Sydney Cancer Conference (9-10 September 2021).
13. Kazi J Nahar*, Felix Marsh-Wakefield*, Robert V Rawson, Tuba N Gide, Angela Ferguson, Ruth Olivia, Camelia Quek, Stephen Tattersal, Christopher J Kiely, Neomal Sandanayake, Matteo S Carlino, James Wilmott, **Richard A Scolyer**, Georgina V Long*, Alexander M Menzies*, Umaimainthan Palendira* (*contributed equally). Systemic myeloid cells and local T cells propel immunotherapy induced colitis. Accepted for oral presentation at Sydney Cancer Conference (9-10 September 2021).
14. Georgina V. Long, Victoria Atkinson, Serigne N. Lo, Alexander Guminski, Shahneen Sandhu, Michael P. Brown, Maria Gonzalez, **Richard A. Scolyer**, Louise Emmett, Alexander M. Menzies, Grant A. McArthur. Five-year Overall Survival from the Anti-PD1 Brain Collaboration (ABC Study): Randomized Phase 2 Study of Nivolumab or Nivolumab + Ipilimumab In Patients With Melanoma Brain Metastases. Accepted for oral rapid talk at ASCO 2021 (4-8 June 2021 – virtual).

15. Camelia Quek*, Ines P Silva*, Ghamdan Al-Eryani*, Aron Mayer*, Nenad Bartonicek, Kate Harvey, Chi Buckley, Oliver Braubach, Robyn P M Saw, Jonathan Stretch, Kerwin Shannon, Alex M Menzies, **Richard A Scolyer***, Georgina V Long*, Alexander Swarbrick*, James Wilmott* (*contributed equally). Spatially resolved single-cell sequencing reveals unfavourable immune diversity and intratumoural vessels in resistance melanoma patients treated with checkpoint inhibitor immunotherapy. Abstract submitted-accepted to European Association for Cancer Research (EACR) Bioinformatics in Cancer Conference (virtual) 18-19 May 2021.
16. Mathias Seviiri, Georgina V. Long, Catherine M. Olsen, David C. Whiteman, **Richard A. Scolyer**, Stuart MacGregor, and Matthew H. Law. Higher genetic risk for melanoma is associated with improved survival from melanoma. Selected for oral presentation at Australian Polygenic Risk Symposium (APRS) 2021, 20-22 April 2021.
17. Jordan W. Conway, Robert V. Rawson, James S. Wilmott, Georgina V. Long, **Richard A. Scolyer**, Inês Pires da Silva. The tumour immune microenvironment (TIME) at different sites of melanoma metastases (mets). Cancer Research Network Postgraduate and Early career Researcher Symposium 2020 – oral presented by Jordan Conway on 10th November 2020.
18. Grace H. Attrill*, Carina Owen*, Tasnia Ahmed, Serigne Lo, Andrew Colebatch, Jordan W. Conway, Inês Pires da Silva, Matteo S. Carlino, Alexander M. Menzies, Mainthan Palendira, **Richard A. Scolyer**, Georgina V. Long, James S. Wilmott (*contributed equally). Tumour specific, tumour resident, cytotoxic T cells are associated with reduced recurrence in adjuvant PD-1 treatment stage III melanoma. Cancer Research Network Postgraduate and Early career Researcher Symposium 2020 – presented by Grace Attrill on 10th November 2020.
19. Rebecca Simpson, Marcel Batten, Erin Shanahan, Mark Read, Ines Silva, Alexandra Aangelatos, Jian Tan, Rosilene Ribeiro, Chandra Adhikari, Jordan Conway, Alex Menzies, Robin Saw, Jonathan Stretch, Omgo Nieweg, Andrew Spillane, Laurence Macia, Maria Gonzales, Kerwin Shannon, Rebecca Velickovic, Christian Blank, Andrew Holmes, James Wilmott, **Richard A. Scolyer**, Georgina V. Long. Gut microbiota predicts response and adverse events during anti-PD1/anti-CTLA4 neoadjuvant immunotherapy. Event: Sydney Catalyst Postgraduate and Early Career Researcher Symposium 2020 – Friday 30th October 2020, Sydney (oral presentation by Rebecca Simpson).
20. Catherine Bai, Camelia Quek, Ping Shang, Umaimainthan Palendira, Grace Attrill, Tuba Nur Gide, Georgina V. Long, **Richard A. Scolyer** and James S. Wilmott. Immunogenetic features of adolescent and young adult (AYA) melanoma and their implications for response to checkpoint-based immunotherapies. Selected for oral presentation at Kids Cancer Alliance ECR Symposium 17-18 September 2020.
21. Moncrieff, Marc D.; Lo, Serigne; **Scolyer, Richard**; Nobes, Jenny; Heaton, Martin; Snelling, Andrew; Carr, Michael J.; Zager, Jonathan S.; Kisyova, Rumi; Mason, Jennifer; Wilson, Ewan; Wade, Ryckie; Peach, Howard; Nessim, Carolyn; Nolan, Grant; Pritchard-Jones, Rowan; Olofsson Bagge, Roger; Johansson, Iva; Wright, Lucie; Patel, Nakul; Sondak, Vernon K.; Thompson, John F. A Quest for the Lost Tribe: Surgical Management of AJCC IB Melanoma with the Advent of Adjuvant Systemic Therapy. Selected for oral presentation at SSO 2021 (Society of Surgical Oncology) – International Conference on Surgical Cancer Care – March 18-20 (virtual event).
22. Maria Gonzalez, Alexander M. Menzies, Thomas Pennington, Robyn Saw, Andrew J. Spillane, Jonathan Stretch, Kerwin F. Shannon, Sydney Ch'ng, Omgo E. Nieweg, Maria Cruzado, Monica Osorio, Robert Rawson, Peter Ferguson, Helen Rizos, Serigne Lo, Richard A. Scolyer, Georgina V. Long. A phase II study of neoadjuvant pembrolizumab and lenvatinib for resectable stage III melanoma: the Neopele study. Selected for oral presentation at virtual ASCO 2020.
23. CU Blank, ILM Reijers, JM Versluis, EA Rozeman, K Sikorska, L Grijpink, M Gonzalez, R Zucker, A Spillane, JA van der Hage, DJ Grünhagen, RA Scolyer, B van de Wiel, AM Menzies, ACJ van Akkooi, GAP Hospers, KPM Suijkerbuijk, AM van der Veldt, HW Kapiteijn and GV Long. Preliminary results of PRADO: a study to test personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in high risk resectable stage III melanoma. Selected for oral presentation at virtual ASCO 2020.
24. Batten M,* Shanahan ER*, Simpson R, Read M, Silva IP, A Angelatos, J Tan, Adhikari C, Menzies AM, Saw RPM, Stretch J, Nieweg OE, Spillane AJ, Macia L, Gonzales M, Shannon KF, Velickovic R, Riegers I, Blank CU, Holmes AJ, Wilmott JS, Scolyer RA, Long GV Gut microbiota predicts response and adverse events during anti-PD1, anti-CTLA4 neoadjuvant immunotherapy. Selected for oral presentation at virtual AACR Apr 2020.

RESEARCH GRANTS

1. **Provost's Equipment and Contingency Fund – Equipment Grant.** CIA: Wojciech Chrzanowski. Other CIs: , Georgina Long, Richard Scolyer, James Wilmott, Carolyn Sue, Daniel Whitten, Elizabeth New, Huyen Phan, Qingyu Lei, Greg Neely, Sally Kim, Phil Hansbro industry partners: Therakii, Cytiva, IZON; Hien Duong, Tania Sorrel, Shailendra Sawleshwarkar, Johannes Alfenaar, Ben Marais, Shobha Shukla, Tony Weiss, Anna Waterhouse, Andrew McLachlan, Sophie Stocker, Kamini Divakarla, Nicholas Hunt, Elizabeth New, Victoria Coleman, Mark Gillies, Fanfan Zhou, Ling Zhu, Ting Zhang; industry partner: Roche; Irene Koprinska, Kristina Cook, Jonathan Arnold, Lambert Initiative; Anna Waterhouse, Michael Kassiou, Markus Muellner. *Title:* PAVONE – transformative, automated high-throughput testing platform for nanomedicine, mechanopharmacology, mechanobiology, and precision medicine. Amount: AU\$217,000. Duration: 1 June 2022 to 31 December 2022.
2. **Australian Melanoma Research Foundation (AMRF) Inaugural Warren Meanwell Melanoma Research Grant 2022.** Bruna Melhoranse Gouveia (Lead Investigator/Applicant). Pascale Guitera, Richard A. Scolyer, Anne Cust, Serigne Lo (Co-investigators). *Title:* The Lentigo Maligna Spectrum Project. Duration: tbc. Amount AU\$20,000 (awarded 9.6.2022).
3. **Faculty of Medicine and Health, The University of Sydney: Rewarding Research Success 2022** (RC: K9173/PC: RX450). Awarded to Richard A Scolyer as a one-off uplift of funding to support research activities. Amount: \$75,000. Duration: 1 January 2002 – 31 December 2022 (awarded 27 May 2022).
4. Philanthropic support via Melanoma Institute Australia
5. **Tour de Cure – Community Grant 2022.** Grantor: Tour de Cure Ltd as trustee for Tour de Cure Trust (Ref: CG-103-2022). Grantee: Melanoma Institute Australia. Chief Investigator: **Richard A. Scolyer**. *Title:* Digital Histological Imaging for Melanoma. Duration: 18 month. Amount: AU\$148,150 (April 2022- September 2023)
6. **Cancer Institute NSW – Translational Program Grant** (Grant no. 2021/TPG2114). Chief Investigator: Dr James Wilmott. Co-Investigators: Professor Georgina Long, Professor **Richard A. Scolyer**, Professor Michael Boyer, Associate Professor Serigne Lo, Associate Professor Alexander Menzies, Professor Rachael Morton, Dr Wendy Cooper, Dr Tuba Gide, Professor Anne Cust. *Title:* Personalised Immunotherapy Program - Precision immunotherapies for multiple solid tumours using a biomarker driven adaptive enrichment clinical trials platform. Duration 5yrs. Amount AU\$3,748,551 (1.1.2022 to 31.12.2026)

7. **National Health and Medical Research Council (NHMRC) - Synergy Grant 2021** (Grant no. APP200992). CIs: M. Janda, CIB: A. Cust, CIC: HP. Soyer, N. Gillespie, L. Gordon, Z. Ge. AIs: B. Betz-Stablein, A. McInerney-Leo, C. Lawn, P. Fernandez Peñas, K. Canfell, V. Mar, L. Caffery, A. Eriksson, **RA Scolyer (AI)**. *Title:* Roadmap Options for Melanoma Screening in Australia (Melanoma-ROSA). Duration: 5 yrs. Amount: AU\$5m (1.1.2022 –31.12.2026)
8. **National Health and Medical Research Council (NHMRC) 2021 Centres of Research Excellence** (Grant no. APP2006551). CIs: Prof. Monika Janda (CIA), Prof H. Peter Soyer (CIB), A/Prof. Victoria Mar (CIC), Prof Pablo Fernandez-Penas (CID), Prof. Rachael Morton (CIE), Prof. Anne Cust (CIF), Prof. Rory Wolfe (CIG), **Prof. Richard A Scolyer (CIH)**, A/Prof. Liam Caffery (CII) and Dr Zongyuan Ge (CIJ). *Title:* Centre of Excellence in Skin Imaging and Precision Diagnosis. Duration: 5 yrs. Amount: AU\$2.5m (1.11.2021 – 31.10.2026)
9. **National Health and Medical Research Council (NHMRC) - Clinical Trials and Cohort Studies Grant 2020** (commencing 2021) (Grant no. APP2001517). CIs: Victoria Mar, Monika Janda, Peter Soyer, Pablo Fernandez Penas, Anne Cust, Rachael Morton, Rory Wolfe, **Richard Scolyer (CIH)**, Zongyuan Ge, Craig Lawn. AIs: AIs: A.Prof Anders Eriksson, Dr Duncan Lambie, A.Prof Pascale Guitera, Nikki Adler, Dr Aideen McInerney-Leo, Prof. Catriona McLean, Prof. David Whiteman, Dr Brigid Betz-Stablein, Dr Rashidul Alam Mahmud, Dr Peter Ferguson. *Title:* Reconceiving early detection of melanoma. Duration: 5 yrs. Amount: AU\$3,217,920 (1.7.2021 –30.6.2026)
10. **National Health and Medical Research Council (NHMRC) - Ideas Grant 2021** (Grant no. APP2012860). CIA: Prof. Helen Rizos, CIB: Assoc Prof. Matteo Carlino, CIC: Dr Su Yin Lim, CID: Dr Elena Shklovskaya. AIs: Prof. Georgina Long, Prof. Jean Yang, Prof. **Richard A. Scolyer (AI)**. *Title:* Restoring Anti-Tumour Immunity in Melanoma. Duration: 4 years. Amount: AU\$1,134,001 (1.1.2022 –31.12.2025)
11. **The Medical Research Future Fund (MRFF) - International Clinical Trial Collaborations Grant Program (2019 for 2020 start)** (Grant no. MRF1192497): Chief Investigators (CIs): CIA – A.Prof Shahneen Sandhu, CIB – Prof Sarah-Jane Dawson, CIC – Prof Georgina V. Long, CID – A.Prof Matteo Carlino, CIE – A. Prof Alexander Menzies, CIF – **Prof Richard A. Scolyer**, CIG – Prof. Helen Rizos, CIH – Prof. Paul Lorigan, CII – A. Prof Victoria Atkinson CIJ – Prof Michael Henderson. AIs: Alison Button-Sloan, Andrew Haydon, Andrew Spillane, Grant McArthur, Michael Millward, Robyn Saw, Victoria Mar. *Title:* Circulating tumour DNA guided Therapy for stage IIB/C BRAF mutant positive mElanoma after surgiCal resecTION (DETECTION). Duration: 5yrs. Amount: AU\$3,230,670 (1.06.2020 –31.05.2025)
12. **The Medical Research Future Fund (MRFF) - Efficient Use of Existing Medicines Grant** (commencing 2021) (Grant no. MRF2007157). CIs: Long G, **Scolyer RA (CIB)**, McArthur G, Menzies A, Spillane A, Carlino M, Gyorki D, Saw R, Lo S, Morton RL. *Title:* NADINA Phase 3 trial comparing response driven neo-adjuvant combination of ipilimumab + nivolumab versus adjuvant nivolumab. Duration: 4yrs. Amount AU\$2,023,376 (1.6.2021 – 31.5.2025)
13. **NSW Government - Biospecimen Collection Grants 2020-2024** (Grant no. H20/113397). Chief Investigator: **Richard A. Scolyer**, PI: Matteo Carlino (Westmead Hospital), Valerie Jakrot (Ethics and governance, Research Projects), Rebecca Velickovic (Biospecimen Bank Operations & Research Projects, Serigne Lo, Risk Modelling, James Wilmott, Genomic analysis, Collaboration: Alex Swarbrick (Garvan), Helen Rizos (Macquarie Uni), Roger Reddell (CMRI), Matthew Law (QIMR Berghofer), Host Organisation Name: Melanoma Institute Australia (MIA). *Title:* The Melanoma Institute Australia Biospecimen Bank – External Collections. Duration: 5 years. Amount: AU\$100,000 (Nov 2020 to 30 June 2024)
14. **Cancer Institute NSW (from NHMRC Ideas Grant)** (Grant no. RG 21-07). CIs: Dr Jessamy Tiffen, Prof Peter Hersey, Dr Stuart Gallagher, Dr Sara Alavi. AI (s): James Wilmott, Georgina Long, **Richard Scolyer**. *Title:* Unleashing the Immune Response Against Melanoma by Targeting a Critical Epigenetic Axis. Duration: 3 years. Amount: AU\$447,726 (1.4.2021 –1.4.2024)
15. **Melanoma Research Alliance Grant 2020**. Andrew Spillane, Felicity Newell, Alexander Swarbrick, Serigne Lo, Ines Silva (Pis), James Wilmott (Young Investigator) and **Richard A. Scolyer** (Administrative Principal Investigator). *Title:* Effective therapies for patients with high risk in-transit disease. Duration: 3 years. Amount: (total) US\$874,865.40 (3 x instalments of US\$299,730.40, \$292,612, and \$282,523, in Year 1, Year 2, and Year 3) (1.7.2020 –30.06.2023)
16. **The Medical Research Future Fund (MRFF) - Research Grant** (Grant no. MRF1167738): Mark Shackleton, Michael Poulsen and Richard Scolyer. *Title:* Combination of Avelumab with Peptide Receptor Radionuclide Therapy (PRRT) or Conventional Fractionated Radiotherapy (RT) in Metastatic Merkel Cell Carcinoma (MCC). Duration: 3 years. Amount: AU\$520,413.46 (1.12.2020 –15.05.2023).
17. **2020 Ramaciotti Foundations Health Investment Grant** (Grant no. 2020HIG141). Awarded to: Dr James S. Wilmott. Administered by: Melanoma Institute Australia. Other participants: Georgina Long, **Richard A. Scolyer**, Alexander Menzies, Matteo Carlino, Ines Da Silva, Tuba Nur Gide, Serigne Lo. Other technical staff/professional staff: Ping Shang, Zarwa Yaseem, Eva Shteinman, Tuba Nur Gide. *Title:* Precision Immunotherapy Platform to match novel drug immunotherapy combinations with advanced cancer patients (PIP-MATCH). Duration: 2 years. Amount: AU\$150,000 (2.7.2021 –31.12.2022).
18. **American Cancer Society (ACS) & Melanoma Research Alliance (MRA) Team Award Grant** (Grant no. 687055). Davies MA (Administrative PI), Huse JT (PI), Gershenwald JE (PI), Tetzlaff MT (PI), McQuade JL (PI), **Scolyer RA (PI)**. *Title:* Molecular predictors and vulnerabilities of melanoma brain metastasis. Duration: 3 years. Amount: US\$999,999.00 (1.1.2020 – 31.12.2022)
19. **National Health and Medical Research Council (NHMRC) - Practitioner Fellowship** (Grant no: APP1141295). **Scolyer RA**. Project: Improving clinical outcomes of melanoma patients. Awarded AUD577,188.50. Start date: 1.1.2018 – End date: 31.12.2022.
20. **National Health and Medical Research Council (NHMRC) – Program Grant** (Grant no. APP1132519). CIA: Prof. Mark Smyth. CI: Prof. **Richard A. Scolyer**, Prof. Georgina V. Long. *Title:* Immunotherapy in cancer and virus infection. Institution: The Council of the Queensland Institute of Medical Research. Duration: 5 years. Amount AU\$9,312,735 (1.1.2018 –31.12.2022)
21. **The Medical Research Future Fund (MRFF) - Research Grant** (Grant no. MRF1175082): Victoria, Mar, Anne Cust, H.Peter Soyer, Rachael Morton, Rory Wolfe, Pascale Guitera, Paul White, Monika Janda, Paul Fishburn, John Kelly, Alexander Chamberlain, Anthony Azzi, Caroline Watts, Catriona McLean, Graham Mann, Helmut Schaidler, **Richard Scolyer**, Robert Miller, Scott Menzies, Yan Pan. *Title:* Assessing diagnostic accuracy for melanoma with compared to without access to Melanoma Surveillance Photography in high-risk individuals. Duration: 3 years. Amount: AU\$2,416,998 (1.6.2019 –31.10.2022)
22. **National Health and Medical Research Council (NHMRC) – CRE Grant 2017** (Grant no. APP1135285). Mann G, Cust A, **Scolyer RA**, Braithwaite J, Kelly J, Morton R, Spillane A, Saw R, Henderson M, Yang J. *Title:* Centre of Research Excellence in Melanoma: Person, tumour and system-focussed knowledge to drive better outcomes in melanoma. Duration: 5 years. Amount: AU\$2,486,945.00 (1.11.2017 – 31.10.2022)

23. **Agency: National Institutes of Health (NIH). Institute: National Cancer Institute (NCI)** (Grant no. P01 CA 206980-01A1). Berwick M, Thomas N, Mann G, **Scolyer R**, Cust A. *Title:* Integration of Clinical and Molecular Biomarkers for Melanoma Survival. Duration: 5 years. Amount: US\$9,792,042 (total) (1.6.2017 – 31.5.2022)
24. Tour de Cure Grant Program 2019 (for funding 2020). Grantor: Tour de Cure Ltd as trustee for Tour de Cure Trust (Ref: RSP-054-2020). Grantee: Melanoma Institute Australia. Chief Investigator: **Richard A. Scolyer**. *Title:* Microbiota: a tool for predicting and enhancing outcomes in cancer immunotherapy. Duration: 1 year. Amount: AU\$100,000 (31.12.2020 - 31.12.2021)
25. Tour de Cure Grant Program 2019 (for funding 2020). Grantor: Tour de Cure Ltd as trustee for Tour de Cure Trust. Grantee: Melanoma Institute Australia. Chief Investigator: **Ines da Silva**. AI: Richard A. Scolyer, et al. *Title:* Improving survival in melanoma by matching optimal drug therapy for individual patients. Duration: 1 year. Amount: AU\$199,526. (31.12.2020 - 31.12.2021)
26. 2020 NSW Premier's Award for Outstanding Cancer Research - Outstanding Cancer Researcher of the Year. Awarded to **Richard A. Scolyer**. Amount: AU\$50,000. (27.11.2020 – 27.11.2021).
27. Cancer Council NSW - Project Grant. CIs: Long GV, **Scolyer RA**, Carlino M, Wilmott J. *Title:* Personalised Immunotherapies: Clinical implementation of genomic and transcriptomic biomarkers of response to stratify cancer patients for precision medicine. Amount: AU\$425,095 (2019–2021)
28. National Health and Medical Research Council (NHMRC) - Program Grant 2016 (for 2017) (Grant ID: APP1093017). CIs: Kefford RF, Thompson JF, Hersey P, Mann GJ, **Scolyer RA**, Hayward N, Long GV. *Title:* Molecular determinants of risk, progression and treatment response in melanoma. Amount: AU\$14,663,120.00. 5 years. (1.1.2016 – 31.12.2020 nb: extended to 31.12.21 due to COVID).
29. National Health and Medical Research Council (NHMRC) - Project Grant (Grant ID: APP1108328). Damian D, Martin A, Halliday G, Eris J, Lowe PM, Fernandez Peñas P, McKenzie C, **Scolyer RA**, Chong A, Vardy J. *Title:* ONTRANS: Oral Nicotinamide for skin cancer chemoprevention after Transplant. Awarded: AUD624,823.60 over 7 years. (1.1.2016 – 30.6.2021)
30. The University of Sydney – University of Geneva Partnership Collaboration Awards (PCA) 2019 Round. CI: **Scolyer, RA**. *Project Title:* Out-of-sample prediction estimation to accurately predict response to immunotherapy drugs in metastatic melanoma. Amount: AU\$39,893 (2019).
31. National Health and Medical Research Council (NHMRC) - Project Grant (Grant ID: GNT1144829). CIA: Prof. Des Richardson, CIB: Dr Darius Lane, CIC: dr Zaklina Kovacevic, CID: Dr Yohan Suryo Rahmanto, CIE: Dr James Wilmott, CIF: Prof. Ashani Weeranatna. AIs: Richard A. Scolyer. *Title:* Melanotransferrin: A “Missing Link” and a Novel Pharmacological Target for Treatment. Amount: AU\$613,848. (1.1.2018 – 31.12.2020).
32. National Health and Medical Research Council (NHMRC) and The University of Sydney - Equipment Grant (Ref: IRMA ID: G201287). CIs: Prof. Des Richardson, Prof. **Richard Scolyer** (CIB), Prof. Glenda Halliday. *Title:* Meso QuickPlex SQ 120 system for Shared Use in the Open Access, Multi-User, Bosch Molecular Biology Facility. Amount: AU\$180,000 (2018).
33. Bosch - Small Equipment Grant. CIs: Nicholas King, Georges Grau, **Richard Scolyer**, Georgina Long, Bob Bao, Michael Buckland, Steve Wise, Kimberley Kaufman, Daniela Traini, Thomas Grewal, Kim Chan, Xiangjian Zheng, Fanfan Zhou, Ling Zhu, Rose Martiniello-Wilks, Donna Lai. *Title:* qNano Gold TRPS Nanoparticle Analysis System for Shared Use in the Open-access Bosch Molecular Biology Facility. Amount: AU\$26,000 (2018).
34. Cancer Research Trust New Zealand. CIs: Chatterjee A, Mathy J, Stockwell P, **Scolyer RA**, Long GV, Wilmott J. *Title:* Generating whole genome-scale epigenetic and transcriptomic maps of New Zealand melanoma patients. Awarded: NZ\$65,662 (2018).
35. National Health and Medical Research Council (NHMRC) / Cancer Council (Grant ID: APP1146229). CIs: Palendira M, Wilmott J, Menzies A, **Scolyer RA**, Long GV, Luciani F, Gebhardt T. *Project:* The Role of Tumour-Resident CD8+ T cells in Metastatic Melanoma and Immunotherapy. Amount: AU\$448,374 (2017).
36. NSW Department of Health OHMR grant and Curran Foundation Grant 2017. CIs: Mann G, **Scolyer RA**, Guo J, Mattick J, Reddel R, Hayward N, Joshua A, Waddell N, Pearson J, Wilmott J, Long, G. *Project:* NSW-China partnership in mucosal melanoma research: integrated genomics for better clinical outcomes. Amount: AU\$750,000 (2017-2019).
37. National Health and Medical Research Council (NHMRC) - Project Grant (Grant ID: APP1129422). CIs: Holst J, **Scolyer RA**, Long GV, Menzies AM, Wilmott J. *Project Title:* Nutrient stress-mediated adaptive responses as novel targets in BRAF mutant melanoma. Amount: AU\$449,174.00 (2017-2020).
38. Bosch Small Equipment Grant. Richardson D, Lai D, Cole L, Halliday G, Chan-Ling T, Zreiqat H, **Scolyer RA**, Hibbs D, Long GV, Hawkins C, Assinder S, Bagley E, Lovelace M, Camp A, Dixon K, Sahni S, Jansson P, Kalinowski D, Kovacevic Z, Lane D, Merlot A, Lok H, Huang M, Duraipandi P. *Project:* State-of-the-Art Nanolive 3D Cell Explorer for the Multi-User Bosch Molecular Biology Facility. Awarded AU\$29,600.00. (2016)
39. Cancer Council NSW – Fellowship Grant. CI: **Scolyer RA**. *Title:* Nutrient stress-mediated adaptive responses as novel targets in BRAF mutant melanoma. Amount: AU\$449,174.00 (2017-2020).
40. National Health and Medical Research Council (NHMRC) - Equipment Grant (IRMA Grant ID: 181556). Richardson D, **Scolyer RA**, Murray M, Long GV, Slobodman B. *Title:* NanoString nCounter SPRINT Profiler System for Shared Use in the Open Access, Multi-User, Bosch Molecular Biology Facility. Amount: AU\$199,000.00 (2015).
41. Cancer Research Institute – Clinical Team Grant. CIs: Smyth M, **Scolyer RA**, Long GV, Stagg J, Antonia S. *Title:* Targeting adenosine in the tumor microenvironment. Amount: AU\$60,199.00. (2015)
42. Cancer Institute NSW - Research Infrastructure Grant (Grant ID: 2015/RIG121). CIs: Richardson D, **Scolyer RA**, Hersey P, Long GV, Halliday G, Damian D, Mason R, Murray M, Hong A, Lee CS, Kalinowski D, Buckland M, Murphy C, Kovacevic Z, Merlot A, Dong Q, Rendina L, Sahni S, Vemulpad S, Kumar N, Martiniello-Wilks R, Lok H, Hoy A, Jansson P, Lyons G, Lane D, Ho J, Codd R, Huq F, Zhou F, De Souza P, Chrzanowski W, Charles K, Grau G, Holst J, Chan-Ling T, Sunde M, Naylor M, Grewal T, Lay P, Munoz L, Christopherson R, Hambly B, Assinder S, McLennan S, Shackel N, Dixon K, Siva D, Gamble J, Lai D. *Project title:* Advanced Technical Support for the Open Access, Multi-Disciplinary Sydney Cancer Research Core Facility. Amount: AUD272,876.00 (2015)
43. Cancer Institute NSW - Equipment Grant (Grant ID: 15/REG/1-12). CIs: Richardson D, **Scolyer RA**, Long GV, Halliday G, Murray M, Lee CS, Kumar N, Mason R, Payne R, Lay P. *Title:* Biacore T200 Molecular Interaction Analysis System for the Open Access, Multi-Disciplinary Sydney Cancer Research Core Facility. Amount: AU\$354,048.00 (2014-2015)
44. NSW Government Health, Office for Health and Medical Research, Genomics Collaborative Grants Program. CIs: Mann GM, Long GV, Rizos H, **Scolyer RA**, Thompson JF, Kefford RF. *Title:* Genetic factors in outcome of new therapies for metastatic melanoma. Amount: AU\$811,150.00 (2014)
45. Melanoma Research Alliance Award. CIs: Clark R, Coughlan KJ, **Scolyer RA**, Mihm MC. *Title:* Enhancing immune responses to melanoma with IL-9. Amount: AU\$27,000.00 (1.5.2015 – 30.4.2018)

46. National Health and Medical Research Council (NHMRC) - Equipment Grant (IRMA grant ID_176705). CIs: Richardson D, **Scolyer RA**, Ng M, Murray M, Kril J. *Title: Hypoxic Chambers for Seahorse XF Extracellular Flux Analyzers for Shared Use in the Open Access, Multi-User, Bosch Molecular Biology Facility.* Amount: AU\$178,670.00 (2014)
47. Cancer Australia - Priority-driven Collaborative Cancer Research Scheme (PdCCRS). CIs: Fogarty G, Hong A, Burmeister B, Novak A, Drummond K, Thompson JF, Dolven-Jacobsen K, Mandel C, Paton E, Hruby G, Dhillon H, Morton R, **Scolyer RA**. ANZMTG 01.07 WBRTMeL. Amount: AU\$335,963. 3 years (once the current funding comes to an end) (2015-2017).
48. Cancer Australia -Priority-drive Collaborative Cancer Research Scheme (PdCCRS). CI: Guitera P. Others: Kelly J, Hong A, Foote M, Soyer P, Stretch J, Craythorne E, Shannon K, Ruben J, Thompson JF, **Scolyer RA**, Paton E, King M, Ruiz R, Sidhu S, Malvey J, Viney R, Rajadhyaksha M. *Title: ANZMTG 02.12 – A randomized controlled multicentre trial of imiquimod versus radiotherapy for lentigo maligna (LM) when staged surgical excision with 5mm margins is not possible, is refused, or fails (RADICAL).* Amount: AU\$600,000.00. 3 years (2014).
49. Sydney Local Health District (SLHD) - Cancer Services Research Grant. CIs: Wilmott JS and **Scolyer RA**. *Title: The mutational landscape of melanoma in adolescents and young adult. Whole Genome Sequencing (Hiseq X ten) of 17 patients (34 genomes).* Amount: AU\$60,000.00 (2014)
50. National Health and Medical Research Council (NHMRC) - Equipment Grant. Richardson DR, **Scolyer R**, Black JL, Halliday GM, Kril J, Murray M, Christopherson R, King NJC, Hardikar A, Triccas J, Lee CS, Burgess J, Naylor M, Mason RS, Ryan R, Brennan-Speranza T, Joshua DE, Hong A, Poronnik P, Frank Lovicu F, Kalinowski D, Sharland AF, Johnstone D, Oliver B, Ammit A, Groundwater P, Zreiqat H, Dixon K, Lyons G, Lu Z, Sunde M, Zhu L, Sahni S, Hibbs D, Morris B, Goldsbury C, Lay P, Byrne M, Lok H, McLennan SM, Slobedman B, Buckland M, Kovacevic Z, Bao S, Assinder SJ, Ju Y, Codd R, Lane D, Fu D, Owens T, Fraser S, Shafie NH, Sutherland G, Lai D, Huang M, Williamson P, Day M, Camp A, de Graaf S, Dong Q, Jansson P, Rendina L, Hambly B, dos Remedios C, Allbutt H, Barrs V, Huq F, Ho J, Murphy CR. *Title: CLARIOstar Multimode Microplate Reader for Shared Use in the Open Access, Multi-user Bosch Molecular Biology Core Facility.* Amount: AU\$60,000.00 (2014)
51. Ramaciotti Centre - Equipment Grant. Jonathan Stone, Judy Black, Anand Hardikar, Sue McLennan, MacDonald Christie, **Richard Scolyer**, Nicholas King, Des Richardson, Cheok Soon Lee, Cris dos Remedios, Barry Slobedman, Steve Chadban, Alexandra Sharland, Michael Buckland, Angela Hong, Donna Lai. *Title: QuantStudio 12K Flex OpenArray High-throughput Genetic Analysis System for Shared Use in the Open Access Multi-user Bosch Molecular Biology Core Facility.* Amount: AUD74,000.00 (2013.)
52. Cancer Institute New South Wales Research Equipment Grant (Ref: 13/REG/1-01). CIs: O'Toole S, **Scolyer RA**, Horvath L, Kohonen-Cornish M, Kench J. *Title: Implementing Next Generation Sequencing of Advanced Lung Cancer and Melanoma in Clinical Practice.* Amount: AUD152,784.00 (2013)
53. The University of Sydney's Cancer Research Fund – Equipment Grant. Richardson DR, **Scolyer, RA**, Boyer M, Halliday G, Damian D, Christopherson R, Joshua D, Kench JG Hong A, Murray M, Lee CS, Kalinowski D, Naylor M, Lay P, Lyons G, Kovacevic Z, Mason R, Dixon K, Chan-Ling T, Hawkins C, McLennan S, Sunde M, Lovejoy D, Owens T, Rendina L, Jansson P, dos Remedios C, Charles K, Lane D, Witting P, Dong Q, Ammit A, Groundwater P, Assinder S, Bao B, Byrne S, Zhou F, Buckland M, Grewal T, Huq F, Lai D, Codd R, Zhang D, Fu D, de Graaf S, Huang M, Payne R, Slobedman B, Barrs V, Ho J, Williamson P, Murphy C. *Title: Robotic High Throughput Western Analysis for the Open Access, Multi-User Sydney Cancer Research Core Facility.* Amount: AU\$200,000.00 (2013)
54. National Health and Medical Research Council (NHMRC) - Equipment Grant. Richardson DR., **Scolyer RA**, Boyer, M, Halliday G, Damian D, Christopherson R, Joshua D, Kench JG, Hong A, Murray M, Lee CS, Kalinowski D, Naylor M, Lay P, Lyons G, Kovacevic Z, Mason R, Dixon K, Chan-Ling T, Hawkins C, McLennan S, Sunde M, Lovejoy D, Owens T, Rendina L, Jansson P, dos Remedios C, Charles K, Lane D, Witting P, Dong Q, Ammit A, Groundwater P, Assinder S, Bao B, Byrne S, Zhou F, Buckland M, Grewal T, Huq F, Lai D, Codd R, Zhang D, Fu D, de Graaf S, Huang M, Payne R, Slobedman B, Barrs V, Ho J, Williamson P, Murphy C. *Title: 00QX100 Droplet Digital PCR System for Shared Use at the Multi-User Molecular Biology Core Facility.* Amount: AU\$74,750 (2013)
55. Cancer Institute NSW – Research Infrastructure Grant (Grant ID: 13/REG/1-03). CIs: Richardson D, **Scolyer RA**, Lee CS, Halliday GM, Murray M, Lay P, Christie M, Kench JG, Damian DL, Hersey P. *Title: BioMark HD High-throughput Real Time & Digital PCR System for the Open Access, Multi-Disciplinary Sydney Cancer Research Core Facility.* Amount: AU\$326,895 (2013)
56. National Health and Medical Research Council (NHMRC) – Practitioner Fellowship (Grant no. GNT1045866): CI: **Scolyer RA**. Amount: AUD444,013.50 (2013-2017).
57. Cancer Institute NSW - Infrastructure Grant. Richardson DR, Boyer M, **Scolyer R**, Hambley T, Murray M, Lay P, Lee CS, Hersey P, Halliday G, Weninger W, Clarke C, Mason R, Kalinowski D, Buckland M, Lovejoy D, Murphy C, Groundwater P, Kovacevic Z, Dong Q, Siva D, Hawkins C, Rendina L, Zhang D, Christie M, De Souza P, Codd R, Conigrave A, Vemulapad S, Kumar N, Naylor M, Assinder S, Lok H, Hoy A, Jansson P, Lyons G, Lane D, Fraser S, Dixon K, Ho J, and Lay D. *Title: Advanced Technical Support for the Open Access, Multi-Disciplinary Sydney Cancer Research Core Facility.* Amount: \$236,153 + \$135,000 from USYD - Total: AUD371,153.00.
58. National Health and Medical Research Council (NHMRC) - Equipment Grant. Richardson DR, **Scolyer RA**, Stocker R, Weninger R, Black J, Allen D, Murray M, Mason R, Twigg S, King NJ, Horvath L, Lovicu F, Lee CS, Halliday G, Lovejoy D, Joshua D, Sharland A, Roufagalis B, Hambly B, Morris B, Bao B, Bishop GA, Hibbs D, Lane D, Zhou F, Hanrahan J, Dixon K, Rendina LM, Byrne M, Naylor M, Cole NJ, Jansson P, Dong Q, Codd R, Rayne R, Assinder S, Chadban S, Fraser S, McLennan S, Suryo Rahmanto Y, Lai D, Yu Y, Ju Y-K, Buckland M, Kovacevic Z, Saletta F, Zreiqat H, Kalinowski D, Groundwater P, Simes J, Zhang D, Boyer M, Murphy C. *Title: GeneAtlas Personal Microarray System for Shared Use at the Multi-User Molecular Biology Core Facility.* Institution: The University of Sydney (2010-2011). Award: AUD74,000.
59. The University of Sydney Cancer Research Fund - Research Infrastructure Grant. Richardson DR, **Scolyer R**, Simes J, Weninger W, Murphy C, Lee CS, Halliday G, Damien D, Joshua D, Qihan D, Byrne S, Naylor M, Lyons G, Assinder S, Buckland,M, Yu Y, Hong A, Dixon K, Lay P, Fanfan Z, Suryo Rahmanto Y, Ho PJ, Charles K, Sharland A, Jansson P, Lai D, Bao B, Kovacevic Z, Saletta F, Lovejoy D, Hambly B, Lane D, Kalinowski DS, Roufagalis B, Groundwater P, Christopherson R, Gamble JR, Murray M, Zhang D, Horvath L, Mason RS, Boyer M. IncuCyte FLR. Project *Title: Imaging System for Cancer Researchers at the Multi-User Bosch Molecular Biology Core Facility.* Amount: \$144, 200 (internal funding: \$30,000) Total: AU\$174,200.00 (2011-2012)
60. Cancer Institute NSW – Research Infrastructure Grant (Ref: 11/REG/1-to13). Doble P, Beavis A, Hare D, Thompson JF, **Scolyer RA**. *Title: Three dimensional lymph node imaging: improving detection of sentinel nodes to reduce false negatives.* Amount: AU\$447,155 (2011)
61. Cancer Institute NSW - Research Infrastructure Grant (Ref: 10/CRF/1-09). CIs: Richardson DR, Boyer M, Weninger W, **Scolyer RA**, Halliday G, Lee C.S, Hambley T, Murray M, Lay P, Mason R.S, AIs: Joshua D, Murphy C, McLachlan A, King NJC, Dong Q, Naresh K, dos Remedios C, Rendina L, Davies M, Assinder S, Kovacevic Z, Zreiqat H, Vemulapad S, Bao B, Yu Y, Bishop A, Vanderberg R,

- Zhang D, Groundwater P, Hawkins C, Kalinowski D, De Souza P, Lane D, Ryan R, Hambly B, Jansson P, Moscato P, Saletta F, Fraser S, Sharland A, Lovejoy D, Codd R, Jamie J, Byrne M, Kench J, Suryo Rahmanto Y, Lai D. Title: Seahorse Extracellular Flux (XF) Analyzer for the Multi-Disciplinary Sydney Cancer Research Core Facility. Amount: AUD315,000.00 (2011)
62. Cancer Institute NSW - Clinical Research Fellowship. (Grant ID: 10/CRF/1-09). CI: **Scolyer RA**. Project Title: Identification and validation of biomarkers of prognosis and treatment response in melanoma to effect change in clinical care and patient outcome. Amount: AUD749,202.00. 3 years (2011-2013).
 63. National Health and Medical Research Council (NHMRC) Project Grant. Project Grant Application (Ref: 1004632). Phan T, **Scolyer RA**. Scientific Title: The role of subcapsular sinus macrophages in lymph node metastases. Amount: AU\$435,444.00 - 3 years (2011-2013).
 64. National Health and Medical Research Council (NHMRC) Program Grant. Kefford R, Thompson J, Hersey P, Mann G, **Scolyer RA**, Haywood N. Molecular determinants of risk, progression and treatment response in melanoma. Amount: AU\$12,050,000 (2011-2016).
 65. Cancer Institute NSW - Translational Research program (Grant ID: 10/TPG/1-02). CIs: Mann G, Thompson J, Kefford R, **Scolyer RA**, Hersey P, Menzies S, Spillane A, Rizos H, Zhang X, Christopherson R. Amount: AUD3,736,500.00 (2010-2015).
 66. National Health and Medical Research Council (NHMRC) Equipment Grant. Richardson DR, Stone J, Black J, King N, Mason RS, Hunt NJ, Kril J, Murray M, **Scolyer RA**, Halliday GM, Vandenberg R, McMinn P, Chadban S, Byrne M, Ryan R, Dong Q, Lee CS, Bishop AG, Haass N, Fraser S, Hambly B, Sharland A, Kalinowski D, Assinder S, Yu Y, Bao B, Ju YK, Lovejoy D, Buckland M, Lane D, do Remedios C, Kovacevic Z, Sutherland G, Zhang D, Morris B, Rahmanto YS, Murphy C. PyroMark Q96 ID system for the Multi-User Sydney Cancer Gene Expression Facility. Amount: USYD AU\$20,000 NHMRC: AU\$74,000.00 (2010-2011)
 67. Cancer Institute of NSW Research - Equipment Grant (Grant ID: 10/REG/1-16). Richardson DR, Halliday GM, **Scolyer RA**, Clarke S, Lee CS, Reichardt JK, Murray M, Clarke C, Boyer M, Kefford R, Mason RS, Murphy CR, McLachlan, Gamble JR, Lay P, Dong Q, Kumar N, Lyons G, Byrne G, Gurney HP, Davies M, Assinder SJ, Rahmanto Y, Jamie J, Vemulpad S, Bao S, Haass NK, Kench JG, Kalinowski DS, Lovejoy DB, Groundwater P, Hawkins C, De Souza P, Lane D, Zhang D, Moscato P, Lai D. Title: GenomeLab GeXP Genetic Analysis System for the Multi-Disciplinary Sydney Cancer Gene Expression Facility. Amount: AUD97,438.00.00 (2010-2011)).
 68. National Health and Medical Research Council (NHMRC) - Program Grant. CIs: Kefford R, Thompson J, Hersey P, Mann G, **Scolyer RA**, Haywood N. Title: Molecular determinants of risk, progression and treatment response in melanoma. Amount: AU\$12,050,000.00 (2006- 2010).
 69. Cancer Institute NSW Research Infrastructure Grant 2009. Richardson DR, Halliday GM, Mason RS, Murphy CR, Kumar N, Horvath L, Weninger W, Lee CS, Lyons G, Lay P, Boyer M, Byrne S, Assinder S, Rahmanto Y, Iland HJ, Jamie J, Vemulpad S, **Scolyer RA**, Vadas M, Gamble JR, Bao S, Hambly TW, Haass NK, O'Brien PM, Kench JG, Dong Q, Kalinowski DS, Reichardt JK, Rasko JEJ, Lovejoy DB, King NJC. Title: PALM Microbeam Laser Microdissection (LM) Microscope for the Multi-User Sydney Cancer Gene Expression Facility. Amount: AUD632,578.00 (2009).
 70. National Health and Medical Research Council (NHMRC) Project Grant. CIs: Richardson, D.R. and Suryo-Rahmanto, Y. AIs: Associate investigators: **Scolyer RA**, Kefford RF, Halliday G, Walker G, Rothwell T. Title: The Role of Melanoma Tumour Antigen, Melanotransferrin (MTf), in Melanoma Tumourigenesis (#570951). Amount: AUD 541,250 (2009-2011).
 71. Commonwealth Government of Australia, Cancer Australia, Quality Use of Pathology Program. CIs: Patrick J, Barton M, **Scolyer RA**. Project: Information Extraction from narrative Pathology Reports. Amount: AUD272,000.00 (2008-2009).
 72. Cancer Institute NSW Clinical Research Fellowship. CI: **Scolyer RA**. Amount: AUD 969,812 (2008-2010).
 73. Cancer Institute of NSW Registrars Program 2007. **Scolyer RA** (Supervisor). Dr Caroline Cooper. Amount: AUD105,000 (2007)
 74. Cancer Institute New South Wales Clinical Research Fellowship. Chief Investigator: Karim RZ. Co-investigators: Lee CS, **Scolyer RA**. Title: Epithelial-stromal interactions in phyllodes breast tumours. Amount: AUD 535,910.00 (2007-2009).
 75. Cancer Institute New South Wales Clinical Fellowship 2007. **Scolyer RA** (Supervisor), Arnold C (Clinical Fellow). Project title: Development of pathological and clinical pathways for "Treat, Resect, Analyse for Melanoma" ("TRAM") protocol. Amount: AUD 138,016.00 (2007).
 76. National Health and Medical Research Council (NHMRC) Project Grant. Ref: 45940. CIs: Suter C, **Scolyer R**, Bova R, Martin D. Project Title: Inborn epimutations as markers of disease risk. Amount: AUD331,800.00 (2007- 2009).
 77. Cancer Institute New South Wales Clinical Research Fellowship. Chief Investigator: R Murali. Co-investigators: **Scolyer RA**, CS Lee. Sentinel Lymph Node Evaluation in Patients with Melanoma – clinical, pathological and genetic studies to improve prognostication and patient management. Amount: AUD535,910.00.(2007-2009)
 78. Cancer Institute New South Wales Clinical Fellowship 2006. **Scolyer RA** (Supervisor), Karim RZ (Clinical Fellow).Project title: Expression of cell cycle regulatory proteins in melanoma. Amount: AUD 120,000.00 (2006).
 79. Cancer Institute of NSW, Clinical Trials Partnership Grant. Chief Investigators: Thompson J, Armstrong B, Beard J, Curtin A. Collaborators: Barton M, Frommer M, Holt P, Mann G, **Scolyer RA**. Title: Partnership in patterns of care for melanoma. Amount: AUD357,000.00 (2006-2007).
 80. National Health and Medical Research Council (NHMRC) Program Grant. Chief Investigators: Kefford R, Thompson J, Hersey P, Mann G, **Scolyer RA**. Project Title: Molecular determinants of risk, progression and treatment response in melanoma. Amount: AUD8,050,000.00 (2006- 2010).
 81. Cancer Institute of NSW Program Grant for Excellence in Translational Research. Chief Investigators: Mann G, Thompson J, Kefford R, **Scolyer RA**, Menzies S, Hersey P, Christopherson R. Amount: AUD3,750,000.00 (2005 2009).
 82. Glaxosmithkline Australia Pty Ltd . Chief Investigators: Lee CS, McKenzie P, **Scolyer RA**, Millward M, Thompson J. Project Title: Assessment of erbB1 and erbB2 in metastatic melanoma. Amount: AUD45,000 (2003- 2004).
 83. The University of Sydney Cancer Research Fund. Chief Investigators: **Scolyer RA**, McCarthy WH. AIs: Thompson JF, McKenzie PR, Watson GF, Uren RF, Lee CS. Project Title: Diagnostic accuracy of fine needle aspiration biopsy in metastatic melanoma. Amount: AUD95,000.00 (2003-2004).
 84. The University of Sydney Cancer Research Fund. Chief investigator: Thompson JF. AIs: **Scolyer RA**, Li L-XL, Dawson M. Project Title: Sentinel lymph node evaluation in melanoma patients. Amount: AUD95,000.00 (2003-2004)
 85. Royal College of Pathologists of Australasia - Technical Assistance Research Grant 2002. CI: **Scolyer RA**. Project Title: Immunohistochemical assessment of apoptotic factors in melanomas. Amount: AUD5000 (2002).

RESEARCH TOOLS / RISK PREDICTION CALCULATORS

RAS, in his capacity as Co-Medical Director at Melanoma Institute Australia, together with the MIA team has developed a series of online Risk Prediction Calculators to guide clinicians in prevention, early detection and optimum treatment of melanoma. These Risk Prediction Tools are intended to guide informed discussions about treatment between clinicians and their patients. The tools are underpinned by data published in peer-reviewed journals.

1. Prediction Tool (Early Melanoma): First Primary Melanoma Risk – <https://www.melanomarisks.org.au/FirstMelLand>
2. Prediction Tool (Early Melanoma): Sentinel Node Metastasis Risk – <https://www.melanomarisks.org.au/SNLLand>
3. Prediction Tool (Early Melanoma): Subsequent Primary Melanoma Risk – <https://www.melanomarisks.org.au/SNLLand>
4. Prediction Tool (Early Melanoma): Thin Melanoma Recurrence Risk – <https://www.melanomarisks.org.au/ThinMelLand>
5. Risks Prediction Calculator (Advanced Melanoma): Immunotherapy Outcome Prediction - <https://www.melanomarisks.org.au/IOCLand>

CONTRIBUTIONS TO LARGE DATASETS FOR RESEARCH

1. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4. RNAseq count matrix from 158 tumor biopsies from melanoma patients treated with anti-PD-1 monotherapy (n = 63) or combined anti-PD-1 and anti-CTLA-4 (n = 57). https://github.com/miabioinformatics/Gide_CancerCell2019.
2. International melanoma database & discovery platform. American Joint Committee on Cancer Melanoma Database collected 50,000 patient records from around the globe (RS Vice Chair AJCC Melanoma Expert Panel).
3. Australian Melanoma Genome Project. RAS co-lead of AMGP which is part of the International Cancer Genome Consortium. Database contains whole genome sequencing data of 500 melanomas.
4. Melanoma Institute Australia (MIA) Patient Research Database. The largest single institutional collection of melanoma patient records dating from patients managed in the 1960's. This is an important international resource that has underpinned analyses performed to develop the 6th, 7th and 8th editions of the AJCC staging system. Also supports much of the research at MIA.
5. TEAM (Treat, Excise, Analyse Melanoma) Database. Consists of blood and tissue samples of patients treated with novel systemic therapies usually as part of clinical trials. The samples are taken before (PRE) and early during treatment (EDT) and on disease progression (PROG) is relapse occurs. Detailed morphologic and molecular analysis of cohorts of patients have been analysed resulting in numerous high impact findings published in some of the worlds leading journals (including Nature). Others (e.g. Wilmott et al CCR 2012 have been highly cited (>300) and received multiple awards including from the American Association of Cancer Researchers and a NSW Premier award. The data has also changed clinical trial design and clinical management.
6. MIA Biospecimen Bank. RAS has led, overseen, developed, and supervised this biospecimen bank for >20 years and is the world's largest collection of fresh frozen blood (>15,000 specimens) and melanoma specimens (>5000 including >1000 primary tumours) with linked clinical data. It has become an important international resource that underpinned the two largest genomics projects ever conducted in melanoma: TCGA (RS lead pathologist) and Aust Mel Genome Project (RS co-lead investigator). Also supports much of the tissue based research at MIA.
7. The Cancer Genome Atlas (TCGA) melanoma project. I was lead pathologist for the TCGA melanoma project- RS & team contributed one third of samples worldwide and was part of manuscript writing committee, analysis, clinical and disease working groups. Published in Cell 2015: Whole genome sequencing, Exome sequencing, RNAseq, small RNAseq, Methylation array and Protein array data. RS & the MIA team contributed the samples and data for 1/3 of all the cases in the study. <http://dx.doi.org/10.1016/j.cell.2015.05.044>.
8. International Cancer Genome Consortium: Australian Melanoma Genome Project. The Australian Melanoma Genome Project (AMGP) is analysing whole genomes from melanomas that include cutaneous, acral and mucosal melanoma subtypes. See links: <https://www.ebi.ac.uk/ega/studies/EGAS00001001552> and <https://dcc.icgc.org/releases/current/Projects/MELA-AU>. RS & team contributed 95% of the samples.

BOOKS and CHAPTERS (incl GUIDELINES)

1. **Scolyer RA**. Chapter: 12.0.0.2: Mucosal melanoma within Chapter 12.0: Melanocytic lesions. In: WHO Classification of Urinary and Male Genital Tumours, 5th edition. Lyon (France): International Agency for Research on Cancer; 2022. (WHO classification of tumours series, 5th ed.; vol. 8). <https://publications.iarc.fr>.
2. de la Fouchardiere A, Reyes-Mugica, M, **Scolyer RA**. Chapter 14.5.1.3: Blue naevus. In: WHO Classification of Paediatric Tumours. Lyon (France): International Agency for Research on Cancer; 2022. (WHO classification of tumours series, 5th ed.; vol. 7). <https://publications.iarc.fr/>.
3. Alexandrescu S, Bui M, Perry A, Reyes -Múgica M and **Scolyer RA**. Chapter 5.2.9.6: Solitary circumscribed neuroma. In: WHO Classification of Paediatric Tumours. Lyon (France): International Agency for Research on Cancer; 2022. (WHO classification of tumours series, 5th ed.; vol. 7). <https://publications.iarc.fr/>.
4. **Scolyer RA** and de la Fouchardière A. Chapter 6.1.2.3: Adrenal melanoma. In: WHO Classification Endocrine and Neuroendocrine Tumours. Lyon (France): International Agency for Research on Cancer; 2022. (WHO classification of tumours series, 5th ed.; vol. tbc). <https://publications.iarc.fr/>.
5. **Scolyer RA**, de la Fouchardière A, Travis, WD. Chapter: 1.5.0.1: Melanoma of the lung. In: WHO Classification of Thoracic Tumours. Lyon (France): International Agency for Research on Cancer; 2021. (WHO classification of tumours series, 5th ed.; vol. 5). <https://publications.iarc.fr/595>. ISBN: 978-92-832-4506-3.
6. de la Fouchardière A, **Scolyer RA**, Selim MA. Chapter: 14.0.1.6: Dysplastic melanocytic naevus. . In: WHO Classification of Tumours Editorial Board. Female genital tumours. Lyon (France): International Agency for Research on Cancer; 2020. (WHO classification of tumours series, 5th ed.; vol. 4). <https://publications.iarc.fr/592>. ISBN: 978-92-832-4504-9.
7. **Scolyer RA**, Wilkinson N, Malpica A. Singh R (Editor). Chapter: 14.0.2.1: Mucosal melanoma. In: WHO Classification of Tumours Editorial Board. Female genital tumours. Lyon (France): International Agency for Research on Cancer; 2020. (WHO classification of tumours series, 5th ed.; vol. 4). <https://publications.iarc.fr/592>. ISBN: 978-92-832-4504-9.

8. **Scoflyer RA**, Ferguson PM. Chapter 2.10.6: Solitary circumscribed neuroma. In: WHO Classification of Tumours Editorial Board. Soft Tissue and Bone tumours. Lyon (France): International Agency for Research on Cancer; 2020. (WHO classification of tumours series, 5th ed.; vol. 3). ISBN: 978-92-832-4502-5.
9. Keung EZ, Balch CM, Thompson JF, Kirkwood JM, **Scoflyer RA**, Sondak VS, Gershenwald JE. Melanoma prognosis and staging. In: *Cutaneous Melanoma*, 6th Ed, pp. 271-97, Eds Balch CM, Houghton AN, Sober AJ, Atkins MB, Thompson JF, Gershenwald JE, Kefford RF, Halpern A, Kirkwood JM, Garbe C. Springer Publishing, Switzerland, 2020.
10. **Scoflyer RA** and Busam KJ. Chapter 312 - Prognosis, Staging, and Reporting of Melanomas. *Pathology of Melanocytic Tumours*. Published by Elsevier 2019. 1600 John F. Kennedy Blvd. Ste 1600, Philadelphia, PA 19103-2899. ISBN: 978-0-323-37457-6.
11. **Scoflyer RA**, Lezcano C, Busam KJ. Chapter 27 – Metastatic Melanoma. Section IV Metastatic Melanoma, 313. *Pathology of Melanocytic Tumours*. Published by Elsevier 2019. 1600 John F. Kennedy Blvd. Ste 1600, Philadelphia, PA 19103-2899. ISBN: 978-0-323-37457-6.
12. **Scoflyer RA** and Busam KJ. Chapter 26 – Melanocytic Nevi in Lymph Nodes. *Pathology of Melanocytic Tumours*. Published by Elsevier 2019. 1600 John F. Kennedy Blvd. Ste 1600, Philadelphia, PA 19103-2899. ISBN: 978-0-323-37457-6.
13. Busam KJ and **Scoflyer RA**. Chapter 20 – Uncommon Variants of Melanoma and Collision Scenarios. *Pathology of Melanocytic Tumours*. Published by Elsevier 2019. 1600 John F. Kennedy Blvd. Ste 1600, Philadelphia, PA 19103-2899. ISBN: 978-0-323-37457-6.
14. **Scoflyer RA**, Ferguson PM and Busam KJ. Chapter 14 – Acral and Subungual Melanoma. *Pathology of Melanocytic Tumours*. Published by Elsevier 2019. 1600 John F. Kennedy Blvd. Ste 1600, Philadelphia, PA 19103-2899. ISBN: 978-0-323-37457-6.
15. Busam KJ and **Scoflyer RA**. Chapter 9 – Combined Melanocytic Nevi. *Pathology of Melanocytic Tumours*. Published by Elsevier 2019. 1600 John F. Kennedy Blvd. Ste 1600, Philadelphia, PA 19103-2899. ISBN: 978-0-323-37457-6.
16. Busam KJ, Yeh I and **Scoflyer RA**. Chapter 6 – Deep Penetrating Nevi. *Pathology of Melanocytic Tumours*. Published by Elsevier 2019. 1600 John F. Kennedy Blvd. Ste 1600, Philadelphia, PA 19103-2899. ISBN: 978-0-323-37457-6.
17. **Scoflyer RA**, Prieto VG. Chapter: 14.1.1.1: Mucosal melanoma of the digestive system. *Digestive System Tumours, WHO Classification of Tumours, 5th Edition, Volume 1*. IARC Press, Lyon, France (Jan 2019) 5th ed. ISBN: 978-9-28-324499-8.
18. Bailey TA, Thompson JF, **Scoflyer RA**. Desmoplastic Melanoma. In: *Melanoma* pp. 469-81. Eds Fisher DE, Bastian BC. Springer Nature, New York, 2019.
19. **Scoflyer RA**, Prieto VC, Elder DE, Cochran AJ, Mihm MC JR. Classification and Histopathology of Melanoma. In: *Cutaneous Melanoma 6th Edition "Pathology" section*. Meteor Springer 2019.
20. Keung EZ, Balch CM, Thompson JF, Kirkwood JM, **Scoflyer RA**, Sondak VS, Gershenwald JE. Melanoma prognosis and staging. In: *Cutaneous Melanoma*, 6th Ed, pp. 271-97, Eds Balch CM, Houghton AN, Sober AJ, Atkins MB, Thompson JF, Gershenwald JE, Kefford RF, Halpern A, Kirkwood JM, Garbe C. Springer Publishing, Switzerland, 2020. DOI https://doi.org/10.1007/978-3-030-05070-2_4.
21. Thompson JF, Kefford RF, Stevens GN, **Scoflyer RA**. History of melanoma. In: *Melanoma: A Modern Multidisciplinary Approach*, pp. 1-13; ed A Riker, Springer International Publishing, Cham, Switzerland 2018.
22. Shashank A, Guminski AD, Abu Alrub NKA, **Scoflyer RA**, Damian DL, Thompson JF. Basal cell carcinoma. In: *Textbook of Complex General Surgical Oncology*, pp. 219-27. Eds Morita SY, Balch CM, Klimberg VS, Pawlik TM, Posner MC, Tanabe KK. McGraw Hill Education, New York, 2018.
23. Read RL, **Scoflyer RA**, Thompson JF. Uncommon cutaneous malignancies. In: *Textbook of Complex General Surgical Oncology*, pp. 213-8. Eds Morita SY, Balch CM, Klimberg VS, Pawlik TM, Posner MC, Tanabe KK. McGraw Hill Education, New York, 2018.
24. DE Elder, D Massi, **RA Scoflyer**, R Willemze (Editors). *WHO Classification of Skin Tumours, 4th Edition, Volume 11*. IARC Press, Lyon, France (2018) 4th ed. ISBN: 978-9-28-322440-2
25. Elder D, Massi D, **Scoflyer RA**. Chapter 1.1: Introduction. *WHO Classification of Skin Tumours, 4th Edition, Volume 11*. IARC Press, Lyon, France (2018) 4th ed. ISBN: 978-9-28-322440-2
26. Messina J, Epstein, EH, Kossard S, McKenzie C, Patel R, Patterson JW, **Scoflyer RA**. Chapter 1.2.1: Basal cell carcinoma. *WHO Classification of Skin Tumours, 4th Edition, Volume 11*. IARC Press, Lyon, France (2018) 4th ed. ISBN: 978-9-28-322440-2
27. **Scoflyer RA**. Chapter 1.2.1.1: Nodular basal cell carcinoma. *WHO Classification of Skin Tumours, 4th Edition, Volume 11*. IARC Press, Lyon, France (2018) 4th ed. ISBN: 978-9-28-322440-2
28. **Scoflyer RA**. Chapter 1.2.1.2: Superficial basal cell carcinoma. *WHO Classification of Skin Tumours, 4th Edition, Volume 11*. IARC Press, Lyon, France (2018) 4th ed. ISBN: 978-9-28-322440-2
29. **Scoflyer RA**. Chapter 1.2.1.3: Micronodular basal cell carcinoma. *WHO Classification of Skin Tumours, 4th Edition, Volume 11*. IARC Press, Lyon, France (2018) 4th ed. ISBN: 978-9-28-322440-2
30. **Scoflyer RA**. Chapter 1.2.1.4: Infiltrating basal cell carcinoma. *WHO Classification of Skin Tumours, 4th Edition, Volume 11*. IARC Press, Lyon, France (2018) 4th ed. ISBN: 978-9-28-322440-2
31. **Scoflyer RA**. Chapter 1.2.1.5: Sclerosing/morpheic basal cell carcinoma. *WHO Classification of Skin Tumours, 4th Edition, Volume 11*. IARC Press, Lyon, France (2018) 4th ed. ISBN: 978-9-28-322440-2
32. **Scoflyer RA**. Chapter 1.2.1.6: Basosquamous carcinoma. *WHO Classification of Skin Tumours, 4th Edition, Volume 11*. IARC Press, Lyon, France (2018) 4th ed. ISBN: 978-9-28-322440-2
33. **Scoflyer RA**. Chapter 1.2.1.7: Pigmented basal cell carcinoma. *WHO Classification of Skin Tumours, 4th Edition, Volume 11*. IARC Press, Lyon, France (2018) 4th ed. ISBN: 978-9-28-322440-2
34. **Scoflyer RA**. Chapter 1.2.1.8: Basal cell carcinoma with sarcomatoid differentiation. *WHO Classification of Skin Tumours, 4th Edition, Volume 11*. IARC Press, Lyon, France (2018) 4th ed. ISBN: 978-9-28-322440-2
35. **Scoflyer RA**. Chapter 1.2.1.9: Basal cell carcinoma with adnexal differentiation. *WHO Classification of Skin Tumours, 4th Edition, Volume 11*. IARC Press, Lyon, France (2018) 4th ed. ISBN: 978-9-28-322440-2
36. **Scoflyer RA**. Chapter 1.2.1.10: Fibroepithelial basal cell carcinoma. *WHO Classification of Skin Tumours, 4th Edition, Volume 11*. IARC Press, Lyon, France (2018) 4th ed. ISBN: 978-9-28-322440-2
37. Pulitzer MP, Beer T, Cerio R, Kao GF, Murphy G, Nagoree E, **Scoflyer RA**. Chapter 1.2.3 Squamous cell carcinoma in situ (Bowen disease). *WHO Classification of Skin Tumours, 4th Edition, Volume 11*. IARC Press, Lyon, France (2018) 4th ed. ISBN: 978-9-28-322440-2
38. Elder DE, Scoflyer RA, Daniela M, Lazar AJ, de la Fouchardière A. Chapter 2.1.1 Melanocytic tumour classification and the pathway concept of melanoma pathogenesis. *WHO Classification of Skin Tumours, 4th Edition, Volume 11*. IARC Press, Lyon, France (2018) 4th ed. ISBN: 978-9-28-322440-2
39. **Scoflyer RA**, Elder D, Massi D, Lazar AJ, de la Fouchardière A. Chapter 2.1.2 Genomic landscape of melanoma. *WHO Classification of Skin Tumours, 4th Edition, Volume 11*. IARC Press, Lyon, France (2018) 4th ed. ISBN: 978-9-28-322440-2

40. Elder D, Massi Daniela, **Scohyer RA**. Chapter 2.2.3 Junctional, compound, and dermal naevi. *WHO Classification of Skin Tumours, 4th Edition, Volume 11*. IARC Press, Lyon, France (2018) 4th ed. ISBN: 978-9-28-322440-2
41. Elder DE, Massi D, **Scohyer RA**. Chapter 2.2.4 Dysplastic naevus. *WHO Classification of Skin Tumours, 4th Edition, Volume 11*. IARC Press, Lyon, France (2018) 4th ed. ISBN: 978-9-28-322440-2
42. **Scohyer RA**. Chapter 2.2.10 Deep penetrating naevus and melanocytoma. *WHO Classification of Skin Tumours, 4th Edition, Volume 11*. IARC Press, Lyon, France (2018) 4th ed. ISBN: 978-9-28-322440-2
43. **Scohyer R.A**. Chapter 2.2.12 Combined naevus, including combined BAP1-inactivated naevus / melanocytoma. *WHO Classification of Skin Tumours, 4th Edition, Volume 11*. IARC Press, Lyon, France (2018) 4th ed. ISBN: 978-9-28-322440-2
44. Elder D.E, Massi D, **Scohyer RA**. Chapter 2.3.1 Lentigo maligna melanoma. *WHO Classification of Skin Tumours, 4th Edition, Volume 11*. IARC Press, Lyon, France (2018) 4th ed. ISBN: 978-9-28-322440-2
45. **Scohyer RA**. Chapter 2.3.2 Desmoplastic melanoma. *WHO Classification of Skin Tumours, 4th Edition, Volume 11*. IARC Press, Lyon, France (2018) 4th ed. ISBN: 978-9-28-322440-2
46. de la Fouchardi re A, **Scohyer RA**, Calonje E, Fullen D.R, Gerami P, Requena L, Barnhill RL. Chapter 2.7.1 Melanoma arising in blue naevus. *WHO Classification of Skin Tumours, 4th Edition, Volume 11*. IARC Press, Lyon, France (2018) 4th ed. ISBN: 978-9-28-322440-2
47. **Scohyer RA**, de la Fouchardi re A. Chapter 2.7.2 Blue naevus and cellular blue naevus. *WHO Classification of Skin Tumours, 4th Edition, Volume 11*. IARC Press, Lyon, France (2018) 4th ed. ISBN: 978-9-28-322440-2
48. Massi D, **Scohyer RA**, Elder D.. Chapter 3.1 Introduction. *WHO Classification of Skin Tumours, 4th Edition, Volume 11*. IARC Press, Lyon, France (2018) 4th ed. ISBN: 978-9-28-322440-2
49. Massi DM, Elder D.E, **Scohyer RA**, Singh R. Chapter 3.2.1 Adnexal adenocarcinoma not otherwise specified. *WHO Classification of Skin Tumours, 4th Edition, Volume 11*. IARC Press, Lyon, France (2018) 4th ed. ISBN: 978-9-28-322440-2
50. **Scohyer RA**, Zembowicz A. Chapter 3.2.2 Microcystic adnexal carcinoma. *WHO Classification of Skin Tumours, 4th Edition, Volume 11*. IARC Press, Lyon, France (2018) 4th ed. ISBN: 978-9-28-322440-2
51. **Scohyer RA**, A Zembowicz. Chapter 3.2.3 Porocarcinoma. *WHO Classification of Skin Tumours, 4th Edition, Volume 11*. IARC Press, Lyon, France (2018) 4th ed. ISBN: 978-9-28-322440-2
52. **Scohyer RA**, A Zembowicz. Chapter 3.2.4 Malignant neoplasms arising from spiradenoma, cylindroma, or spiradenocylindroma. *WHO Classification of Skin Tumours, 4th Edition, Volume 11*. IARC Press, Lyon, France (2018) 4th ed. ISBN: 978-9-28-322440-2
53. **Scohyer RA**, A Zembowicz. Chapter 3.2.5 Malignant mixed tumour. *WHO Classification of Skin Tumours, 4th Edition, Volume 11*. IARC Press, Lyon, France (2018) 4th ed. ISBN: 978-9-28-322440-2
54. **Scohyer RA**, A Zembowicz. Chapter 3.2.6 Hidradenocarcinoma. *WHO Classification of Skin Tumours, 4th Edition, Volume 11*. IARC Press, Lyon, France (2018) 4th ed. ISBN: 978-9-28-322440-2
55. **Scohyer RA**, A Zembowicz. Chapter 3.2.7 Mucinous carcinoma. *WHO Classification of Skin Tumours, 4th Edition, Volume 11*. IARC Press, Lyon, France (2018) 4th ed. ISBN: 978-9-28-322440-2
56. **Scohyer RA**, A Zembowicz. Chapter 3.2.8 Endocrine mucin-producing sweat gland carcinoma. *WHO Classification of Skin Tumours, 4th Edition, Volume 11*. IARC Press, Lyon, France (2018) 4th ed. ISBN: 978-9-28-322440-2
57. **Scohyer RA**, A Zembowicz. Chapter 3.2.9 Digital papillary adenocarcinoma. *WHO Classification of Skin Tumours, 4th Edition, Volume 11*. IARC Press, Lyon, France (2018) 4th ed. ISBN: 978-9-28-322440-2
58. **Scohyer RA**, A Zembowicz. Chapter 3.2.10 Adenoid cystic carcinoma. *WHO Classification of Skin Tumours, 4th Edition, Volume 11*. IARC Press, Lyon, France (2018) 4th ed. ISBN: 978-9-28-322440-2
59. **Scohyer RA**, A Zembowicz. Chapter 3.2.11 Apocrine carcinoma. *WHO Classification of Skin Tumours, 4th Edition, Volume 11*. IARC Press, Lyon, France (2018) 4th ed. ISBN: 978-9-28-322440-2
60. **Scohyer RA**, A Zembowicz. Chapter 3.2.12 Squamoid eccrine ductal carcinoma. *WHO Classification of Skin Tumours, 4th Edition, Volume 11*. IARC Press, Lyon, France (2018) 4th ed. ISBN: 978-9-28-322440-2
61. **Scohyer RA**, A Zembowicz. Chapter 3.2.13 Syringocystadenocarcinoma papilliferum. *WHO Classification of Skin Tumours, 4th Edition, Volume 11*. IARC Press, Lyon, France (2018) 4th ed. ISBN: 978-9-28-322440-2
62. **Scohyer RA**, A Zembowicz. Chapter 3.2.14 Secretory carcinoma. *WHO Classification of Skin Tumours, 4th Edition, Volume 11*. IARC Press, Lyon, France (2018) 4th ed. ISBN: 978-9-28-322440-2
63. **Scohyer RA**, A Zembowicz. Chapter 3.2.15 Cribriform carcinoma. *WHO Classification of Skin Tumours, 4th Edition, Volume 11*. IARC Press, Lyon, France (2018) 4th ed. ISBN: 978-9-28-322440-2
64. Lazar AJ, Billings SD, **Scohyer RA**, Massi D, Elder D. Chapter 5.1 Introduction. *WHO Classification of Skin Tumours, 4th Edition, Volume 11*. IARC Press, Lyon, France (2018) 4th ed. ISBN: 978-9-28-322440-2
65. **Scohyer R**. Chapter 5.7.2 Solitary circumscribed neuroma. *WHO Classification of Skin Tumours, 4th Edition, Volume 11*. IARC Press, Lyon, France (2018) 4th ed. ISBN: 978-9-28-322440-2
66. **Scohyer RA**. Chapter 5.8.6 Ewing sarcoma. *WHO Classification of Skin Tumours, 4th Edition, Volume 11*. IARC Press, Lyon, France (2018) 4th ed. ISBN: 978-9-28-322440-2
67. **Scohyer RA**, Lazar AJ, Massi D. 6.1 Introduction. *WHO Classification of Skin Tumours, 4th Edition, Volume 11*. IARC Press, Lyon, France (2018) 4th ed. ISBN: 978-9-28-322440-2
68. de la Fouchardi re A, **Scohyer RA**. Chapter 6.6 BAP1 tumour predisposition syndrome. *WHO Classification of Skin Tumours, 4th Edition, Volume 11*. IARC Press, Lyon, France (2018) 4th ed. ISBN: 978-9-28-322440-2
69. Jakkett LA, **Scohyer RA**, Bishop JF, Thompson JF. Chapter 17: Primary melanoma of the lung. In: *Textbook of Uncommon Cancer*, Fifth Edition, Eds. Raghaven D, Ahluwalia MS, Blanke CD, Brown J, Kim ES, Reaman GH, Sekeres MA. John Wiley & Sons Ltd, Hoboken, 2017, 287-92.
70. Soyer P, Guitera P, Hong A, **Scohyer RA**, Stretch J, Strutton G, Cancer Council Australia Melanoma Guidelines Working Party. What are the most effective treatment/management interventions to improve outcomes in patients with lentigo maligna? *Cancer Council Australia Melanoma Guidelines. Wiki 2017*
71. Hughes M, Gyorki D, Kelly J, Stretch J, **Scohyer RA**, Varey A, Hong A, Cancer Council Australia Melanoma Guidelines Working Party. Primary desmoplastic neurotropic melanomas. *Cancer Council Australia Melanoma Guidelines Wiki 2017*
72. Hughes M, Gyorki D, Kelly J, Stretch J, **Scohyer RA**, Varey A, Hong A, Cancer Council Australia Melanoma Guidelines Working Party. What is the optimal management for primary desmoplastic neurotropic melanomas? *Cancer Council Australia Melanoma Guidelines Wiki 2017*.

73. Hughes M, Gyorki D, Kelly J, Stretch J, **Scoflyer RA**, Varey A, Hong A, Cancer Council Australia Melanoma Guidelines Working Party. What is the role of sentinel node biopsy for desmoplastic neurotropic melanomas? *Cancer Council Australia Melanoma Guidelines Wiki* 2017.
74. Hughes M, Gyorki D, Kelly J, Stretch J, **Scoflyer RA**, Varey A, Hong A, Cancer Council Australia Melanoma Guidelines Working Party. Should primary desmoplastic (and desmoplastic neurotropic) melanomas be treated differently? *Cancer Council Australia Melanoma Guidelines Wiki* 2017.
75. Kelly JW, de Menezes D, **Scoflyer RA**, Beer TW, Fishburn P, Soyer P, Ng J, Damian D, Thompson JF. Indications and outcomes from different biopsy methods for melanoma: Evidence review and recommendations from new Australian Melanoma Clinical Practice Guidelines. *Cancer Council Australia Melanoma Guidelines Wiki* 2017
76. **Scoflyer RA**, Kelly J, Soyer PH, Coventry B, James C, Fishburn P, Stretch JP, Lee S, McLean C. What clinical informRGS7 is recurrentlylation should the clinician give the pathologist to aid diagnosis of melanoma? *Cancer Council Australia Melanoma Guidelines Wiki* 2017.
77. Gyorki D, Barbour A, Mar V, Sandhu S, Hanikeri M, **Scoflyer RA**. Should all patients with a positive sentinel lymph node biopsy have a complete node dissection? *AJCC 8th Edition* 2017.
78. Kelly J, Beer T, Damian D, Ng J, Fishburn P, **Scoflyer RA**, Soyer P. What type of biopsy should be performed for a suspicious pigmented skin lesion? In: *Cancer Council Australia Melanoma Guidelines. Wiki* 2017.
79. Gershenwald JE, **Scoflyer RA**, Hess KR, Thompson JF, Long GV, Ross MI, Lazar AJ, Atkins MB, Balch CM, Barnhill R, Bilimoria KY, Brierley JD, Buzaid AC, Byrd DR, Chapman PB, Cochran AJ, Coit DG, Eggermont AM, Elder DE, Faries MB, Flaherty KT, Garbe C, Gardner JM, Gimotty PA, Halpern AC, Haydu LE, Johnson T, Kirkwood JM, Lee AWM, McArthur GA, Mihm MC, Prieto VG, Sober AJ, Wahl RL, Wong SL, Sondak VK. Melanoma of the Skin. In: *AJCC Cancer Staging Manual*. 8th Edition. pp: 563-85. Eds: Amin MB, Edge SB, Greene FL, Carducci MA, Compton CA. Springer, New York 2017.
80. Jackett L, Vilain RE, Rawson R, **Scoflyer RA**. Chapter 9 Pathology. In: *Melanoma Principles and Practice. Melanoma Institute Australia*, Sydney, 2016.
81. Guitera P, Collgros H, Wang S, **Scoflyer RA**. Chapter 6 Benign melanocytic lesions. In: *Melanoma Principles and Practice. Melanoma Institute Australia*, Sydney, 2016.
82. Guitera P, Rocha L, Wang S, **Scoflyer RA**. Chapter 5 Melanoma Mimics. In: *Melanoma Principles and Practice. Melanoma Institute Australia*, Sydney, 2016.
83. Stretch JR, **Scoflyer RA**, Vilain RE, Varey AHR. Chapter 3 Histogenesis. In *Melanoma Principles and Practice. Melanoma Institute Australia*, Sydney, 2016.
84. Damian DL, **Scoflyer RA**, Stevens G, Menzies AM, Thompson JF. Skin cancer: non-melanoma. In: *Oxford Textbook of Oncology*, 3rd Edition, Chapter 49, pp: 690 - 698, Eds Kerr DJ, Haller DG, van de Velde CJH, Baumann M, Oxford University Press, Oxford, 2016.
85. Thompson JF, Scoflyer RA, Kefford RF. Skin cancer: melanoma. In: *Oxford Textbook of Oncology*, 3rd Edition, Chapter 49, pp: 674 – 689, Eds Kerr DJ, Haller DG, van de Velde CJH, Baumann M, Oxford University Press, Oxford, 2016.
86. Jackett LA, **Scoflyer RA**, Bishop JF, Thompson JF. Chapter 17: Primary melanoma of the lung. In: *Textbook of Uncommon Cancer*, Fifth Edition, Eds. Raghavan D, Ahluwalia MS, Blanke CD, Brown J, Kim ES, Reaman GH, Sekeres MA. John Wiley & Sons Ltd, Hoboken, 2017, 287-92.
87. Vilain RE, **Scoflyer RA**. Chapter 9 Histopathological Assessment & Synoptic Reporting. In *Melanoma Essentials - A Concise Guide*. Stretch, Smith, Varey and Chakera, Melanoma Institute Australia, Jul 2015.
88. Stretch JR, **Scoflyer RA**. Chapter 8 Histogenesis. In *Melanoma Essentials - A Concise Guide*. Stretch, Smith, Varey and Chakera, Melanoma Institute Australia, Jul 2015.
89. Guitera P, Rocha L, Wang S, **Scoflyer RA**. Chapter 5 Melanoma Mimics. In *Melanoma Essentials - A Concise Guide*. Stretch, Smith, Varey and Chakera, Melanoma Institute Australia, Jul 2015.
90. Guitera P, Collgros H, Wang S, **Scoflyer RA**. Chapter 2 Benign Melanocytic Lesions. In *Melanoma Essentials - A Concise Guide*. Stretch, Smith, Varey and Chakera, Melanoma Institute Australia, Jul 2015.
91. Scoflyer RA, Busam KJ, Barnhill RL (2014) Metastatic Melanoma. In: Barnhill R, Piepkorn M, Busam K. (eds) *Pathology of Melanocytic Nevi and Melanoma*. Springer, Berlin, Heidelberg. DOI: 10.1007/978-3-642-38385-4_13.
92. **Scoflyer RA**, Thompson JF, Mahar A, Murali R. Metastases to Skin in Dermatopathology: A Volume in the *Foundations in Diagnostic Pathology Series*. Expert Consult. Busam KJ (Ed). Saunders Elsevier 2014.
93. Murali R, Scoflyer RA, Bastian BC. Skin: Spitz tumors. *Atlas Genet Cytogenet Oncol Haematol*. 2013; 17(1):48-59.
94. **Scoflyer RA**, Bishop, J.F. and Thompson, J.F. (2012). Primary Melanoma of the Lung. In Textbook of Uncommon Cancer (eds D. Raghavan, C.D. Blanke, D.H. Johnson, P.L. Moots, G.H. Reaman, P.G. Rose and M.A. Sekeres). doi:10.1002/9781118464557.ch23
95. Murali R, **Scoflyer RA**, Bastian BC. Spitz Tumors. *Atlas Genet Cytogenet Oncol Haematol*, May 2012. URL: <http://AtlasGeneticsOncology.org/Tumors/CarcinoidID5523.html>
96. **Scoflyer RA**, Bishop JF, Thompson JF. "Primary Melanoma of the Lung" in *Textbook of Uncommon Cancer*. 4th Ed. Raghavan D, Brecher ML, Johnson DH, Meropol NJ, Moots PL, Rose PG (Eds). John Wiley & Sons Ltd, West Sussex, UK, 2012. (in press).
97. **Scoflyer RA**, Evans A, Frishberg D, Prieto V, Thompson J, Trotter M, Walsh, M, Walsh N Required and recommended pathology reporting elements for invasive melanoma. *International Collaboration in Cancer Reporting pilot*. 2011
98. **Scoflyer RA**, Murali R, Thompson JF. 17 - Cutaneous Metastases, Editor: Klaus J Busam, In *Foundations in Diagnostic Pathology, Dermatopathology*, W.B. Saunders, 2010, Pages 637-650 ISBN 9780043066542, DOI:10.1016/B978-0-443-06654-2.00017-2.
99. Ashford RU, **Scoflyer RA**, McCarthy SW, Bonar SF, Karim RZ, Stalley PD. The role of intra-operative pathological evaluation in the management of musculo-skeletal tumours. In *Recent Results in Cancer Research: Treatment of Bone and Soft Tissue Sarcomas* Vol. 179 Tunn, Per-Ulf (Ed.) 2009, XXII, 362 p. 11-24.
100. Ashford RU, **Scoflyer RA**, McCarthy SW, Bonar SF, Karim RZ, Stalley PD (2009) The Role of Intra-operative Pathological Evaluation in the Management of Musculoskeletal Tumours. In: Tunn PU. (eds) Treatment of Bone and Soft Tissue Sarcomas. *Recent Results in Cancer Research*, vol 179. Springer, Berlin, Heidelberg. DOI: 10.1007/978-3-540-77960-5_2.
101. **Scoflyer RA**, Mihm MC, Cochran AJ, Busam KJ, McCarthy SW. Pathology of Melanoma. in Balch Cm, Houghton AN, Sober AJ, Soong S-J, Atkins MB, Thompson JF (Eds): *Cutaneous Melanoma, 5th Edition*. Quality Medical Publishing, St Louis, 2009. pp. 205-250.
102. Australian Cancer Network Melanoma Guidelines Revision Working Party. Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand. Cancer Council Australia and Australian Cancer Network, Sydney and New Zealand Guidelines Group, Wellington (2008).

103. **Scoflyer** RA Tan K-B. Case 2: Unsuspected Merkel cell carcinoma. In: Zembowicz A, Duncan L, Mihm M, Murphy G, Tahan S (Eds). *Cases in Dermatopathology: Critical Values (Diagnoses) in Dermatopathology*. Brisbane: Knowledge Books & Software, 2007. pp. 9-19.
104. Murali R, **Scoflyer** RA. Case 27. Pigmented dermatofibrosarcoma protruberans (Bednar tumor). In: Zembowicz A, Flotte T, Mihm M, Murphy G, Tahan S (Eds). *Cases in Dermatopathology: Pigmented Skin Lesions*. Brisbane: Knowledge Books & Software, 2006. pp. 199-212.
105. **Scoflyer** RA, Murali R, McCarthy SW. Case 16. Atypical deep penetrating nevus forming a component of a combined nevus. In: Zembowicz A, Flotte T, Mihm M, Murphy G, Tahan S (Eds). *Cases in Dermatopathology: Pigmented Skin Lesions*. Brisbane: Knowledge Books & Software, 2006. pp. 105-24.
106. Thompson JF, **Scoflyer** RA, Uren RF. Surgical management of primary cutaneous melanoma: excision margins and the role of sentinel lymph node examination. *Surg Oncol Clin N Am* 2006; 15: 301-18.
107. Thompson, J., Bishop, J., **Scoflyer**, R. (2006). Primary melanoma of the lung. In Derek Raghavan, Martin L Brecher and David H Johnson et al (Eds.), *Textbook of Uncommon Cancer*, (pp. 293-297). United States: John Wiley & Sons.
108. De Vries E, Bray F, Coebergh JW, Cerroni L, Ruiter DJ, Elder DE, Thompson JF, Barnhill RL, van Muijen GNP, **Scoflyer** RA, LeBoit P. Malignant Melanoma: Introduction. In: *WHO Classification of Tumours. Pathology and Genetics of Skin Tumours*. Eds: LeBoit PE, Burg G, Weedon D, Sarasin A. IARC Press, Lyon, 2006. pp 52-65.
109. **Scoflyer** RA, Bishop JF and Thompson JF. Primary melanoma of the lung. In: *Textbook of Uncommon Cancer*. 3rd Edition. Chapter 24, pp 293-297. Eds. D Raghavan, D Brecher, DH Johnson, NJ Meropol, PL Moots and PG Rose. John Wiley & Sons, London, 2006. doi:10.1002/0470030542.ch24
110. McCarthy SW, Crotty KA, **Scoflyer** RA. "Desmoplastic Melanoma and Desmoplastic Neurotropic Melanoma". In LeBoit PE, Burg G, Weedon D, Sarasin A (Eds.): *WHO Classification of Tumours. Pathology and Genetics of Skin Tumours*. IARC Press: Lyon 2006. pp. 76-8.
111. **Scoflyer** RA, Li L-XL, McCarthy SW, Shaw HM, Stretch JR, Sharma R, Thompson JF. Micromorphometric features of positive sentinel nodes predict involvement of non-sentinel nodes in patients. In: *The Yearbook of Dermatology and Dermatologic Surgery*, Eds: Thiers BH, Lang PG. Elsevier Mosby, Philadelphia, 2005. pp 375-6.
112. **Scoflyer** RA. Case 13. Digital Papillary Adenocarcinoma. In: Zembowicz A. Ed. *Cases in Dermatopathology: Adnexal Neoplasms*. Brisbane: Knowledge Books & Software, 2005. pp. 99-109.
113. **Scoflyer** RA. Case 12. Nipple Adenoma. In: Zembowicz A. Ed. *Cases in Dermatopathology: Adnexal Neoplasms*. Brisbane: Knowledge Books & Software, 2005. pp 83-98.
114. Thompson JF, Uren RF, **Scoflyer** RA, Stretch JR. Selective sentinel lymphadenectomy: progress to date and prospects for the future. In *Selective Sentinel Lymphadenectomy for Human Solid Cancer*, Eds. Leong SPL, Kitagawa Y, Kitajima M. Springer, New York, 2005 pp.269-287.
115. **Scoflyer** RA. Case 12: Lipofibromatosis. **Scoflyer** RA, Folpe AL. eds. In: *Soft Tissue Pathology: A Memorable Mistake and What I Learnt from It*. Brisbane: Knowledge Books & Software, 2004. pp. 99-108.
116. **Scoflyer** RA, McCarthy SW. Case 12: Deep penetrating naevus-like melanoma. Eds. **Scoflyer** RA, McCarthy SW, Elder DE. In: *Melanocytic Skin Lesions: Difficult Problems, Important Issues and Controversies*. Brisbane: Knowledge Books & Software, 2004. pp. 73-90.
117. **Scoflyer** RA., Folpe AL. Editors. *Soft Tissue Pathology: A Memorable Mistake and What I Learnt from It*. Knowledge Books & Software, Brisbane 2004.
118. **Scoflyer** RA, McCarthy SW, Elder DE. Editors. *Melanocytic Skin Lesions: Difficult Problems, Important Issues and Controversies*. Knowledge Books & Software, Brisbane 2004.
119. Harper CG, **Scoflyer** RA. Alcoholism and Dementia. In: *The Neuropathology of Dementia*. 2nd Ed. Esiri M, Morris H, Trojanowski J (Eds). Cambridge University Press, Cambridge, 2004. pp. 427-41.

PUBLICATIONS

H-INDEX – 120 / CITATIONS – 63,508 (as at 3 August 2022 - via Google Scholar)

Accepted for publication

1. Rebecca C. Simpson*, Erin R. Shanahan*, Marcel Batten*, Irene L.M. Reijers*, Mark Read#, Ines P. Silva#, Judith M. Versluis#, Rosilene Ribeiro, Alexandra S. Angelatos, Jian Tan, Chandra Adhikari, Alexander M. Menzies, Robyn P.M. Saw, Maria Gonzalez, Kerwin F. Shannon, Andrew J. Spillane, Rebecca Velickovic, Laurence Macia, Andrew J. Holmes, James S. Wilmott, Christian U. Blank, **Richard A. Scoflyer**, Georgina V. Long (*#these authors have contributed equally). Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and gut microbiome. 23.7.22: *accepted for publication to Nature Medicine*. PMID: TBC
2. Busam KJ, Judge M, Bichakjian C, Coit D, Kutzner H, Requena L, **Scoflyer** RA, Stefanato CM, Wood BA and Walsh NM. Dataset for the reporting of Merkel Cell Carcinoma: Recommendations from the International Collaboration on Cancer Reporting (ICCR). 20.7.22: *accepted for publication in Am J Surgical Pathol*. PMID: TBC
3. Asmi Chakraborty, Mariana Perez, Jordan D. Carroll, Aristotelis Antonopoulos, Anne Dell, Littel Ortega, Norhan B. B. Mohammed, Michael Wells, Caleb Staudinger, Anthony Griswold, Kevin B. Chandler, Cristina Marrero, Ramon Jimenez, Yoshihiko Tani, James S. Wilmott, John F. Thompson, Wei Wang, Robert Sackstein, **Richard A. Scoflyer**, George F. Murphy, Stuart M. Haslam, and Charles J. Dimitroff. Hypoxia controls the glycome signature and a novel galectin-8 – ligand axis to promote pro-tumorigenic properties of metastatic melanoma. 14.7.22: *accepted for publication in Journal of Investigative Dermatology*. PMID: TBC
4. Grace H. Attrill, Hansol Lee, Annie T. Tasker, Nurudeen Adegoke, Angela L. Ferguson, Ines Pires da Silva, Robyn P.M. Saw, John F. Thompson, Umaimainthan Palendira, Georgina V. Long, Peter M. Ferguson, **Richard A. Scoflyer**, James S. Wilmott. Detailed spatial immunophenotyping of primary melanomas reveals immune cell subpopulations associated with patient outcome. 11.7.22: *accepted for publication in Frontiers in Immunology*. PMID: TBC
5. R.V Rawson, E.R Shteinman, S. Ansar, I.A Vergara, J.F Thompson, G.V Long, **R.A Scoflyer**, J.S Wilmott. Diagnostic utility of PRAME, p53 and 5-hmC immunostaining for distinguishing melanomas from naevi, neurofibromas, scars and other histological mimics. 19.5.22: *accepted for publication to Pathology*. PMID: TBC

6. Andrea Lynne Leslie Smith; Caroline Watts; Michael Henderson; Georgina Long; Frances Rapport; Robyn Saw; **Richard Scolyer**; Andrew Spillane; John Thompson; Anne Cust. Factors influencing acceptance, adoption and adherence to the Australian Melanoma Management Guidelines sentinel node biopsy recommendations: a qualitative study using an implementation science framework. 23.7.21: initial draft circulated by Andrea Smith to co-authors for review-comment. 5.8.21: RAS provided feedback-comments. 7.10.21: final version circulated for review-comment by 15.10.21. 10.10.21: RAS reviewed and provided feedback-comments on latest draft. 6.11.21: submitted to Implementation Science Communications for publication. 24.11.21: further email from ISC confirming submission. 28.6.22: further feedback-comments required. PMID: TBC

Published (peer reviewed)

1. Luo L, Shen R, Arora A, Orlov I, Busam KJ, Lezcano C, Lee TK, Hernando E, Gorlov I, Amos C, Ernstoff MS, Seshan V, Cust AE, Wilmott J, **Scolyer RA**, Mann G, Nagore E, Funchain P, Ko J, Ngo P, Edmiston SN, Conway K, Googe PB, Olilla D, Lee JE, Fang S, Rees JR, Thompson CL, Gerstenblith M, Bosenberg M, Gould Rothberg B, Osman I, Saenger Y, Reynolds AZ, Schwartz M, Boyce T, Holmen S, Brunsgaard E, Bogner P, Kuan PF, Wiggins C, Thomas NE, Begg CB, Berwick M; For InterMEL. Landscape of Mutations in Early Stage Primary Cutaneous Melanoma - An InterMEL Study. Pigment Cell Melanoma Res. 2022 Jul 25. doi: 10.1111/pcmr.13058. Online ahead of print. PMID: 35876628
2. Gaetano L, Domenico B, Lo SN, Hamed T, Potter AJ, Thompson JF, **Scolyer RA**, Guitera P. Association between excision margins and local recurrence in 1407 patients with primary in situ melanomas. JAAD Int. 2022 Jun 16;8:102-108. doi: 10.1016/j.jdin.2022.06.001. eCollection 2022 Sep. PMID: 35875393
3. Moncrieff MD, Lo SN, **Scolyer RA**, Heaton MJ, Nobes JP, Snelling AP, Carr MJ, Nessim C, Wade R, Peach AH, Kisyoova R, Mason J, Wilson ED, Nolan G, Pritchard Jones R, Johansson I, Olofsson Bagge R, Wright LJ, Patel NG, Sondak VK*, Thompson JF*, Zager JS* (*Joint senior authors with equal merit (alphabetical)). Clinical Outcomes and Risk Stratification of Early-Stage Melanoma Micrometastases From an International Multicenter Study: Implications for the Management of American Joint Committee on Cancer IIIA Disease. J Clin Oncol. 2022 Jul 18;JCO2102488. doi: 10.1200/JCO.21.02488. Online ahead of print. PMID: 35849790
4. Aung TN, Shafi S, Wilmott JS, Nourmohammadi S, Vathiotis I, Gavrielatou N, Fernandez A, Yaghoobi V, Sinnberg T, Amaral T, Ikenberg K, Khosrotehrani K, Osman I, Acs B, Bai Y, Martinez-Morilla S, Moutafi M, Thompson JF, **Scolyer RA**, Rimm DL. Objective assessment of tumor infiltrating lymphocytes as a prognostic marker in melanoma using machine learning algorithms. EBioMedicine. 2022 Jul 7;82:104143. doi: 10.1016/j.ebiom.2022.104143. Online ahead of print. PMID: 35810563
5. Thazin Aung, Saba Shafi, James Wilmott, Saeed Nourmohammadi, Ioannis Vathiotis, Niki Gavrielatou, Aileen Fernandez, Vesal Yaghoobi, Tobias Sinnberg, Teresa Amaral, Kristian Ikenberg, Kiarash Khosrotehrani, Iman Osman, Balazs Acs, Yalai Bai, Sandra Martinez-Morilla, Myrto Moutafi, John Thompson, **Richard A. Scolyer**, and David L. Rimm. Objective Assessment of Tumor Infiltrating Lymphocytes as a Prognostic Marker in Melanoma using Machine Learning Algorithms. 27.1.22: submitted to eBioMedicine for publication. Mar '22 peer review feedback received by lead author and response prepared. 7.4.22: RAS provided form as required. 10.5.22: email from Thazin Aung – journal has responded with further peer review feedback-comments which need to be addressed.
6. Wang KYX*, Pupo GM*, Tembe V*, Patrick E, Strbenac D, Schramm SJ, Thompson JF, **Scolyer RA**, Muller S, Tarr G, Mann GJ*, Yang JYH* (*equal contribution). Cross-Platform Omics Prediction procedure: a statistical machine learning framework for wider implementation of precision medicine. NPJ Digit Med. 2022 Jul 4;5(1):85. doi: 10.1038/s41746-022-00618-5. PMID: 35788693
7. Lawless AK*, Coker DJ*, Lo SN, Ahmed T, **Scolyer RA**, Ch'ng S, Nieweg OE, Shannon K, Spillane A, Stretch JR, Thompson JF#, Saw RPM# (*These authors contributed equally to the work and are considered co-first authors. #These authors contributed equally to the work and are considered co-senior authors.) Clinicopathological Characteristics Predicting Further Recurrence and Survival Following Resection of In-Transit Melanoma Metastases. Ann Surg Oncol. 2022 Jun 30. doi: 10.1245/s10434-022-11997-0. Online ahead of print. PMID: 35771368
8. Burton EM, Amaria RN, Cascone T, Chalabi M, Gross ND, Mittendorf EA, **Scolyer RA**, Sharma P, Ascierto PA. Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge-December 1st-2nd, 2021. J Transl Med. 2022 Jun 15;20(1):271. doi: 10.1186/s12967-022-03472-x. PMID: 35706041
9. Attrill GH, Owen CN, Ahmed T, Vergara IA, Colebatch AJ, Conway JW, Nahar KJ, Thompson JF, Pires da Silva I, Carlino MS, Menzies AM, Lo S, Palendira U, **Scolyer RA**^, Long GV^, Wilmott JS^ (^ These authors contributed equally to this manuscript). Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy. J Immunother Cancer. 2022 Jun;10(6):e004771. doi: 10.1136/jitc-2022-004771. PMID: 35688560
10. Semsarian CR, Ma T, Nickel B, **Scolyer RA**, Ferguson PM, Soyer HP, Parker L, Barratt A, Thompson JF, Bell KJL. Do we need to rethink the diagnoses melanoma in situ and severely dysplastic naevus? Br J Dermatol. 2022 Jun;186(6):1030-1032. doi: 10.1111/bjd.21010. Epub 2022 Apr 7. PMID: 35007335
11. Barnhill R, van Laere S, Vermeulen P, Roman-Roman S, Gardrat S, Alsafadi S, Tarin M, Champenois G, Nicolas A, Matet A, Cassoux N, Servois V, Rodrigues M, **Scolyer R**, Lazar A, Romano E, Piperno-Neumann S, Mariani P, Lugassy C. L1CAM and laminin vascular network: Association with the high-risk replacement histopathologic growth pattern in uveal melanoma liver metastases. Lab Invest. 2022 Jun 7. doi: 10.1038/s41374-022-00803-w. Online ahead of print. PMID: 35672380
12. Yaseen Z, Gide TN, Conway JW, Potter AJ, Quek C, Hong AM, Long GV, **Scolyer RA**, Wilmott JS. Validation of an Accurate Automated Multiplex Immunofluorescence Method for Immuno-profiling Melanoma. Front Mol Biosci. 2022 May 19;9:810858. doi: 10.3389/fmolb.2022.810858. PMID: 35664673
13. Reijers ILM, Menzies AM*, van Akkooi ACJ*, Versluis JM*, van den Heuvel NMJ*, Saw RPM, Pennington TE, Kapiteijn E, van der Veldt AAM, Suijkerbuijk KPM, Hospers GAP, Rozeman EA, Klop WMC, van Houdt WJ, Sikorska K, van der Hage JA, Grünhagen DJ, Wouters MW, Witkamp AJ, Zuur CL, Lijnsvelt JM, Torres Acosta A, Griepink-Ongering LG, Gonzalez M, Jóźwiak K, Bierman C, Shannon KF, Ch'ng S, Colebatch AJ, Spillane AJ, Haanen JBAG, Rawson RV, van de Wiel BA, van de Poll-Franse LV, **Scolyer RA**, Boekhout AH#, Long GV#, Blank CU# (*shared second authors # shared last authors). Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nat Med. 2022 Jun;28(6):1178-1188. doi: 10.1038/s41591-022-01851-x. Epub 2022 Jun 5. PMID: 35661157
14. Moncrieff MD, Lo SN, **Scolyer RA**, Heaton MJ, Nobes JP, Snelling AP, Carr MJ, Nessim C, Wade R, Peach AH, Kisyoova R, Mason J, Wilson ED, Nolan G, Jones RP, Sondak VK, Thompson JF, Zager JS. ASO Visual Abstract: Evaluation of Indications for Sentinel Node Biopsy in Early-Stage Melanoma with the Advent of Adjuvant Systemic Therapy: An International Multicenter Study. Ann Surg Oncol. 2022 May 25. doi: 10.1245/s10434-022-11822-8. Online ahead of print. PMID: 35612683

15. Li AT, Miin Yip J, Choksi H, London K, Potter AJ, Lo SN, Saw RPM, Shannon KF, Pires da Silva I, Valey AHR, Menzies AM, Long GV, Shivalingam B, **Scoflyer RA**, Thompson JF, Ch'ng S. Lack of association between anatomical sites of scalp melanomas and brain metastases does not support direct vascular spread. *Melanoma Res.* 2022 Aug 1;32(4):260-268. doi: 10.1097/CMR.0000000000000827. Epub 2022 May 13. PMID: 35579680
16. Moncrieff MD, Lo SN, **Scoflyer RA**, Heaton MJ, Nobes JP, Snelling AP, Carr MJ, Nessim C, Wade R, Peach AH, Kisyova R, Mason J, Wilson ED, Nolan G, Pritchard Jones R, Sondak VK*, Thompson JF*, Zager JS* (*Joint senior authors). Evaluation of the Indications for Sentinel Node Biopsy in Early-Stage Melanoma with the Advent of Adjuvant Systemic Therapy: An International, Multicenter Study. *Ann Surg Oncol.* 2022 May 13. doi: 10.1245/s10434-022-11761-4. Online ahead of print. PMID: 35562521
17. Diefenbach RJ, Lee JH, Stewart A, Menzies AM, Carlino MS, Saw RPM, Stretch JR, Long GV, **Scoflyer RA**, Rizos H. Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA. *Front Oncol.* 2022 Apr 12;12:820510. doi: 10.3389/fonc.2022.820510. eCollection 2022. PMID: 35494035
18. Jobson D, Roffey B, Arnold C, Azzi A, Button-Sloan A, Dawson T, Fernandez-Penas P, Fishburn P, Gyorki DE, Hiscutt EL, Jakrot V, Lilleyman A, Lochhead A, Long GV, Mailer S, Mann G, McCormack CJ, Muir J, Pratt GF, **Scoflyer RA**, Shackleton M, Shumack S, Soyer HP, Tan CG, Webb A, Zalcborg J, Morton R, Mar V. Development of melanoma clinical quality indicators for the Australian melanoma clinical outcomes registry (MelCOR): A modified Delphi study. *Australas J Dermatol.* 2022 Apr 29. doi: 10.1111/ajd.13848. Online ahead of print. PMID: 35486539
19. Marsland M, Dowdell A, Jiang CC, Wilmott JS, **Scoflyer RA**, Zhang XD, Hondermarck H#, Faulkner S.# (#contributed equally to the study). Expression of NGF/proNGF and Their Receptors TrkA, p75^{NTR} and Sortilin in Melanoma. *Int J Mol Sci.* 2022 Apr 12;23(8):4260. doi: 10.3390/ijms23084260.. PMID: 35457078
20. Colebatch AJ, Adhikari C, Diefenbach RJ, Rawson RV, Ferguson PM, Rizos H, Long GV, McCarthy SW, Thompson JF, Wilmott JS, **Scoflyer RA**. Comprehensive Clinical, Histopathologic, and Molecular Analysis and Long-term Follow-up of Patients With Nodal Blue Nevus. *Am J Surg Pathol.* 2022 Aug 1;46(8):1048-1059. doi: 10.1097/PAS.0000000000001902. Epub 2022 Apr 20. PMID: 35439782
21. Hanna S, Marinos E, Bryan D, Ahmed T, Lo SN, Carlino MS, Smith A, Cairns G, Shannon K, Long GV, **Scoflyer RA**, Saw RPM. Effect of the SunSafe Training Program on the attitudes, knowledge, and behaviour of Australian high school students towards sun safety: a prospective study. *Clin Exp Dermatol.* 2022 Apr 18. doi: 10.1111/ced.15220. Online ahead of print. PMID: 35434843
22. Wang M†, Zadeh S†, Pizzolla A, Thia K, Gyorki DE, McArthur GA, **Scoflyer RA**, Long G, Wilmott JS, Andrews MC, Au-Yeung G, Wepler A, Sandhu S, Trapani JA, Davis MJ, Neeson PJ (†contributed equally). Characterization of the treatment-naïve immune microenvironment in melanoma with *BRAF* mutation. *J Immunother Cancer.* 2022 Apr;10(4):e004095. doi: 10.1136/jitc-2021-004095. PMID: 35383113
23. Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, Chiarion-Sileni V, de la Cruz Merino L, Khattak MA, Schadendorf D, Long GV, Ascierto PA, Mandala M, De Galitiis F, Haydon A, Dummer R, Grob JJ, Robert C, Carlino MS, Mohr P, Poklepovic A, Sondak VK, **Scoflyer RA**, Kirkwood JM, Chen K, Diede SJ, Ahsan S, Ibrahim N, Eggermont AMM; KEYNOTE-716 Investigators.* (*A complete list of investigators who participated in the KEYNOTE-716 study is provided in Table 1 of the Supplementary Appendix, available at NEJM.org). Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. *Lancet.* 2022 Apr 30;399(10336):1718-1729. doi: 10.1016/S0140-6736(22)00562-1. Epub 2022 Apr 1. PMID: 35367007
24. Weiss JM, Hunter MV, Cruz NM, Baggolini A, Tagore M, Ma Y, Misale S, Marasco M, Simon-Vermot T, Campbell NR, Newell F, Wilmott JS, Johansson PA, Thompson JF, Long GV, Pearson JV, Mann GJ, **Scoflyer RA**, Waddell N, Montal ED, Huang TH, Jonsson P, Donoghue MTA, Harris CC, Taylor BS, Xu T, Chaligné R, Shliha PV, Hendrickson R, Jungbluth AA, Lezcano C, Koche R, Studer L, Ariyan CE, Solit DB, Wolchok JD, Merghoub T, Rosen N, Hayward NK, White RM. Anatomic position determines oncogenic specificity in melanoma. *Nature.* 2022 Mar 30. doi: 10.1038/s41586-022-04584-6. Online ahead of print. PMID: 35355015
25. Star P, Jackett LA, Cheung K, Wilmott JS, Ho G, Smith A, Long GV, **Scoflyer RA**, Martin LK. Multiple eruptive squamoproliferative lesions during anti-PD1 immunotherapy for metastatic melanoma: pathogenesis, immunohistochemical analysis and treatment. *Dermatol Ther.* 2022 Jun;35(6):e15472. doi: 10.1111/dth.15472. Epub 2022 Apr 5. PMID: 35347815
26. Ho G, Schwartz RJ, Regio Pereira A, Dimitrou F, Paver E, McKenzie C, Saw RPM, **Scoflyer RA**, Long GV, Guitera P. Reflectance confocal microscopy - a non-invasive tool for monitoring systemic treatment response in stage III unresectable primary scalp melanoma. *J Eur Acad Dermatol Venereol.* 2022 Jul;36(7):e583-e585. doi: 10.1111/jdv.18076. Epub 2022 Mar 29. PMID: 35285090
27. El Sharouni MA, **Scoflyer RA**, van Gils CH, Ch'ng S, Nieweg OE, Pennington TE, Saw RPM, Shannon K, Spillane A, Stretch J, Witkamp AJ, Sigurdsson V, Thompson JF, van Diest PJ*, Lo SN* (*Contributed equally). Time interval between diagnostic excision-biopsy of a primary melanoma and sentinel node biopsy: effects on the sentinel node positivity rate and survival outcomes. *Eur J Cancer.* 2022 May;167:123-132. doi: 10.1016/j.ejca.2021.12.035. Epub 2022 Mar 5. PMID: 35256245
28. Potter AJ, Colebatch AJ, Rawson RV, Ferguson PM, Cooper WA, Gupta R, O'Toole S, Saw RPM, Ch'ng S, Menzies AM, Long GV, **Scoflyer RA**. Pathologist initiated reflex BRAF mutation testing in metastatic melanoma: experience at a specialist melanoma treatment centre. *Pathology.* 2022 Mar 3;S0031-3025(22)00062-9. doi: 10.1016/j.pathol.2021.12.290. Online ahead of print. PMID: 35249747
29. Colebatch AJ*, Paver EC*, Vergara IA, Thompson JF, Long GV, Wilmott JS, **Scoflyer RA** (*authors contributed equally to the work and are considered co-first authors). Elevated non-coding promoter mutations are associated with malignant transformation of melanocytic naevi to melanoma. *Pathology.* 2022 Mar 2;S0031-3025(22)00061-7. doi: 10.1016/j.pathol.2021.12.289. Online ahead of print. PMID: 35248370
30. Cochran AJ, Wen DR, Huang RR, Abrishami P, Smart C, Binder S, **Scoflyer RA**, Thompson JF, Stern S, Van Kreuningen L, Elashoff DE, Sim MS, Wang HJ, Faries MB; MSLT-I Study Group. Sentinel lymph node melanoma metastases: Assessment of tumor burden for clinical prediction of outcome in the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). *Eur J Surg Oncol.* 2022 Jun;48(6):1280-1287. doi: 10.1016/j.ejso.2022.01.021. Epub 2022 Feb 12. PMID: 35246348
31. El Sharouni MA, **Scoflyer RA**, van Gils CH, Ch'ng S, Nieweg OE, Pennington TE, Saw RP, Shannon K, Spillane A, Stretch J, Witkamp AJ, Sigurdsson V, Thompson JF, van Diest PJ*, Lo SN* (*contributed equally). Effect of the time interval between melanoma diagnosis and sentinel node biopsy on the size of metastatic tumour deposits in node-positive patients. *Eur J Cancer.* 2022 May;167:133-141. doi: 10.1016/j.ejca.2021.12.036. Epub 2022 Feb 22. PMID: 35216870
32. Pennington TE, Zhao CY, Colebatch AJ, Fernandez-Peñas P, Guitera P, Burke H, **Scoflyer RA**, Menzies AM, Carlino MS, Lo S, Long GV, Saw RP. Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanoma. *Australas J Dermatol.* 2022 May;63(2):e133-e137. doi: 10.1111/ajd.13807. Epub 2022 Feb 21. PMID: 35188271

33. Pires da Silva I#, Ahmed T#, McQuade JL, Nebhan CA, Park JJ, Versluis JM, Serra-Bellver P, Khan Y, Slattery T, Oberoi HK, Ugurel S, Haydu LE, Herbst R, Utikal J, Pföhler C, Terheyden P, Weichenthal M, Gutzmer R, Mohr P, Rai R, Smith JL, **Scoflyer RA**, Arance AM, Pickering L, Larkin J, Lorigan P, Blank CU, Schadendorf D, Davies MA, Carlino MS, Johnson DB, Long GV§, Lo SN§, Menzies AM§ (# §These authors contributed equally). Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma. *J Clin Oncol*. 2022 Apr 1;40(10):1068-1080. doi: 10.1200/JCO.21.01701. Epub 2022 Feb 10. PMID: 35143285
34. Reijers ILM, Rawson RV, Colebatch AJ, Rozeman EA, Menzies AM, van Akkooi ACJ, Shannon KF, Wouters MW, Saw RPM, van Houdt WJ, Zuur CL, Nieweg OE, Ch'ng S, Klop WMC, Spillane AJ, Long GV*, **Scoflyer RA***, van de Wiel BA*, Blank CU* (*shared last authors). Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma. *JAMA Surg*. 2022 Feb 9. doi: 10.1001/jamasurg.2021.7554. Online ahead of print. PMID: 35138335
35. Guitera P, Waddell A, Paton E, Fogarty GB, Hong A, **Scoflyer RA**, Stretch JR, O'Donnell BA, Pellacani G. Re: Reply to letter to the editor re: 'A practical guide on the use of Imiquimod cream to treat Lentigo Maligna' (*original PMID: 34529272*). *Australas J Dermatol*. 2022 May;63(2):e198-e199. doi: 10.1111/ajd.13797. Epub 2022 Feb 2 PMID: 35107826.
36. Muir CA, Wood CCG, Clifton-Bligh RJ, Long GV, **Scoflyer RA**, Carlino MS, Menzies AM*, Tsang VHM* (*contributed equally and are co-senior authors of this research article). Association of Antithyroid Antibodies in Checkpoint Inhibitor-Associated Thyroid Immune-Related Adverse Events. *J Clin Endocrinol Metab*. 2022 Apr 19;107(5):e1843-e1849. doi: 10.1210/clinem/dgac059. PMID: 35104870 (nb: 14.5.2: this paper was one of the top 10 percent of articles published in the journal in 2020-2021, assessed by rate of citation)
37. El Sharouni MA, Rawson RV, Sigurdsson V, Witkamp AJ, van Gils CH, **Scoflyer RA**, Thompson JF*, van Diest PJ*, Lo SN*. (*Contributed equally). The progressive relationship between increasing Breslow thickness and decreasing survival is lost in patients with ultra-thick melanomas (≥ 15 mm in thickness). *J Am Acad Dermatol*. 2022 Aug;87(2):298-305. doi: 10.1016/j.jaad.2022.01.040. Epub 2022 Feb 1. PMID: 35121073
38. van Akkooi ACJ*, Hieken TJ*, Burton EM*, Ariyan C, Ascierto PA, Asero SVMA, Blank CU, Block MS, Boland GM, Caraco C, Chng S, Davidson BS, Duprat Neto JP, Faries MB, Gershenwald JE, Grunhagen DJ, Gyorki DE, Han D, Hayes AJ, van Houdt WJ, Karakousis GC, Klop WMC, Long GV, Lowe MC, Menzies AM, Bagge RO, Pennington TE, Rutkowski P, Saw RPM, Scoflyer RA, Shannon KF, Sondak VK, Tawbi H, Testori AAE, Tetzlaff MT, Thompson JF, Zager JS, Zuur CL, Wargo JA, Spillane AJ#, Ross MI#, International Neoadjuvant Melanoma Consortium (INMC) (*shared first authorship, #Shared Senior Authorship). Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). *Ann Surg Oncol*. 2022 Jun;29(6):3694-3708. doi: 10.1245/s10434-021-11236-y. Epub 2022 Jan 28. PMID: 35089452 & 35426590 (correction).
39. Schwartz RJ, Ho G, Smith A, Collgros H, Regio Pereira A, Gouveia B, Long GV, Menzies AM, Potter AJ, Paver E, Star P, **Scoflyer RA**, Martin LK.. Successful treatment of eruptive keratoacanthomas with acitretin for patients on checkpoint inhibitor immunotherapy. *J Eur Acad Dermatol Venereol*. 2022 Jun;36(6):e445-e448. doi: 10.1111/jdv.17940. Epub 2022 Jan 28. PMID: 35043483
40. McLean AEB, Kao SC, Barnes DJ, Wong KKH, **Scoflyer RA**, Cooper WA*, Kohonen-Corish MRJ*. (*These authors contributed equally). The Emerging Role of the Lung Microbiome and its importance in Lung Cancer Diagnosis and Treatment. *Lung Cancer*. 2022 Jan 20;165:124-132. doi: 10.1016/j.lungcan.2022.01.011. Online ahead of print. PMID: 35123155 and PMID: 35279297 (Corrigendum)
41. Lô SN, Ma J, Manuguerra M, Moreno-Betancur M, **Scoflyer RA**, Thompson JF. Competing risks analysis with missing cause-of-failure-penalized likelihood estimation of cause-specific Cox models. *Stat Methods Med Res*. 2022 May;31(5):978-994. doi: 10.1177/09622802211070254. Epub 2022 Jan 17. PMID: 35037794
42. **RA Scoflyer**. Pathology: The Next Chapter. Editorial. *Pathology*. 2022 Feb;54(1):4-5. doi: 10.1016/j.pathol.2021.12.001. Epub 2022 Jan 10. PMID: 35022138
43. Semsarian CR, Ma T, Nickel B, **Scoflyer RA**, Ferguson PM, Soyer HP, Parker L, Barratt A, Thompson JF, Bell KJL. Do we need to rethink the diagnoses melanoma in situ and severely dysplastic naevus? *Br J Dermatol*. 2022 Jan 10. doi: 10.1111/bjd.21010. Online ahead of print. PMID: 35007335
44. Pereira AR*, Corral-Forteza M*, Collgros H, El Sharouni MA, Ferguson PM, **Scoflyer RA**, Guitera P (*contributed equally). Dermoscopic features and screening strategies for the detection of small-diameter melanomas. *Clin Exp Dermatol*. 2022 May;47(5):932-941. doi: 10.1111/ced.15094. Epub 2022 Feb 15. PMID: 34997617
45. Newell F#, Pires da Silva I#, Johansson PA#, Menzies AM#, Wilmott JS#, Addala V, Carlino MS, Rizos H, Nones K, Edwards JJ, Lakis V, Kazakoff SH, Mukhopadhyay P, Ferguson PM, Leonard C, Koufariotis LT, Wood S, Blank CU, Thompson JF, Spillane AJ, Saw RPM, Shannon KF, Pearson JV, Mann GJ, Hayward NK§, **Scoflyer RA**§, Waddell N§, Long GV§. (#These authors contributed equally to this work. §These authors jointly supervised this work). Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance. *Cancer Cell*. 2022 Jan 10;40(1):88-102.e7. doi: 10.1016/j.ccell.2021.11.012. Epub 2021 Dec 23. PMID: 34951955
46. **Scoflyer RA**, Atkinson V, Gyorki DE, Lambie D, O'Toole S, Saw RPM, Amanuel B, Angel CM, Button-Sloan AE, Carlino MS, Ch'ng S, Colebatch AJ, Daneshvar D, Pires da Silva I, Dawson T, Ferguson PM, Foster-Smith E, Fox SB, Gill AJ, Gupta R, Henderson MA, Hong AM, Howle JR, Jackett LA, James C, Lee CS, Lochhead A, Loh D, McArthur GA, McLean CA, Menzies AM, Nieweg OE, O'Brien BH, Pennington TE, Potter AJ, Prakash S, Rawson RV, Read RL, Rtshiladze MA, Shannon KF, Smithers BM, Spillane AJ, Stretch JR, Thompson JF, Tucker P, Varey AHR, Vilain RE, Wood BA, Long GV. BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: Practical guidance for the Australian setting. *Pathology*. 2022 Feb;54(1):6-19. doi: 10.1016/j.pathol.2021.11.002. Epub 2021 Dec 20. PMID: 34937664
47. Benton S, Zhao J, Zhang B, Bahrami A, Barnhill RL, Busam K, Cerroni L, Cook MG, de la Fouchardière A, Elder DE, Johansson I, Landman G, Lazar A, LeBoit P, Lowe L, Massi D, Duncan LM, Messina J, Mihic-Probst D, Mihm MC Jr, Piepkorn MW, Schmidt B, **Scoflyer RA**, Shea CR, Tetzlaff MT, Tron VA, Xu X, Yeh I, Yun SJ, Zembowicz A, Gerami P.. Impact of Next-generation Sequencing on Interobserver Agreement and Diagnosis of Spitzoid Neoplasms. *Am J Surg Pathol*. 2021 Dec 1;45(12):1597-1605. doi: 10.1097/PAS.0000000000001753. PMID: 34757982
48. Ackermann DM, Dieng M, Medcalf E, Jenkins MC, van Kemenade CH, Janda M, Turner RM, Cust AE, Morton RL, Irwig L, Guitera P, Soyer HP, Mar V, Hersch JK, Low D, Low C, Saw RPM, **Scoflyer RA**, Drabarek D, Espinoza D, Azzi A, Lilleyman AM, Smit AK, Murchie P, Thompson JF, Bell KJL. Assessing the Potential for Patient-led Surveillance After Treatment of Localized Melanoma (MEL-SELF): A Pilot Randomized Clinical Trial. *JAMA Dermatol*. 2022 Jan 1;158(1):33-42. doi: 10.1001/jamadermatol.2021.4704. PMID: 34817543

49. Liyanage UE, MacGregor S, Bishop DT, Shi J, An J, Ong JS, Han X, **Scolyer RA**, Martin NG, Medland SE, Byrne EM, Green AC, Saw RPM, Thompson JF, Stretch J, Spillane A, Jiang Y, Tian C; 23andMe Research Team, Gordon SG, Duffy DL, Olsen CM, Whiteman DC, Long GV, Iles MM, Landi MT, Law MH. Multi-trait genetic analysis identifies auto-immune loci associated with cutaneous melanoma. *J Invest Dermatol*. 2022 Jun;142(6):1607-1616. doi: 10.1016/j.jid.2021.08.449. Epub 2021 Nov 20. PMID: 34813871
50. Haeffliger S, Guitera P, Melhoranse Gouveia B, Colebatch AJ, **Scolyer RA**, Rtshiladze M, Martin LK. Case report of a challenging medium-sized congenital melanocytic nevus (CMN): Highlighting a role for reflectance confocal microscopy (RCM) for evaluating changing CMN in children. *Pediatr Dermatol*. 2021 Nov;38(6):1549-1552. doi: 10.1111/pde.14846. Epub 2021 Nov 4. PMID: 34738265
51. Watts CG*, McLoughlin K*, Goumas C, van Kemenade CH, Aitken JF, Soyer HP, Fernandez Peñas P, Guitera P, **Scolyer RA**, Morton RL, Menzies SW, Caruana M, Kang YJ, Mann GJ, Chakera AH, Madronio CM, Armstrong BK, Thompson JF, Cust AE (* these authors contributed equally). Association Between Melanoma Detected During Routine Skin Checks and Mortality. *JAMA Dermatol*. 2021 Dec 1;157(12):1425-1436. doi: 10.1001/jamadermatol.2021.3884. PMID: 34730781
52. Quek C, Bai X, Long GV, **Scolyer RA***, Wilmott JS.* (*last authors – equal contributions / last name in alphabetical order). High-Dimensional Single-Cell Transcriptomics in Melanoma and Cancer Immunotherapy. *Genes (Basel)*. 2021 Oct 16;12(10):1629. doi: 10.3390/genes12101629. PMID: 34681023
53. Peri A, Greenstein E, Alon M*, Pai JA*, Dingjan T, Reich-Zeliger S, Barnea E, Barbolin C, Levy R, Arnedo-Pac C, Kalaora S, Dassa B, Feldmesser E, Shang P, Greenberg P, Levin Y, Benedek G, Levesque MP, Adams DJ, Lotem M, Wilmott JS, **Scolyer RA**, Jönsson GB, Admon A, Rosenberg SA, Cohen CJ, Niv MY, Lopez-Bigas N, Satpathy AT, Friedman N‡, Samuels Y (* These authors contributed equally to this work. ‡Deceased on 19 February 2021). Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma. *J Clin Invest*. 2021 Oct 15;131(20):e129466. doi: 10.1172/JCI129466. PMID: 34651586
54. Güvenç C, Antoranz A, Szumera-Ciećkiewicz A, Teterycz PP, Rutkowski PR, Rawson RV, **Scolyer RA**, Thompson JF, Newton-Bishop J, Stas M, Boecxstaens V, Bechter O, Vercauteren J, Garmyn M, van den Oord J, Bosio FM. Road to Metastasis: The TWEAK Pathway as a Discriminant between Metastasizing and Non-Metastasizing Thick Melanomas. *Int J Mol Sci*. 2021 Sep 29;22(19):10568. doi: 10.3390/ijms221910568. PMID: 34638912
55. Guitera P, Waddell A, Paton E, Fogarty GB, Hong A, **Scolyer RA**, Stretch JR, O'Donnell BA, Pellacani G. A practical guide on the use of imiquimod cream to treat lentigo maligna. *Australas J Dermatol*. 2021 Nov;62(4):478-485. doi: 10.1111/ajd.13720. Epub 2021 Sep 16. PMID: 34529272
56. Potter AJ, Dimitriou F, Karim RZ, Mahar A, Chan C, Long GV, **Scolyer RA**. Cutaneous Clear Cell Sarcoma With An Epidermal Component Mimicking Melanoma. *Pathology*. 2022 Apr;54(3):369-371. doi: 10.1016/j.pathol.2021.05.097. Epub 2021 Aug 19. PMID: 34420793
57. Jakkett LA, Satgunaseelan L, Roper E, Lo SN, Thompson JF, **Scolyer RA**. Residual melanoma in wide local excision specimens after 'complete' excision of primary cutaneous in situ and invasive melanomas. *Pathology*. 2022 Feb;54(1):71-78. doi: 10.1016/j.pathol.2021.05.094. Epub 2021 Aug 13. PMID: 34392983
58. Li AT, Vakharia K, Lo SN, Valey AHR, Carlino MS, Saw RPM, Shannon KF, Howle JR, Pennington TE, Stretch JR, Nieweg OE, Spillane AJ, Long GV, Menzies AM, **Scolyer RA**, Thompson JF, Ch'ng S. ASO Visual Abstract: Survival Outcomes of Salvage Metastasectomy after Failure of Modern-Era Systemic Therapy for Melanoma. *Ann Surg Oncol*. 2021 Aug 10. doi: 10.1245/s10434-021-10529-6. Online ahead of print. PMID: 34378093
59. Ch'ng S, **Scolyer RA**, Thompson JF. ASO Author Reflections: Surgical Resection May Improve the Outcome for Patients with Residual Metastatic Melanoma When Modern Systemic Therapies Have Not Achieved Complete Disease Control. *Ann Surg Oncol*. 2021 Oct;28(11):6124-6125. doi: 10.1245/s10434-021-10514-z. Epub 2021 Aug 9. PMID: 34373967
60. Rocha LKFL, Vilain RE, **Scolyer RA**, Lo SN, Drummond M, Star P, Fogarty GB, Hong AM, Guitera P. Confocal microscopy, dermoscopy, and histopathology features of atypical intraepidermal melanocytic proliferations associated with evolution to melanoma in situ. *Int J Dermatol*. 2022 Feb;61(2):167-174. doi: 10.1111/ijd.15815. Epub 2021 Aug 5. PMID: 34351639
61. Li AT, Vakharia K, Lo SN, Valey AHR, Carlino MS, Saw RPM, Shannon KF, Howle JR, Pennington TE, Stretch JR, Nieweg OE, Spillane AJ, Long GV, Menzies AM, **Scolyer RA**, Thompson JF, Ch'ng S. Survival Outcomes of Salvage Metastasectomy After Failure of Modern-Era Systemic Therapy for Melanoma. *Ann Surg Oncol*. 2021 Oct;28(11):6109-6123. doi: 10.1245/s10434-021-10489-x. Epub 2021 Aug 4. PMID: 34347220
62. Aivazian K, Ahmed T, El Sharouni MA, Stretch JR, Saw RPM, Spillane AJ, Shannon KF, Ch'ng S, Nieweg OE, Thompson JF, Lo SN, **Scolyer RA**. Histological regression in melanoma: impact on sentinel lymph node status and survival. *Mod Pathol*. 2021 Nov;34(11):1999-2008. doi: 10.1038/s41379-021-00870-2. Epub 2021 Jul 10. PMID: 34349230 (correction) to 34247192
63. Haas L, Elewaut A, Gerard CL, Umkehrer C, Leiendecker L, Pedersen M, Krecioch I, Hoffmann D, Novatchkova M, Kuttke M, Neumann T, da Silva IP, Witthock H, Cuendet MA, Carotta S, Harrington KJ, Zuber J, **Scolyer RA**, Long GV, Wilmott JS, Michielin O, Vanharanta S, Wiesner T, Obenaus AC. Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma. *Nat Cancer*. 2021 Jul;2(7):693-708. doi: 10.1038/s43018-021-00221-9. Epub 2021 Jul 15. PMID: 35121945
64. Gide TN*, Pires da Silva I*, Quek C, Ferguson PM, Batten M, Shang P, Ahmed T, Menzies AM, Carlino MS, Saw RPM, Thompson JF, **Scolyer RA***, Long GV*, Wilmott JS* (*contributed equally to this work). Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/- Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets. *Cancers (Basel)*. 2021 Jun 25;13(13):3186. doi: 10.3390/cancers13133186. PMID: 34202352
65. **Scolyer RA**, El Sharouni MA, Thompson JF. Characterizing the Clinical Implications of Histologic Regression in Melanoma Requires Clear Diagnostic Criteria That Are Consistently Applied-Reply.. (*in response to*) Characterizing the Clinical Implications of Histologic Regression in Melanoma Requires 2 Clear Diagnostic Criteria, Consistently Applied By: Mark C. Mochel and David E. Elder relating to El Sharouni MA, Aivazian K, Witkamp AJ, et al. *Association of Histologic Regression 57 with a Favorable Outcome in Patients with Stage 1 and Stage 2 Cutaneous Melanoma*. *JAMA Dermatol*. 2021 Aug 1;157(8):1006-1007. doi: 10.1001/jamadermatol.2021.1497. PMID: 34190966
66. Parakh S, Musafir A, Paessler S, Witkowski T, Suen CSNLW, Tutuka CSA, Carlino MS, Menzies AM, **Scolyer RA**, Cebon J, Dobrovic A, Long GV, Klein O, Behren A.. *PDCD1* Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma. *Front Immunol*. 2021 Jun 9;12:672521. doi: 10.3389/fimmu.2021.672521. eCollection 2021. PMID: 34177913
67. Rawson RV, Wilmott JS, **Scolyer RA**. Mucosal melanoma: a review emphasizing the molecular landscape and implications for diagnosis and management. *Surg Pathol Clin*. 2021 Jun;14(2):293-307. doi: 10.1016/j.jpath.2021.01.005. Epub 2021 Apr 28.. PMID: 34023107

68. Ch'ng S, Uyulmaz S, Carlino MS, Pennington TE, Shannon KF, Rtshiladze M, Stretch JR, Nieweg OE, Valey AHR, Hsiao E, Kapoor R, Pires da Silva I, Lo SN, Spillane AJ, **Scolyer RA**, Long GV, Hong AM, Saw RPM, Thompson JF, Menzies AM. Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies. *Eur J Cancer*. 2021 Aug;153:8-15. doi: 10.1016/j.ejca.2021.04.037. Epub 2021 Jun 12. PMID: 34126335
69. Menzies AM, **Scolyer RA**, Long GV. Neoadjuvant immunotherapy in melanoma – the new frontier. *Clin Cancer Res*. 2021 Aug 1;27(15):4133-4135. doi: 10.1158/1078-0432.CCR-21-1236. Epub 2021 Jun 3. PMID: 34083235
70. Gallagher SJ, Bailey T, Rawson RV, Mahar AM, Thompson JF, Long GV, Wilmott JS, **Scolyer RA**. Melanoma with osseous or chondroid differentiation: a report of eight cases including SATB2 expression and mutation analysis. *Pathology*. 2021 Dec;53(7):830-835. doi: 10.1016/j.pathol.2021.02.012. Epub 2021 Jun 2. PMID: 34090666.
71. Cree IA, Tan PH, Travis WD, Wesseling P, Yagi Y, White VA, Lokuhetty D, **Scolyer RA**. Counting mitoses: SI(ze) matters!. *Mod Pathol*. 2021 Sep;34(9):1651-1657. doi: 10.1038/s41379-021-00825-7. Epub 2021 Jun 2. PMID: 34079071
72. Robertson SJ, Orme L, Teixeira R, Shamassi M, Newell F, Patch AM, Yeh I, Gard G, Wilmott J, Jackett L, LeBoit P, Fellowes A, MacArthur G, Fox S, Hayward NK, Bastian B, **Scolyer R**, Waddell N, Penington A, Shackleton M. Evaluation of Crizotinib Treatment in a Patient With Unresectable *GOPC-ROS1* Fusion Agminated Spitz Nev. *JAMA Dermatol*. 2021 Jul 1;157(7):836-841. doi: 10.1001/jamadermatol.2021.0025. PMID: 34076666
73. Friedman EB, **Scolyer RA**, Williams GJ, Thompson JF. Melanoma In Situ: A Critical Review and Re-Evaluation of Current Excision Margin Recommendations. *Adv Ther*. 2021 Jul;38(7):3506-3530. doi: 10.1007/s12325-021-01783-x. Epub 2021 May 28. PMID: 34047915
74. Star P, Rawson RV, Drummond M, Lo S, **Scolyer RA**, Guitera P. Lentigo maligna: defining margins and predictors of recurrence utilising clinical, dermoscopic, confocal microscopy and histopathology features. *J Eur Acad Dermatol Venereol*. 2021 Sep;35(9):1811-1820. doi: 10.1111/jdv.17349. Epub 2021 Jun 17. PMID: 33998703
75. Wu SZ, Roden DL, Al-Eryani G, Bartonicek N, Harvey K, Cazet AS, Chan CL, Junankar S, Hui MN, Millar EA, Beretov J, Horvath L, Joshua AM, Stricker P, Wilmott JS, Quek C, Long GV, **Scolyer RA**, Yeung BZ, Segara D, Mak C, Warrier S, Powell JE, O'Toole S, Lim E, Swarbrick A. Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis. *Genome Med*. 2021 May 10;13(1):81. doi: 10.1186/s13073-021-00885-z. PMID: 33971952
76. Ackermann DM, Smit AK, Janda M, van Kemenade CH, Dieng M, Morton RL, Turner RM, Cust AE, Irwig L, Hersch JK, Guitera P, Soyer HP, Mar V, Saw RPM, Low D, Low C, Drabarek D, Espinoza D, Emery J, Murchie P, Thompson JF, **Scolyer RA**, Azzi A, Lilleyman A, Bell KJL. Can patient-led surveillance detect subsequent new primary or recurrent melanomas and reduce the need for routinely scheduled follow-up? A protocol for the MEL-SELF randomised controlled trial. *Trials*. 2021 May 4;22(1):324. doi: 10.1186/s13063-021-05231-7. PMID: 33947444
77. Giblin W, Bringman-Rodenbarger L, Guo AH, Kumar S, Monovich AC, Mostafa AM, Skinner ME, Azar M, Mady AS, Chung CH, Kadambi N, Melong KA, Lee HJ, Zhang L, Sajjakulnukit P, Trefely S, Varner EL, Iyer S, Wang M, Wilmott JS, Soyer HP, Sturm RA, Pritchard AL, Andea AA, **Scolyer RA**, Stark MS, Scott DA, Fullen DR, Bosenberg MW, Chandrasekaran S, Nikolovska-Coleska Z, Verhaegen ME, Snyder NW, Rivera MN, Osterman A, Lyssiotis CA, Lombard DB. The deacetylase SIRT5 supports melanoma viability by influencing chromatin dynamics. *J Clin Invest*. 2021 Jun 15;131(12):e138926. doi: 10.1172/JCI138926. PMID: 33945506
78. Delahunt B, Neill B, Burnett JR, **Scolyer RA**. Publication metrics: it really is all about the numbers. *Reply letter to Clarivate in response to original article: "Publication Metrics: What do they mean? Pathology*. 2020 Aug 16. PMID: 32814621". *Pathology*. 2021 Jun;53(4):561-563. doi: 10.1016/j.pathol.2021.03.001. Epub 2021 Apr 23. PMID: 33902921
79. Muir CA, Clifton-Bligh RJ, Long GV, **Scolyer RA**, Lo SN, Carlino MS, Tsang VHM*, Menzies AM* (*contributed equally and co-senior authors). Thyroid immune-related adverse events following immune checkpoint inhibitor treatment. *J Clin Endocrinol Metab*. 2021 Aug 18;106(9):e3704-e3713. doi: 10.1210/clinem/dgab263. PMID: 33878162. 7.9.21: selected as JCEM's Featured Article.
80. Dessinioti C, Geller AC, Whiteman DC, Garbe C, Grob JJ, Kelly JW, **Scolyer RA**, Rawson RV, Lallas A, Pellacani G, Stratigos AJ. Not all melanomas are created equal: A review and call for more research into nodular melanoma. *Br J Dermatol*. 2021 Apr 16. doi: 10.1111/bjd.20388. Online ahead of print. PMID: 33864261
81. Park JJ, Diefenbach RJ, Byrne N, Long GV, **Scolyer RA**, Gray ES, Carlino MS, Rizos H. Circulating Tumor DNA Reflects Uveal Melanoma Responses to Protein Kinase C Inhibition. *Cancers (Basel)*. 2021 Apr 6;13(7):1740. doi: 10.3390/cancers13071740. PMID: 33917514
82. Lee H, Da Silva IP, Palendira U, **Scolyer RA**, Long GV, Wilmott JS. Targeting NK Cells to Enhance Melanoma Response to Immunotherapies. *Cancers (Basel)*. 2021 Mar 17;13(6):1363. doi: 10.3390/cancers130613. PMID: 33802954
83. Rawson RV#, Adhikari C#, Bierman C#, Lo S, Shklovskaya E, Rozeman EA, Menzies AM, van Akkooi ACJ, Shannon KF, Gonzalez M M, Guminski AD, Tetzlaff MT, Stretch JR, Eriksson H, van Thienen JV, Wouters MW, Haanen JBAG, Klop WMC, Zuur CL, van Houdt WJ, Nieweg OE, Ch'ng S, Rizos H, Saw RPM, Spillane AJ, Wilmott JS, Blank CU*, Long GV*, van de Wiel BA*, **Scolyer RA*** (## These authors contributed equally to this work). Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma. *Ann Oncol*. 2021 Jun;32(6):766-777. doi: 10.1016/j.annonc.2021.03.006. Epub 2021 Mar 17. PMID: 33744385
84. Versluis JM, Reijers ILM, Rozeman EA, Menzies AM, van Akkooi ACJ, Wouters MW, Ch'ng S, Saw RPM, **Scolyer RA**, van de Wiel BA, Schilling B, Long GV, Blank CU. Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma. *Eur J Cancer*. 2021 May;148:51-57. doi: 10.1016/j.ejca.2021.02.012. Epub 2021 Mar 15. PMID: 33735809
85. Vergara IA, Mintoff CP, Sandhu S, McIntosh L, Young RJ, Wong SQ, Colebatch A, Cameron DL, Kwon JL, Wolfe R, Peng A, Ellul J, Dou X, Fedele C, Boyle S, Arnau GM, Raleigh J, Hatzimihalis A, Szeto P, Mooi J, Widmer DS, Cheng PF, Amann V, Dummer R, Hayward N, Wilmott J, **Scolyer RA**, Cho RJ, Bowtell D, Thorne H, Alsop K, Cordner S, Woodford N, Leditschke J, O'Brien P, Dawson SJ, McArthur GA, Mann GJ, Levesque MP, Papenfuss AT, Shackleton M. Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling. *Nat Commun*. 2021 Mar 4;12(1):1434. doi: 10.1038/s41467-021-21576-8. PMID: 33664264
86. Gherardin NA*, Waldeck K*, Caneborg A*, Martelotto LG, Balachander S, Zethoven M, Petrone PM, Pattison A, Wilmott JS, Quiñones-Parras SM, Rossello F, Posner A, Wong A, Weppler AM, Shannon KF, Hong A, Ferguson PM, Jakrot V, Raleigh J, Hatzimihalis A, Neeson PJ, Deleso P, Johnston M, Chua M, Becker JC, Sandhu S, McArthur GA, Gill AJ, **Scolyer RA**, Hicks RJ, Godfrey DI, Tothill RW (*Contributed equally). (Delta gamma) $\gamma\delta$ T cells in Merkel cell carcinomas have a proinflammatory profile prognostic of patient survival. *Cancer Immunol Res*. 2021 Jun;9(6):612-623. doi: 10.1158/2326-6066.CIR-20-0817. Epub 2021 Mar 5. PMID: 33674358

87. El Sharouni MA, Varey AHR, Witkamp AJ, Ahmed T, Sigurdsson V, van Diest PJ, **Scolyer RA**, Thompson JF*, Lo SN*, van Gils CH* (*contributed equally). Predicting sentinel node positivity in patients with melanoma: external validation of a risk-prediction calculator (the Melanoma Institute Australia nomogram) using a large European population-based patient cohort. *Br J Dermatol*. 2021 Aug;185(2):412-418. doi: 10.1111/bjd.19895. Epub 2021 May 9. PMID: 33657653
88. Gibson M, **Scolyer RA**, Soyer HP, Ferguson P, McGeechan K, Irwig L, Bell K. Estimating the potential impact of interventions to reduce over-calling and under-calling of melanoma. *J Eur Acad Dermatol Venereol*. 2021 Jul;35(7):1519-1527. <https://doi.org/10.1111/jdv.17189>. Epub 2021 Apr 4. PMID: 33630379
89. El Sharouni MA, Ahmed T, Varey AHR, Elias SG, Witkamp AJ, Sigurdsson V, Suijkerbuijk KPM, van Diest PJ, Scolyer RA, van Gils CH, Thompson JF*, Blokx WAM*, Lo SN* (*Contributed equally). Development and Validation of Nomograms to Predict Local, Regional, and Distant Recurrence in Patients with Thin (T1) Melanomas. *J Clin Oncol*. 2021 Apr 10;39(11):1243-1252. doi: 10.1200/JCO.20.02446. Epub 2021 Feb 18. PMID: 33600211
90. Garg M, Couturier DL, Nsengimana J, Fonseca NA, Wongchenko M, Yan Y, Lauss M, Jönsson GB, Newton-Bishop J, Parkinson C, Middleton MR, Bishop DT, McDonald S, Stefanos N, Tadross J, Vergara IA, Lo S, Newell F, Wilmott JS, Thompson JF, Long GV, Scolyer RA, Corrie P, Adams DJ, Brazma A, Rabbie R. Tumour gene expression signature in primary melanoma predicts long-term outcomes. *Nat Commun*. 2021 Feb 18;12(1):1137. doi: 10.1038/s41467-021-21207-2. PMID: 33602918 & 35581257 (Author correction)
91. Kelly G, Al-Ejeh F, McCuaig RD, Casciello F, Kamal N, Ferguson B, Pritchard AL, Ali S, Silva I, Wilmott JS, Long GV, **Scolyer RA**, Rao S, Hayward NK, Gannon F, Lee JS. G9a inhibition enhances checkpoint inhibitor blockade response in melanoma. *Clin Cancer Res*. 2021 May 1;27(9):2624-2635. doi: 10.1158/1078-0432.CCR-20-3463. Epub 2021 Feb 15. PMID: 33589432
92. Rozeman EA, Hoefsmit EP, Reijers ILM, Saw RPM, Versluis JM, Krijgsman O, Dimitriadis P, Sikorska K, van de Wiel BA, Eriksson H, Gonzalez M, Torres Acosta A, Grijpink-Ongering LG, Shannon K, Haanen JBAG, Stretch J, Ch'ng S, Nieweg OE, Mallo HA, Adriaansz S, Kerkhoven RM, Cornelissen S, Broeks A, Klop WMC, Zuur CL, van Houdt WJ, Peeper DS, Spillane AJ, van Akkooi ACJ, **Scolyer RA**, Schumacher TNM, Menzies AM, Long GV, Blank CU. Survival and Biomarker Analyses from the OpACIN-neo and OpACIN Neoadjuvant Immunotherapy Trials in Stage III Melanoma. *Nat Med*. 2021 Feb 8. doi: 10.1038/s41591-020-01211-7. Online ahead of print. PMID: 33558721
93. Simpson RC, Shanahan E, **Scolyer RA**, Long GV. Targeting the Microbiome to Overcome Resistance. *Cancer Cell*. 2021 Feb 8;39(2):151-153. doi: 10.1016/j.ccell.2021.01.016. PMID: 33561397
94. Menzies AM*, Amaria RN*, Rozeman EA*, Huang AC*, Tetzlaff MT*, van de Wiel BA*, Lo S*, Tarhini AA, Burton EM, Pennington TE, Saw RPM, Xu X, Karakousis GC, Ascierto PA, Spillane AJ, van Akkooi ACJ, Davies MA^, Mitchell TC^, Tawbi HA^, **Scolyer RA**^, Wargo JA^, Blank CU^, Long GV^ (*^ denotes joint senior author). Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). *Nat Med*. 2021 Feb;27(2):301-309. doi: 10.1038/s41591-020-01188-3. Epub 2021 Feb 8. PMID: 33558722
95. Hughes TM, Williams GJ, Gyorki DE, Kelly JW, Stretch JR, Varey AHR, Hong AM, **Scolyer RA**, Thompson JF. Desmoplastic Melanoma: A review of its pathology and clinical behaviour, and of management recommendations in published guidelines. *J Eur Acad Dermatol Venereol*. 2021 Jun;35(6):1290-1298. doi: 10.1111/jdv.17154. Epub 2021 Mar 3. PMID: 33544941
96. Collgros H, Rodriguez-Lomba E, Regio Pereira A, Lo SN, **Scolyer RA**, Guitera P. Lentiginous melanoma (lentigo maligna and lentigo maligna melanoma) in Australia: clinicopathological characteristics, management and recurrence rates after 10-year follow-up at a tertiary centre. *J Eur Acad Dermatol Venereol*. 2021 Jun;35(6):1315-1322. doi: 10.1111/jdv.17135. Epub 2021 Mar 3. PMID: 33502077.
97. Vergara IA, Wilmott JS, Long GV, **Scolyer RA**. Genetic drivers of non-cutaneous melanomas: challenges and opportunities in a heterogeneous landscape. *Exp Dermatol*. 2022 Jan;31(1):13-30. doi: 10.1111/exd.14287. Epub 2021 Feb 1. PMID: 33455025
98. Dessinoti C, Geller AC, Stergiopoulou A, Dimou N, Lo S, Keim U, Gershenwald JE, Haydu LE, Dummer R, Mangana J, Hauschild A, Egberts F, Vieira R, Brinca A, Zalaudek I, Deinlein T, Evangelou E, Thompson JF, Scolyer RA, Peris K, Garbe C*, Stratigos AJ*. (*equally contributing senior authors). A multicentre study of naevus-associated melanoma vs. de novo melanoma, tumour thickness and body site differences. *Br J Dermatol*. 2021 Jul;185(1):101-109. doi: 10.1111/bjd.19819. Epub 2021 Apr 1. PMID: 33454993
99. Mangantig E, MacGregor S, Iles MM, **Scolyer RA**, Cust AE, Hayward NK, Montgomery GW, Duffy DL, Thompson JF, Henders A, Bowdler L, Rowe C, Cadby G, Mann GJ, Whiteman DC, Long GV, Ward SV, Khosrotehrani K, Barrett JH, Law MH. Germline variants are associated with increased primary melanoma tumor thickness at diagnosis. *Hum Mol Genet*. 2021 Jan 6;29(21):3578-3587. doi: 10.1093/hmg/ddaa222. PMID: 33410475
100. Paver EC, Cooper WA, Colebatch AJ, Ferguson PM, Hill SK, Lum T, Shin JS, O'Toole S, Anderson L, **Scolyer RA**, Gupta R. Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation. *Pathology*. 2020 Dec 30;S0031-3025(20)31006-0. doi: 10.1016/j.pathol.2020.10.007. Online ahead of print. PMID: 33388161
101. El Sharouni MA, Aivazian K, Witkamp AJ, Sigurdsson V, van Gils CH, **Scolyer RA**, Thompson JF, van Diest PJ, Lo SN. Association of Histologic Regression With a Favorable Outcome in Patients With Stage 1 and Stage 2 Cutaneous Melanoma. *JAMA Dermatol*. 2021 Feb 1;157(2):166-173. doi: 10.1001/jamadermatol.2020.5032. PMID: 33355600
102. Hoefsmit EP, Rozeman EA, Van TM, Dimitriadis P, Krijgsman O, Conway JW, Pires da Silva I, van der Wal JE, Ketelaars SLC, Bresser K, Broeks A, Kerkhoven RM, Reeves JW, Warren S, Kvistborg P, Scolyer RA, Kapiteijn EW, Peeper DS, Long GV, Schumacher TNM, Blank CU. Comprehensive analysis of cutaneous and uveal melanoma liver metastases. *J Immunother Cancer*. 2020 Dec;8(2):e001501. doi: 10.1136/jitc-2020-001501. PMID: 33262254
103. El Sharouni MA*, Stodell MD*, Ahmed T, Suijkerbuijk KPM, Cust AE, Witkamp AJ, Sigurdsson V, van Diest PJ, **Scolyer RA***, Thompson JF*, van Gils CH*, Lo SN*. (*Contributed equally). Sentinel node biopsy in patients with melanoma improves the accuracy of staging when added to clinicopathological features of the primary tumor. *Ann Oncol*. 2020 Nov 27;S0923-7534(20)43170-9. doi: 10.1016/j.annonc.2020.11.015. Online ahead of print. PMID: 33253862
104. Nahar KJ, Rawson RV, Ahmed T, Tattersall S, Sandanayake N, Kiely CJ, Lo S, Carlino M, Palendira U, **Scolyer RA**, Long GV, Menzies AM. Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab. *J Immunother Cancer*. 2020 Nov;8(2):e001488. doi: 10.1136/jitc-2020-001488. PMID: 33234603
105. Shklovskaya E, Lee JH, Lim SY, Stewart A, Pedersen B, Ferguson P, Saw RP, Thompson JF, Shivalingam B, Carlino MS, **Scolyer RA**, Menzies AM, Long GV, Kefford RF, Rizos H. Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma. *Cancers (Basel)*. 2020 Nov 14;12(11):E3374. doi: 10.3390/cancers12113374. PMID: 33202676

106. Fischer GM, Carapeto FCL, Joon AY, Haydu LE, Chen H, Wang F, Van Arnam JS, McQuade JL, Wani K, Kirkwood JM, Thompson JF, Tetzlaff MT, Lazar AJ, Tawbi HA, Gershenwald JE, **Scohyer RA**, Long GV, Davies MA. Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker. *Cancer Med*. 2020 Nov;9(22):8650-8661. doi: 10.1002/cam4.3474. Epub 2020 Oct 5. PMID: 33016647
107. Braun M, Aguilera AR, Sundararajan A, Corvino D, Stannard K, Krumeich S, Das I, Lima LG, Meza Guzman LG, Li K, Li R, Salim N, Jorge MV, Ham S, Kelly G, Vari F, Lepletier A, Raghavendra A, Pearson S, Madore J, Jacquelin S, Efferm M, Quine B, Koufariotis LT, Casey M, Nakamura K, Seo EY, Hölzel M, Geyer M, Kristiansen G, Taheri T, Ahern E, Hughes BGM, Wilmott JS, Long GV, **Scohyer RA**, Batstone MD, Landsberg J, Dietrich D, Pop OT, Flatz L, Dougall WC, Veillette A, Nicholson SE, Möller A, Johnston RJ, Martinet L, Smyth MJ, Bald T. CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T Cells. *Immunity*. 2020 Oct 13;53(4):805-823.e15. doi: 10.1016/j.immuni.2020.09.010. PMID: 33053330
108. Marsavela G, Lee J, Calapre L, Wong SQ, Pereira MR, McEvoy AC, Reid AL, Robinson C, Warburton L, Abed A, Khattak MA, Meniawy TM, Dawson SJ, Sandhu S, Carlino MS, Menzies AM, **Scohyer RA**, Long GV, Amanuel B, Millward M, Ziman MR, Rizos H, Gray ES. Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy. *Clin Cancer Res*. 2020 Nov 15;26(22):5926-5933. doi: 10.1158/1078-0432.CCR-20-2251. Epub 2020 Oct 16. PMID: 33067256
109. Newell F, Wilmott JS, Johansson PA, Nones K, Addala V, Mukhopadhyay P, Broit N, Amato CM, Van Gulick R, Kazakoff SH, Patch AM, Koufariotis LT, Lakis V, Leonard C, Wood S, Holmes O, Xu Q, Lewis K, Medina T, Gonzalez R, Saw RPM, Spillane AJ, Stretch JR, Rawson RV, Ferguson PM, Dodds TJ, Thompson JF, Long GV, Levesque MP, Robinson WA, Pearson JV, Mann GJ, **Scohyer RA**, Waddell N, Hayward NK. Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity. *Nat Commun*. 2020 Oct 16;11(1):5259. doi: 10.1038/s41467-020-18988-3. PMID: 33067454
110. Aivazian K, Mahar A, Jackett LA, Kimble RM, **Scohyer RA**. GLI activated epithelioid cell tumour: report of a case and proposed new terminology. *Pathology*. 2021 Feb;53(2):267-270. doi: 10.1016/j.pathol.2020.07.013. Epub 2020 Oct 6. PMID: 33032812
111. Rabbie R*, Ferguson P*, Wong K, Couturier DL, Moran U, Turner C, Emanuel P, Haas K, Saunus JM, Davidson MR, Lakhani SR, Shivalingam B, Long GV, Parkinson C, Osman I, **Scohyer RA**, Corrie P, Adams DJ. (*contributed equally). The mutational landscape of melanoma brain metastases presenting as the first visceral site of recurrence. *Br J Cancer*. 2020 Oct 7. doi: 10.1038/s41416-020-01090-2. Online ahead of print. PMID: 33024263
112. Valey, AHR; Lo, SN.; **Scohyer, RA.**; Thompson, JF. Predicting sentinel node status in patients with melanoma: does gene expression profiling improve accuracy? *JCO precision oncology*, 2020-09 (4), p.990-991. PMID: TBC
113. Crouch G*, Sinha S*, Lo S, Saw RPM, Lee KK, Stretch J, Shannon K, Guitera P, **Scohyer RA**, Thompson JF, Ch'ng S. (*contributed equally). Clinical outcomes following surgical treatment of lentigo maligna of the head and neck. *Eur J Surg Oncol*. 2021 May;47(5):1145-1151. doi: 10.1016/j.ejso.2020.09.028. Epub 2020 Sep 23. PMID: 33023795
114. Attrill GH, Ferguson PM, Palendira U, V Long G, Wilmott JS, **Scohyer RA**. The tumour immune landscape and its implications in cutaneous melanoma. *Pigment Cell Melanoma Res*. 2021 May;34(3):529-549. doi: 10.1111/pcmr.12926. Epub 2020 Oct 1. PMID: 32939993
115. Edwards J, Ferguson PM, Lo SN, Pires da Silva I, Colebatch AJ, Lee H, Saw RP, Thompson JF, Menzies AM, Long GV, Newell F, Pearson J, Waddell N, Hayward N, Johansson PA, Mann G, **Scohyer RA***, Palendira U*, Wilmott JS*. (*contributed equally to this work). Tumor mutation burden and structural chromosomal aberrations are not associated with T-cell density or patient survival in acral, mucosal, and cutaneous melanomas. *Cancer Immunol Res*. 2020 Nov;8(11):1346-1353. doi: 10.1158/2326-6066.CIR-19-0835. Epub 2020 Sep 11. PMID: 32917657
116. El Sharouni MA, Ahmed T, Witkamp AJ, Sigurdsson V, van Gils CH, Nieweg OE, **Scohyer RA**, Thompson JF, van Diest PJ*, Lo SN*, Paul J van Diest* (*contributed equally). Predicting recurrence in patients with sentinel node-negative melanoma: validation of the EORTC nomogram using population-based data. *Br J Surg*. 2021 May 27;108(5):550-553. doi: 10.1002/bjs.11946. PMID: 34043770
117. Delahunt B, Neill B, Burnett JR, **Scohyer RA**. "Editorial" Publication metrics: what do they mean? *Pathology*. 2020 Oct;52(6):619-620. doi: 10.1016/j.pathol.2020.07.002. Epub 2020 Aug 16. PMID: 32814621
118. Diefenbach RJ, Lee JH, Menzies AM, Carlino MS, Long GV, Saw RPM, Howle JR, Spillane AJ, **Scohyer RA**, Kefferd RF, Rizos H. Design and testing of a custom melanoma next generation sequencing panel for analysis of circulating tumor DNA. *Cancers (Basel)*. 2020 Aug 10;12(8):E2228. doi: 10.3390/cancers12082228. PMID: 32785074
119. Kashani-Sabet M, Miller JR 3rd, Lo S, Nosrati M, Stretch JR, Shannon KF, Spillane AJ, Saw RPM, Cleaver JE, Kim KB, Leong SP, Thompson JF, **Scohyer RA**. Reappraisal of the prognostic significance of mitotic rate supports its reincorporation into the melanoma staging system. *Cancer*. 2020 Aug 11. doi: 10.1002/cncr.33088. Online ahead of print. PMID: 32780467
120. Sasson SC, Zunders JJ, Nahar K, Munier CML, Fairfax BP, Olsson-Brown A, Jolly C, Read SA, Ahlenstiel G, Palendira U, **Scohyer RA**, Carlino MS, Payne MJ, Cheung VTF, Gupta T, Klenerman P, Long GV, Brain O, Menzies AM, Kelleher AD. Mucosal-associated invariant T (MAIT) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy-related colitis in a pathology distinct from ulcerative colitis. *Clin Exp Immunol*. 2020 Dec;202(3):335-352. doi: 10.1111/cei.13502. Epub 2020 Aug 19. PMID: 32734627
121. Tetzlaff MT*, Adhikari C*, Lo S*, Rawson RV, Amaria RN, Menzies AM, Wilmott JS, Ferguson PM, Ross MI, Spillane AJ, Vu KA, Ma J, Ning J, Haydu L, Saw RPM, Wargo JA, Tawbi HA, Gershenwald JE, Long GV#, Davies MA#, **Scohyer RA#** (*Authors contributed equally to this work / #Authors jointly supervised this work). Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma. *Ann Oncol*. 2020 Nov;31(11):1569-1579. doi: 10.1016/j.annonc.2020.07.016. Epub 2020 Jul 31. PMID: 32739408
122. Law MH, Aoude LG, Duffy DL, Long GV, Johansson PA, Pritchard AL, Khosrotehrani K, Mann GJ, Montgomery GW, Iles MM, Cust AE, Palmer JM; Melanoma GWAS Consortium, Shannon KF, Spillane AJ, Stretch JR, Thompson JF, Saw RPM, **Scohyer RA**, Martin NG, Hayward NK, MacGregor S. Multiplex melanoma families are enriched for polygenic risk. *Hum Mol Genet*. 2020 Oct 10;29(17):2976-2985. doi: 10.1093/hmg/ddaa156. PMID: 32716505

123. Grossman D, Okwundu N, Bartlett EK, Marchetti MA, Othus M, Coit DG, Hartman RI, Leachman SA, Berry EG, Korde L, Lee SJ, Bar-Eli M, Berwick M, Bowles T, Buchbinder EI, Burton EM, Chu EY, Curiel-Lewandrowski C, Curtis JA, Daud A, Deacon DC, Ferris LK, Gershenwald JE, Grossmann KF, Hu-Lieskovan S, Hyngstrom J, Jeter JM, Judson-Torres RL, Kendra KL, Kim CC, Kirkwood JM, Lawson DH, Leming PD, Long GV, Marghoob AA, Mehnert JM, Ming ME, Nelson KC, Polsky D, **Scoflyer RA**, Smith EA, Sondak VK, Stark MS, Stein JA, Thompson JA, Thompson JF, Venna SS, Wei ML, Swetter SM. Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit. *JAMA Dermatol*. 2020 Jul 29. doi: 10.1001/jamadermatol.2020.1729. Online ahead of print. PMID: 32725204
124. Georgina V Long and **Richard A Scoflyer**. Translating Basic Cancer Discoveries to the Clinic. Feature Article: A Critical Nexus. *Cancer cell*, 08 June 2020, Vol.37(6), pp.735-737. DOI:https://doi.org/10.1016/j.ccell.2020.05.017. PMID: 32516583
125. Lo SN *, Ma, J *, **Scoflyer RA**, Stretch JR, Saw RPM, Nieweg OE, Shannon KF, Spillane AJ, Ch'ng S, Mann GJ, Gershenwald JE, Thompson JF*, Varey AHR* (* contributed equally). Improved Risk Prediction Calculator for Sentinel Node Positivity in Patients With Melanoma: The Melanoma Institute Australia Nomogram. JF, Varey AHR. *J Clin Oncol*. 2020 Jun 12;JCO1902362. doi: 10.1200/JCO.19.02362. [Epub ahead of print] PMID: 32530761
126. Watts CG, Smith AL, Robinson S, Chang CS, Goumas C, Schmid H, Kelly JW, Hong AM, **Scoflyer RA**, Long GV, Spillane AJ, Henderson M, Gyorki DE, Mar VJ, Morton RL, Saw RP, Varey AH, Mann GJ, Thompson JF, Cust AE. Australian general practitioners' attitudes and knowledge of sentinel lymph node biopsy in melanoma management.. *Aust J Gen Pract*. 2020 Jun;49(6):355-362. doi: 10.31128/AJGP-10-19-5138. PMID: 32464734
127. Harris CG, Lo S, Ahmed T, **Scoflyer RA**, Ferguson PM, Karim RZ, Lam TK, Lee KK, Shannon KF, Spillane AJ, Stretch JR, Thompson JF, Saw RP. Primary dermal melanoma: clinical behaviour, prognosis and treatment. *Eur J Surg Oncol*. 2020 Nov;46(11):2131-2139. doi: 10.1016/j.ejso.2020.04.043. Epub 2020 May 1. PMID: 32417156
128. Johansson PA, Brooks K, Newell F, Palmer JM, Wilmott JS, Pritchard AL, Broit N, Wood S, Carlino MS, Leonard C, Koufariotis LT, Nathan V, Beasley AB, Howlie M, Dawson R, Rizos H, Schmidt CW, Long GV, Hamilton H, Kiilgaard JF, Isaacs T, Gray ES, Rolfe OJ, Park JJ, Stark A, Mann GJ, **Scoflyer RA**, Pearson JV, van Baren N, Waddell N, Wadt KW, McGrath LA, Warrier SK, Glasson W, Hayward NK. Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours. *Nat Commun*. 2020 May 15;11(1):2408. doi: 10.1038/s41467-020-16276-8. PMID: 32415113
129. Ziemys A, Kim M, Menzies AM, Wilmott JS, Long GV, **Scoflyer RA**, Kwong L, Holder A, Boland G. Integration of Digital Pathologic and Transcriptomic Analyses Connects Tumor-Infiltrating Lymphocyte Spatial Density With Clinical Response to BRAF Inhibitors. *Front Oncol*. 2020 May 14;10:757. doi: 10.3389/fonc.2020.00757. eCollection 2020. PMID: 32528881
130. Lepletier A#, Madore J#, O'Donnell JS, Johnston RL, Li XY, McDonald E, Ahern E, Kuchel A, Eastgate M, Pearson SA, Mallardo D, Ascierto PA, Massi D, Merelli B, Mandala M, Wilmott JS, Menzies AM, Leduc C, Stagg J, Routy B, Long GV, **Scoflyer RA**, Bald T, Waddell N, Dougall WC, Teng MWL, Smyth MJ (# authors contributed equally to this work). Tumor CD155 expression is associated with resistance to anti-PD1 immunotherapy in metastatic melanoma. *Clin Cancer Res*. 2020 Jul 15;26(14):3671-3681. doi: 10.1158/1078-0432.CCR-19-3925. Epub 2020 Apr 28. PMID: 32345648
131. Landi MT, Bishop DT, MacGregor S, Machiela MJ, Stratigos AJ, Ghiorzo P, Brossard M, Calista D, Choi J, Fagnoli MC, Zhang T, Rodolfo M, Trower AJ, Menin C, Martinez J, Hadjisavvas A, Song L, Stefanaki I, **Scoflyer R**, Yang R, Goldstein AM, Potrony M, Kypreou KP, Pastorino L, Queirolo P, Pellegrini C, Cattaneo L, Zawistowski M, Gimenez-Xavier P, Rodriguez A, Elefanti L, Manoukian S, Rivoltini L, Smith BH, Loizidou MA, Del Regno L, Massi D, Mandala M, Khosrotehrani K, Akslen LA, Amos CI, Andresen PA, Avril MF, Azizi E, Soyer HP, Bataille V, Dalmasso B, Bowdler LM, Burdon KP, Chen WV, Codd V, Craig JE, Dębniak T, Falchi M, Fang S, Friedman E, Simi S, Galan P, Garcia-Casado Z, Gillanders EM, Gordon S, Green A, Gruis NA, Hansson J, Harland M, Harris J, Helsing P, Henders A, Hočevár M, Höiom V, Hunter D, Ingvar C, Kumar R, Lang J, Lathrop GM, Lee JE, Li X, Lubiński J, Mackie RM, Malt M, Malvey J, McAloney K, Mohamdi H, Molven A, Moses EK, Neale RE, Novaković S, Nyholt DR, Olsson H, Orr N, Fritsche LG, Puig-Butlle JA, Qureshi AA, Radford-Smith GL, Randerson-Moor J, Requena C, Rowe C, Samani NJ, Sanna M, Schadendorf D, Schulze HJ, Simms LA, Smithers M, Song F, Swerdlow AJ, van der Stoep N, Kukutsch NA, Visconti A, Wallace L, Ward SV, Wheeler L, Sturm RA, Hutchinson A, Jones K, Malasky M, Vogt A, Zhou W, Pooley KA, Elder DE, Han J, Hicks B, Hayward NK, Kanetsky PA, Brummett C, Montgomery GW, Olsen CM, Hayward C, Dunning AM, Martin NG, Evangelou E, Mann GJ, Long G, Pharoah PDP, Easton DF, Barrett JH, Cust AE, Abecasis G, Duffy DL, Whiteman DC, Gogas H, De Nicolo A, Tucker MA, Newton-Bishop JA; GenoMEL Consortium; Q-MEGA and QTWIN Investigators; ATHENS Melanoma Study Group; andMe; SDH Study Group; IBD Investigators; Essen-Heidelberg Investigators; AMFS Investigators; MelaNostrum Consortium, Peris K, Chanock SJ, Demenais F, Brown KM, Puig S, Nagore E, Shi J, Iles MM, Law MH. Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility. *Nat Genet*. 2020 Apr 27. doi: 10.1038/s41588-020-0611-8. PMID: 32341527
132. Lee JH, Menzies AM, Carlino MS, McEvoy AC, Sandhu S, Weppler AM, Diefenbach RJ, Dawson SJ, Kefford RF, Millward MJ, Al-Ogaili Z, Tra T, Gray ES, Wong SQ, **Scoflyer RA**, Long GV, Rizos H. Longitudinal monitoring of ctDNA in patients with melanoma and brain metastases treated with immune checkpoint inhibitors. *Clin Cancer Res*. 2020 Aug 1;26(15):4064-4071. doi: 10.1158/1078-0432.CCR-19-3926. Epub 2020 Apr 22. PMID:32321716
133. Jenny Lee, Elena Shklovskaya, Su Yin Lim, Matteo Carlino, Alexander Menzies, Ashleigh Stewart, Bernadette Pedersen, Malama Irvine, Sara Alavi, Jean Yang, Dario Strbenac, Robyn Saw, John Thompson, James Wilmott, **Richard Scoflyer**, Georgina Long, Richard Kefford, and Helen Rizos. Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition. *Nat Commun*. 2020 Apr 20;11(1):1897. doi: 10.1038/s41467-020-15726-7. PMID: 32312968
134. Ipenburg NA, Lo SN, Vilain RE, Holtkamp LHJ, Wilmott JS, Nieweg OE, Thompson JF, **Scoflyer RA**. The prognostic value of tumor mitotic rate in children and adolescents with cutaneous melanoma: A retrospective cohort study. *J Am Acad Dermatol*. 2020 Apr;82(4):910-919. doi: 10.1016/j.jaad.2019.10.065. Epub 2019 Nov 2. PMID:31682859
135. Barnhill R, van Dam PJ, Vermeulen P, Champenois G, Nicolas A, Rawson RV, Wilmott JS, Thompson JF, Long GV, Cassoux N, Roman-Roman S, Busam KJ, **Scoflyer RA**, Lazar AJ, Lugassy C. Replacement and desmoplastic histopathological growth patterns in cutaneous melanoma liver metastases: frequency, characteristics, and robust prognostic value. *J Pathol Clin Res*. 2020 Jul;6(3):195-206. doi: 10.1002/cjp.2.161. Epub 2020 Apr 18. PMID: 32304183
136. Mckelvey KJ; Hudson AL; Prasanna Kumar R; Wilmott JS; Attrill GH; Long GV; **Scoflyer RA**; Clarke SJ; Wheeler HR; Diakos CI; Howell VM; Mckelvey KJ. Temporal and spatial modulation of the tumor and systemic immune response in the murine G1261 glioma model. *PLoS One*. 2020 Apr 2;15(4):e0226444. doi: 10.1371/journal.pone.0226444. eCollection 2020. PMID: 32240177

137. Tsang VHM, McGrath RT, Clifton-Bligh RJ, **Scolyer RA**, Jakrot V, Guminski AD, Long GV, Menzies AM. Response to Letter to the Editor: "Checkpoint Inhibitor-Associated Autoimmune Diabetes is Distinct From Type 1 Diabetes". *J Clin Endocrinol Metab*. 2020 Jun 1;105(6):e2317-8. doi: 10.1210/clinem/dgaa144. PMID: 32188993 (*original article PMID: 31265074*).
138. Pirozyan MR, McGuire HM, Emran AA, Tseng HY, Tiffen JC, Lee JH, Carlino MS, Menzies AM, Long GV, Scolyer RA, Fazekas de St Groth B, Hersey P. Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients. *Front Immunol*. 2020 Mar 10;11:372. doi: 10.3389/fimmu.2020.00372. eCollection 2020. PMID: 32210968
139. Rapport F*, Smith AL*, Cust AE, Mann GJ, Watts CG, Gyorki DE, Henderson M, Hong AM, Kelly JW, Long GV, Mar VJ, Morton RL, Saw RP, **Scolyer RA**, Spillane AJ, Thompson JF, Braithwaite J. (*These authors contributed equally to this work). Identifying challenges to implementation of clinical practice guidelines for sentinel lymph node biopsy in patients with melanoma in Australia: protocol for a mixed methods study. *BMJ Open*. 2020 Feb 27;10(2):e032636. doi: 10.1136/bmjopen-2019-032636. PMID: 32111612
140. Elder DE, Bastian BC, Cree IA, Massi D, **Scolyer RA**. The 2018 World Health Organization Classification of Cutaneous, Mucosal, and Uveal Melanoma: Detailed Analysis of 9 Distinct Subtypes Defined by Their Evolutionary Pathway. *Arch Pathol Lab Med*. 2020 Feb 14. doi: 10.5858/arpa.2019-0561-RA. PMID: 32057276.
141. Niebling MG, Haydu LE, Lo SN, Rawson RV, Lamboo LGE, Stollman JT, Karim RZ, Thompson JF, **Scolyer RA**. The prognostic significance of microsatellites in cutaneous melanoma. *Mod Pathol*. 2020 Jul;33(7):1369-1379. doi: 10.1038/s41379-020-0500-9. Epub 2020 Feb 13. PMID: 32055007
142. Malesu R, Martin AJ, Lyons JG, **Scolyer RA**, Chen AC, McKenzie CA, Madore J, Halliday GM, Damian DL. Nicotinamide for skin cancer chemoprevention: effects of nicotinamide on melanoma in vitro and in vivo. *Photochemical & Photobiological Sciences*. 2020 Feb 19;19(2):171-179. doi: 10.1039/c9pp00388f. PMID: 31942903
143. Haydu LE, Lo SN, McQuade JL, Amaria RN, Wargo J, Ross MI, Cormier JN, Lucci A, Lee JE, Ferguson SD, Saw RPM, Spillane AJ, Shannon KF, Stretch JR, Hwu P, Patel SP, Diab A, Wong MKK, Glitza Oliva IC, Tawbi H, Carlino MS, Menzies AM, Long GV, Lazar AJ, Tetzlaff MT, **Scolyer RA**, Gershenwald JE, Thompson JF, Davies MA. Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. *J Clin Oncol*. 2020 May 1;38(13):1429-1441. doi: 10.1200/JCO.19.01508. Epub 2020 Jan 28. PMID: 31990608
144. Elder, DE, Karakousis G, **Scolyer RA**. Staging for Melanoma - Toward a New Paradigm? *J Natl Cancer Inst*. 2020 Sep 1;112(9):873-874. doi: 10.1093/jnci/djaa009. PMID: 31977050
145. Pruessmann W*, Rytlewski J*, Wilmott J*, Mihm MC Jr, Attrill GH, Dyring-Andersen B, Fields P, Zhan Q, Colebatch AJ, Ferguson PM, Thompson JF, Kallenbach K, Yusko E, Clark RA, Robins H, **Scolyer RA***, Kupper TS*. (*authors contributed equally). Molecular analysis of primary melanoma T cells identifies patients at risk for metastatic recurrence. *Nat Cancer*. 2020 Feb;1(2):197-209. doi: 10.1038/s43018-019-0019-5. Epub 2020 Jan 20. PMID: 33305293
146. Luke JJ, Ascierto PA, Carlino MS, Gershenwald JE, Grob JJ, Hauschild A, Kirkwood JM, Long GV, Mohr P, Robert C, Ross M, Scolyer RA, Yoon CH, Poklepovic A, Rutkowski P, Anderson JR, Ahsan S, Ibrahim N, M Eggermont AM. KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. *Future Oncol*. 2020 Jan;16(3):4429-4438. doi: 10.2217/fon-2019-0666. Epub 2019 Dec 24. PMID: 31870188
147. Jackett LA, **Scolyer RA**. A Review of Key Biological and Molecular Events Underpinning Transformation of Melanocytes to Primary and Metastatic Melanoma. *Cancers (Basel)*. 2019 Dec 17;11(12). pii: E2041. doi: 10.3390/cancers11122041. Review. PMID: 31861163
148. Diefenbach RJ, Lee JH, Strbenac D, Yang JYH, Menzies AM, Carlino MS, Long GV, Spillane AJ, Stretch JR, Saw RPM, Thompson JF, Ch'ng S, **Scolyer RA**, Kefford RF, Rizos H. Analysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic Melanoma. *Cancers (Basel)*. 2019 Nov 29;11(12). pii: E1905. doi: 10.3390/cancers11121905. PMID: 31795494
149. Jackett LA, Colebatch AJ, Rawson RV, Ferguson PM, Thompson JF, McCarthy SW, Wilmott JS, **Scolyer RA**. Molecular Profiling of Noncoding Mutations Distinguishes Nevod Melanomas From Mitotically Active Nevi in Pregnancy. *Am J Surg Pathol*. 2020 Mar;44(3):357-367. doi: 10.1097/PAS.0000000000001406. PMID: 31743128
150. Robert V. Rawson, **Richard A. Scolyer**. From Breslow to BRAF and immunotherapy: evolving concepts in melanoma pathogenesis and disease progression and their implications for changing management over the last 50 years. *Hum Pathol*. 2020 Jan;95:149-160. doi: 10.1016/j.humpath.2019.09.017. Epub 2019 Nov 6. Review. PMID: 31704364
151. House IG, Savas P, Lai J, Chen AXY, Oliver AJ, Teo ZL, Todd KL, Henderson MA, Giuffrida L, Petley EV, Sek K, Mardiana S, Gide TN, Quek C, **Scolyer RA**, Long GV, Wilmott JS, Loi S, Darcy PK, Beavis PA.. Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade. *Clin Cancer Res*. 2020 Jan 15;26(2):487-504. doi: 10.1158/1078-0432.CCR-19-1868. Epub 2019 Oct 21. PMID: 31636098
152. **Scolyer RA**, Rawson RV, Gershenwald JE, Ferguson PM, Prieto VG. Melanoma pathology reporting and staging. *Mod Pathol*. 2020 Jan;33(Suppl 1):15-24. doi: 10.1038/s41379-019-0402-x. Epub 2019 Nov 22. PMID: 31758078
153. Margot Den Hondt*, Matthew Starr*, Michael Millett, Julian Smyth, **Richard A. Scolyer**, Kerwin F. Shannon, John F. Thompson, Sydney Ch'ng (*authors contributed equally). Surgical management of the neck in patients with metastatic melanoma in parotid lymph nodes. *J Surg Oncol*. 2019 Dec;120(8):1462-1469. doi: 10.1002/jso.25732. Epub 2019 Oct 25. PMID: 31650567
154. Diefenbach, RJ; Lee, J.H; Chandler, D; Wang, Y; Pflueger, C; Long, GV; **Scolyer, RA**; Carlino, MS; Menzies, AM; Kefford, RF; Rizos, H. Hypermethylation of circulating free DNA in cutaneous melanoma. *Appl. Sci*. 2019 Nov 25, 9(23), 5074; <https://doi.org/10.3390/app9235074>.
155. Hong AM, Fogarty GB, Dolven-Jacobsen K, Burmeister BH, Lo SN, Haydu LE, Vardy JL, Nowak AK, Dhillon HM, Ahmed T, Shivalingam B, Long GV, Menzies AM, Hruby G, Drummond KJ, Mandel C, Middleton MR, Reisse CH, Paton EJ, Steel V, Williams NC, **Scolyer RA**, Morton RL, Thompson JF. Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III Trial. *J Clin Oncol*. 2019 Nov 20;37(33):3132-3141. doi: 10.1200/JCO.19.01414. Epub 2019 Sep 25. PMID: 31553661.
156. Robinson M, Primiero C, Guitera P, Hong A, **Scolyer RA**, Stretch JR, Strutton G, Thompson JF, Soyer HP. Evidence-Based Clinical Practice Guidelines for the Management of Patients with Lentigo Maligna. *Dermatology*. 2019 Oct 22;1-6. PMID: 31639788
157. Gide TN, Silva IP, Quek C, Ahmed T, Menzies AM, Carlino MS, Saw RPM, Thompson JF, Batten M, Long GV, **Scolyer RA**, Wilmott JS. Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients. *Oncoimmunology*. 2019 Oct 16;9(1):1659093. doi: 10.1080/2162402X.2019.1659093. eCollection 2020. PMID: 32002281

158. **Scohyer RA**, Gershenwald JE, Thompson JF. Isolated Immunohistochemistry-positive Cells Without Morphologic Characteristics of Melanoma Should Not Result in Designation as a Positive Sentinel Lymph Node According to the AJCC 8th Edition Staging System. *Am J Surg Pathol*. 2019 Oct;43(10):1442-1444. doi: 10.1097/PAS.0000000000001326. PMID: 31306154
159. Henderson MA, Gyorki D, Burmeister BH, Ainslie J, Fisher R, Di Iulio J, Smithers BM, Hong A, Shannon K, **Scohyer RA**, Carruthers S, Coventry BJ, Babington S, Duprat J, Hoekstra HJ, Thompson JF. Inguinal and Ilio-inguinal Lymphadenectomy in Management of Palpable Melanoma Lymph Node Metastasis: A Long-Term Prospective Evaluation of Morbidity and Quality of Life. *Ann Surg Oncol*. 2019 Sep 12. PMID: 31515719.
160. Edwards J, Batten M, Ferguson A, Palendira U, Wilmott JS, Long GV, **Scohyer RA**. Novel Immune Targets in Melanoma-Response. *Clin Cancer Res*. 2019 Sep 1;25(17):5424-5425. doi: 10.1158/1078-0432.CCR-19-1866. PMID: 31481485
161. Friedman EB, **Scohyer RA**, Thompson JF. Management of pigmented skin lesions during pregnancy. *Aust J Gen Pract*. 2019 Sep;48(9):621-624. doi: 10.31128/AJGP-04-19-48952. PMID: 31476830
162. Rtshiladze MA, Stretch JR, **Scohyer RA**, Guitera P. Diagnosing melanoma: the method matters. *Med J Aust*. 2019 Sep;211(5):209-210. doi: 10.5694/mja2.50307. Epub 2019 Aug 14. PMID: 31414490
163. Ipenburg NA, Nieweg OE, Ahmed T, van Doorn R, **Scohyer RA**, Long GV, Thompson JF, Lo S. External validation of a prognostic model to predict survival of patients with sentinel node-negative melanoma. *Br J Surg*. 2019 Sep;106(10):1319-1326. doi: 10.1002/bjs.11262. Epub 2019 Jul 16. PMID: 31310333
164. Friedman EB, **Scohyer RA**, Thompson JF. Management of pigmented skin lesions in childhood and adolescence. *Aust J Gen Pract*. 2019 Aug;48(8):539-544. doi: 10.31128/AJGP-04-19-48951. PMID: 31370129
165. Lo SN, Hong AM, Haydu LE, Ahmed T, Paton EJ, Steel V, Hruby G, Tran A, Morton RL, Nowak AK, Vardy JL, Drummond KJ, Dhillon HM, Mandel C, **Scohyer RA**, Middleton MR, Burmeister BH, Thompson JF, Fogarty GB. Whole brain radiotherapy (WBRT) after local treatment of brain metastases in melanoma patients: Statistical Analysis Plan. *Trials*. 2019 Aug 5;20(1):477. doi: 10.1186/s13063-019-3555-5. PMID: 31382986
166. Colebatch AJ, Ferguson P, Newell F, Kazakoff SH, Witkowski T, Dobrovic A, Johansson PA, Saw RP, Stretch JR, McArthur GA, Long GV, Thompson JF, Pearson JV, Mann GJ, Hayward NK, Waddell N, **Scohyer RA**, Wilmott JS. Molecular genomic Profiling of Melanocytic Nevi. *J Invest Dermatol*. 2019 Aug;139(8):1762-1768. doi: 10.1016/j.jid.2018.12.033. Epub 2019 Feb 14. PMID: 30772300
167. Rozeman EA, Menzies AM, van Akkooi ACJ, Adhikari C, Bierman C, van de Wiel BA, **Scohyer RA**, Krijgsman O, Sikorska K, Eriksson H, Broeks A, van Thienen JV, Guminski AD, Acosta AT, Ter Meulen S, Koenen AM, Bosch LJW, Shannon K, Pronk LM, Gonzalez M, Ch'ng S, Grijpink-Ongering LG, Stretch J, Heijmink S, van Tinteren H, Haanen JBAG, Nieweg OE, Klop WMC, Zuur CL, Saw RPM, van Houdt WJ, Peeper DS, Spillane AJ, Hansson J, Schumacher TN, Long GV, Blank CU. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. *Lancet Oncol*. 2019 Jul;20(7):948-960. doi: 10.1016/S1470-2045(19)30151-2. Epub 2019 May 31. PMID: 31160251
168. Long GV, Saw RPM, Lo S, Nieweg OE, Shannon KF, Gonzalez M, Guminski A, Lee JH, Lee H, Ferguson PM, Rawson RV, Wilmott JS, Thompson JF, Kefford RF, Ch'ng S, Stretch JR, Emmett L, Kapoor R, Rizos H, Spillane AJ, **Scohyer RA**, Menzies AM. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF^{V600} mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. *Lancet Oncol*. 2019 Jul;20(7):961-971. doi: 10.1016/S1470-2045(19)30331-6. Epub 2019 Jun 3. PMID: 31171444
169. Amaria RN*, Menzies AM*, Burton EM*, **Scohyer RA***, Tetzlaff MT*, Antdbacka R, Ariyan C, Basset R, Carter B, Daud A, Faries M, Fecher LA, Flaherty K, Gershenwald JE, Hamid O, Hong A, Kirkwood J, Lo S, Margolin K, Messina J, Postow M, Rizos H, Ross MI, Rozeman EA, Saw RPM, Sondak V, Sullivan RJ, Taube JM, Thompson JF, van de Wiel BA, Eggermont AM, Davies MA, The International Neoadjuvant Melanoma Consortium members, Ascierto PA ‡, Spillane AS ‡, van Akkooi ACJ ‡, Wargo JA ‡, Blank CU ‡, Tawbi HA ‡, Long GV ‡. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. **Contributed equally/ ‡Contributed equally*. *Lancet Oncol*. 2019 Jul;20(7):e378-e389. doi: 10.1016/S1470-2045(19)30332-8. Review. PMID: 31267972
170. Newell F, Kong Y, Wilmott JS, Johansson PA, Ferguson PM, Cui C, Li Z, Kazakoff SH, Burke H, Dodds TJ, Patch AM, Nones K, Tembe V, Shang P, van der Weyden L, Wong K, Holmes O, Lo S, Leonard C, Wood S, Xu Q, Rawson RV, Mukhopadhyay P, Dummer R, Levesque MP, Jönsson G, Wang X, Yeh I, Wu H, Joseph N, Bastian BC, Long GV, Spillane AJ, Shannon KF, Thompson JF, Saw RPM, Adams DJ, Si L, Pearson JV, Hayward NK, Waddell N, Mann GJ, Guo J, **Scohyer RA**. Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. *Nat Commun*. 2019 Jul 18;10(1):3163. PMID: 31320640
171. Tsang VHM, McGrath RT, Clifton-Bligh RJ, **Scohyer RA**, Jakrot V, Guminski AD, Long GV, Menzies AM. Checkpoint Inhibitor-Associated Autoimmune Diabetes is Distinct From Type 1 Diabetes. *Clin Endocrinol Metab*. 2019 Jul 2. pii: jc.2019-00423. PMID: 31265074
172. Guo D, Lui GYL, Lai SL, Wilmott JS, Tikoo S, Jackett LA, Quek C, Brown DL, Sharp DM, Kwan RYQ, Chacon D, Wong JH, Beck D, van Geldermalsen M, Holst J, Thompson JF, Mann GJ, **Scohyer RA**, Stow JL, Weninger W, Haass NK, Beaumont KA. RAB27A promotes melanoma cell invasion and metastasis via regulation of pro-invasive exosomes. *Int J Cancer*. 2019 Jun 15;144(12):3070-3085. doi: 10.1002/ijc.32064. Epub 2019 Jan 3. PMID: 30556600
173. **Scohyer RA**, Soyer HP, Kelly JW, James C, McLean CA, Coventry BJ, Ferguson PM, Rawson RV, Mar VJ, de Menezes SL, Fisburn P, Stretch JR, Lee S, Thompson JF, on behalf of the Australian Melanoma Clinical Practice Guidelines Working Party. Improving diagnostic accuracy for suspicious melanocytic skin lesions: New Australian melanoma clinical practice guidelines stress the importance of clinician/pathologist communication. *Aust J Gen Pract*. 2019 Jun;48(6):357-362. doi: 10.31128/AJGP-11-18-4759. PMID: 31220881
174. Edwards J, Tasker A, Pires da Silva I, Quek C, Batten M, Ferguson A, Allen R, Allanson B, Saw RPM, Thompson JF, Menzies AM, Palendira U, Wilmott JS, Long GV, **Scohyer RA**. Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials. *Clin Cancer Res*. 2019 Jun 1;25(11):3247-3258. doi: 10.1158/1078-0432.CCR-18-4011. Epub 2019 Feb 18. PMID: 30777877
175. Lee JH, Robyn, Saw PPM, Thompson JF, Lo S, Spillane AJ, Shannon KF, Stretch J, Howle J, Menzies AM, Carlino MS, Kefford RF, Long GV, **Scohyer RA**, Rizos H. Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients. *Ann Oncol*. 2019 May;30(5):815-822. doi: 10.1093/annonc/mdz075. Epub 2019 Dec 4. PMID: 30860590 & 31987349
176. Haydu L, Thompson J, **Scohyer RA**, Gershenwald J. Embracing changes to the American Joint Committee on Cancer 8th edition melanoma staging system. *Eur J Cancer*. 2019 May;112:9-11. doi: 10.1016/j.ejca.2019.01.103. Epub 2019 Mar 15. PMID: 30884440

177. Gide TN, Allanson BM, Menzies AM, Ferguson PM, Madore J, Saw RPM, Thompson JF, Long GV, Wilmott JS, **Scoflyer RA**. Inter- and intra-patient heterogeneity of indoleamine 2,3-dioxygenase expression in primary and metastatic melanoma cells and the tumour microenvironment. *Histopathology*. 2019 May;74(6):817-828. doi: 10.1111/his.13814. PMID: 30589949
178. Guitera P, Collgros H, Madronio CM, Goumas C, Mann GJ, Watts CG, Pereira AR, Armstrong BK, Drummond M, Morton RL, **Scoflyer RA**, Menzies SW, Thompson JF, Cust AE. The steadily growing problem of lentigo maligna and lentigo maligna melanoma in Australia: Population-based data on diagnosis and management. *Australas J Dermatol*. 2019 May;60(2):118-125. doi: 10.1111/ajd.12928. Epub 2018 Oct 9. PMID:30302753
179. Thompson JF, Lo S, **Scoflyer RA**. Quality of Life Following Surgical Excision of Early-Stage Melanoma of the Head and Neck. *JAMA Dermatol*. 2019 Apr 1;155(4):502. doi: 10.1001/jamadermatol.2018.5742. PMID:30758490
180. Ding LW, Sun QY, Edwards JJ, Fernandez LT, Ran XB, Zhou SQ, **Scoflyer RA**, Wilmott JS, Thompson JF, Doan N, Said JW, Venkatachalam N, Xiao JF, Loh XY, Pein M, Xu L, Mullins DW, Yang H, Lin DC, Koeffler HP. LNK suppresses interferon signaling in melanoma. *Nat Commun*. 2019 May 20;10(1):2230. PMID: 31110180
181. Menzies SW, Liyanarachchi S, Coates E, Smith A, Cooke-Yarborough C, Lo S, Armstrong B, **Scoflyer RA**, Guitera P. Estimated risk of progression of lentigo maligna to lentigo maligna melanoma. *Melanoma Res*. 2020 Apr;30(2):193-197. doi: 10.1097/CMR.0000000000000619. PMID:31095041
182. Mittal D, Lepletier A, Madore J, Aguilera AR, Stannard K, Blake SJ, Whitehall VLJ, Liu C, Bettington ML, Takeda K, Long GV, **Scoflyer RA**, Lan R, Siemers N, Korman A, Teng MWL, Johnston RJ, Dougall WC, Smyth MJ. CD96 Is an Immune Checkpoint That Regulates CD8⁺ T-cell Antitumor Function. *Cancer Immunol Res*. 2019 Apr;7(4):559-571. doi: 10.1158/2326-6066.CIR-18-0637. Epub 2019 Mar 20. PMID: 30894377
183. Hong AM, Ferguson P, Dodds T, Jones D, Li M, Yang J, **Scoflyer RA**. Significant association of PD-L1 expression with human papillomavirus positivity and its prognostic impact in oropharyngeal cancer. *Oral Oncol*. 2019 May;92:33-39. doi: 10.1016/j.oraloncology.2019.03.012. Epub 2019 Mar 18. PMID: 31010620.
184. Qutob N, Masuho I, Alon M, Emmanuel R, Cohen I, Di Pizio A, Madore J, Elkahouloun A, Ziv T, Levy R, Gartner JJ, Hill VK, Lin JC, Hevroni Y, Greenberg P, Brodezi A, Rosenberg SA, Kosloff M, Hayward NK, Admon A, Niv MY, **Scoflyer RA**, Martemyanov KA, Samuels Y. Author Correction: RGS7 is recurrently mutated in melanoma and promotes migration and invasion of human cancer cells. *Sci Rep*. 2019 Mar 9;9(1):4523. doi: 10.1038/s41598-018-37932-6. PMID: 30850615
185. Gide TN, Quek C, Menzies AM, Tasker AT, Shang P, Holst J, Madore J, Lim SY, Velickovic R, Wongchenko M, Yan Y, Lo S, Carlino MS, Guminski A, Saw RPM, Pang A, McGuire HM, Palendira U, Thompson JF, Rizos H, Silva IPD, Batten M, **Scoflyer RA***, Long GV*, Wilmott JS* (*joint senior/last authors - contributed equally to this work). Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. *Cancer Cell*. 2019 Feb 11;35(2):238-255.e6. doi: 10.1016/j.ccell.2019.01.003. PMID: 30753825
186. Park SL, Buzzai A, Rautela J, Hor JL, Hochheiser K, Efferm M, McBain N, Wagner T, Edwards J, McConville R, Wilmott JS, **Scoflyer RA**, Tuting T, Palendira U, Gyorki D, Mueller SN, Huntington ND, Bedoui S, Holzel M, Mackay LK, Waithman J, Gebhardt T. Author Correction: Tissue-resident memory CD8(+) T cells promote melanoma-immune equilibrium in skin. *Nature*. 2019 Feb;566(7745):E10. doi: 10.1038/s41586-019-0958-0. PMID: 30742076
187. Friedman EB, Moncrieff MD, Lo S, **Scoflyer RA**, Thompson JF. Sentinel lymph node biopsy remains the most accurate method of obtaining staging and prognostic information for patients with primary cutaneous melanomas. *Australas J Dermatol*. 2019 Feb;60(1):75-76. doi: 10.1111/ajd.12942. Epub 2018 Oct 7. No abstract available. PMID: 30294907
188. Dodds TJ, Wilmott JS, Jakkett LA, Lo SN, Long GV, Thompson JF, **Scoflyer RA**. Primary anorectal melanoma: clinical, immunohistology and DNA analysis of 43 cases. *Pathology*. 2019 Jan. PMID: 30497801
189. Quek C, Rawson RV, Ferguson PM, Shang P, Silva I, Saw RPM, Shannon K, Thompson JF, Hayward NK, Long GV, Mann GJ, **Scoflyer RA**, Wilmott JS. Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas. *Oncotarget*. 2019 Jan 29;10(9):930-941. doi: 10.18632/oncotarget.26584. eCollection 2019 Jan 29. PMID: 30847022
190. Zhao X, Little P, Hoyle AP, Pegna GJ, Hayward MC, Ivanova A, Parker JS, Marron DL, Soloway MG, Jo H, Salazar AH, Papakonstantinou MP, Bouchard DM, Jefferys SR, Hoadley KA, Ollila DW, Frank JS, Thomas NE, Googe PB, Ezzell AJ, Collichio FA, Lee CB, Earp HS, Sharpless NE, Hugo W, Wilmott JS, Quek C, Waddell N, Johansson PA, Thompson JF, Hayward NK, Mann GJ, Lo RS, Johnson DB, **Scoflyer RA**, Hayes DN, Moschos SJ. The Prognostic Significance of Low-Frequency Somatic Mutations in Metastatic Cutaneous Melanoma. *Front Oncol*. 2019 Jan 4;8:584. doi: 10.3389/fonc.2018.00584. eCollection 2018. PMID: 30662871
191. Dessinioti C, Dimou N, Geller AC, Stergiopoulou A, Lo S, Keim J, Gershenwald JE, Haydu LE, Ribero S, Quaglino P, Puig S, Malvehy J, Kandolf-Sekulovic L, Radevic T, Kaufmann R, Meister L, Nagore E, Traves V, Champsas GG, Plaka M, Dreno B, Valey E, Ramirez DM, Dummer R, Mangana J, Hauschild A, Egberts F, Peris K, Del Regno L, Forsea AM, Zurac SA, Vieira R, Brinca A, Zalaudek I, Deinlein T, Linos E, Evangelou E, Thompson JF, **Scoflyer RA**, Garbe C, Stratigos AJ. Distinct clinicopathological and prognostic features of thin nodular primary melanomas: an international study from 17 centers. *J Natl Cancer Inst*. 2019 Dec 1;111(12):1314-1322. doi: 10.1093/jnci/djz034. PMID:30863861
192. Chakera AH, Quinn MJ, Lo S, Drummond M, Haydu LE, Bond JS, Stretch JR, Saw RPM, Lee KJ, McCarthy WH, **Scoflyer RA**, Thompson JF. Subungual Melanoma of the Hand. *Ann Surg Oncol*. 2018. PMID: 30565042
193. Lee H, Quek C, Silva I, Tasker A, Batten M, Rizos H, Lim SY, Nur Gide T, Shang P, Attrill GH, Madore J, Edwards J, Carlino MS, Guminski A, Saw RPM, Thompson JF, Ferguson PM, Palendira U, Menzies AM, Long GV, **Scoflyer RA**, Wilmott JS. Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients. *Oncoimmunology*. 2018 Oct 31;8(2):e1537581. doi: 10.1080/2162402X.2018.1537581. eCollection 2019. PMID: 30713793
194. Pires da Silva I, Wang KYX, Wilmott JS, Holst J, Carlino MS, Park JJ, Quek C, Wongchenko M, Yan Y, Mann G, Johnson DB, McQuade JL, Rai R, Kefford RF, Rizos H, **Scoflyer RA**, Yang JYH, Long GV, Menzies AM. Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K *<i>BRAF</i>*-Mutant Melanoma. *Clin Cancer Res*. 2019 Feb 15;25(4):1272-1279. doi: 10.1158/1078-0432.CCR-18-1680. Epub 2019 Jan 10. PMID: 30630828
195. Minocha R, Martin AJ, Chen AC, **Scoflyer RA**, Lyons JG, McKenzie CA, Madore J, Halliday GM, Damian DL. A reduction in inflammatory macrophages may contribute to skin cancer chemoprevention by nicotinamide. *J J Invest Dermatol*. 2019 Feb;139(2):467-469. doi: 10.1016/j.jid.2018.08.018. Epub 2018 Sep 20. PMID: 30244097

196. Lo SN, Stodell M, **Scohyer RA**, Thompson JF. Comment on “Prognostic value of sentinel lymph node biopsy according to Breslow thickness for cutaneous melanoma”. *J Am Acad Dermatol*. 2019 Jan;80(1):e21-e22. doi: 10.1016/j.jaad.2018.07.068. Epub 2018 Sep 15. PMID: 30227195
197. Wang KYX, Menzies AM, Silva IP, Wilmott JS, Yan Y, Wongchenko M, Kefford RF, **Scohyer RA**, Long GV, Tarr G, Mueller S, Yang JYH. bcGST - an interactive bias-correction method to identify over-represented gene-sets in boutique arrays. *Bioinformatics*. 2019 Apr 15;35(8):1350-1357. doi: 10.1093/bioinformatics/bty783. PMID: 30215668
198. Friedman EB, Dodds TJ, Lo S, Ferguson PM, Beck M, Saw RPM, Stretch JR, Lee KK, Nieweg OE, Spillane AJ, **Scohyer RA**, Thompson JF. Correlation Between Surgical and Histologic Margins in Melanoma Wide Excision Specimens. *Ann Surg Oncol*. 2019 Jan;26(1):25-32. doi: 10.1245/s10434-018-6858-y. Epub 2018 Oct 16. PMID: 30327975
199. Wilmott JS; Johansson PA; Newell F; Waddell N; Ferguson P; Quek C; Patch A-M; Nones K; Shang P; Pritchard AL; Kazakoff S; Holmes O; Leonard C; Wood S; Xu Q; Saw RPM; Spillane AJ; Stretch JR; Shannon KF; Kefford RF; Menzies AM; Long GV; Thompson JF; Pearson JV; Mann GJ; Hayward NK; Scohyer RA. Whole genome sequencing of melanomas in adolescent and young adults reveals distinct mutation landscapes and the potential role of germline variants in disease susceptibility. *Int J Cancer*. 2019 Mar 1;144(5):1049-1060. doi: 10.1002/ijc.31791. Epub 2018 Nov 21. PMID: 30178487
200. Vargas AC, Selinger C, Satgunaseelan L, Cooper WA, Gupta R, Stalley P, Brown W, Soper J, Schatz J, Boyle R, Thomas DM, Tattersall MH, Bhadri V, Maclean F, Bonar SF, **Scohyer RA**, Karim RZ, McCarthy SW, Mahar A, O'Toole SA. FISH analysis of selected soft tissue tumors: Diagnostic experience in a tertiary center. *Asia Pac J Clin Oncol*. 2019 Feb;15(1):38-47. doi: 10.1111/ajco.12980. Epub 2018 May 28. PMID: 29806089
201. Park SL, Buzzai A, Rautela J, Hor JL, Hochheiser K, Efferm M, McBain N, Wagner T, Edwards J, McConville R, Wilmott JS, **Scohyer RA**, Tuting T, Palendira U, Gyorki D, Mueller SN, Huntington ND, Bedoui S, Holzel M, Mackay LK, Waithman J, Gebhardt T. Tissue-resident memory CD8(+) T cells promote melanoma-immune equilibrium in skin. *Nature*. 2019 Jan;565(7739):366-371. doi: 10.1038/s41586-018-0812-9. Epub 2018 Dec 31. Erratum in: *Nature*. 2019 Feb;566(7745):E10. PMID: 30598548
202. Thompson JF, **Scohyer RA**, Lo SN. ASO Author Reflections: Long-Term Survival of Patients with Thin (T1) Cutaneous Melanomas. *Ann Surg Oncol*. 2018 Dec;25(Suppl 3):918-919. doi: 10.1245/s10434-018-7014-4. Epub 2018 Nov 9. PMID: 30414034
203. Edwards J, Wilmott JS, Madore J, Gide TN, Quek C, Tasker A, Ferguson A, Chen J, Hewaviseni R, Hersey P, Gebhardt T, Weninger W, Britton WJ, Saw RPM, Thompson JF, Menzies AM, Long GV, **Scohyer RA**, Palendira U. CD103⁺ Tumor-Resident CD8⁺ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti-PD-1 Treatment. *Clin Cancer Res*. 2018 Jul 1;24(13):3036-3045. doi: 10.1158/1078-0432.CCR-17-2257. Epub 2018 Mar 29. PMID: 29599411
204. Griewank KG, Koelsche C, van de Nes JAP, Schrimpf D, Gessi M, Möller I, Sucker A, **Scohyer RA**, Buckland ME, Murali R, Pietsch T, von Deimling A, Schadendorf D. Integrated Genomic Classification of Melanocytic Tumors of the Central Nervous System Using Mutation Analysis, Copy Number Alterations, and DNA Methylation Profiling. *Clin Cancer Res*. 2018 Sep 15;24(18):4494-4504. Epub 2018 Jun 11. PMID: 29891723
205. Isaksson K, Nielsen K, Mikiver R, Nieweg OE, **Scohyer RA**, Thompson JF, Ingvar C. Sentinel lymph node biopsy in patients with thin melanomas: Frequency and predictors of metastasis based on analysis of two large international cohorts. *J Surg Oncol*. 2018 Sep;118(4):599-605. doi: 10.1002/jso.25208. Epub 2018 Sep 9. PMID: 30196533
206. Tetzlaff MT, Messina JL, Stein JE, Xu X, Amaria RN, Blank CU, van de Wiel BA, Ferguson PM, Rawson RV, Ross MI, Spillane AJ, Gershenwald JE, Saw RPM, van Akkooi ACJ, van Houdt WJ, Mitchell TC, Menzies AM, Long GV, Wargo JA, Davies MA, Prieto VG, Taube JM, **Scohyer RA**. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. *Ann Oncol*. 2018 Aug 1;29(8):1861-1868. doi: 10.1093/annonc/mdy226. PMID: 29945191
207. Strub T, Ghiraldini FG, Carcamo S, Li M, Wroblewska A, Singh R, et al. SIRT6 haploinsufficiency induces BRAF(V600E) melanoma cell resistance to MAPK inhibitors via IGF signalling. *Nat Commun*. 2018 Aug 24;9(1):3440. doi: 10.1038/s41467-018-05966-z. PMID: 30143629
208. Christoph Krisp, Robert Parker, Dana Pascovici, Nicholas K. Hayward, James S. Wilmott, John F. Thompson, Graham J. Mann, Georgina V. Long, **Richard A. Scohyer** and Mark P. Molloy. Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis. *Br J Cancer*. 2018 Sep;119(6):713-723. doi: 10.1038/s41416-018-0227-2. Epub 2018 Aug 17. PMID: 30116025
209. Salomon MP, Orozco JIJ, Wilmott JS, Hothi P, Manughian-Peter AO, Cobbs CS, **Scohyer RA**, Hoon DSB, Marzese DM. Brain metastasis DNA methylomes, a novel resource for the identification of biological and clinical features. *Sci Data*. 2018 Nov 6;5:180245. doi: 10.1038/sdata.2018.245. PMID: 30398472
210. Allanson BM, Weber MA, Jackett LA, Chan C, Lau L, Ziegler DS, Warby M, Mayoh C, Cowley MJ, Tucker KM, Long GV, Maher A, Anazodo A, **Scohyer RA**. Oral malignant gastrointestinal neuroectodermal tumour with junctional component mimicking mucosal melanoma. *Pathology*. 2018 Oct;50(6):648-653. doi: 10.1016/j.pathol.2018.07.002. Epub 2018 Aug 31. PMID: 30177220
211. Orozco JIJ, Knijnenburg TA, Manughian-Peter AO, Salomon MP, Barkhoudarian G, Jalas JR, Wilmott JS, Hothi P, Wang X, Takasumi Y, Buckland ME, Thompson JF, Long GV, Cobbs CS, Shmulevich I, Kelly DF, **Scohyer RA**, Hoon DSB, Marzese DM. Epigenetic profiling for the molecular classification of metastatic brain tumors. *Nat Commun*. 2018 Nov 6;9(1):4627. doi: 10.1038/s41467-018-06715-y. PMID: 30401823
212. Thompson JF, **Scohyer RA**, Lo SN. ASO Author Reflections: Long-Term Survival of Patients with Thin (T1) Cutaneous Melanomas. *Ann Surg Oncol*. 2018 Dec;25(Suppl 3):918-919. doi: 10.1245/s10434-018-7014-4. Epub 2018 Nov 9. PMID: 30414034
213. Gershenwald JE, **Scohyer RA**. Correction to: Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond. *Ann Surg Oncol*. 2018 Dec;25(Suppl 3):993-994. doi: 10.1245/s10434-018-6689-x. PMID: 30105437
214. Cai H, Cho EA, Li Y, Sockler J, Parish CR, Chong BH, Edwards J, Dodds TJ, Ferguson PM, Wilmott JS, **Scohyer RA**, Halliday GM, Khachigian LM. Melanoma protective antitumor immunity activated by catalytic DNA. *Oncogene*. 2018 Sep;37(37):5115-5126. doi: 10.1038/s41388-018-0306-0. Epub 2018 May 29. PMID: 29844573
215. Lo SN, **Scohyer RA**, Thompson JF. Long-Term Survival of Patients with Thin (T1) Cutaneous Melanomas: A Breslow Thickness Cut Point of 0.8 mm Separates Higher-Risk and Lower-Risk Tumors. *Ann Surg Oncol*. 2018 Apr;25(4):894-902. doi: 10.1245/s10434-017-6325-1. Epub 2018 Jan 12. PMID: 29330716
216. Ferguson PM, Gershenwald JE, **Scohyer RA**. Staging of Cutaneous Melanoma: Is There Room for Further Improvement? *JAMA Netw Open*. 2018 May 18;1(1):e180086. PMID: 30646045

217. Dodds TJ, Lo S, Jackett L, Nieweg O, Thompson JF, **Scoflyer RA**. Prognostic Significance of Periadnexal Extension in Cutaneous Melanoma and its Implications for Pathologic Reporting and Staging. *Am J Surg Pathol*. 2018 Mar;42(3):359-366. PMID: 29240580
218. Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, Edwards J, Gonzalez M, **Scoflyer RA**, Menzies A, McArthur G. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. *Lancet Oncol*. 2018 May;19(5):672-681. doi: 10.1016/S1470-2045(18)30139-6. Epub 2018 Mar 27. PMID: 29602646
219. Lee JH, Long GV, Menzies AM, Lo S, Guminski A, Whitbourne K, Peranec M, **Scoflyer R**, Kefford RF, Rizos H, Carlino MS. Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies. *JAMA Oncol*. 2018 May 1;4(5):717-721. doi: 10.1001/jamaoncol.2017.5332. PMID: 29423503
220. Gershenwald JE, **Scoflyer RA**. Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond. *Ann Surg Oncol*. 2018 Aug;25(8):2105-2110. doi: 10.1245/s10434-018-6513-7. Epub 2018 May 30. PMID: 29850954
221. Bell KJL, Cust AE, **Scoflyer RA**. The Importance of Population-Based Estimates of Melanocytic Pathology. *JAMA Dermatol*. 2018 Jan 1;154(1):15-17. doi: 10.1001/jamadermatol.2017.4061. PMID: 29094157
222. Lee M, Teber ET, Holmes O, Nones K, Patch A, Dagg R, Lau L, Lee J, Napier C, Arthur J, Grimmond S, Hayward N, Johansson P, Mann GJ, **Scoflyer RA**, Wilmott JS, Reddel R, Pearson J, Waddell N, Pickett H. Telomere sequence content can be used to determine ALT activity in tumours. *Nucleic Acids Res*. 2018 June PMID: 29718321
223. Lim SY, Lee JH, Gide TN, Menzies AM, Guminski A, Carlino MS, Breen EJ, Yang JYH, Ghazanfar S, Kefford RF, **Scoflyer RA**, Long GV, Rizos H. Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy. *Clin Cancer Res*. 2019 Mar 1;25(5):1557-1563. doi: 10.1158/1078-0432.CCR-18-2795. Epub 2018 Nov 8. PMID: 30409824
224. Qutob N, Masuho I, Alon M, Emmanuel R, Cohen I, Di Pizio A, Madore J, Elkhouloun A, Ziv T, Levy R, Gartner JJ, Hill VK, Lin JC, Hevroni Y, Greenberg P, Brodezi A, Rosenberg SA, Kosloff M, Hayward NK, Admon A, Niv MY, **Scoflyer RA**, Martemyanov KA, Samuels Y. RGS7 is recurrently mutated in melanoma and promotes migration and invasion of human cancer cells. *Sci Rep*. 2018 Jan PMID: 29330521
225. Lim SY, Lee JH, Welsh SJ, Ahn SB, Breen E, Khan A, Carlino MS, Menzies AM, Kefford RF, **Scoflyer RA**, Long GV, Rizos H. Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients. *Biomark Res*. 2017 Nov 10;5:32. doi: 10.1186/s40364-017-0112-9. eCollection 2017. PMID: 29152306
226. Guitera P, Star P, Goodwin A, Kapoor R, Conway RM, Long GV, **Scoflyer RA**, et al. Germline BAP1-positive patients: the dilemmas of cancer surveillance and a proposed interdisciplinary consensus monitoring strategy. *Eur J Cancer*. 2018 Mar;92:48-53. doi: 10.1016/j.ejca.2017.12.022. Epub 2018 Feb 3. PMID: 29413689
227. Sykes EK, McDonald CE, Ghazanfar S, Mactier S, Thompson JF, **Scoflyer RA**, Yang JY, Mann GJ, Christopherson RI. A 14-Protein Signature for Rapid Identification of Poor Prognosis Stage III Metastatic Melanoma. *Proteomics Clin Appl*. 2018 May;12. Epub 2018 Jan 19. PMID: 29227041
228. Haydu LE, **Scoflyer RA**, Thompson JF. Conditional survival estimates for cancer patients. *Oncotarget*. 2017 Oct 4;8(49):84639-84640. doi: 10.18632/oncotarget.21497. eCollection 2017 Oct 17. PMID: 29156671
229. Holtkamp LHJ, Wang S, Wilmott JS, Madore J, Vilain R, Thompson JF, Nieweg OE, **Scoflyer RA**. Reply to comment on: Detailed Pathological Examination of Completion Node Dissection Specimens and Outcome in Melanoma Patients with Minimal (< 0.1 mm) Sentinel Lymph Node Metastases. *Ann Surg Oncol*. 2017 Dec;24(Suppl 3):660. doi: 10.1245/s10434-017-6170-2. Epub 2017 Oct 27. PMID: 29079922
230. Ferguson P, Long GV, **Scoflyer RA**, Thompson J. The impact of genomics on the surgical management of melanoma. *Br J Surg*. 2018 Jan;105(2):e31-e47. doi: 10.1002/bjs.10751 PMID: 29341162
231. Cooper WA, Barnet M, Kao SC, **Scoflyer RA**. Biomarkers that predict response to immunotherapy – no magic bullet. *Cancer Forum*, Apr 2018, Vol.42(1), p.92-101. See *USyd library*. (Not in PubMed)
232. Nur Gide T, Wilmott J, **Scoflyer RA**, Long GV. Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma. *Clinical Cancer Research Clin Cancer Res*. 2018 Mar 15;24(6):1260-1270. doi: 10.1158/1078-0432.CCR-17-2267. Epub 2017 Nov 10. Review. PMID: 29127120
233. Solinas A, Mahar A, Cooper W, Thompson J, Spillane A, **Scoflyer RA**. Pigmented Paget's disease of the nipple mistaken for melanoma in situ: a diagnostic pitfall for the unwary. *Pathology*. 2018 Apr;50(3):364-367. doi: 10.1016/j.pathol.2017.09.018. Epub 2018 Mar 1. PMID: 29490872
234. Colebatch A, **Scoflyer RA**. Trajectories of premalignancy during the journey from melanocyte to melanoma. *Pathology Sep 2017* PMID: 29132722
235. Wang JY, Liu GZ, Wilmott J, La T, Feng YC, Yari H, Yan XG, Thorne R, Scoflyer RA, Zhang XD, Jin L. Skp2-Mediated Stabilization of MTH1 to promotes survival of melanoma cells upon oxidative stress. *Cancer Res*. 2017 Nov 15;77(22):6226-6239. doi: 10.1158/0008-5472.CAN-17-1965. Epub 2017 Sep 25. PMID: 28947420
236. Kakavand H, Rawson RV, Pupo GM, Yang JYH, Menzies AM, Carlino MS, Kefford RF, Julie Howle JR, Saw R, Thompson JF, Wilmott JS, Long GV, **Scoflyer RA**, Rizos H. PD-L1 expression and immune escape in melanoma resistance to MAPK inhibitors. *Clin Cancer Res*. 2017 Oct 15;23(20):6054-6061. doi: 10.1158/1078-0432.CCR-16-1688. Epub 2017 Jul 19. PMID: 28724663
237. Glodde N, Bald T, Boorn-Konijnenberg D, Nakamura K, O'Donnell J, Szczepanski S, Brandes M, Eickhoff S, Das I, Shridhar N, Hinze D, Rogava M, Van der Sluis T, Ruotsalainen J, Gaffal E, Landsberg J, Ludwig K, Wilhelm C, Riek-Burchardt M, Müller A, Gebhardt C, **Scoflyer RA**, Long G, Janzen V, Teng M, Kastenmüller W, Mazzzone M, Smyth M, Tüting T, Hölzel M. Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy. *Immunity*. 2017 Oct 17;47(4):789-802.e9. doi: 10.1016/j.immuni.2017.09.012. PMID: 29045907
238. Eroglu Z, Zaretsky JM, Hu-Lieskovan S, Won Kim D, Algazi A, Johnson DB, Liniker E, Kong B, Munhoz R, Rapisuwon S, Gherardini PF, Chmielowski B, Wang X, Shintaku P, Wei C, Sosman JA, Joseph R, Postow MA, Carlino MS, Hwu W-J, **Scoflyer RA**, Messina J, Cochran AJ, Long GV, Ribas A. High response rate to PD-1 blockade in desmoplastic melanomas. *Nature* 2018 Jan 18;553(7688):347-350. doi: 10.1038/nature25187. Epub 2018 Jan 10. PMID: 29320474
239. Grogan J, Cooper C, Dodds T, Guitera P, Menzies A, **Scoflyer RA**. Punch "scoring": a technique that facilitates melanoma diagnosis of clinically suspicious pigmented lesions *Histopathology* 2017 Aug PMID: 28796900
240. Rawson RV, Watson GF, Maher AM, McCarthy SW, Thompson JF, **Scoflyer RA**. Germline BAP1 mutations also predispose to cutaneous squamous cell carcinoma. *Pathology*. 2017 Aug;49(5):539-542. doi: 10.1016/j.pathol.2017.03.005. Epub 2017 Jul 8. PMID: 28693747
241. Gershenwald JE*, **Scoflyer RA***, Hess KR*, Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM, McArthur GA, Haydu LE, Eggermont AM, Flaherty KT, Balch CM, Thompson JF (*joint first authors=contributed equally to this work). Melanoma staging:

- Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. *CA Cancer Journal for Clinicians* 2017 Nov;67(6):472-492. doi: 10.3322/caac.21409. Epub 2017 Oct 13. PMID: 29028110.
242. Wilmott JS, Hayward NK, Mann GJ, **Scoflyer RA**. Advantages of whole-genome sequencing for identification of tumor etiology and clinically actionable genomic aberrations: lessons from the Australian Melanoma Genome Project. *Melanoma Manag*. 2017 Sep;4(3):147-149. doi: 10.2217/mmt-2017-0008. Epub 2017 Jul 26. PMID: 30190918
 243. Kakavand H, Jackett LA, Menzies AM, Gide TN, Carlino MS, Saw RPM, Thompson JF, Wilmott JS, Long GV, Scoflyer RA. Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients. *Mod Pathol*. 2017 Dec;30(12):1666-1676. doi: 10.1038/modpathol.2017.89. Epub 2017 Aug 4. PMID: 28776578
 244. Beckers RK, Selinger CI, Vilain R, Madore J, Wilmott JS, Harvey K, Holliday A, Cooper CL, Robbins E, Gillett D, Kennedy CW, Gluch L, Carmalt H, Mak C, Warriar S, Gee HE, Chan C, McLean A, Walker E, McNeil CM, Beith JM, Swarbrick A, **Scoflyer RA**, O'Toole SA. Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. *Histopathology*. Published 2016 Jul ;69(1):25-34. PMID: 26588661
 245. Somasundaram R, Wagner S, Zhang G, Perego M, Fukunaga-Kalabis M, Wagner C, Hristova D, Garg K, Hards R, Wei Z, Wu L, Frederick D, Flaherty K, **Scoflyer RA**, Long GV, Maurer M, Krepler C, Damle M, Ellingsworth C, Grinman L, Dunagin M, Raj A, Scholler N, Gross L, Beqiri M, Liu Q, Bennett K, Griss J, Schaidler H, Czerniecki B, Schuchter L, Herlyn D, Herlyn M, Xu X, Tian T, Zhang J, Hudgens C, Chen G, Tetzlaff M, Choi H, Watson I, Davies M, Wargo J, Hafner C, Mayerhoefer M, Karanikas G, Jalili A, Bauer-Pohl V, Weihsengruber F, Rappersberger K, Koller J, Lang R. Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. *Nature Communications* 2017 Jun PMID: 28928360
 246. Kao SC, Cheng YY, Williams M, Kirschner MB, Madore J, Lum T, Sarun KH, Linton A, McCaughan B, Klebe S, van Zandwijk N, **Scoflyer RA**, Boyer MJ, Cooper WA, Reid G. Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma. *J Thorac Oncol*. 2017 Sep;12(9):1421-1433. doi: 10.1016/j.jtho.2017.05.024. Epub 2017 Jun 16. PMID: 28629895
 247. Reinhardt J, Landsberg J, Schmid-Burgk JL, Ramis BB, Bald T, Glodde N, Lopez-Ramos D, Young A, Ngiow SF, Nettersheim D, Schorle H, Quast T, Kolanus W, Schadendorf D, Long GV, Madore J, **Scoflyer RA**, Ribas A, Smyth MJ, Tumei PC, Tüting T, Hölzel M. MAPK signaling and inflammation link melanoma phenotype switching to induction of CD73 during immunotherapy. *Cancer Res*. 2017 Jun 26. PMID: 28652246
 248. Vargas AC, Selinger CI, Satgunaseelan L, Cooper WA, Gupta R, Stalley P, Brown W, Soper J, Schatz J, Boyle R, Thomas DM, Tattersall MH, Bhadri VA, Maclean F, Bonar SF, **Scoflyer RA**, Karim RZ, McCarthy SW, Mahar A, O'Toole SA. Atypical Ewing sarcoma breakpoint region 1 fluorescence in-situ hybridization signal patterns in bone and soft tissue tumours: diagnostic experience with 135 cases. *Histopathology*. 2016 Dec;69(6):1000-1011. Epub 2016 Sep 21. PMID: 27385661
 249. Rawson R, Robbins E, Kapoor R, **Scoflyer RA**, Long GV. Recurrent bowel obstruction: unusual presentation of Pembrolizumab-induced pancreatitis in annular pancreas. *European Journal Of Cancer* 2017 July 6 PMID: 28689094
 250. Valey A, Goumas C, Hong A, Mann G, Fogarty G, Stretch J, Saw R, Spillane A, Shannon K, Lee K, Quinn M, Thompson JF, **Scoflyer RA**. Neurotropic melanoma: an analysis of the clinicopathological features, management strategies and survival outcomes for 671 patients treated at a tertiary referral center. *Mod Pathol*. 2017 Nov;30(11):1538-1550. doi: 10.1038/modpathol.2017.76. Epub 2017 Jul 21. PMID: 28731051
 251. Young A, Ngiow SF, Madore J, Reinhardt J, Landsberg J, Chitsazan A, Rautela J, Bald T, Barkauskas DS, Ahern E, Huntington ND, Schadendorf D, Long GV, Boyle GM, Hölzel M, **Scoflyer RA**, Smyth MJ. Targeting adenosine in BRAF-mutant melanoma reduces tumor growth and metastasis. *Cancer Res*. 2017 Sep 1;77(17):4684-4696. doi: 10.1158/0008-5472.CAN-17-0393. Epub 2017 Jun 26. PMID:28652244
 252. Damian DL, Martin AJ, **Scoflyer RA**, Chen AC, Halliday GM. Authors' response to a reply to 'A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients'. *Br J Dermatol*. Published 2017 Feb;176(2) PMID: 27893156
 253. van de Nes JAP, Koelsche C, Gessi M, Möller I, Sucker A, **Scoflyer RA**, Buckland ME, Pietsch T, Murali R, Schadendorf D, Griewank KG. Activating CYSLTR2 and PLCB4 mutations in primary leptomeningeal melanocytic tumors. *J Invest Dermatol*. 2017 May 9. PMID:28499758
 254. Mar VJ, **Scoflyer RA**, Long GV. Computer-assisted diagnosis for skin cancer: have we been outsmarted? *Lancet invitation to write a Comment*, Vol 389 May 20, 2017 PMID:28534744
 255. Maher NG, A. Solinas, **R.A. Scoflyer**, S. Puig, G. Pellacani, P. Guitera. Detection of desmoplastic melanoma with dermoscopy and reflectance confocal microscopy. *J Eur Acad Dermatol Venereol*. 2017 Dec;31(12):2016-2024. doi: 10.1111/jdv.14381. Epub 2017 Jul 3. PMID: 28573666
 256. Vilain RE, Kakavand H, Menzies AM, Madore J, Wilmott JS, Liniker E, Kong B, Cooper AJ, Howle JR, Saw RPM, Jakrot V, Lo S, Thompson JF, Carlino MS, Kefford RF, Long GV, **Scoflyer RA**. Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in melanoma. *Clin Cancer Res*. 2017 Sep 1;23(17):5024-5033. doi: 10.1158/1078-0432.CCR-16-0698. Epub 2017 May 16. PMID:28512174
 257. Saletta, Federica; Vilain, Ricardo E; Gupta, Aditya Kumar; Nagabushan, Sumanth; Yuksel, Aysen; Catchpoole, Daniel; **Scoflyer, Richard A**; Byrne, Jennifer A; Mccowage, Geoffrey. Programmed Death-Ligand 1 Expression in a Large Cohort of Pediatric Patients With Solid Tumor and Association With Clinicopathologic Features in Neuroblastoma. *JCO Precision Oncology*, 11/2017, Issue 1, pp.1-12. DOI: <http://dx.doi.org/10.1200/PO.16.00049> via *USyd library*.
 258. Pupo GM, Boyd SC, Fung C, Carlino MS, Menzies AM, Pedersen B, Johansson P, Hayward NK, Kefford RF, **Scoflyer RA**, Long GV, Rizos H. Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered *BRAF* transcript splicing. *Biomark Res*. 2017 May 11;5:17. doi: 10.1186/s40364-017-0098-3. eCollection 2017. PMID: 28503307.
 259. James S Wilmott, Helen Rizos, **Richard A. Scoflyer**, Georgina V Long. The "Tricky Business" of Identifying Mechanisms of Resistance to Anti-PD-1. *Clin Cancer Res*. 2017 Jun 15;23(12):2921-2923. doi: 10.1158/1078-0432.CCR-17-0669. Epub 2017 May 3. PMID: 28468948
 260. Valey AHR, Madronio CM, Cust AE, Goumas C, Mann GJ, Armstrong BK, **Scoflyer RA**, Curtin AM, Thompson JF. Poor adherence to national clinical management guidelines: A population-based, cross-sectional study of the surgical management of melanoma in New South Wales, Australia. *Annals of Surgical Oncology*, March 2017 PMID: 28547563
 261. Lee JH, Long GV, Boyd S, Lo S, Menzies AM, Tembe V, Guminski A, Jakrot V, **Scoflyer RA**, Mann GJ, Kefford RF, Carlino MS, Rizos H. Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. *Ann Oncol*. 2017 May 1;28(5):1130-1136. doi: 10.1093/annonc/mdx026. PMID: 28327969

262. Hendrix MJ, Kandela I, Mazar AP, Seftor EA, Seftor RE, Margaryan NV, Strizzi L, Murphy GF, Long GV, **Scolyer RA**. Targeting melanoma with front-line therapy does not abrogate Nodal-expressing tumor cells. *Lab Invest*. 2017 Feb;97(2):176-186. doi: 10.1038/labinvest.2016.107. Epub 2016 Oct 24. PMID: 27775691
263. Johansson PA, Pritchard AL, Patch AM, Wilmott JS, Pearson JV, Waddell N, **Scolyer RA**, Mann GJ, Hayward NK. Mutation load in melanoma is affected by MC1R genotype. *Pigment Cell Melanoma Res*. 2017 Mar;30(2):255-258. doi: 10.1111/pcmr.12571. Epub 2017 Mar 7. PMID: 28024115
264. Rawson RV, Johansson PA, Hayward NK, Waddell N, Patch AM, Lo S, Pearson JV, Thompson JF, Mann GJ, **Scolyer RA**, Wilmott JS. Unexpected UVR and non-UVR mutation burden in some acral and cutaneous melanomas. *Lab Invest*. 2017 Feb;97(2):130-145. doi: 10.1038/labinvest.2016.143. Epub 2017 Jan 9. PMID:28067894
265. Haydu LE, **Scolyer RA**, Lo S, Quinn MJ, Saw RP, Shannon KF, Spillane AJ, Stretch JR, McCarthy WH, Thompson JF. Conditional Survival: An Assessment of the Prognosis of Patients at Time Points After Initial Diagnosis and Treatment of Locoregional Melanoma Metastasis. *J Clin Oncol*. 2017 May 20;35(15):1721-1729. doi: 10.1200/JCO.2016.71.9393. Epub 2017 Apr 4. PMID: 28375785
266. Griewank KG, Müller H, Jaccett LA, Emberger M, Möller I, van de Nes JA, Zimmer L, Livingstone E, Wiesner T, Scholz SL, Cosgarea I, Sucker A, Schimming T, Hillen U, Schilling B, Paschen A, Reis H, Mentzel T, Kutzner H, Rütten A, Murali R, **Scolyer RA**, Schadendorf D. SF3B1 and BAP1 mutations in blue nevus-like melanoma. *Mod Pathol*. 2017 Apr 14 PMID: 28409567
267. Hayward NK, Wilmott JS, Waddell N, Johansson PA, Field MA, Nones K, Patch A-M, Kakavand H, Alexandrov LB, Burke H, Jakrot V, Kazakoff S, Holmes O, Leonard C, Sabarinathan R, Mularoni L, Wood S, Xu Q, Waddell N, Tembe V, Pupo GM, de Paoli-Iseppi R, Vilain RE, Shang P, Lau LMS, Dagg RA, Schramm S-J, Pritchard A, Grimmond SM, Pickett HA, Yang JY, Stretch JR, Behren A, Kefford RF, Hersey P, Long GV, Cebon J, Shackleton M, Spillane AJ, Saw RPM, Lopez-Bigas N, Pearson JV, Thompson JF, **Scolyer RA***, Mann GJ* (*joint senior/last authors). Whole-genome landscapes of major melanoma subtypes. *Nature*. 2017 May 11;545(7653):175-180. doi: 10.1038/nature22071. Epub 2017 May 3. PMID: 28467829
268. Uribe P, Collgros H, **Scolyer RA**, Menzies SW, Guitera P. In vivo reflectance confocal microscopy for the diagnosis of melanoma and melanotic macules of the lip. *JAMA Dermatology*. Accepted for publication February 2017 PMID: 28467525
269. Maher NG, Solinas A, **Scolyer RA**, Guitera P. In vivo reflectance confocal microscopy for evaluating melanoma of the lip and its differential diagnoses. *Oral Surg Oral Med Oral Pathol Oral Radiol*. 2017 Jan;123(1):84-94. doi: 10.1016/j.oooo.2016.08.011. Epub 2016 Aug 24. PMID: 27720652
270. O'Donnell JS, Long GV, **Scolyer RA**, Teng MW, Smyth MJ. Resistance to PD1/PDL1 checkpoint inhibition. *Cancer Treat Rev*. 2017 Jan;52:71-81. doi: 10.1016/j.ctrv.2016.11.007. Epub 2016 Nov 27. PMID: 27951441
271. Lee JJ, Vilain RE, Granter SR, Hu NR, Bresler SC, Xu S, Frank AH, Mihm MC, Jr., Saw RP, Fletcher CD, **Scolyer RA**, Murphy GF, Lian CG. 5-Hydroxymethylcytosine is a nuclear biomarker to assess biological potential in histologically ambiguous heavily pigmented melanocytic neoplasms. *J Cutan Pathol*. 2017 Mar;44(3):249-255. doi: 10.1111/cup.12880. Epub 2017 Feb 6. PMID: 28032662
272. A Chen AC, Martin AJ, Dalziel RA, McKenzie CA, Lowe PM, Eris JM, **Scolyer RA**, Dhillon HM, Vardy JL, Bielski VA, Halliday GM, Damian DL. A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients. *Br J Dermatol*. 2016 Nov;175(5):1073-1075. doi: 10.1111/bjd.14662. Epub 2016 Aug 10. PMID: 27061568
273. Crookes TR, **Scolyer RA**, Lo S, Drummond M, Spillane AJ. Extranodal Spread is Associated with Recurrence and Poor Survival in Stage III Cutaneous Melanoma Patients. *Ann Surg Oncol*. 2017 May;24(5):1378-1385. doi: 10.1245/s10434-016-5723-0. Epub 2017 Jan 27. PMID: 28130620
274. Patrick E, Schramm SJ, Ormerod JT, **Scolyer RA**, Mann GJ, Mueller S, Yang JY. A multi-step classifier addressing cohort heterogeneity improves performance of prognostic biomarkers in three cancer types. *Oncotarget*. Nov 2016; 8:2807-2815. doi: 10.18632/oncotarget.13203. PMID: 27833072
275. Maher NG, Blumetti TP, Gomes EE, Cheng HM, Satgunaseelan L, Lo S, Rezze GG, **Scolyer RA**, Guitera P. Melanoma diagnosis may be a pitfall for optical coherence tomography assessment of equivocal amelanotic or hypomelanotic skin lesions. *Br J Dermatol*. 2017 Aug;177(2):574-577. doi: 10.1111/bjd.15187. Epub 2017 Jun 22. PMID:27861726
276. Hong AM, Vilain RE, Romanes S, Yang J, Smith E, Jones D, **Scolyer RA**, Lee CS, Zhang, M, Rose B. PD-L1 expression in tonsillar cancer is associated with human papillomavirus positivity and improved survival: implications for anti-PD1 clinical trials. *Oncotarget*. 2016 Nov 22;7(47):77010-77020. doi: 10.18632/oncotarget.12776. PMID:27776338
277. van Kempen LC, Redpath M, Elchebly M, Klein KO, Papadakis AI, Wilmott JS, **Scolyer RA**, Edqvist PH, Pontén F, Schadendorf D, van Rijk AF, Michiels S, Dumay A, Helbling-Leclerc A, Dessen P, Wouters J, Stass M, Greenwood CM, Ghanem GE, van den Oord J, Feunteun J, Spatz A. The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene. *Sci Transl Med*. 2016 Dec 14;8(369):369ra177. PMID:27974665
278. Moller I, Murali R, Muller H, Wiesner T, Jaccett LA, Scholz SL, Cosgarea I, van de Nes JA, Sucker A, Hillen U, Schilling B, Paschen A, Kutzner H, Rütten A, Bockers M, **Scolyer RA**, Schadendorf D, Griewank KG. Activating cysteinyl leukotriene receptor 2 (CYSLTR2) mutations in blue nevi. *Mod Pathol*. 2017 Mar;30(3):350-356. doi: 10.1038/modpathol.2016.201. Epub 2016 Dec 9. PMID: 27934878
279. Deken MA, Gadiot J, Jordanova ES, Lacroix R, van Gool M, Kroon P, Pineda C, Geukes Foppen MH, **Scolyer RA**, Song J-Y, Verbrugge I, Hoeller C, Dummer R, Haanen JBAG, Long GV, Blank CU. Targeting the MAPK and PI3K pathways in combination with PD1 blockade. *Oncoimmunology*. 2016 Oct 14;5(12):e1238557. doi: 10.1080/2162402X.2016.1238557. eCollection 2016. PMID:28123875
280. Prieto-Granada CN, Lezcano C, Scolyer RA, Mihm MC Jr, Piris A. Lethal melanoma in children: a clinicopathological study of 12 cases. *Pathology*. 2016 Dec;48(7):705-711. doi: 10.1016/j.pathol.2016.08.008. Epub 2016 Oct 27. PMID: 27956274
281. Jaccett LA, McCarthy SW, **Scolyer RA**. SOX10 expression in cutaneous scars: a potential diagnostic pitfall in the evaluation of melanoma re-excision specimens. *Pathology*. 2016 Oct;48(6):626-8. doi: 10.1016/j.pathol.2016.06.009. Epub 2016 Aug 28. PMID: 27580960
282. Rawson R, Robbins E, McCarthy SW, **Scolyer RA**. Angiomatoid Spitz naevus: novel observations and clues to diagnosis of a rare variant. *Pathology*. 2016 Dec;48(7):739-742. doi:10.1016/j.pathol.2016.08.015. PMID: 27780602
283. Satgunaseelan L, Gupta R, Madore J, Chia N, Lum T, Palme CE, Boyer M, Scolyer RA, Clark JR. Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype. *Pathology*. 2016 Oct;48(6):574-80. doi: 10.1016/j.pathol.2016.07.003. Epub 2016 Aug 30. PMID: 27590194
284. Lazova R, Seeley EH, Kutzner H, Scolyer RA, Scott G, Cerroni L, Fried I, Kozovska ME, Rosenberg AS, Prieto VG, Shehata BM, Durham MM, Henry G, Rodriguez-Peralto JL, Riveiro-Falkenbach E, Schaefer JT, Danialan R, Fraita S, Vollenweider-Roten S, Sepehr A, Sanguenza M, Hijazi N, Corredora Y, Kowal R, Harris OM, Bravo F, Boyd AS, Gueorguieva R, Caprioli RM. Imaging mass spectrometry assists in the classification of diagnostically challenging atypical Spitzoid neoplasms. *J Am Acad Dermatol*. 2016 Dec;75(6):1176-1186.e4. doi: 10.1016/j.jaad.2016.07.007. Epub 2016 Aug 5. PMID: 27502312

285. McKenzie CA, Chen AC, Choy B, Fernández-Peñas P, Damian DL, Scolyer RA. Classification of high risk basal cell carcinoma subtypes: experience of the ONTRAC study with proposed definitions and guidelines for pathological reporting. *Pathology*. 2016 Aug;48(5):395-7. doi: 10.1016/j.pathol.2016.05.005. Epub 2016 Jun 14. PMID: 27311865
286. Guitera P, Menzies SW, Argenziano G, Longo C, Losi A, Drummond M, **Scolyer RA**, Pellacani G. Dermoscopy and in vivo confocal microscopy are complementary techniques for diagnosis of difficult amelanotic and light-coloured skin lesions. *Br J Dermatol* 2016 Dec;175(6):1311-1319 PMID: 27177158
287. Kakavand H, Walker E, Lum T, Wilmott JS, Selinger CI, Smith E, Saw RP, Yu B, Cooper WA, Long GV, O'Toole SA, Scolyer RA. BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting. *Histopathology*. 2016 Oct;69(4):680-6. doi: 10.1111/his.12992. Epub 2016 Jun 15. PMID: 27151331
288. Welsh SJ, Rizos H, **Scolyer RA**, Long GV. Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next? *Eur J Cancer*. 2016 Jul;62:76-85. doi: 10.1016/j.ejca.2016.04.005. Epub 2016 May 24. PMID: 27232329
289. De Paoli-Iseppi R, Johansson PA, Menzies AM, Dias KR, Pupo GM, Kakavand H, Wilmott JS, Mann GJ, Hayward NK, Dinger ME, Long GV, Scolyer RA. Comparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision making. *Pathology*. 2016 Apr;48(3):261-6. doi: 10.1016/j.pathol.2016.01.001. Epub 2016 Mar 9. PMID: 27020503
290. Cheng HM, Lo S, **Scolyer RA**, Meekings A, Carols G, Guitera P. Accuracy of optical coherence tomography for the diagnosis of superficial basal cell carcinoma: a prospective, consecutive, cohort study of 168 cases.. *Br J Dermatol*. 2016 Dec;175(6):1290-1300. PMID: 27146027
291. Fox C, Lambie D, Wilmott JS, Pinder A, Pavey S, Lê Cao KA, Akalin T, Karaarslan IK, Ozdemir F, Scolyer RA, Yamada M, Soyer HP, Schaidt H, Gabrielli B. Multiparameter analysis of naevi and primary melanomas identifies a subset of naevi with elevated markers of transformation. *Pigment Cell Melanoma Res*. 2016 Jul;29(4):444-52. doi: 10.1111/pcmr.12489. PMID: 27166757
292. Ge L, Vilain RE, Lo S, Aivazian K, **Scolyer RA**, Thompson JF. Breslow Thickness Measurements of Melanomas Around American Joint Committee on Cancer Staging Cut-Off Points: Imprecision and Terminal Digit Bias Have Important Implications for Staging and Patient Management. *Ann Surg Oncol*. 2016 Aug;23(8):2658-63. doi: 10.1245/s10434-016-5196-1. Epub 2016 Apr 13. PMID: 27075324
293. **Scolyer RA**, Vilain RE, Mihm MC Jr. Advances in melanoma: revolutionary progress delivering improved patient management and outcomes. *Pathology*. 2016 Feb;48(2):105-7. doi: 10.1016/j.pathol.2015.12.011. Epub 2016 Jan 14. PMID: 27020382
294. Vilain RE, McCarthy SW, **Scolyer RA**. The regenerating naevus. *Pathology*. 2016 Feb;48(2):108-12. doi: 10.1016/j.pathol.2015.12.009. Epub 2016 Jan 13. PMID: 27020383
295. Jayawardana K, Schramm SJ, Tembe V, Mueller S, Thompson JF, **Scolyer RA**, Mann GJ, Yang J. Identification, Review, and Systematic Cross-Validation of microRNA Prognostic Signatures in Metastatic Melanoma. *J Invest Dermatol*. 2016 Jan;136(1):245-254. doi: 10.1038/JID.2015.355. Review. PMID: 26763444
296. Madore J, Strbenac D, Vilain R, Menzies AM, Yang JY, Thompson JF, Long GV, Mann GJ, **Scolyer RA**, Wilmott JS. PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma. *Clin Cancer Res*. 2016 Aug 1;22(15):3915-23. doi: 10.1158/1078-0432.CCR-15-1714. Epub 2016 Mar 9. PMID: 26960397
297. Mahar AL, Compton C, Halabi S, Hess KR, Gershenwald JE, **Scolyer RA**, Groome PA. Critical assessment of clinical prognostic tools in melanoma. *Ann Surg Oncol*. 2016 Sep;23(9):2753-61. doi: 10.1245/s10434-016-5212-5. Epub 2016 Apr 6. Review. PMID: 27052645
298. Kakavand H, Wilmott JS, Long GV, **Scolyer RA**. Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists. *Pathology*. 2016 Feb;48(2):194-202. doi: 10.1016/j.pathol.2015.12.010. Epub 2016 Jan 20. Review. PMID: 27020392
299. van de Nes J, Gessi M, Sucker A, Möller I, Stiller M, Horn S, Scholz SL, Pischler C, Stadler N, Schilling B, Zimmer L, Hillen U, **Scolyer RA**, Buckland ME, Lauriola L, Pietsch T, Waha A, Schandendorf D, Murali R, Griewank KG. Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous system. *J Neurooncol*. 2016 May;127(3):435-44. doi: 10.1007/s11060-015-2052-2. Epub 2016 Jan 7. PMID: 26744134
300. Busam KJ, Vilain RE, Lum T, Busam JA, Hollmann TJ, Saw RP, Coit DC, **Scolyer RA**, Wiesner T. Primary and metastatic cutaneous melanomas express ALK through alternative transcriptional initiation. *Am J Surg Pathol*. 2016 Jun;40(6):786-95. doi: 10.1097/PAS.0000000000000611. PMID: 26872010
301. Bosisio F, Wilmott JS, Volders N, Mercier M, Wouters J, Stas M, Blokx W, Massi D, Thompson JF, **Scolyer RA**, van Baren N, van den Oord J. Plasma cells in primary melanoma. Prognostic significance and possible role of IgA. *Mod Pathol*. 2016 Apr;29(4):347-58. doi: 10.1038/modpathol.2016.28. Epub 2016 Feb 12. PMID: 26867783
302. Lyle M, Haydu LE, Menzies AM, Thompson JF, Saw RPM, Spillane AJ, Kefford RF, Mann GJ, Cooper WA, Yu B, **Scolyer RA**, O'Toole SA, Long GV. The molecular profile of metastatic melanoma in Australia. *Pathology*. 2016 Feb;48(2):188-93. doi: 10.1016/j.pathol.2015.12.008. Epub 2016 Jan 18. PMID: 27020391
303. Kakavand H, Wilmott JS, Menzies AM, Vilain RE, Haydu LE, Yearley JH, Thompson JF, Kefford RF, Hersey P, Long GV, **Scolyer RA**. PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients. *Clin Cancer Res*. 2015 Jul 15;21(14):3140-8. doi: 10.1158/1078-0432.CCR-14-2023. Epub 2015 Jan 21. PMID: 25609064
304. Wong SQ, Waldeck K, Vergara IA, Schröder J, Madore J, Wilmott JS, Colebatch AJ, De Paoli-Iseppi R, Li J, Lupat R, Semple T, Arnau GM, Fellowes A, Leonard JH, Hruby G, Mann GJ, Thompson JF, Cullinane C, Johnston M, Shackleton M, Sandhu S, Bowtell DDL, Johnstone RW, Fox SB, McArthur GA, Papenfuss AT, **Scolyer RA**, Gill AJ, Hicks RJ, Tothill RW. UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas. *Cancer Res*. 2015 Dec 15;75(24):5228-34. doi: 10.1158/0008-5472.CAN-15-1877. Epub 2015 Dec 1. PMID: 26627015
305. Arafeh R, Qutob N, Emmanuel R, Keren-Paz A, Madore J, Elkahloun A, Wilmott JS, Gartner JJ, Di Pizio A, Winograd-Katz S, Sindiri S, Rotkopf R, Dutton-Regester K, Johansson P, Pritchard A, Waddell N, Hill VK, Lin JC, Hevroni Y, Rosenberg SA, Khan J, Ben-Dor S, Niv MY, Ulitsky I, Mann GJ, **Scolyer RA**, Hayward NK, Samuels Y. Recurrent inactivating RASA2 mutations in melanoma. *Nat Genet*. 2015 Dec;47(12):1408-10. doi: 10.1038/ng.3427. Epub 2015 Oct 26. PMID: 26502337
306. Gray ES, Rizos H, Reid AL, Boyd SC, Pereira MR, Lo J, Tembe V, Freeman J, Lee JHJ, **Scolyer RA**, Siew K, Lomma C, Cooper A, Khattak MA, Meniawy TM, Long GV, Carlino MS, Millward M, Ziman M. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. *Oncotarget*. 2015 Dec 8;6(39):42008-18. doi: 10.18632/oncotarget.5788. PMID: 26524482

307. Kakavand H, Vilain RE, Wilmott JS, Burke H, Yearley JH, Thompson JF, Hersey P, Long GV, **Scohyer RA**. Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases. *Mod Pathol*. 2015 Dec;28(12):1535-44. doi: 10.1038/modpathol.2015.110. Epub 2015 Sep 25. PMID:26403784
308. Johnson DB, Menzies AM, Zimmer L, Eroglud Z, Yea F, Zhaoa S, Rizos H, Sucker A, **Scohyer RA**, Gutzmerj R, Gogas H, Kefford RF, Thompson JT, Becker JC, Berking C, Egbertsn F, Loquai C, Goldinger S, Pupo GM, Hugo W, Kong X, Garraway LA, Sosman JA, Ribas A, Lo RS, Long GV, Schadendorf D. Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. *Eur J Cancer*. 2015 Dec;51(18):2792-9. doi: 10.1016/j.ejca.2015.08.022. Epub 2015 Nov 19. PMID: 26608120
309. Chi MN, Guo ST, Wilmott JS, Guo XY, Yan XG, Wang CY, Liu XY, Jin L, Tseng H-Y, Croft A, Hondermarck H, Liu T, **Scohyer RA**, Jiang CC, Zhang XD. INPP4B is upregulated and functions as an oncogenic driver through SGK3 in a subset of melanomas. *Oncotarget*. 2015 Nov 24;6(37):39891-907. doi: 10.18632/oncotarget.5359. PMID: 26573229
310. Ko JS, Prieto VG, Elson PJ, Vilain RE, Pulitzer MP, **Scohyer RA**, Reynolds JP, Piliang MP, Ernstoff MS, Gastman BR, Billings SD. Histological pattern of Merkel cell carcinoma sentinel lymph node metastasis improves stratification of Stage III patients. *Mod Pathol*. 2016 Feb;29(2):122-30. doi: 10.1038/modpathol.2015.109. Epub 2015 Nov 6. PMID: 26541273
311. Chen AC, Martin AJ, Choy B, Fernández-Peñas P, Dalziel RA, McKenzie CA, **Scohyer RA**, Dhillon HM, Vardy JL, Kricker A, St George G, Chinniah N, Halliday GM, Damian DL. A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. *N Engl J Med*. 2015 Oct 22;373(17):1618-26. doi: 10.1056/NEJMoa1506197. PMID: 26488693
312. Henderson MA, Burmeister BH, Ainslie J, Fisher R, Di Iulio J, Smithers BM, Hong A, Shannon K, **Scohyer RA**, Carruthers S, Coventry BJ, Babington S, Duprat J, Hoekstra HJ, Thompson JF. Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. *Lancet Oncol*. 2015 Sep;16(9):1049-1060. doi: 10.1016/S1470-2045(15)00187-4. Epub 2015 Jul 20. PMID:26206146
313. Sanborn Z, Chung J, Purdom E, Wang NJ, Kakaband H, Wilmott JS, Butler T, Thompson JF, Mann GJ, Haydu LE, Saw RP, Busam KJ, Lo R, Collisson EA, Hur JS, Spellman P, Cleaver JE, Gray JW, Huh N, Murali R, **Scohyer RA**, Bastian BC, Cho RJ. Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination. *Proc Natl Acad Sci U S A*. 2015 Sep 1;112(35):10995-1000. doi: 10.1073/pnas.1508074112. Epub 2015 Aug 18. PMID: 26286987
314. MacKenzie Ross AD, Haydu LE, Quinn MJ, Saw RP, Shannon KF, Spillane AJ, Stretch JR, **Scohyer RA**, Thompson JF. The Association Between Excision Margins and Local Recurrence in 11,290 Thin (T1) Primary Cutaneous Melanomas: A Case-Control Study. *Ann Surg Oncol*. 2016 Apr;23(4):1082-9. doi: 10.1245/s10434-015-4942-0. Epub 2015 Nov 11. PMID: 26561405
315. Wilmott JS, Field MA, Johansson PA, Kakavand H, Shang P, De Paoli-Iseppi R, Vilain R, Pupo GM, Tembe V, Jakrot V, Shang CA, Cebon J, Shackleton M, Fitzgerald A, Thompson JF, Hayward NK, Mann GJ, **Scohyer RA**. Tumour procurement, DNA extraction, coverage analysis and optimisation of mutation-detection algorithms for human melanoma genomes. *Pathology*. 2015 Dec;47(7):683-93. doi: 10.1097/PAT.0000000000000324. Erratum in: *Pathology*. 2016 Jan;48(1):104. PMID: 26517638
316. Menzies AM, Wilmott JS, Drummond M, Lo S, Lyle M, Chan MMK, Thompson JF, Guminski A, Carlino MS, **Scohyer RA**, Kefford RF, Long GV. Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors. *Cancer*. 2015 Nov 1;121(21):3826-35. doi: 10.1002/cncr.29586. Epub 2015 Jul 28. PMID: 26218930
317. Menzies AM, Yeh I, Botton T, Bastian BC, **Scohyer RA**, Long GV. Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion. *Pigment Cell Melanoma Res*. 2015 Sep;28(5):607-10. doi: 10.1111/pcmr.12388. Epub 2015 Jul 3. PMID: 26072686
318. Shain AH, Garrido M, Botton T, Talevich E, Yeh I, Sanborn Z, Chung J, Wang NJ, Kakavand H, Mann GJ, Thompson JF, Wiesner T, Roy R, Olshen AB, Gagnon A, Gray JW, Huh N, Hur JS, Busam KJ, **Scohyer RA**, Cho RJ, Murali R, Bastian BC. Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. *Nat Genet*. 2015 Oct;47(10):1194-9. doi: 10.1038/ng.3382. Epub 2015 Sep 7. PMID: 26343386
319. Cooper WA, Tran T, Vilain RE, Madore J, Selinger CI, Kohonen-Corish M, Yip P, Yu B, O'Toole SA, McCaughan BC, Yearley JH, Horvath LG, Kao S, Boyer M, **Scohyer RA**. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma Lung Cancer. *Lung Cancer*. 2015 Aug;89(2):181-8. doi: 10.1016/j.lungcan.2015.05.007. Epub 2015 May 18. PMID: 26024796
320. Stark M, Klein K, Weide B, Haydu L, Pflugfelder A, Tang YH, Palmer J, Whiteman D, **Scohyer RA**, Mann GJ, Thompson JF, Long GV, Barbour A, Soyer HP, Garbe C, Herington A, Pollock P, Hayward N. The prognostic and predictive value of melanoma-related microRNAs using tissue and serum: a microRNA expression analysis. *EBioMedicine*. 2015 May 12;2(7):671-80. doi: 10.1016/j.ebiom.2015.05.011. eCollection 2015 Jul. PMID:26288839
321. Haydu LE, Stollman JT, **Scohyer RA**, Spillane AJ, Quinn MJ, Saw RP, Shannon KF, Stretch JR, Bonenkamp JJ, Thompson JF. Minimum Safe Pathologic Excision Margins for Primary Cutaneous Melanomas (1-2 mm in Thickness): Analysis of 2131 Patients Treated at a Single Center. *Ann Surg Oncol*. 2016 Apr;23(4):1071-81. doi: 10.1245/s10434-015-4575-3. Epub 2015 May 9. PMID: 25956574
322. Fogarty GB, Hong A, Dolven-Jacobsen K, Reisse CH, Burmeister B, Haydu LH, Dhillon H, Steel V, Shivalingam B, Drummond K, Vardy J, Nowak A, Hruba G, **Scohyer RA**, Mandel C, Thompson JF. First interim analysis of a randomised trial of whole brain radiotherapy in melanoma brain metastases confirms high data quality. *BMC Res Notes*. 2015 May 8;8:192. PMID: 25952979
323. Theodosakis N, Meeth K, Micevic G, **Scohyer RA**, Long GV, Marzuka A, Stern D, Bosenberg M. BRAF inhibition decreases cellular glucose uptake in melanoma in association with reduction in cell volume. *Mol Cancer Ther*. 2015 Jul;14(7):1680-92. doi: 10.1158/1535-7163.MCT-15-0080. Epub 2015 May 6. PMID: 25948295
324. Vilain RE, McCarthy SW, Thompson JF, **Scohyer RA**. BAP1-inactivated spitzoid naevi. *Am J Surg Pathol*. 2015 May;39(5):722. PMID: 25871468
325. Hardy KM, Strizzi L, Margaryan NV, Gupta K, Murphy GF, **Scohyer RA**, Hendrix MJ. Targeting Nodal in Conjunction with Dacarbazine Induces Synergistic Anticancer Effects in Metastatic Melanoma. *Mol Cancer Res*. 2015 Apr;13(4):670-80. doi: 10.1158/1541-7786.MCR-14-0077. Epub 2015 Mar 12. PMID: 25767211
326. Anforth R, Menzies AM, Byth K, Carlos G, Chou S, Sharma R, **Scohyer RA**, Kefford RF, Long GV, Fernandez-Penas P. Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy. *J Am Acad Dermatol*. 2015 May;72(5):809-15.e1. doi: 10.1016/j.jaad.2015.01.018. Epub 2015 Mar 3. PMID: 25748298

327. Liu XY, Lai F, Yan XG, Jiang CC, Guo ST, Wang CY, Croft A, Tseng HY, Wilmott JS, **Scolyer RA**, Jin L, Zhang XD. RIP1 Kinase Is an Oncogenic Driver in Melanoma. *Cancer Res.* 2015 Apr 15;75(8):1736-48. doi: 10.1158/0008-5472.CAN-14-2199. Epub 2015 Feb 27. PMID: 25724678
328. Holtkamp LHJ, Wang S, Wilmott JS, Madore J, Vilain R, Thompson JF, Nieweg OE, **Scolyer RA**. Detailed pathological examination of completion node dissection specimens and outcome in melanoma patients with minimal (<0.1 mm) sentinel lymph node metastases. *Ann Surg Oncol.* 2015 Sep;22(9):2972-7. doi: 10.1245/s10434-015-4615-z. Epub 2015 May 20. PMID: 25990968
329. Wilmott JS, Hersey P, Long GV, **Scolyer RA**. Synergistic effects of MAPK and immune checkpoint inhibitors in melanoma: what is the best combination strategy? *Melanoma Manag.* 2015 Feb;2(1):15-19. Epub 2015 Feb 25. PMID: 30190826
330. Kiyohara E, Donovan N, Takeshima L, Huang S, Wilmott JS, **Scolyer RA**, Jones P, Somers EB, O'Shannessy DJ, Hoon DS. Endosomal Expression in Metastatic Melanoma Tumor Microenvironment Vasculature: Potential Therapeutic Implications. *Cancer Microenviron.* 2015 Aug;8(2):111-8. Epub 2015 Jun 18. PMID: 26085332
331. Luk PP, Vilain R, Crainic O, McCarthy SW, Thompson JF, **Scolyer RA**. Punch biopsy of melanoma causing tumour cell implantation: another peril of utilising partial biopsies for melanocytic tumours. *Australas J Dermatol.* 2015 Aug;56(3):227-31. Epub 2015 Mar 31. PMID: 25827527
332. Vilain R, McCarthy SW, Thompson JF, **Scolyer RA**. Letter to the Editor Re: Yeh et. al, Ambiguous melanocytic tumors with loss of 3p21. *Am J Surg Pathol* January 7, 2015.
333. Carlino MS, Kwan V, Miller DK, Saunders CA, Yip D, Nagrial AM, Tomlinson J, Grimmond SM, **Scolyer RA**, Kefford RF, Biankin AV, Long GV. New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma. *J Clin Oncol.* 2015 Apr 10;33(11):e52-6. doi: 10.1200/JCO.2013.51. 5783. Epub 2014 May 12. PMID: 24821886
334. Phan TG, Long GV, **Scolyer RA**. Checkpoint inhibitors for cancer immunotherapy. Multiple checkpoints on the long road towards cancer immunotherapy. *Immunol Cell Biol* 2015 Apr;93(4):323-5. PMID: 25686808
335. Wilmott JS, Colebatch A, Kakavand H, Shang P, Carlino MS, Thompson JF, Long GV, **Scolyer RA**, Hersey P. Expression of the Class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma. *Mod Pathol.* 2015 Jul;28(7):884-94. doi: 10.1038/modpathol.2015.34. Epub 2015 Apr 3. PMID: 25836739
336. Anforth RM, Carlos GR, **Scolyer RA**, Chou S, Fernandez-Peñas P. Eruptive naevi in a patient treated with LGX818 for BRAF mutant metastatic melanoma. *Melanoma Res.* 2015 Feb; Vol.25(1), pp.91-94. PMID:25380183
337. Read RL, Haydu LE, Saw RPM, Quinn MJ, Shannon K, Spillane AJ, Stretch JR, **Scolyer RA**, Thompson, JF. In-transit Melanoma Metastases: Incidence, Prognosis, and the Role of Lymphadenectomy. *Ann Surg Oncol.* 2015 Feb;22(2):475-81. PMID: 25256128
338. Carlino MS, Fung C, Shahheydari H, Todd JR, Nagrial AM, **Scolyer RA**, Kefford RF, Long GV, Rizos, H. Pre-existing MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients. *Clin Cancer Res.* 2015 Jan 1;21(1):98-105. doi: 10.1158/1078-0432.CCR-14-0759. Epub 2014 Nov 4. PMID:25370473
339. Madore J, Vilain R, Menzies AM, Kakavand H, Wilmott JS, Hyman J, Yearley JH, Kefford RF, Thompson JF, Long GV, Hersey P, **Scolyer RA**. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. *Pigment Cell Melanoma Res.* 2015 May;28(3):245-53. doi: 10.1111/pcmr.12340. Epub 2014 Dec 22. PMID: 25477049
340. Sharma N, Ho S, Bing TK, McCormack C, **Scolyer R**, Lee J. Eruptive disseminated Spitz naevus (EDSN) in a young girl of Indian origin. *Pigment Cell Melanoma Res.* 2015 May;28(3):254-66. doi: 10.1111/pcmr.12343. Epub 2015 Jan 5. PMID: 25482351
341. Wang J, Huang SK, Marzese DM, Hsu SC, Kawas NP, Chong KK, Long GV, Menzies AM, Scolyer RA, Izraely S, Sagi-Assif O, Witz IP, Hoon DSB. Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas. *J Invest Dermatol.* 2015 Feb;135(2):532-541. doi: 10.1038/jid.2014.418. Epub 2014 Sep 22. PMID: 25243790
342. Tembe V, Schramm SJ, Stark MS, Patrick E, Jayaswal V, Tang YH, Barbour A, Hayward NK, Thompson JF, Scolyer RA, Yang YH, Mann GJ. MicroRNA and mRNA expression profiling in metastatic melanoma reveal associations with BRAF mutation and patient prognosis. *Pigment Cell Melanoma Res.* 2015 May;28(3):254-66. doi: 10.1111/pcmr.12343. Epub 2015 Jan 5. PMID: 25490969
343. Gopal VNV, Rizos H, Chen G, Deng W, Frederick DT, Cooper ZA, **Scolyer RA**, Pupo G, Komurov K, Sehgal V, Zhang J, Patel L, Pereira CG, Broom BM, Mills GB, Ram P, Smith PD, Wargo JA, Long GV, Davies MA. Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1 α and Oxidative Phosphorylation in melanoma. *Cancer Res.* 2014 Dec 1;74(23):7037-47. doi: 10.1158/0008-5472.CAN-14-1392. Epub 2014 Oct 8. PMID: 25297634
344. Long GV, Fung C, Menzies AM, Pupo GM, Carlino MS, Hyman J, Shahheydari H, Tembe V, Thompson JF, Saw RP, Howle J, Hayward NK, Johansson P, **Scolyer RA**, Kefford RF, Rizos H. Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. *Nat Commun.* 2014 Dec 2;5:5694. doi: 10.1038/ncomms6694. PMID: 25452114
345. Lamboo LGE, Haydu LE, **Scolyer RA**, Quinn MJ, Saw RPM, Shannon KF, Spillane AJ, Stretch JR, Bonenkamp JJ, Thompson JF. The optimum excision margin and regional node management for primary cutaneous T3 melanomas (2-4 mm in Thickness): a retrospective study of 1587 patients treated at a single center. *Ann Surg.* 2014 Dec;260(6):1095-102. doi: 10.1097/SLA.0000000000000792. PMID: 25072430
346. Liu YL, Lai F, Wilmott JS, Yan XG, Liu XY, Luan Q, Guo ST, Jiang CC, Tseng HY, **Scolyer RA**, Jin L, Zhang XD. Noxa upregulation by oncogenic activation of MEK/ERK through CREB promotes autophagy in human melanoma cells. *Oncotarget.* 2014 Nov 30;5(22):11237-51. PMID: 25365078
347. Sebaratnam DF, Martin LK, Venugopal SS, Mangos G, Freiman J, de Souza P, Farnsworth A, Cheung K, **Scolyer RA**, Murrell DF. Diffuse melanosis cutis in the setting of BRAF(V600E) metastatic melanoma. *Int J Dermatol.* 2014 Nov;53(11):1409-11. DOI: 10.1111/ijd.12614 PMID: 25257244
348. Seifried S, Haydu LE, Quinn MJ, **Scolyer RA**, Stretch JR, Thompson JF. Melanoma of the vulva and vagina: principles of staging and their relevance to management based on a clinicopathologic analysis of 85 cases. *Ann Surg Oncol.* 2015;22(6):1959-66. doi: 10.1245/s10434-014-4215-3. Epub 2014 Nov 11. PMID: 25384702
349. Hersey P, Kakavand H, Wilmott J, van der Westhuizen A, Gallagher S, Gowrishankar K, Scolyer R. How anti-PD1 treatments are changing the management of melanoma. *Melanoma Manag.* 2014 Nov;1(2):165-172. doi: 10.2217/mmt.14.14. Epub 2014 Dec 4. Review. PMID: 30190821
350. Marzese DM, **Scolyer RA**, Roqué M, Vargas-Roig LM, Huynh JL, Wilmott JS, Murali R, Buckland ME, Barkhoudarian G, Thompson JF, Morton DL, Kelly DF, Hoon DS. DNA Methylation and Gene Deletion Analysis of Brain Metastases in Melanoma Patients Identifies Mutually Exclusive Molecular Alterations. *Neuro Oncol.* 2014 Nov;16(11):1499-509. doi: 10.1093/neuonc/nou107. Epub 2014 Jun 26. PMID: 24968695

351. Mactier S, Kaufman KL, Wang P, Crossett B, Pupo GM, Kohnke PL, Thompson JF, **Scolyer RA**, Yang JY, Mann, GJ. Protein signatures correspond to survival outcomes of AJCC stage III melanoma patients. *Pigment Cell Melanoma Res.* 2014 Nov;27(6):1106-16. doi: 10.1111/pcmr.12290. Epub 2014 Aug 14. PMID: 24995518
352. Joose A, van der Ploeg APT, Haydu LE, Nijsten TEC, de Vries E, **Scolyer RA**, Eggermont AMM, Coebergh JWW, Thompson JF. Sex differences in melanoma survival are not related to mitotic rate of the primary tumor. *Ann Surg Oncol.* 2015 May;22(5):1598-603. doi: 10.1245/s10434-014-4166-8. Epub 2014 Nov 19. PMID: 25408275
353. McCormack CJ, Conyers RK, **Scolyer RA**, Kirkwood J, Speakman D, Wong N, Kelly JW, Henderson MA. Atypical Spitzoid neoplasms: a review of potential markers of biological behavior including sentinel node biopsy. *Melanoma Res.* 2014 Oct;24(5):437-47. doi: 10.1097/CMR.0000000000000084. Review. PMID: 24892957
354. Sutton SK, Koach J, Tan O, Liu B, Carter DR, Wilmott JS, Yosufi B, Haydu LE, Mann GJ, Thompson JF, Long GV, Liu T, McArthur G, Zhang XD, **Scolyer RA**, Cheung BB, Marshall GM. TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells. *Oncotarget* 2014 Oct 30;5(20):10127-39. PMID: 25333256
355. Zimmer L, Haydu LE, Menzies AM, **Scolyer RA**, Kefford RF, Thompson JF, Schadendorf D, Long GV. Reply to M. Perier-Muzet et al. *J Clin Oncol.* 2014 Oct 1;32(28):3203. doi: 10.1200/JCO.2014.56.8477. Epub 2014 Sep 2. PMID: 25185100
356. Wadt KA, Aoude LG, Johansson P, Solinas A, Pritchard A, Crainic O, Andersen MT, Kiilgaard JF, Heegaard S, Sunde L, Federspiel B, Madore J, Thompson JF, McCarthy SW, Goodwin A, Tsao H, Jönsson G, Busam K, Gupta R, Trent JM, Gerdes AM, Brown KM, **Scolyer RA**, Hayward NK. A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma. *Clin Genet.* 2015 Sep;88(3):267-72. doi: 10.1111/cge.12501. Epub 2014 Nov 6. PMID: 25225168
357. Schatton T, **Scolyer RA**, Thompson JF, Mihm MC Jr. Tumor-infiltrating lymphocytes and their significance in melanoma prognosis. *Methods Mol Biol.* 2014;1102:287-324. doi: 10.1007/978-1-62703-727-3_16. Review. PMID: 24258985
358. Vilain R, Wilmott JS, **Scolyer RA**. A light shines on melanoma metastagenesis. *Pigment Cell Melanoma Res.* 2014 Sep;27(5):696-7. doi: 10.1111/pcmr.12270. Epub 2014 Jun 19. PMID: 24890897
359. van der Ploeg APT, Haydu LE, Spillane AJ, **Scolyer RA**, Quinn MJ, Saw RPM, Shannon KF, Stretch JR, Thompson JF. Melanoma Patients with an Unknown Primary Tumor Site Have a Better Outcome than Those with a Known Primary Following Therapeutic Lymph Node Dissection for Macroscopic (Clinically Palpable) Nodal Disease. *Ann Surg Oncol.* 2014 Sep;21(9):3108-16. doi: 10.1245/s10434-014-3679-5. Epub 2014 May 7. PMID: 24802907
360. Lezcano C, Lee CW, Larson AR, Menzies AM, Kefford RF, Thompson JF, Mihm MC Jr, Ogino S, Long GV, **Scolyer RA**, Murphy GF. Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors. *Mod Pathol.* 2014 Sep;27(9):1193-202. doi: 10.1038/modpathol.2013.226. Epub 2014 Jan 17. PMID: 24434899
361. Wouters J, Stas M, Govaere O, Barrette K, Dudek A, Vankelecom H, Haydu LE, Thompson JF, Scolyer RA, van den Oord JJ. A novel hypoxia-associated subset of FN1 high MITF low melanoma cells: identification, characterization, and prognostic value. *Mod Pathol.* 2014 Aug;27(8):1088-100. doi: 10.1038/modpathol.2013.228. Epub 2014 Jan 3. PMID: 24390218
362. van der Ploeg APT, Haydu LE, Spillane AJ, Quinn MJ, Saw RPM, Shannon KF, Stretch JR, Uren RF, **Scolyer RA**, Thompson JF. Outcome following sentinel node biopsy plus wide local excision versus wide local excision only for primary cutaneous melanoma: analysis of 5840 patients treated at a single institution. *Ann Surg* July 2014;260(1):149-157. PMID: 24633018
363. Laing ME, Coates E, Jopp-McKay A, **Scolyer RA**, Guitera P. Atypical naevus spilus: detection by in vivo confocal microscopy. *Clin Exp Dermatol.* 2014 Jul;39(5):616-9. PMID: 24934914
364. Niebling MG, Haydu LE, Karim RZ, Thompson JF, **Scolyer RA**. Pathology Review Significantly Affects Diagnosis and Treatment of Melanoma Patients: An Analysis of 5011 Patients Treated at a Melanoma Treatment Center. *Ann Surg Oncol.* 2014 Jul;21(7):2245-51. doi: 10.1245/s10434-014-3682-x. Epub 2014 Apr 19. PMID: 24748128
365. Larson AR, Shi YG, Dresser K, Zhan Q, Lezcano C, Woda BA, Yosufi B, Thompson JF, **Scolyer RA**, Mihm MC Jr, Murphy GF, Lian CG. Loss of 5-hydroxymethylcytosine correlates with increasing morphologic dysplasia in melanocytic tumors. *Mod Pathol.* 2014 Jul;27(7):936-44. doi: 10.1038/modpathol.2013.224. Epub 2014 Jan 3. PMID: 24390216
366. Carlino MS, Haydu LE, Kakavand H, Menzies AM, Hamilton AL, Yu B, Ng CC, Cooper WA, Thompson JF, Kefford RF, O'Toole SA, **Scolyer RA**, Long GV. Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma. *Br J Cancer.* 2014 Jul 15;111(2):292-9. doi: 10.1038/bjc.2014.287. Epub 2014 Jun 10. PMID: 24918823
367. Jayawardana K, Schramm SJ, Haydu L, Thompson JF, Scolyer RA, Mann GJ, Müller S, Yang JY. Determination of prognosis in metastatic melanoma through integration of clinico-pathologic, mutation, mRNA, microRNA, and protein information. *Int J Cancer.* 2015 Feb 15;136(4):863-74. doi: 10.1002/ijc.29047. Epub 2014 Jul 24. PMID: 24975271
368. Guitera P, Haydu LE, Menzies SW, **Scolyer RA**, Hong A, Fogarty GB, Gallardo F, Segura S. Surveillance for treatment failure of lentigo maligna with dermoscopy and in vivo confocal microscopy: new descriptors. *Br J Dermatol.* 2014 Jun;170(6):1305-12. PMID: 24641247
369. Dutton-Regester K, Gartner JJ, Emmanuel R, Qutob N, Davies MA, Gershenwald JE, Robinson W, Robinson S, Rosenberg SA, **Scolyer RA**, Mann GJ, Thompson JF, Hayward NK, Samuels Y. A highly recurrent RPS27 5'UTR mutation in melanoma. *Oncotarget.* 2014 May 30;5(10):2912-7. PMID: 24913145
370. Menzies AM, Wilmott JS, Long GV, **Scolyer RA**. Intra-patient heterogeneity of BRAF mutation status: fact or fiction? *Br J Cancer.* 2014 Oct 14;111(8):1678-9. doi: 10.1038/bjc.2013.796. Epub 2013 Dec 24. PMID: 24366302
371. Sarchio SNE, **Scolyer RA**, Beaugie C, McDonald D, Marsh-Wakefield F, Halliday GM, Byrne SN. Pharmacologically antagonizing the CXCR4-CXCL12 chemokine pathway with AMD3100 inhibits sunlight-induced skin cancer. *J Invest Dermatol.* 2014 Apr;134(4):1091-1100. doi: 10.1038/jid.2013.424. Epub 2013 Oct 14. PMID: 24226205
372. Chien AJ, Haydu LE, Biechele TL, Kulikauskas RM, Rizos H, Kefford RF, **Scolyer RA**, Moon RT, Long GV. Targeted BRAF Inhibition Impacts Survival in Melanoma Patients with High Levels of Wnt/ β -Catenin Signaling. *PLoS One.* 2014 Apr 14;9(4):e94748. doi: 10.1371/journal.pone.0094748. eCollection 2014. PMID: 24733413
373. Rizos H, Menzies AM, Pupo GM, Carlino MS, Fung C, Hyman J, Haydu LE, Mijatov B, Becker TM, Boyd SC, Howle J, Saw R, Thompson JF, Kefford RF, **Scolyer RA**, Long GV. BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact. *Clin Cancer Res.* 2014 Apr 1;20(7):1965-77. doi: 10.1158/1078-0432.CCR-13-3122. Epub 2014 Jan 24. PMID: 24463458
374. Kaufman KL, Mactier S, Armstrong NJ, Mallawaarachy D, Byrne SN, Haydu LE, Jakrot V, Thompson JF, Mann GJ, **Scolyer RA**, Christopherson RI. Surface antigen profiles of leukocytes and melanoma cells in lymph node metastases are associated with survival in

- AJCC stage III melanoma patients. *Clin Exp Metastasis*. 2014 Apr;31(4):407-21. doi: 10.1007/s10585-014-9636-7. Epub 2014 Jan 17. PMID: 24435119
375. Kakavand H, Crainic O, Lum T, O'Toole SA, Kefford RF, Thompson JF, Wilmott JS, Long GV, **Scoflyer RA**. Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas. *Pathology*. 2014 Apr;46(3):193-8. DOI: 10.1097/PAT.0000000000000077. PMID: 24614711
 376. Song EJ, Damian DL, **Scoflyer RA**, Thompson JF. Primary oesophageal melanoma - a case report. *World J Surg Oncol*. 2014 Mar 31;12:77. doi: 10.1186/1477-7819-12-77. PMID: 24679002
 377. Parmenter TJ, Kleinschmidt M, Kinross KM, Bond ST, Li J, Kaadige MR, Rao A, Sheppard KE, Hugo W, Pupo GM, Pearson RB, McGee SL, Long GV, **Scoflyer RA**, Rizos H, Lo RS, Cullinan C, Ayer DE, Ribas A, Johnstone RW, Hicks RJ, McArthur GA. Response of BRAF-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis. *Cancer Discov*. 2014 Apr;4(4):423-33. doi: 10.1158/2159-8290.CD-13-0440. Epub 2014 Jan 27. PMID: 24469106
 378. Wilmott JS, Haydu LE, Menzies AM, Lum T, Hyman J, Thompson JF, Hersey P, Kefford RF, **Scoflyer RA**, Long GV. Dynamics of Chemokine, Cytokine, and Growth Factor Serum Levels in BRAF-Mutant Melanoma Patients during BRAF Inhibitor Treatment. *J Immunol*. 2014 Mar 1;192(5):2505-13. doi: 10.4049/jimmunol.1302616. Epub 2014 Jan 31. PMID: 24489105
 379. Gerami P, Busam K, Cochran A, Cook MG, Duncan LM, Elder DE, Fullen DR, Guitart J, Leboit PE, Mihm MC Jr, Prieto VG, Rabkin MS, **Scoflyer RA**, Xu X, Yun SJ, Obregon R, Yazdan P, Cooper C, Weitner BB, Rademaker A, Barnhill RL. Histomorphologic Assessment and Interobserver Diagnostic Reproducibility of Atypical Spitzoid Melanocytic Neoplasms With Long-term Follow-up. *Am J Surg Pathol*. 2014 Mar 10; 38(7):934-940. PMID: 24618612
 380. Zimmer L, Haydu LE, Menzies AM, **Scoflyer RA**, Kefford RF, Thompson JF, Schadendorf D, Long GV. Incidence of new primary melanomas after diagnosis of stage III and IV melanoma. *J Clin Oncol*. 2014 Mar 10;32(8):816-23. doi: 10.1200/JCO.2013.49.5572. Epub 2013 Dec 2. PMID: 24297954
 381. Menzies AM, Lum T, Wilmott JS, Hyman J, Kefford RF, Thompson JF, O'Toole S, Long GV, **Scoflyer RA**. Inpatient homogeneity of BRAFV600E expression in melanoma. *Am J Surg Pathol*. 2014 Mar;38(3):377-82. PMID: 24335665
 382. Griewank KG, van de Nes J, Schilling B, Moll I, Sucker A, Kakavand H, Haydu LE, Asher M, Zimmer L, Hillen U, Thompson JF, **Scoflyer RA**, Schadendorf D, Murali R. Genetic and clinico-pathologic analysis of metastatic uveal melanoma. *Mod Pathol*. 2014 Feb;27(2):175-83. doi: 10.1038/modpathol.2013.138. Epub 2013 Jul 26. PMID: 23887304
 383. Griewank KG, **Scoflyer RA**, Thompson JF, Flaherty KT, Schadendorf D, Murali R. Genetic alterations and personalized medicine in melanoma: progress and future prospects. *J Natl Cancer Inst*. 2014 Feb;106(2):djt435. doi: 10.1093/jnci/djt435. Review. PMID: 24511108
 384. Shi H, Hong A, Kong X, Koya RC, Song C, Moriceau G, Hugo W, Yu CC, Ng C, Chodon T, **Scoflyer RA**, Kefford RF, Ribas A, Long GV, Lo RS. A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. *Cancer Discov*. 2014 Jan;4(1):69-79. doi: 10.1158/2159-8290.CD-13-0279. Epub 2013 Nov 21. PMID: 24265152
 385. van der Ploeg AP, van Akkooi AC, Haydu LE, Scoflyer RA, Murali R, Verhoef C, Thompson JF, Eggermont AM. The prognostic significance of sentinel node tumour burden in melanoma patients: an international, multicenter study of 1539 sentinel node-positive melanoma patients. *Eur J Cancer*. 2014 Jan;50(1):111-20. doi: 10.1016/j.ejca.2013.08.023. Epub 2013 Sep 25. PMID: 24074765
 386. Marzese DM, **Scoflyer RA**, Huynh JL, Huang SK, Hirose H, Chong KK, Kiyohara E, Wang J, Kawas NP, Donovan NC, Hata K, Wilmott JS, Murali R, Buckland ME, Shivalingham B, Thompson JF, Morton DL, Kelly DF, Hoon DS. Epigenome-wide DNA Methylation Landscape of Melanoma Progression to Brain Metastasis Reveals Aberrations on Homeobox D Cluster Associated with Prognosis. *Hum Mol Genet*. 2014 Jan 1;23(1):226-38. doi: 10.1093/hmg/ddt420. Epub 2013 Sep 6. PMID: 24014427
 387. Fogarty GB, Hong A, **Scoflyer RA**, Lin E, Haydu LE, Guitera P, Thompson JF. Radiotherapy for lentigo maligna: a literature review and recommendations for treatment. *Br J Dermatol*. 2014 Jan;170(1):52-8. PMID: 24032599
 388. Wilsher MJ, McCarthy SW, **Scoflyer RA**. Prominent angiotropism in a small atypical spitzoid dysplastic melanocytic naevus: what is its significance? *Pathology*. 2013 Dec;45(7):701-3. PMID: 24247631
 389. **Scoflyer RA**, Judge MJ, Evans A, Frishberg DP, Prieto VG, Thompson JF, Trotter MJ, Walsh MY, Walsh NM, Ellis DW. Data set for pathology reporting of cutaneous invasive melanoma: recommendations from the international collaboration on cancer reporting (ICCR). *Am J Surg Pathol*. 2013 Dec;37(12):1797-814. doi: 10.1097/PAS.0b013e31829d7f35. PMID: 24061524
 390. Dutton-Regester K, Kakavand H, Aoude LG, Stark MS, Gartside MG, Johansson P, O'Connor L, Lanagan C, Tembe V, Pupo GM, Haydu L, Schmidt CW, Mann GJ, Thompson JF, **Scoflyer RA***, Hayward NK*. Melanomas of unknown primary have a mutation profile consistent with cutaneous sun-exposed melanoma. *Pigment Cell Melanoma Res*. 2013 Nov;26(6):852-60. doi: 10.1111/pcmr.12153. Epub 2013 Aug 23. PMID: 23890154
 391. Hu W, Jin L, Jiang CC, Long GV, **Scoflyer RA**, Wu Q, Zhang XD, Mei Y, Wu M. AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma. *Cell Death Dis*. 2013 Nov 7;4:e914. DOI: 10.1038/cddis.2013.441 PMID: 24201813
 392. Hruby G, **Scoflyer RA**, Thompson JF. The important role of radiation treatment in the management of Merkel cell carcinoma. *Br J Dermatol*. 2013 Nov;169(5):975-82. doi: 10.1111/bjd.12481. Review. PMID: 23898924
 393. Niebling MG, Haydu LE, Karim RZ, Thompson JF, **Scoflyer RA**. Reproducibility of AJCC Staging Parameters in Primary Cutaneous Melanoma: An Analysis of 4,924 Cases. *Ann Surg Oncol*. 2013 Nov;20(12):3969-75. doi: 10.1245/s10434-013-3092-5. Epub 2013 Jul 13. PMID: 23851608
 394. Murai R, **Scoflyer RA**, Thompson JF. Completion lymph node dissection in melanoma patients with positive sentinel lymph nodes. *Eur J Surg Oncol*. 2013 Oct;39(10):1164-5. doi: 10.1016/j.ejso.2013.07.006. Epub 2013 Jul 24. PMID: 23890716
 395. Schramm S-J, Li SS, Jayaswal V, Fung DCY, Campain AE, Pang CNI, **Scoflyer RA**, Yang YH, Mann GJ, Wilkins MR. Disturbed protein-protein interaction networks in metastatic melanoma are associated with worse prognosis and increased functional mutation burden. *Pigment Cell Melanoma Res*. 2013 Sep;26(5):708-22. doi: 10.1111/pcmr.12126. Epub 2013 Jul 5. PMID: 23738911
 396. Murali R, Wilmott JS, Jakrot V, Al-Ahmadie HA, Wiesner T, McCarthy SW, Thompson JF, **Scoflyer RA**. BAP1 expression in cutaneous melanoma: a pilot study. *Pathology*. 2013 Oct;45(6):606-9. PMID: 24018818
 397. Kakavand H, **Scoflyer RA**, Thompson JF, Mann GJ. Identification of new prognostic biomarkers for Stage III metastatic melanoma patients. *Oncimmunology*. 2013 Sep 1;2(9):e25564. Epub 2013 Jul 3. PMID: 24228228
 398. Dong L, Jin L, Tseng H-Y, Wang CY, Wilmott JS, Yosufi B, Yan BG, Jiang CC, **Scoflyer RA**, Zhang XD, Guo ST. Oncogenic Suppression of PHLPP1 in Human Melanoma. *Oncogene*. 2014 Sep 25;33(39):4756-66. doi: 10.1038/onc.2013.420. Epub 2013 Oct 14. PMID: 24121273

399. Gerami P, Cooper C, Bajaj S, Wagner A, Fullen D, Busam K, **Scoflyer RA**, Xu X, Elder DE, Abraham RM, Prieto VG, Guitart J, Liu P, Pestova E, Barnhill RL. Outcomes of atypical spitz tumors with chromosomal copy number aberrations and conventional melanomas in children. *Am J Surg Pathol*. 2013 Sep;37(9):1387-94. PMID:23797719
400. Mar VJ, Wong SQ, Li J, **Scoflyer RA**, McLean C, Papenfuss AT, Tothill RW, Kakavand H, Mann GJ, Thompson JF, Behren A, Cebon JS, Wolfe R, Kelly JW, Dobrovic A, McArthur GA. BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage. *Clin Cancer Res*. 2013 Sep 1;19(17):4589-98. doi: 10.1158/1078-0432.CCR-13-0398. Epub 2013 Jul 5. PMID: 23833303
401. Harish V, Bond JS, **Scoflyer RA**, Haydu LE, Saw RP, Quinn MJ, Bengner RS, Uren RF, Stretch JR, Shannon KF, Thompson JF. Margins of excision and prognostic factors for cutaneous eyelid melanomas. *J Plast Reconstr Aesthet Surg*. 2013 Aug;66(8):1066-73. doi: 10.1016/j.bjps.2013.04.032. Epub 2013 May 17. PMID: 23688975
402. Ryu SW, Saw R, **Scoflyer RA**, Crawford M, Thompson JF, Sandroussi C. Liver resection for metastatic melanoma: Equivalent survival for cutaneous and ocular primaries. *J Surg Oncol*. 2013 Aug;108(2):129-35. doi: 10.1002/jso.23361. Epub 2013 Jun 27. PMID: 23813600
403. Shiao CJ, Thompson JF, **Scoflyer RA**. Controversies and evolving concepts in the diagnosis, classification and management of lentigo maligna. *Expert Rev Dermatol*. April 2013, Vol. 8, No. 2, Pages 195-214. DOI: 10.1586/edm.13.17. EID: 2-s2.0-84875747030. (not in PubMed)
404. Delahunt B, **Scoflyer RA**, Srigley JR. Premalignancy: the lull before the storm. *Pathology*. 2013 Apr;45(3):207-8. doi: 10.1097/PAT.0b013e32835f618e. PMID: 23503325
405. Long GV, Wilmott JS, Haydu LE, Tembe V, Sharma R, Rizos H, Thompson JF, Howle J, **Scoflyer RA**, Kefford RF. Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment, and on progression. *Pigment Cell Melanoma Res*. 2013 Jul;26(4):499-508. doi: 10.1111/pcmr.12098. Epub 2013 May 3. PMID: 23557327
406. Pasquali S, van der Ploeg AP, Mocellin S, Stretch JR, Thompson JF, **Scoflyer RA**. Lymphatic biomarkers in primary melanomas as predictors of regional lymph node metastasis and patient outcomes. *Pigment Cell Melanoma Res*. 2013 May;26(3):326-37. doi: 10.1111/pcmr.12064. Epub 2013 Feb 4. Review. PMID: 23298266
407. Becker TM, Boyd SC, Mijatov B, Gowrishankar K, Snoyman S, Pupo GM, **Scoflyer RA**, Mann GJ, Kefford RF, Zhang XD, Rizos H. Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor. *Oncogene*. 2014 Feb 27;33(9):1158-66. doi: 10.1038/onc.2013.45. Epub 2013 Mar 4. PMID: 23455323
408. Ye Y, Jin L, Wilmott JS, Hu WL, Yosufi B, Thorne RF, Liu T, Rizos H, Yan XG, Dong L, Tay KH, Tseng HY, Guo ST, de Bock CE, Jiang CC, Wang CC, Wu M, Zhang LJ, Hersey P, **Scoflyer RA**, Zhang XD. PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma. *Nat Commun*. 2013 Feb 26;4:1508. PMID: 23443536
409. Karim RZ, O'Toole SA, **Scoflyer RA**, Cooper CL, Chan B, Selinger C, Yu B, Carmalt H, Mak C, Tse GM, Tan PH, Putti TC, Lee CS. Recent insights into the molecular pathogenesis of mammary phyllodes tumours. *J Clin Pathol*. 2013 Jun;66(6):496-505. doi: 10.1136/jclinpath-2012-201082. Epub 2013 Feb 12. Review. PMID: 23404800
410. Fung C, Pupo G, **Scoflyer RA**, Kefford RF, Rizos H. p16(INK) (4a) deficiency promotes DNA hyper-replication and genetic instability in melanocytes. *Pigment Cell Melanoma Res*. 2013 Mar;26(2):236-46. doi: 10.1111/pcmr.12062. Epub 2013 Jan 24. PMID: 23279822
411. Wilmott JS, Menzies AM, Haydu LE, Capper D, Preusser M, Zhang YE, Thompson JF, Kefford RF, von Deimling A, **Scoflyer RA**, Long GV. BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma. *Br J Cancer*. 2013 Mar 5;108(4):924-31. doi: 10.1038/bjc.2013.29. Epub 2013 Feb 12. PMID: 23403819
412. Cho EA, Moloney FJ, Cai H, Au-Yeung A, China C, **Scoflyer RA**, Yosufi B, Raftery MJ, Deng JZ, Morton SW, Hammond PT, Arkenau HT, Damian DL, Francis DJ, Chesterman CN, Barnetson RS, Halliday GM, Khachigian LM. Safety and tolerability of an intratumorally injected DNase, Dz13, in patients with nodular basal-cell carcinoma: a phase 1 first-in-human trial (DISCOVER). *Lancet*. 2013 May 25;381(9880):1835-43. doi: 10.1016/S0140-6736(12)62166-7. Epub 2013 May 7. PMID: 23660123
413. Gerami P, **Scoflyer RA**, Xu X, Elder DE, Abraham RM, Fullen D, Prieto VG, Leboit PE, Barnhill RL, Cooper C, Yazdan P, Guitart J, Liu P, Pestova E, Busam K. Risk Assessment for Atypical Spitzoid Melanocytic Neoplasms Using FISH to Identify Chromosomal Copy Number Aberrations. *Am J Surg Pathol*. 2013 May;37(5):676-84. PMID: 23388126
414. Pasquali S, Haydu LE, **Scoflyer RA**, Winstanley JB, Spillane AJ, Quinn MJ, Saw RP, Shannon KF, Stretch JR, Thompson JF. The importance of adequate primary tumor excision margins and sentinel node biopsy in achieving optimal locoregional control for patients with thick primary melanomas. *Ann Surg*. 2013 Jul;258(1):152-7. PMID: 23426339
415. Wevers KP, Murali R, Bastiaannet E, **Scoflyer RA**, Suurmeijer AJ, Thompson JF, Hoekstra HJ. Assessment of a new scoring system for predicting non-sentinel node positivity in sentinel node-positive melanoma patients. *Eur J Surg Oncol*. 2013 Feb;39(2):179-84. doi: 10.1016/j.ejso.2012.10.014. Epub 2012 Nov 6. PMID: 23137997
416. Menzies SW, Moloney FJ, Byth K, Avramidis M, Argenziano G, Zalaudek I, Braun RP, Malvey J, Puig S, Rabinovitz HS, Oliviero M, Cabo H, Bono R, Pizzichetta MA, Claeson M, Gaffney DC, Soyer HP, Stanganelli I, **Scoflyer RA**, Guitera P, Kelly J, McCurdy O, Llambrich A, Marghoob AA, Zaballos P, Kirchesch HM, Piccolo D, Bowling J, Thomas L, Terstappen K, Tanaka M, Pellacani G, Pagnanelli G, Ghigliotti G, Ortega BC, Crafter G, Perusquia Ortiz AM, Tromme I, Karaarslan IK, Ozdemir F, Tam A, Landi C, Norton P, Kacar N, Rudnicka L, Slowinska M, Simionescu O, Di Stefani A, Coates E, Kreusch J. Dermoscopic evaluation of nodular melanoma. *JAMA Dermatol*. 2013 Jun;149(6):699-709. doi: 10.1001/jamadermatol.2013.2466. PMID: 23553375
417. Guitera P, Moloney FJ, Menzies SW, Stretch JR, Quinn MJ, Hong A, Fogarty G, **Scoflyer RA**. Improving management and patient care in lentigo maligna by mapping with in vivo confocal microscopy. *JAMA Dermatol*. 2013 Jun;149(6):692-8. doi: 10.1001/jamadermatol.2013.2301. PMID: 23553208
418. Boyd SC, Mijatov B, Pupo GM, Tran SL, Gowrishankar K, Shaw HM, Goding CR, **Scoflyer RA**, Mann GJ, Kefford RF, Rizos H, Becker TM. Oncogenic B-RAF(V600E) signaling induces the T-Box3 transcriptional repressor to repress E-cadherin and enhance melanoma cell invasion. *J Invest Dermatol*. 2013 May;133(5):1269-77. doi: 10.1038/jid.2012.421. Epub 2012 Nov 29. PMID: 23190890
419. **Scoflyer RA**, Thompson JF, O'Toole SA, Karim RZ, Mihm MC Jr, McCarthy SW, Murali R. Recent advances and important issues in melanoma pathology: an update for oncologists. *Cancer Forum*, Nov 2012, Vol.36(3), p.151-158. EID: 2-s2.0-84873440474. *via USyd library (no in PubMed)* http://cancerforum.org.au/Issues/2012/November/Forum/Recent_advances_melanoma_pathology_update_oncologists.htm
420. **Scoflyer RA**, Thompson JF. Mitotic rate in melanoma should be recorded as the number of mitoses per mm² (not per high power field): surgeons tell your pathologists! *Am J Surg*. 2013 Jul;206(1):142-3. doi: 10.1016/j.amjsurg.2012.11.012. Epub 2013 May 10. PMID: 23668722
421. **Scoflyer RA**, Thompson JF. Biospecimen banking: the pathway to personalized medicine for patients with cancer. *J Surg Oncol*. 2013 Jun;107(7):681-2. doi: 10.1002/jso.23309. Epub 2012 Dec 27. PMID: 23280671

422. Murali, Weisner T, **Scoflyer RA**. Tumours associated with BAP1 mutations. *Pathology*. 2013 Feb;45(2):116-26. PMID: 23277170
423. Murali R, **Scoflyer RA**, Armstrong BK. Multiple primary cutaneous melanomas: recent studies highlight features associated with more indolent behaviour. *Pathology*. 2013 Jan;45(1):1-3. PMID: 23255028
424. Bogun Y, **Scoflyer RA**, Guitera P. Asymptomatic linear pigmentation of the skin. Linear lichen planus pigmentus (LPP). *Int J Dermatol*. 2013 Aug;52(8):935-7. PMID: 23869926
425. Wilmott JS*, Tembe V*, Howle JR, Sharma R, Thompson JF, Rizos H, Lo RS, Kefford RF, **Scoflyer RA**, Long GV. Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine. *Mol Cancer Ther*. 2012 Dec;11(12):2704-8. doi: 10.1158/1535-7163.MCT-12-0530. Epub 2012 Sep 7. PMID: 22962325
426. **Scoflyer RA**, Karim RZ, Thompson JF, Stretch JR, McCarthy SW, Murali R. Digital papillary adenocarcinoma: a tumour that should be considered in the differential diagnosis of neoplasms involving the digits. *Pathology*. 2013 Jan;45(1):55-61. PMID: 23255030
427. Anforth RM, Blumetti TCMPI, Kefford RF, Sharma R, **Scoflyer RA**, Kossard S, Long GV, Fernandez-Penas P. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. *Br J Dermatol*. 2012 Nov;167(5):1153-60. Epub 2012 Oct 5. PMID: 22804352
428. Lian CG, Xu Y, Ceol C, Wu F, Larson A, Dresser K, Xu W, Tan L, Zhan Q, Lee C-W, Hu D, Lian BQ, Kleffel S, Yang Y, Khorasani AJ, Lezcano C, Duncan LM, **Scoflyer RA**, Thompson JF, Kakavand H, Houvras Y, Zon L, Mihm MC Jr, Kaiser UB, Schatton T, Woda BA, Murphy GF, Shi YG. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. *Cell*. 2012 Sep 14;150(6):1135-46. PMID:22980977
429. Long GV*, Wilmott JS*, Capper D, Preusser M, Thompson JF, Kefford RF, von Deimling A, **Scoflyer RA**. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. *Am J Surg Pathol*. 2013 Jan;37(1):61-5. PMID: 23026937
430. Kim J, McCarthy SW, Thompson JF, Pupo GM, Vonthethoff L, Nash P, Mann GJ, **Scoflyer RA**. Cellular blue naevus involving the urinary bladder. *Pathology*. 2012 Dec;44(7):664-8. PMID: 23172087
431. Mann GJ, Pupo GM, Campain AE, Carter CD, Schramm S-J, Pianova S, Gerega SK, De Silva C, Lai K, Wilmott JS, Synnott M, Hersey P, Kefford RF, Thompson JF, Yang YH, **Scoflyer RA**. BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma. *J Invest Dermatol*. 2013 Feb;133(2):509-17. Epub 2012 Aug 30. PMID: 22931913
432. Murali R, **Scoflyer RA**. Thompson JF. Can we better identify thin cutaneous melanomas that are likely to metastasize and cause death? *Ann Surg Oncol*. 2012 Oct;19(11):3310-2. doi: 10.1245/s10434-012-2470-8. Epub 2012 Jul 10. PMID: 22777079
433. Murali R, Brown PT, Kefford RF, **Scoflyer RA**, Thompson JF, Atkins MB, Long GV. Number of primary melanomas is an independent predictor of survival in patients with metastatic melanoma. *Cancer*. 2012 Sep 15;118(18):4519-29. doi: 10.1002/cncr.27693. Epub 2012 Jun 26. PMID: 22736239
434. Lim CS, Whalley D, Haydu LE, Murali R, Tippet J, Thompson JF, Hruby G, **Scoflyer RA**. Increasing tumor thickness is associated with recurrence and poorer survival in patients with Merkel cell carcinoma. *Ann Surg Oncol*. 2012 Oct;19(11):3325-34. doi: 10.1245/s10434-012-2509-x. Epub 2012 Jul 21. PMID: 22820936
435. Thompson JF, **Scoflyer RA**, Kefford RF. Melanoma - a management guide for GPs. *Aust Fam Physician*. 2012 Jul;41(7):470-3. PMID: 22762064
436. Halliday G, Zhou Y, Sou P, Huang X, Rana S, Bugeja M, Painter N, **Scoflyer R**, Muchardt C, Di Girolamo N, Lyons G. The absence of Brm exacerbates photocarcinogenesis. *Exp Dermatol*. 2012 Aug;21(8):599-604. doi: 10.1111/j.1600-0625.2012.01522.x. PMID: 22775994
437. Azimi F*, **Scoflyer RA***, Rumcheva P, Moncrieff M, Murali R, McCarthy SW, Saw RP, Thompson. JF (*joint first authors=contributed equally to this work). Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. *J Clin Oncol*. 2012 Jul 20;30(21):2678-83. doi: 10.1200/JCO.2011.37.8539. Epub 2012 Jun 18. PMID: 22711850
438. Guitera P, Menzies SW, Longo C, Cesinaro AM, **Scoflyer RA**, Pellacani G. In vivo confocal microscopy for diagnosis of melanoma and basal cell carcinoma using a two-step method: analysis of 710 consecutive clinically equivocal cases. *J Invest Dermatol*. 2012 Oct;132(10):2386-2394. doi: 10.1038/jid.2012.172. Epub 2012 Jun 21. PMID: 22718115
439. Wilmott JS, Haydu LE, Bagot M, Zhang E, Jakrot V, McCarthy SW, Lugassy C, Thompson JF, **Scoflyer RA**, Barnhill RL. Angiotropism is an independent predictor of microscopic satellites in primary cutaneous melanoma. *Histopathology*. 2012 Nov;61(5):889-98. doi: 10.1111/j.1365-2559.2012.04279.x. Epub 2012 Jun 20. PMID:22716270
440. Tsang JYS, Mendoza P, Putti TC, Karim RZ, **Scoflyer RA**, Lee CS, Pang ALM Tse GM. E-cadherin expression in the epithelial components of mammary phyllodes tumors. *Hum Pathol*. 2012 Dec;43(12):2117-23. doi: 10.1016/j.humpath.2012.03.028. Epub 2012 Jul 21. PMID: 22820000
441. Shayan R, Karnezis T, Murali R, Wilmott JS, Ashton MW, Taylor GI, Thompson JF, Hersey P, Achen MG, **Scoflyer RA**, Stacker SA. Lymphatic vessel density in primary melanomas predicts sentinel lymph node status and risk of metastasis. *Histopathology*. 2012 Oct;61(4):702-10. doi: 10.1111/j.1365-2559.2012.04310.x. PMID:22734806
442. Salim A, Karim RZ, McCarthy SW, **Scoflyer RA**. Endocrine mucin producing sweat gland carcinoma: a clinicopathological analysis of three cases. *Pathology*. 2012 Oct;44(6):568-71. DOI:10.1097/PAT.0b013e32835833d8. PMID: 22935981
443. Chua TC, **Scoflyer RA**, Kennedy CW, Yan TD, McCaughan BC, Thompson JF. Surgical Management of Melanoma Lung Metastasis: An Analysis of Survival Outcomes in 292 Consecutive Patients. *Ann Surg Oncol*. 2012 Jun;19(6):1774-81. doi: 10.1245/s10434-011-2197-y. PMID: 22290565
444. Guitera P, **Scoflyer RA**, Gill M, Akita H, Arima M, Yokoyama Y, Matsunaga K, Longo C, Bassoli S, Bencini PL, Giannotti R, Pellacani G, Alessi-Fox C, Dalrymple C. Reflectance confocal microscopy for diagnosis of mammary and extramammary Paget's disease. *J Eur Acad Dermatol Venereol*. 2013 Jan;27(1):e24-9. doi: 10.1111/j.1468-3083.2011.04423.x. Epub 2012 Jan 3. PMID: 22211938
445. Wilmott JS, **Scoflyer RA**, Long GV, Hersey P. Combined targeted therapy and immunotherapy in the treatment of advanced melanoma. *Oncoimmunology*. 2012 Sep 1;1(6):997-999. PMID: 23189245
446. Koh SS, Wei JP, Li X, Huang RR, Doan NB, **Scoflyer RA**, Cochran AJ, Binder SW. Differential gene expression profiling of primary cutaneous melanoma and sentinel lymph node metastases. *Mod Pathol*. 2012 Jun;25(6):828-37. doi: 10.1038/modpathol.2012.32. Epub 2012 Mar 9. PMID: 22411186

447. Huynh KT, Takei Y, Kuo C, **Scolyer RA**, Murali R, Chong K, Takeshima L, Sim MS, Morton DL, Turner RR, Thompson JF, Hoon DS. Aberrant hypermethylation in primary tumours and sentinel lymph node metastases in paediatric patients with cutaneous melanoma. *Br J Dermatol*. 2012 Jun;166(6):1319-26. doi: 10.1111/j.1365-2133.2012.10867.x. Epub 2012 May 18. PMID: 22293026
448. Murali R, Haydu LE, Long GV, Quinn MJ, Saw RPM, Shannon K, Stretch JR, Kefford RF, Thompson JF, **Scolyer RA**. Clinical and pathologic factors associated with distant metastasis and survival in patients with thin primary cutaneous melanoma. *Ann Surg Oncol*. 2012 Jun;19(6):1782-9. Epub 2012 Feb 14. PMID: 22350600
449. Burmeister BH, Henderson MA, Ainslie J, Fisher R, Di Iulio J, Smithers BM, Hong A, Shannon K, **Scolyer RA**, Carruthers S, Coventry BJ, Babington S, Duprat J, Hoekstra HJ, Thompson JF. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. *Lancet Oncol*. 2012 Jun;13(6):589-97. Epub 2012 May 9. PMID: 22575589
450. Menzies AM, Haydu LE, Visintin L, Carlino MS, Howle JR, Thompson JF, Kefford RF, **Scolyer RA**, Long GV. Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-mutant Metastatic Melanoma. *Clin Cancer Res* 2012 Jun 15;18(12):3242-9. Epub 2012 Apr 24. PMID: 22535154
451. in 't Hout FE, Haydu LE, Murali R, Bonenkamp JJ, Thompson JF, **Scolyer RA**. Prognostic importance of the extent of ulceration in patients with clinically localized cutaneous melanoma. *Ann Surg*. 2012 Jun;255(6):1165-70. doi: 10.1097/SLA.0b013e31824c4b0b. PMID: 22566014
452. Tsang JY, Mendoza P, Lam CC, Yu AM, Putti TC, Karim RZ, **Scolyer RA**, Lee CS, Tan PH, Tse GM. Involvement of α - and β -catenins and E-cadherin in the development of mammary phyllodes tumours. *Histopathology*. 2012 May 9;61(4):667-674. PMID: 22571452
453. Huang XX, **Scolyer RA**, Abubakar A, Halliday GM. Human 8-oxoguanine-DNA glycosylase-1 is downregulated in human basal cell carcinoma. *Mol Genet Metab*. 2012 May;106(1):127-30. Epub 2012 Mar 3. PMID: 22436579
454. Dutton-Regester K, Aoude LG, Nancarrow DJ, Stark MS, O'Connor L, Lanagan C, Pupo GM, Tembe V, Carter CD, O'Rourke M, **Scolyer RA**, Mann GJ, Schmidt CW, Herington A, Hayward NK. Identification of TFG (TRK-fused gene) as a putative metastatic melanoma tumor suppressor gene. *Genes Chromosomes Cancer*. 2012 May;51(5):452-61. doi: 10.1002/gcc.21932. Epub 2012 Jan 17. PMID: 22250051
455. Tran SL, Haferkamp S, Scurr LL, Gowrishankar K, Becker TM, Desilva C, Thompson JF, **Scolyer RA**, Kefford RF, Rizos H. Absence of distinguishing senescence traits in human melanocytic nevi. *J Invest Dermatol*. 2012 Sep;132(9):2226-34. doi: 10.1038/jid.2012.126. Epub 2012 Apr 19. PMID: 22513787
456. Dutton-Regester K, Irwin D, Hunt P, Aoude LG, Tembe V, Pupo GM, Lanagan C, Carter CD, O'Connor L, O'Rourke M, **Scolyer RA**, Mann GJ, Schmidt CW, Herington A, Hayward NK. A high-throughput panel for identifying clinically relevant mutation profiles in melanoma. *Mol Cancer Ther*. 2012 Apr;11(4):888-97. Epub 2012 Mar 1. PMID: 22383533
457. Murali R, deSila CD, McCarthy SW, Thompson JF, **Scolyer RA**. Sentinel lymph nodes containing very small (<0.1mm) deposits of metastatic melanoma cannot be safely regarded as tumor-negative. *Ann Surg Oncol*. 2012 Apr;19(4):1089-99. dEpub 2012 Jan 21. PMID: 22271204
458. Lim CS, Thompson JF, McKenzie PR, McCarthy SW, **Scolyer RA**. Peritoneal melanosis associated with metastatic melanoma involving the omentum. *Pathology*. 2012 Apr;44(3):255-7. doi: 10.1097/PAT.0b013e3283514015. PMID: 22437742
459. Girouard SD, Laga AC, Mihm MC, **Scolyer RA**, Thompson JF, Zhan Q, Widlund HR, Lee CW, Murphy GF. SOX2 contributes to melanoma cell invasion. *Lab Invest*. 2012 Mar;92(3):362-70. doi: 10.1038/labinvest.2011.188. Epub 2011 Dec 19. PMID: 22184093
460. Shi H, Moriceau G, Kong X, Lee M-K, Lee H, Koya RC, Ng C, Chodon T, **Scolyer RA**, Dahlman KB, Sosman JA, Kefford RF, Long GV, Nelson SF, Ribas A, Lo RS. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. *Nat Commun*. 2012 Mar 6;3:724. doi: 10.1038/ncomms1727. PMID: 22395615
461. Wilmott JS, Long GV, Howle JR, Haydu LE, Sharma R, Thompson JF, Kefford RF, Hersey P, **Scolyer RA**. Selective BRAF inhibitors induce marked T cell infiltration into human metastatic melanoma. *Clin Cancer Res*. 2012 Mar 1;18(5):1386-94. doi: 10.1158/1078-0432.CCR-11-2479. Epub 2011 Dec 12. PMID: 22156613
462. Richard A. Scolyer, Artur Zembowicz, (2012) In Reply. Letters to the Editor. *Archives of Pathology & Laboratory Medicine*: February 2012, Vol. 136, No. 2, pp. 136-137. Doi.org/10.5858/arpa.2011-0451-LE. PMID: 21366452 for original article (not in PubMed)
463. Murali R, Goumas C, Krickler A, From L, Busam KJ, Begg CB, Dwyer T, Gruber SB, Kanetsky PA, Orlov I, Rosso S, Thomas NE, Berwick M, **Scolyer RA**, Armstrong BK; For the GEM Study Group. Clinicopathologic Features of Incident and Subsequent Tumors in Patients with Multiple Primary Cutaneous Melanomas. *Ann Surg Oncol*. 2012 Mar;19(3):1024-33. doi: 10.1245/s10434-011-2058-8. Epub 2011 Sep 13. Erratum in: *Ann Surg Oncol*. 2013 Dec; 30 Suppl 3:S747-8. PMID: 21913010
464. Schramm SJ, Campaign AE, **Scolyer RA**, Yang YH, Mann GJ. Review and cross-validation of gene expression signatures and melanoma prognosis. *J Invest Dermatol*. 2012 Feb;132(2):274-83. doi: 10.1038/jid.2011.305. Epub 2011 Sep 29. PMID: 21956122
465. Cheung BB, Koach J, Tan O, Kim P, Bell JL, D'andreti C, Sutton S, Malyukova A, Sekyere E, Norris M, Haber M, Kavallaris M, Cunningham AM, Proby C, Leigh I, Wilmott JS, Cooper CL, Halliday GM, **Scolyer RA**, Marshall GM. The retinoid signalling molecule, TRIM16, is repressed during squamous cell carcinoma skin carcinogenesis in vivo and reduces skin cancer cell migration in vitro. *J Pathol* 2012 Feb;226(3):451-62. doi: 10.1002/path.2986. Epub 2011 Oct 18. PMID: 22009481
466. Murali R, Haydu LE, Quinn MJ, Saw R, Shannon K, Spillane AJ, Stretch JR, Thompson JF, **Scolyer RA**. Sentinel lymph node biopsy in patients with thin primary cutaneous melanoma. *Ann Surg*. 2012 Jan;255(1):128-33. doi: 10.1097/SLA.0b013e3182306c72. PMID: 21975320
467. Nielsen KR, Chakera AH, Hesse B, **Scolyer RA**, Stretch JF, Thompson JF, Nielsen MB, Uren RF, Oturai PS. The diagnostic value of adding dynamic scintigraphy to standard delayed planar imaging for sentinel node identification in melanoma patients. *Eur J Nucl Med Mol Imaging*. 2011 Nov;38(11):1999-2004. doi: 10.1007/s00259-011-1880-3. Epub 2011 Aug 17. PMID: 21847637
468. Verwer N, **Scolyer RA**, Uren RF, Winstanley J, Brown PT, de Wilt JH, Thompson JF. Treatment and Prognostic Significance of Positive Interval Sentinel Nodes in Patients with Primary Cutaneous Melanoma. *Ann Surg Oncol*. 2011 Nov;18(12):3292-9. doi: 10.1245/s10434-011-1988-5. Epub 2011 Sep 13. PMID: 21913021
469. Scurr LL, McKenzie HA, Becker TM, Irvine M, Lai K, Mann GJ, **Scolyer RA**, Kefford RF, Rizos HM. Selective loss of wild-type p16INK4a expression in human nevi. *J Invest Dermatol*. 2011 Nov;131(11):2329-32. doi: 10.1038/jid.2011.197. Epub 2011 Jul 7. PMID: 21734716
470. Wilmott JS, Zhang XD, Hersey P, **Scolyer RA**. The emerging important role of microRNAs in the pathogenesis, diagnosis and treatment of human cancers. *Pathology*. 2011 Oct;43(6):657-71. doi: 10.1097/PAT.0b013e32834a7358. PMID: 21876471

471. Jin L, Hu WL, Jiang CC, Wang JX, Han CC, Chu P, Zhang LJ, Thorne RF, Wilmott J, **Scoflyer RA**, Hersey P, Zhang XD, Wu M. MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma. *Proc Natl Acad Sci U S A*. 2011 Sep 20;108(38):15840-5. doi: 10.1073/pnas.1019312108. Epub 2011 Sep 6. PMID: 21896753
472. Schrama D, Peitsch WK, Zapotka M, Kneitz H, Houben R, Eib S, Haferkamp S, Moore PS, Shuda M, Thompson JF, Trefzer U, Pföhler C, **Scoflyer RA**, Becker JC. Merkel cell polyomavirus status is not associated with clinical course of Merkel cell carcinoma. *J Invest Dermatol*. 2011 Aug;131(8):1631-8. doi: 10.1038/jid.2011.115. Epub 2011 May 12. PMID: 21562568
473. Bock VL, Lyons JG, Huang XX, Jones AM, McDonald LA, **Scoflyer RA**, Moloney FJ, Barnetson RS, Halliday GM. BRM and BRG1 subunits of the SWI/SNF chromatin remodelling complex are downregulated upon progression of benign skin lesions into invasive tumours. *Br J Dermatol*. 2011 Jun;164(6):1221-7. doi: 10.1111/j.1365-2133.2011.10267.x. Epub 2011 May 13. PMID: 21564052
474. Murali R, Desilva C, Thompson JF, **Scoflyer RA**. Factors predicting recurrence and survival in sentinel lymph node-positive melanoma patients. *Ann Surg*. 2011 Jun;253(6):1155-64. PMID: 21412144
475. Murali R, Zannino D, Synnott M, McCarthy SW, Thompson JF, **Scoflyer RA**. Clinical and pathological features of metastases of primary cutaneous desmoplastic melanoma. *Histopathology*. 2011 May;58(6):886-95. doi: 10.1111/j.1365-2559.2011.03808.x. Epub 2011 Mar 25. PMID: 21438911
476. Murali R, Desilva C, Thompson JF, **Scoflyer RA**. Non-Sentinel Node risk score: reply to letter to the editor. *J Clin Oncol*. Apr 10, 2011:e316-e317. *Original manuscript's PMID: 20823419*
477. **Scoflyer RA**, Long GV, Thompson JF. Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care. *Mol Oncol*. 2011 Apr;5(2):124-36. doi: 10.1016/j.molonc.2011.03.002. Epub 2011 Mar 21. PMID: 21482206
478. Bauer J, Buettner P, Murali R, Okamoto I, Kolaitis NA, Landi MT, **Scoflyer RA**, Bastian BC. BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor and the degree of solar elastosis at the primary tumor site. *Pigment Cell Melanoma Res*. 2011 Apr;24(2):345-51. PMID: 21324100
479. Rajmohan Murali, Chitra Desilva, John F. Thompson, and Richard A. Scoflyer. Reply to I. Satzger et al (original article PMID: 20823419). *Journal of Clinical Oncology* 2011 29:11, e316-e317. (Reply not in PubMed)
480. Long GV, Menzies AM, Nagrial AM, Haydu L, Hamilton AL, Mann GJ, Hughes TM, Thompson JF, **Scoflyer RA**, Kefford RF. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. *J Clin Oncol*. 2011 Apr 1;29(10):1239-46. Epub 2011 Feb 22. PMID: 21343559
481. Zembowicz A, **Scoflyer RA**. Nevus/melanocytoma/melanoma: an emerging paradigm for classification of melanocytic neoplasms? *Arch Pathol Lab Med*. 2011 Mar;135(3):300-6. doi: 10.1043/2010-0146-RA.1. Review. PMID:21366452
482. Svobodová S, Browning J, Macgregor D, Pollara G, **Scoflyer RA**, Murali R, Thompson JF, Deb S, Azad A, Davis ID, Cebon JS. Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate. *Eur J Cancer*. 2011 Feb;47(3):460-9. doi: 10.1016/j.ejca.2010.09.042. Epub 2010 Nov 4. PMID: 21115342
483. Hersey P, Smalley KS, Weeraratna A, Bosenberg M, Zhang XD, Haass NK, Paton E, Mann G, **Scoflyer RA**. Meeting report from the 7th International Melanoma Congress, Sydney, November, 2010. *Pigment Cell Melanoma Res*. 2011 Feb;24(1):e1-15. doi: 10.1111/j.1755-148X.2010.00811.x. Epub 2010 Dec 22. Erratum in: *Pigment Cell Melanoma Res*. 2011 Oct;24(5):989. Tüting, T [added]. PMID: 21232023
484. Hollingsworth J, Cooper WA, Nicoll KD, Wills EJ, Thiruvilangam V, Lee CS, **Scoflyer RA**. Follicular dendritic cell sarcoma of the lung: a report of two cases highlighting its pathological features and diagnostic pitfalls. *Pathology*. 2011 Jan;43(1):67-70. doi: 10.1097/PAT.0b013e3283419e2a. No abstract available. Erratum in: *Pathology*. 2011 Apr;43(3):294. PMID: 21240069
485. **Scoflyer RA**, Prieto VG. Melanoma pathology: important issues for clinicians involved in the multidisciplinary care of melanoma patients. *Surg Oncol Clin N Am*. 2011 Jan;20(1):19-37. PMID: 21111957
486. Lim CS, Cooper CL, Delprado W, Kench J, McCarthy SW, **Scoflyer RA**. Retroperitoneal inflammatory liposarcoma in a patient with non-hodgkin lymphoma: a report highlighting diagnostic pitfalls. *Patholog Res Int*. 2010 Dec 5;2010:505436. doi: 10.4061/2010/505436. PMID: 21188206
487. **Scoflyer RA**, Murali R, McCarthy SW, Thompson JF. Histologically ambiguous ("borderline") primary cutaneous melanocytic tumors: approaches to patient management including the roles of molecular testing and sentinel lymph node biopsy. *Arch Pathol Lab Med*. 2010 Dec;134(12):1770-7. doi: 10.1043/2009-0612-RAR.1. PMID: 21128774
488. Broekaert SMC, Roy R, Okamoto I, van den Oord J, Bauer J, Garbe C, Barnhill RL, Busam KJ, Cochran AJ, Cook MG, Elder DE, McCarthy SW, Mihm MC, Schadendorf D, **Scoflyer RA**, Spatz A, Bastian BC. Genetic and morphologic features for melanoma classification. *Pigment Cell Melanoma Res*. 2010 Dec;23(6):763-70. PMID:20874733
489. Murali R, Moncrieff MD, Hong J, Cooper CL, Shingde MV, Samuel DG, Thompson JF, **Scoflyer RA**. The prognostic value of tumor mitotic rate and other clinicopathologic factors in patients with locoregional recurrences of melanoma. *Ann Surg Oncol*. 2010 Nov;17(11):2992-9. Epub 2010 Apr 28. PMID: 20425144
490. Cadili A, **Scoflyer RA**, Brown PT, Dabbs K, Thompson JF. Total Sentinel Lymph Node Tumor Size Predicts Nonsentinel Node Metastasis and Survival in Patients with Melanoma. *Ann Surg Oncol*. 2010 Nov;17(11):3015-20. Epub 2010 Jun 15. PMID: 20552405
491. Martiniuk F, Damian DL, Thompson JF, **Scoflyer RA**, Tchou-Wong KM, Levis WR. TH17 is involved in the remarkable regression of metastatic malignant melanoma to topical diphenylpyrone. *J Drugs Dermatol*. 2010 Nov;9(11):1368-72. PMID: 21061759
492. Murali R, Desilva C, Thompson JF, **Scoflyer RA**. Non-Sentinel Node Risk Score (N-SNORE): a scoring system for accurately stratifying risk of non-sentinel node positivity in patients with cutaneous melanoma with positive sentinel lymph nodes. *J Clin Oncol*. 2010 Oct 10;28(29):4441-9. doi: 10.1200/JCO.2010.30.9567. Epub 2010 Sep 7. PMID: 20823419
493. Cadili A, Dabbs K, **Scoflyer RA**, Brown PT, Thompson JF. Re-evaluation of a Scoring System to Predict Nonsentinel-Node Metastasis and Prognosis in Melanoma Patients. *J Am Coll Surg*. 2010 Oct;211(4):522-5. Epub 2010 Aug 21. PMID: 20729103
494. Verwer N, Murali R, Winstanley J, Cooper WA, Stretch JR, Thompson JF, **Scoflyer RA**. Lymphoma occurring in patients with cutaneous melanoma. *J Clin Pathol*. 2010 Sep;63(9):777-81. Epub 2010 Jul 29. PMID: 20671047
495. McCarthy SW, **Scoflyer RA**. Pitfalls and important issues in the pathologic diagnosis of melanocytic tumors. *Ochsner J*. 2010 Summer;10(2):66-74. PMID: 21603360
496. **Scoflyer RA**, Murali R, McCarthy SW, Thompson JF. Atypical fibroxanthoma: differential diagnosis from other sarcomatoid skin lesions. *Diagnostic Histopathology* 2010 Sept; 16(9): 401-408. DOI:https://doi.org/10.1016/j.mpdhp.2010.06.007. via USyd Library (Not in PubMed)
497. Murali R, Shaw HM, Lai K, McCarthy SW, Quinn MJ, Stretch JR, Thompson JF, **Scoflyer RA**. Prognostic factors in cutaneous desmoplastic melanoma: a study of 252 patients. *Cancer*. 2010 Sep 1;116(17):4130-8. PMID:20564101

498. Guitera P, Pellacani G, Crotty KA, **Scoflyer RA**, Li L L-X, Bassoli S, Vinceti M, Rabinovitz H, Longo C, Menzies SW. The impact of in vivo reflectance confocal microscopy on the diagnostic accuracy of lentigo maligna and equivocal pigmented and nonpigmented macules of the face. *J Invest Dermatol*. 2010 Aug;130(8):2080-91. doi: 10.1038/jid.2010.84. Epub 2010 Apr 15. PMID: 20393481
499. Mocellin S, Shrager J, **Scoflyer R**, Pasquali S, Verdi D, Marincola FM, Briarava M, Gobbel R, Rossi CR, Nitti D. Targeted Therapy Database (TTD): a model to match patient's molecular profile with current knowledge on cancer biology. *PLoS One*. 2010 Aug 10;5(8):e11965. doi: 10.1371/journal.pone.0011965. PMID: 20706624
500. Wiener M, Acland KM, Shaw HM, Soong SJ, Lin HY, Chen DT, **Scoflyer RA**, Winstanley JB, Thompson JF. Sentinel Node Positive Melanoma Patients: Prediction and Prognostic Significance of Nonsentinel Node Metastases and Development of a Survival Tree Model. *Ann Surg Oncol*. 2010 Aug;17(8):1995-2005. doi: 10.1245/s10434-010-1049-5. Epub 2010 May 2. PMID: 20490699
501. Guitera P, Bourgeat P, Stretch JR, **Scoflyer RA**, Ourselin S, Lean C, Thompson JF, Bourne R. Diagnostic value of 8.5T magnetic resonance spectroscopy of benign and malignant skin lesion biopsies. *Melanoma Res*. 2010 Aug;20(4):311-7. PMID: 20626102
502. Karim RZ, Gerega SK, Yang YH, Spillane A, Carmalt H, **Scoflyer RA**, Lee CS. p16 and pRb immunohistochemical expression increases with increasing tumour grade in mammary phyllodes tumours. *Histopathology*. 2010 Jun;56(7):868-75. doi: 10.1111/j.1365-2559.2010.03562.x. Epub 2010 May 19. PMID: 20497245
503. Kaufman KL, Belov L, Huang P, Mactier S, **Scoflyer RA**, Mann GJ, Christopherson RI. An extended antibody microarray for surface profiling metastatic melanoma. *J Immunol Methods*. 2010 Jun 30;358(1-2):23-34. doi: 10.1016/j.jim.2010.03.017. Epub 2010 Apr 2. PMID: 20363224
504. Murali R, Thompson JF, **Scoflyer RA**. Can histologic parameters of melanoma metastases in sentinel lymph nodes reliably select patients who can be safely spared completion lymph node dissection? *Ann Surg*. 2010 Jun;251(6):1188-9. PMID: 20485116
505. Cooper CL, Murali R, Doubrovsky A, Watson GF, McKenzie PR, Thompson JF, **Scoflyer RA**. Synchronous and metachronous malignancies in patients with melanoma: a clinicopathologic study highlighting the role of fine-needle biopsy cytology and potential diagnostic pitfalls. *Melanoma Res*. 2010 Jun;20(3):203-11. PMID: 20335819
506. Haydu LE, Holt P, Karim RZ, Madronio C, Thompson JF, Armstrong BK, **Scoflyer RA**. Quality of histopathological reporting on melanoma and influence of use of a synoptic template. *Histopathology* 2010 May;56(6):768-74. PMID: 20546342
507. Murali R, McCarthy SW, Bothman J, Janarthanan P, Sharma R, **Scoflyer RA**. Melanoma exhibiting cartilaginous differentiation. *Histopathology* 2010 May;56(6):815-21. PMID: 20546349
508. Scurr LL, Pupo GM, Becker TM, Lai K, Schrama D, Haferkamp S, Irvine M, **Scoflyer RA**, Mann GJ, Becker JC, Kefford RF, Rizos H. IGFBP7 is not required for B-RAF-induced melanocyte senescence. *Cell*. 2010 May 14;141(4):717-27. doi: 10.1016/j.cell.2010.04.021. PMID: 20478260
509. Guitera P, Li LX, **Scoflyer RA**, Menzies SW. Morphologic features of melanophages under in vivo reflectance confocal microscopy. *Arch Dermatol*. 2010 May;146(5):492-8. PMID: 20479296
510. Murali R, Thompson JF, Uren RF, **Scoflyer RA**. Fine-needle biopsy of metastatic melanoma: clinical use and new applications. *Lancet Oncol*. 2010 Apr;11(4):391-400. doi: 10.1016/S1470-2045(09)70332-8. Epub 2010 Jan 25. Review. PMID: 20106719
511. Murali R, Field A, McKenzie PR, McLeod D, Stretch JR, Thompson JF, **Scoflyer RA**. Melanotic schwannoma mimicking metastatic pigmented melanoma: a pitfall in cytological diagnosis. *Pathology*. 2010 Apr;42(3):287-9. doi: 10.3109/00313021003631262. PMID: 20350225
512. Lim C, Murali R, McCarthy SW, **Scoflyer RA**. Pigmented epithelioid melanocytoma: a recently described melanocytic tumour of low malignant potential. *Pathology*. 2010 Apr;42(3):284-6. PMID: 20350224
513. Barnhill RL, Cerroni L, Cook M, Elder DE, Kerl H, LeBoit PE, McCarthy SW, Mihm MC, Mooi WJ, Piepkorn MW, Prieto VG, **Scoflyer RA**. State of the Art, Nomenclature, and Points of Consensus and Controversy Concerning Benign Melanocytic Lesions: Outcome of an International Workshop. *Adv Anat Pathol*. 2010 Mar;17(2):73-90. PMID: 20179431
514. Murali R, **Scoflyer RA**. Tumor-infiltrating lymphocytes and mitotic index in metastatic melanoma as predictors of patient survival. *Proc Natl Acad Sci U S A*. 2010 Mar 30;107(13):E46; author reply E47. doi: 10.1073/pnas.0914657107. Epub 2010 Mar 22. PMID: 20308534
515. Goto Y, Arigami T, Murali R, **Scoflyer RA**, Tanemura A, Takata M, Turner RR, Nguyen L, Nguyen T, Morton DL, Ferone S, Hoon DS. High molecular weight-melanoma-associated antigen as a biomarker of desmoplastic melanoma. *Pigment Cell Melanoma Res*. 2010 Feb;23(1):137-40. doi: 10.1111/j.1755-148X.2009.00660.x. Epub 2009 Dec 4. PMID: 19968820
516. Howman-Giles R, Shaw HM, **Scoflyer RA**, Murali R, Wilmott J, McCarthy SW, Uren RF, Thompson JF. Sentinel lymph node biopsy in pediatric and adolescent cutaneous melanoma patients. *Ann Surg Oncol*. 2010 Jan;17(1):138-43. doi: 10.1245/s10434-009-0657-4. Epub 2009 Aug 12. PMID: 19672660
517. Zhuang L, **Scoflyer RA**, Murali R, McCarthy SW, Zhang XD, Thompson JF, Hersey P. Lactate dehydrogenase 5 expression in melanoma increases with disease progression and is associated with expression of Bcl-XL and Mcl-1, but not Bcl-2 proteins. *Mod Pathol*. 2010 Jan;23(1):45-53. PMID: 19838163
518. Murali R, Thompson JF, **Scoflyer RA**. Location of melanoma metastases in sentinel lymph nodes: what are the implications for histologic processing of sentinel lymph nodes in routine practice? *Am J Surg Pathol*. 2010 Jan;34(1):127-9. PMID: 20035152
519. Mandal RV, Murali R, Lundquist KF, Ragsdale BD, Heenan P, McCarthy SW, Mihm MC Jr, **Scoflyer RA**, Zembowicz A. Pigmented epithelioid melanocytoma: favorable outcome after 5-year follow-up. *Am J Surg Pathol* 2009 Dec;33(12):1778-82. PMID: 19773637
520. Mocellin S, Thompson JF, Pasquali S, Montesco MC, Pilati P, Nitti D, Saw RP, **Scoflyer RA**, Stretch JR, Rossi CR. Sentinel node status prediction by four statistical models: results from a large bi-institutional series (n = 1132). *Ann Surg* 2009;250: 964-969. PMID: 19953714
521. Cooper CL, Danieleto S, Fong E, Harris M, Cooper WA, McCarthy SW, **Scoflyer RA**. Cutaneous metastasis of epithelioid haemangioendothelioma. *Pathology*. 2009;41(6):585-7. PMID: 19900110
522. Sanki A, Uren RF, Moncrieff M, Tran KL, **Scoflyer RA**, Lin HY, Thompson JF. Targeted high-resolution ultrasound is not an effective substitute for sentinel lymph node biopsy in patients with primary cutaneous melanoma. *J Clin Oncol*. 2009 Nov 20;27(33):5614-9. doi: 10.1200/JCO.2008.21.4882. Epub 2009 Sep 28. PMID: 19786669
523. Murali R, McCarthy SW, **Scoflyer RA**. Blue nevi and related lesions: a review highlighting atypical and newly described variants, distinguishing features and diagnostic pitfalls. *Adv Anat Pathol*. 2009 Nov;16(6):365-82. PMID: 19851128
524. Karim RZ, Gerega SK, Yang YH, Horvath L, Spillane A, Carmalt H, **Scoflyer RA**, Lee CS. Proteins from the Wnt pathway are involved in the pathogenesis and progression of mammary phyllodes tumours. *J Clin Pathol*. 2009 Nov;62(11):1016-20. PMID: 19861560
525. Murali R, Cochran AJ, Cook MG, Hillman JD, Karim RZ, Moncrieff M, Starz H, Thompson JF, **Scoflyer RA**. Interobserver reproducibility of histologic parameters of melanoma deposits in sentinel lymph nodes: implications for management of patients with melanoma. *Cancer* 2009 Nov 1;115(21):5026-5037. PMID: 19658180

526. Karim RZ, Li W, Sanki A, Colman MH, Yang JYH, Thompson JF, **Scolyer RA**. Reduced p16 and increased cyclin D1 and pRb expression are correlated with progression in cutaneous melanocytic tumours. *Int J Surg Pathol* 2009 Oct;17(5):361-7. PMID: 19666944
527. Shingde MV, Buckland M, Busam KJ, McCarthy SW, Wilmott J, Thompson JF, **Scolyer RA**. Primary cutaneous Ewing sarcoma/primitive neuroectodermal tumour: a clinicopathological analysis of seven cases highlighting diagnostic pitfalls and the role of FISH testing in diagnosis. *J Clin Pathol* 2009 Oct;62(10):915-9. PMID: 19783720
528. Chakera AH, Hesse B, Burak Z, Ballinger JR, Britten A, Caracò C, Cochran AJ, Cook MG, Drzewiecki KT, Essner R, Even-Sapir E, Eggermont AM, Gmeiner Stopar T, Ingvar C, Mihm MC Jr, McCarthy SW, Mozzillo N, Nieweg OE, **Scolyer RA**, Starz H, Thompson JF, Trifirò G, Viale G, Vidal-Sicart S, Uren R, Waddington W, Chiti A, Spatz A, Testori A. EANM-EORTC general recommendations for sentinel node diagnostics in melanoma. *Eur J Nucl Med Mol Imaging* 2009 Oct;36(10):1713-42. PMID: 19714329
529. Busam KJ, Murali R, Pulitzer M, McCarthy SW, Thompson JF, Shaw HM, Brady MS, Coit DG, Dusza S, Wilmott J, Kayton M, Laquaglia M, **Scolyer RA**. Atypical spitzoid melanocytic tumors with positive sentinel lymph nodes in children and teenagers, and comparison with histologically unambiguous and lethal melanomas. *Am J Surg Pathol* 2009 Sep;33(9):1386-95. PMID: 19609204
530. Orlow I, Tommasi D, Bloom B, Ostrovnaya I, Cotignola J, Mujumdar U, Busam K, Jungbluth AA, **Scolyer RA**, Thompson JF, Armstrong BK, Berwick M, Thomas N, Begg CB. Evaluation of the Clonal Origin of Multiple Primary Melanomas Using Molecular Profiling. *J Invest Dermatol*. 2009 Aug;129(8):1972-82. doi: 10.1038/jid.2009.4. Epub 2009 Mar 12. PMID: 19282844
531. Narita N, Tanemura A, Murali R, **Scolyer RA**, Huang S, Arigami T, Chong KK, Liang EH, Nguyen SL, Thompson JF, Morton DL, Hoon DSB. Functional RET G691S polymorphism in cutaneous malignant melanoma. *Oncogene*. 2009 Aug 27;28(34):3058-68. doi: 10.1038/nc.2009.164. Epub 2009 Jun 29. PMID: 19561646
532. Thompson JF, **Scolyer RA**, Kefford RF. Cutaneous melanoma in the era of molecular profiling. *Lancet*. 2009 Aug 1;374(9687):362-5. doi: 10.1016/S0140-6736(09)61397-0. Review. PMID: 19647595
533. Martin RCW, Murali R, **Scolyer RA**, Fitzgerald P, Coleman MH, Thompson JF. So-called "malignant blue nevus": a clinicopathologic study of 23 patients. *Cancer* 2009 Jul 1;115(13):2949-55. PMID: 19472395
534. Murali R, Loughman NT, McKenzie PR, Watson GF, Thompson JF, **Scolyer RA**. Cytological features of melanoma in exfoliative fluid specimens. *J Clin Pathol* 2009 Jul;62(7):638-43. PMID: 19561232
535. Karim RZ, Gerega SK, Yang YH, Spillane A, Carmalt H, **Scolyer RA**, Lee CS. Phyllodes tumours of the breast: a clinicopathological analysis of 65 cases from a single institution. *Breast*. 2009 Jun;18(3):165-70. doi: 10.1016/j.breast.2009.03.001. Epub 2009 Mar 28. PMID: 19329316
536. Stretch JR, **Scolyer RA**. Surgical strategies and histopathologic issues in the management of lentigo maligna. *Ann Surg Oncol*. 2009 Jun;16(6):1456-8. doi: 10.1245/s10434-009-0433-5. Epub 2009 Mar 26. PMID: 19322612
537. Morey AL, Murali R, McCarthy SW, Mann GJ, **Scolyer RA**. Diagnosis of cutaneous melanocytic tumours by four-colour fluorescence in situ hybridisation. *Pathology* 2009; Jun;41(4):383-7. PMID: 19404853
538. Murali R, Hughes TM, Fitzgerald P, Thompson JF, **Scolyer RA**. Interobserver variation in the histopathologic reporting of key prognostic parameters, particularly clark level, affects pathologic staging of primary cutaneous melanoma. *Ann Surg*. 2009 Apr;249(4):641-7. doi: 10.1097/SLA.0b013e31819ed973. PMID: 19300224
539. Tse GM, Lui PC, Vong JS, Lau KM, Putti TC, Karim R, **Scolyer RA**, Lee CS, Yu AM, Ng DC, Tse AK, Tan PH. Increased Epidermal Growth Factor Receptor (EGFR) expression in malignant mammary phyllodes tumors. *Breast Cancer Res Treat*. 2009 Apr;114(3):441-8. doi: 10.1007/s10549-008-0030-5. Epub 2008 Apr 29. PMID: 18443904
540. Lam TK, Uren RF, **Scolyer RA**, Quinn MJ, Shannon KF, Thompson JF. False-negative sentinel node biopsy because of obstruction of lymphatics by metastatic melanoma: the value of ultrasound in conjunction with preoperative lymphoscintigraphy. *Melanoma Res* 2009 Apr;19(2):94-9. PMID: 19262412
541. Spillane AJ, Cheung BLH, Stretch JR, **Scolyer RA**, Shannon KF, Quinn MJ, Saw RPM, McCarthy WH, Thompson JF. Proposed quality standards for regional lymph node dissections in patients with melanoma. *Ann Surg*. 2009 Mar;249(3):473-80. doi: 10.1097/SLA.0b013e318194d38f. PMID: 19247037
542. Zhuang L, **Scolyer RA**, Lee CS, McCarthy SW, Cooper WA, Zhang XD, Thompson JF, Hersey P. Expression of glucose-regulated stress protein GRP78 is related to progression of melanoma. *Histopathology*. 2009 Mar;54(4):462-70. PMID: 19309398
543. Sanki A, **Scolyer RA**, Thompson JF. Surgery for melanoma metastases of the gastrointestinal tract: indications and results. *Eur J Surg Oncol*. 2009 Mar;35(3):313-9. Epub 2008 Jun 30. PMID: 18590949
544. Karim RZ, **Scolyer RA**, Tse GM, Tan PH, Putti TC, Lee CS. Pathogenic mechanisms in the initiation and progression of mammary phyllodes tumours. *Pathology* 2009 Feb;41(2):105-17. PMID: 19152185
545. Gzell CE, Carroll SL, Suchowerska N, Beith J, Tan K, **Scolyer RA**. Radiation recall dermatitis after pre-sensitization with pegylated liposomal doxorubicin. *Cancer Invest*. 2009 May;27(4):397-401. doi:10.1080/07357900802392667. PMID: 19219651
546. Huang SK, Darfler MM, You J, Bemis KG, Tegeler TJ, Wang M, Wery J-P, Chong KK, **Scolyer RA**, Hoon DSB. LC/MS-based quantitative proteomic analysis of paraffin-embedded archival melanomas reveals potential proteomic biomarkers associated with metastasis. *PLoS One*. 2009;4(2):e4430. doi: 10.1371/journal.pone.0004430. Epub 2009 Feb 16. PMID: 19221597
547. Ashford RU, **Scolyer RA**, McCarthy SW, Bonar SF, Karim RZ, Stalley PD. The role of intra-operative pathological evaluation in the management of musculoskeletal tumours. *Recent Results Cancer Res*. 2009;179:11-24. PMID: 19230531
548. Hare D, Burger FJ, Austin C, Fryer F, Grimm R, Reedy B, **Scolyer RA**, Thompson JF, Doble P. Elemental bio-imaging of melanoma in lymph node biopsies. *Analyst*. 2009 Mar;134(3):450-3. doi: 10.1039/b812745j. Epub 2008 Nov 27. PMID: 19238278
549. Becker TM, Haferkamp S, Dijkstra MK, Scurr LL, Frausto M, Diefenbach E, **Scolyer RA**, Kefford RF, Mann GJ, Rizos H. The chromatin remodelling factor BRG1 is a novel binding partner of the tumor suppressor p16INK4a. *Mol Cancer* 2009 Jan 16;8:4. PMID: 19149898
550. Tan KB, **Scolyer RA**, McCarthy SW, Schatz J, Nabarro M, Lee K, Rusli J, Banu B, Fiona Bonar S. Tumoural calcium pyrophosphate dihydrate crystal deposition disease (tophaceous pseudogout) of the hand: a report of two cases including one with a previously unreported associated florid reactive myofibroblastic proliferation. *Pathology* 2008 Dec;40(7):719-22. PMID: 18985528
551. Shipman AR, Agero AL, Cook I, **Scolyer RA**, Craig P, Pas HH, Wojnarowska F, Murrell DF. Epidermolysis bullosa acquisita requiring multiple oesophageal dilatations. *Clin Exp Dermatol*. 2008 Nov;33(6):787-9. doi: 10.1111/j.1365-2230.2008.02875.x. Epub 2008 Jul 4. PMID: 18627393
552. Murali R, Loughman NT, McKenzie PR, Watson GF, Thompson JF, **Scolyer RA**. Cytologic features of metastatic and recurrent melanoma in patients with primary cutaneous desmoplastic melanoma. *Am J Clin Pathol*. 2008 Nov;130(5):715-23. PMID: 18854263
553. Chen JY, Hruba G, **Scolyer RA**, Murali R, Hong A, Pham TT, Fitzgerald P, Quinn MJ, Thompson JF. Desmoplastic neurotropic melanoma: a clinicopathologic analysis of 128 cases. *Cancer* 2008 Nov 15;113(10):2770-8. PMID: 18823042

554. Moncrieff MD, Kroon HM, Kam PC, Stalley PD, **Scolyer RA**, Thompson JF. Isolated limb infusion for advanced soft tissue sarcoma of the extremity. *Ann Surg Oncol*. 2008 Oct;15(10):2749-56. doi: 10.1245/s10434-008-0045-5. Epub 2008 Jul 22. PMID: 18648882
555. Moncrieff M, **Scolyer R**, Thompson J, Beavis A, Uren R, Stretch J. Correct identification of a sentinel node postselective lymphadenectomy using antimony levels. *Melanoma Res* 2008 Oct;18(5):365-6. PMID: 18781136
556. Warner RE, Quinn MJ, Hruby G, **Scolyer RA**, Uren RF, Thompson JF. Management of merkel cell carcinoma: the roles of lymphoscintigraphy, sentinel lymph node biopsy and adjuvant radiotherapy. *Ann Surg Oncol*. 2008 Sep;15(9):2509-18. doi: 10.1245/s10434-008-9983-1. Epub 2008 Jun 10. PMID: 18543036
557. **Scolyer RA**, Murali R, Satzger I, Thompson JF. The detection and significance of melanoma micrometastases in sentinel nodes. *Surg Oncol*. 2008 Sep;17(3):165-74. doi: 10.1016/j.suronc.2008.06.005. Epub 2008 Jul 18. Review. PMID: 18639451
558. Shaw HM, **Scolyer RA**, Thompson JF. Prognostic significance of histopathological parameters in sentinel nodes of melanoma patients. *Histopathology*. 2008 Sep;53(3):345. doi: 10.1111/j.1365-2559.2008.03090.x. PMID: 18631192
559. Van Es SL, Colman MH, Thompson JF, McCarthy SW, **Scolyer RA**. Angiotropism is an independent predictor of local recurrence and in-transit metastasis in primary cutaneous melanoma. *Am J Surg Pathol* 2008 Sep;32(9): 1396-403. PMID: 18670348
560. **Scolyer RA**, Murali R, McCarthy SW, Thompson JF. Pathologic examination of sentinel lymph nodes from melanoma patients. *Semin Diagn Pathol*. 2008 May;25(2):100-11. PMID: 18697713
561. Murali R, Thompson JF, **Scolyer RA**. Sentinel lymph node biopsy for melanoma: aspects of pathologic assessment. *Future Oncology* 2008 Aug;4(4):535-51. PMID: 18684064
562. Murali R, Thompson JF, Shaw HM, **Scolyer RA**. The prognostic significance of isolated immunohistochemically positive cells in sentinel lymph nodes of melanoma patients. *Am J Surg Pathol*. 2008 Jul;32(7):1106-7; author reply 1107-8. doi: 10.1097/PAS.0b013e318162442e. PMID: 18521043
563. Karim RZ, **Scolyer RA**, Li W, Yee VSK, McKinnon JG, Li L-XL, Uren RF, Lam S, Beavis A, Dawson M, Doble M, Hoon DSB, Thompson JF. False negative sentinel lymph node biopsies in melanoma may result from deficiencies in nuclear medicine, surgery, or pathology. *Ann Surg* 2008 Jun;247(6):1003-1010. PMID: 18520228
564. O'Brien, P., Davies, M., Scurry, J. et al. Erratum: The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro. *Br J Cancer* 98, 1880 (2008). Murali, Rajmohan [added]. <https://doi.org/10.1038/sj.bjc.6604419>.
565. Tan BK, Murali R, Karim RZ, Dutta B, Dutta R, McCarthy SW, **Scolyer RA**. Merkel cell carcinoma with fibrosarcomatous differentiation. *Pathology*. 2008 Apr;40(3):314-6. PMID: 18428059
566. O'Brien PM, Davies MJ, Scurry JP, Smith AN, Barton CA, Henderson MJ, Saunders DN, Clancy JL, Heinzelmann-Schwarz VA, Murali R, **Scolyer RA**, Zeng Y, Williams ED, Scurr L, DeFazio A, Quinn DI, Watts CKW, Hacker NF, Henshall SM, Sutherland RL. The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro. *Br J Cancer*. 2008 Mar 25;98(6):1085-93. doi: 10.1038/sj.bjc.6604281. Epub 2008 Mar 18. Erratum in: *Br J Cancer*. 2008 Jun 3;98(11):1880. PMID: 18349819
567. Beavis A, Dawson M, Doble P, **Scolyer RA**, Bourne R, Li L-XL, Murali R, Stretch JR, Lean CL, Uren RF, Thompson JF. Confirmation of sentinel lymph node identity by analysis of fine-needle biopsy samples using inductively coupled plasma-mass spectrometry. *Ann Surg Oncol*. 2008 Mar;15(3):934-40. doi: 10.1245/s10434-007-9693-0. Epub 2008 Jan 3. PMID: 18172734
568. Sassen S, Shaw HM, Colman MH, **Scolyer RA**, Thompson JF. The complex relationships between sentinel node positivity, patient age, and primary tumor desmoplasia: analysis of 2303 melanoma patients treated at a single center. *Ann Surg Oncol*. 2008 Feb;15(2):630-7. Epub 2007 Dec 14. PMID: 18080717
569. Amersi FF, Terando AM, Goto Y, **Scolyer RA**, Thompson JF, Tran AN, Faries MB, Morton DL, Hoon DSB. Activation of CCR9/CCL25 in cutaneous melanoma mediates preferential metastasis to the small intestine. *Clin Cancer Res*. 2008 Feb 1;14(3):638-45. doi: 10.1158/1078-0432.CCR-07-2025. Erratum in: *Clin Cancer Res*. 2008 Mar 1;14(5):1598. *Clin Cancer Res*. 2008 May 1;14(9):2892. PMID: 18245522
570. Murali R, Thompson JF, **Scolyer RA**. Fine-needle biopsy as a diagnostic technique for metastatic melanoma. *Expert Opin Med Diagn*. 2008 Jan;2(1):1-10. doi: 10.1517/17530059.2.1.1. PMID: 23485113
571. Doubrovsky A, **Scolyer RA**, Murali R, McKenzie PR, Watson GF, Lee CS, McLeod DJ, McCarthy WH, Uren RF, Stretch JR, Saw RPM, Thompson JF. Diagnostic accuracy of fine needle biopsy for metastatic melanoma and its implications for patient management. *Ann Surg Oncol*. 2008 Jan;15(1):323-32. Epub 2007 Nov 8. PMID: 17990041
572. Murali R, Sharma RN, Thompson JF, Stretch JR, Lee CS, McCarthy SW, **Scolyer RA**. Sentinel lymph node biopsy in histologically ambiguous melanocytic tumors with spitzoid features (so-called atypical spitzoid tumors). *Ann Surg Oncol*. 2008 Jan;15(1):302-9. Epub 2007 Nov 14. PMID: 18000712
573. Shaw HM, **Scolyer RA**, Thompson JF. Prognostic significance of histopathological parameters in sentinel nodes of melanoma patients. *Histopathology*. 2008 Jan;52(2):242; author reply 242-4. doi: 10.1111/j.1365-2559.2007.02917.x. PMID: 18184275
574. Karim RZ, van den Berg KS, Coleman MH, McCarthy SW, Thompson JF, **Scolyer RA**. The advantage of using a synoptic pathology report format for cutaneous melanoma. *Histopathology* 2008 Jan;52(2):130-8. PMID: 18184262
575. Tan KB, Moncrieff M, Thompson JF, McCarthy SW, Shaw HM, Quinn MJ, Li L-XL, Crotty KA, Stretch JR, **Scolyer RA**. Subungual melanoma: a study of 124 cases highlighting features of early lesions, potential pitfalls in diagnosis, and guidelines for histologic reporting. *Am J Surg Pathol*. 2007 Dec;31(12):1902-12. PMID: 18043047
576. Sanki A, Li W, Colman MH, Karim RZ, Thompson JF, **Scolyer RA**. Reduced expression of p16 and p27 is correlated with tumour progression in cutaneous melanoma. *Pathology*. 2007 Dec;39(6):551-7. PMID: 18027257
577. **Scolyer RA**, Thompson JF. Primary melanoma of the lung. *Am Surg*. 2007 Sep;73(9):937-8. PMID: 17939434
578. Shaw HM, **Scolyer RA**, Thompson JF. Re: NM patients and SN. *Surgeon*. 2007 Oct;5(5):320. PMID: 17960716
579. Tse GM, Chaiwun B, Lau KM, Scolyer R, Lee CS, Karim RZ, Putti TC, Law BK, Lui PC, Tan PH. Endothelin-1 expression correlates with atypical histological features in mammary phyllodes tumours. *J Clin Pathol*. 2007 Sep;60(9):1051-6. Epub 2006 Dec 8. PMID: 17158636
580. Thompson JF, **Scolyer RA**, Kefford RF, Uren RF. Melanoma Management in 2007. *Australian Family Physician*. 2007 Jul;36(7):487-8; author reply 488-9. PMID: 17672023
581. Elliott B, **Scolyer RA**, Suci S, Lebecque S, Rimoldi D, Gugerli O, Musat E, Sharma RN, Lienard D, Keilholz U, Testori A, Eggermont A, MacKie R, Robert C, Cook M, Thompson JF, Angevin E, Spatz A; European Organization for Research and Treatment of Cancer

- Melanoma Group. Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma. *Clin Cancer Res*. 2007 Jul 1;13(13):3825-30. PMID: 17606713
582. **Scolyer RA**, Murali R, Gershenwald, JE, Cochran AJ, Thompson JF. Clinical relevance of melanoma micrometastases in sentinel nodes: too early to tell. *Ann Oncol* 2007; 18: 806-8. PMID: 17389530
 583. Zhuang L, Lee CS, **Scolyer RA**, McCarthy SW, Zhang XD, Thompson JF, Hersey P. Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. *Mod Pathol*. 2007 Apr;20(4):416-26. PMID: 17384650
 584. Murali R, McCarthy SW, Thompson JF, **Scolyer RA**. Melanocytic nevus with focal atypical epithelioid components (clonal nevus) is a combined nevus. *J Am Acad Dermatol*. 2007 May;56(5):889-90. PMID: 17437894
 585. Cooper CL, Sindler P, Varol C, McCarthy SW, Karim RZ, **Scolyer RA**. Paratesticular rhabdomyoma. *Pathology*. 2007 Jun;39(3):367-9. PMID: 17558870
 586. Jabour J, Cummings R, **Scolyer RA**, Hruby G, Thompson JF, Lee S. Merkel cell carcinoma: assessing the effect of wide local excision, lymph node dissection, and radiotherapy on recurrence and survival in early-stage disease--results from a review of 82 consecutive cases diagnosed between 1992 and 2004. *Ann Surg Oncol*. 2007 Jun;14(6):1943-52. Epub 2007 Mar 14. PMID: 17356954
 587. Tan KB, Murali R, Thompson JF, Arnold CJ, McCarthy SW, **Scolyer RA**. Current perspectives on the pathologic diagnosis and reporting of melanocytic tumors. *Italian Journal Of Dermatology And Venereology* 2007; 142: 83-97.
 588. Li W, Tran N, Lee SC, O'Brien CJ, Tse GM, **Scolyer RA**, Hong A, Milross C, Yu KH, Rose BR. New evidence for geographic variation in the role of human papillomavirus in tonsillar carcinogenesis. *Pathology*. 2007 Apr;39(2):217-22. PMID: 17454751
 589. Maclean FM, Schatz J, McCarthy SW, **Scolyer RA**, Stalley P, Bonar SF. Epithelioid and spindle cell haemangioma of bone. *Skeletal Radiol*. 2007 Jun;36 Suppl 1:S50-7. Epub 2006 May 11. PMID: 16688448
 590. Murali R, Doubrovsky A, Watson GF, McKenzie PR, Lee CS, McLeod DJ, Uren RF, Stretch JR, Saw RP, Thompson JF, **Scolyer RA**. Diagnosis of metastatic melanoma by fine-needle biopsy: analysis of 2,204 cases. *Am J Clin Pathol*. 2007 Mar;127(3):385-97. PMID: 17276948
 591. Heinzelmann-Schwarz VA, Scurry JP, **Scolyer RA**, Smith AN, Gardiner-Garden M, Vanden Bergh P, Biankin AV, Baron-Hay S, Scott C, Ward RL, Fink D, Hacker NF, Sutherland RL, O'Brien PM. Low meprin α expression differentiates primary ovarian mucinous carcinoma from gastrointestinal cancers that commonly metastasise to the ovaries. *J Clin Pathol*. 2007 Jun;60(6):622-6. Epub 2006 Jul 5. PMID: 16822880
 592. Zhuang L, Lee CS, **Scolyer RA**, McCarthy SW, Zhang XD, Thompson JF, Sreaton G, Hersey P. Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor-related apoptosis-inducing ligand. *Hum Pathol*. 2006 Oct;37(10):1286-94. Epub 2006 Jul 18. PMID: 16949935
 593. Ashford RU, McCarthy SW, **Scolyer RA**, Bonar SF, Karim RZ, Stalley PD. Surgical biopsy with intra-operative frozen section. An accurate and cost-effective method for diagnosis of musculoskeletal sarcomas. *J Bone Joint Surg Br*. 2006 Sep;88(9):1207-11. PMID: 16943474
 594. Li W, Sanki A, Karim RZ, Thompson JF, Lee CS, Zhuang L, McCarthy SW, **Scolyer RA**. The role of cell cycle regulatory proteins in the pathogenesis of melanoma. *Pathology*. 2006 Aug;38(4):287-301. PMID: 16916716
 595. **Scolyer RA**, Thompson JF, Shaw HM, McCarthy SW. The importance of mitotic rate as a prognostic factor for localized primary cutaneous melanoma. *J Cutan Pathol*. 2006 May;33(5):395-6; author reply 397-9. PMID: 16640550
 596. Thompson JF, **Scolyer RA**, Uren RF. Surgical management of primary cutaneous melanoma: excision margins and the role of sentinel lymph node examination. *Surg Oncol Clin N Am*. 2006 Apr;15(2):301-18. PMID: 16632216
 597. Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, Scurry JP, Scolyer RA, Smith AN, Bali A, Vanden Bergh P, Baron-Hay S, Scott C, Fink D, Hacker NF, Sutherland RL, O'Brien PM. A distinct molecular profile associated with mucinous epithelial ovarian cancer. *Br J Cancer*. 2006 Mar 27;94(6):904-13. PMID: 16508639
 598. Shaw HM, Quinn MJ, **Scolyer RA**, Thompson JF. Survival in patients with desmoplastic melanoma. *J Clin Oncol*. 2006 Mar 10;24(8):e12; author reply e13. PMID: 16525175
 599. Karim RZ, Wills EJ, McCarthy SW, **Scolyer RA**. Myxoid variant of adrenocortical carcinoma: report of a unique case. *Pathol Int*. 2006 Feb;56(2):89-94. PMID: 16445821
 600. Scolyer, R.A., Thompson, J.F., McCarthy, S.W., Strutton, G.M. and Elder, D.E. (2006), LETTERS TO THE EDITOR. *Australasian Journal of Dermatology*, 47: 71-73. doi:10.1111/j.1440-0960.2006.00230.x. *Original PMID: 16405491*
 601. Bonar SF, Viglione W, Schatz J, **Scolyer RA**, McCarthy SW. An unusual variant of intraneural ganglion of the common peroneal nerve. *Skeletal Radiol*. 2006 Mar;35(3):165-71. Epub 2005 Dec 20. PMID: 16365746
 602. Pua VS, **Scolyer RA**, Barnetson RS. Pravastatin-induced lichenoid drug eruption. *Australas J Dermatol*. 2006 Feb;47(1):57-9. PMID: 16405486
 603. **Scolyer RA**, Thompson JF, McCarthy SW, Strutton GM, Elder DE. Incomplete biopsy of melanocytic lesions can impair the accuracy of pathological diagnosis. *Australas J Dermatol*. 2006 Feb;47(1):71-3; author reply 74-5. PMID: 16405491
 604. Dray MS, McCarthy SW, Palmer AA, Bonar SF, Stalley P, Marjoniemi V, Miller E, **Scolyer RA**. Myopericytoma: a unifying term for a spectrum of tumours that show overlapping features with myofibroma. A review of 14 cases. *J Clin Pathol* 2006; 59: 67-73. PMID: 16394283
 605. de Wilt JH, Farmer SE, **Scolyer RA**, McCaughan BC, Thompson JF. Isolated melanoma in the lung where there is no known primary site: metastatic disease or primary lung tumour? *Melanoma Res*. 2005 Dec;15(6):531-7. PMID: 16314739
 606. **Scolyer RA**, Thompson JF, Gershenwald, JE, Ross, MI, McCarthy SW, Cochran AJ. Intraoperative frozen section evaluation may reduce the accuracy of pathologic assessment of sentinel nodes in melanoma patients. *J Am Coll Surg*. 2005 Nov;201(5):821-3; author reply 823-4. PMID: 16256927
 607. Stretch JR, Somorjai R, Bourne R, Hsaio E, **Scolyer RA**, Dolenko B, Thompson JF, Mountford CE, Lean CL. Melanoma metastases in regional lymph nodes are accurately detected by proton magnetic resonance spectroscopy of fine-needle aspirate biopsy samples. *Ann Surg Oncol*. 2005 Nov;12(11):943-9. Epub 2005 Sep 19. PMID: 16177860
 608. Zhuang L, Lee CS, **Scolyer RA**, McCarthy SW, Palmer AA, Zhang X, Thompson JF, Bron LP, Hersey P. Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma. *J Clin Pathol*. 2005 Nov;58(11):1163-9. PMID: 16254105
 609. Thompson JF, Uren RF, **Scolyer RA**, Stretch JR. Selective sentinel lymphadenectomy: progress to date and prospects for the future. *Cancer Treat Res*. 2005;127:269-87. PMID: 16209088

610. Kim Y, **Scolyer RA**, Chia EM, Steven D, Ghabrial R. Eccrine porocarcinoma of the upper eyelid. *Aust J Dermatol* 2005 Nov;46(4):278-81. PMID: 16197432
611. **Scolyer R**, Thompson J, Stretch J, McCarthy S. Collaboration between clinicians and pathologists: a necessity for the optimal management of melanoma patients. *Cancer Forum* 2005; 29: 76-81. *via USyd Library*
612. Stretch JR, Thompson JF, Lean CL, **Scolyer RA**, Mountford CE. Magnetic Resonance Spectroscopy in the Management of Melanoma. *Cancer Forum* 2005; 29: 73-6. *via USyd Library*.
613. Armour KS, **Scolyer RA**, Barnetson RS. Borderline lepromatous leprosy presenting as a single cutaneous plaque. *Australas J Dermatol*. 2005 Aug;46(3):181-3. PMID: 16008652
614. van Poll D, Thompson JF, Colman MH, McKinnon JG, Saw RP, Stretch JR, **Scolyer RA**, Uren RF. A sentinel node biopsy does not increase the incidence of in-transit metastasis in patients with primary cutaneous melanoma. *Ann Surg Oncol*. 2005 Aug;12(8):597-608. Epub 2005 Jun 16. PMID: 16021534
615. Weber F, Byrne SN, Le S, Brown DA, Breit SN, **Scolyer RA**, Halliday GM. Transforming growth factor-beta1 immobilises dendritic cells within skin tumours and facilitates tumour escape from the immune system. *Cancer Immunol Immunother*. 2005 Sep;54(9):898-906. Epub 2005 Mar 18. PMID: 15776284
616. Thompson JF, Menzies S, Shaw HM, **Scolyer RA**, Kefford RF. Cutaneous melanoma. Reply to de Giorgi V, et al (letter) and Retsas S (letter). *Lancet* 2005; 365: 2004-5. DOI: 10.1016/S0140-6736(05)66687-1 *Original manuscript PMID: 15721476*
617. Tse GM, Wong FC, Tsang AK, Lee CS, Lui PC, Lo AW, Law BKB, **Scolyer RA**, Karim RZ, Putti TC. Stromal nitric oxide synthase (NOS) expression correlates with the grade of mammary phyllodes tumour. *J Clin Pathol*. 2005 Jun;58(6):600-4. PMID: 15917410
618. Yee VS, Thompson JF, McKinnon JG, **Scolyer RA**, Li LX, McCarthy WH, O'Brien CJ, Quinn MJ, Saw RP, Shannon KF, Stretch JR, Uren RF. Outcome in 846 cutaneous melanoma patients from a single center after a negative sentinel node biopsy. *Ann Surg Oncol*. 2005 Jun;12(6):429-39. Epub 2005 Apr 28. PMID: 15886905
619. Karim RZ, Rose BR, Brammah S, **Scolyer RA**. Condylomata acuminata of the urinary bladder with HPV 11. *Pathology*. 2005 Apr;37(2):176-8. PMID: 16028850
620. **Scolyer RA**, Thompson JF. Desmoplastic melanoma: a heterogeneous entity in which subclassification as "pure" or "mixed" may have important prognostic significance. *Ann Surg Oncol*. 2005 Mar;12(3):197-9. Epub 2005 Mar 3. PMID: 15827808
621. Bourne RM, Stanwell PT, Stretch JR, **Scolyer RA**, Thompson JF, Mountford CE, Lean CL. In Vivo and Ex Vivo Proton MR Spectroscopy of Primary and Secondary Melanoma. *Eur J Radiol*. 2005 Mar;53(3):506-13. PMID:15741026
622. Thompson JF, **Scolyer RA**, Kefford RF. Cutaneous melanoma. *Lancet*. 2005 Feb 19-25;365(9460):687-701. DOI: 10.1016/S0140-6736(05)17951-3. PMID: 15721476
623. Starritt EC, Uren RF, **Scolyer RA**, Quinn MJ, Thompson JF. Ultrasound examination of sentinel nodes in the initial assessment of patients with primary cutaneous melanoma. *Ann Surg Oncol*. 2005 Jan;12(1):18-23. Epub 2004 Dec 27. PMID: 15827773
624. Tse GM, Tsang AK, Putti TC, **Scolyer RA**, Lui PC, Law BK, Karim RZ, Lee CS. Stromal CD10 expression in mammary fibroadenomas and phyllodes tumours. *J Clin Pathol*. 2005 Feb;58(2):185-9. DOI:10.1136/jcp.2004.020917. PMID: 15677540
625. McKinnon JG, Starritt EC, **Scolyer RA**, McCarthy WH, Thompson JF. Histopathologic excision margin affects local recurrence rate: analysis of 2681 patients with melanomas < or =2 mm thick. *Ann Surg*. 2005 Feb;241(2):326-33. PMID: 15650644
626. Bron LP, **Scolyer RA**, Thompson JF, Hersey P. Histological expression of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in human primary melanoma. *Pathology*. 2004 Dec;36(6):561-5. PMID:15841691
627. **Scolyer RA**, Thompson JF, McCarthy SW. Sentinel lymph nodes in malignant melanoma: extended histopathologic evaluation improves diagnostic precision. *Cancer*. 2004 Nov 1;101(9):2141-2; author reply 2142-3. PMID: 15372477
628. **Scolyer RA**, Li L-XL, McCarthy SW, Shaw HM, Stretch JR, Sharma R, Thompson JF. Micromorphometric features of positive sentinel lymph nodes predict involvement of nonsentinel nodes in patients with melanoma. *Am J Clin Pathol* 2004 oct;122(4):532-9. PMID: 15487450
629. McCarthy SW, **Scolyer RA**. Melanocytic lesions of the face: diagnostic pitfalls. *Ann Acad Med Singapore*. 2004 Jul;33(4 Suppl):3-14. PMID: 15389301
630. **Scolyer RA**, Thompson JF, Li L-XL, Beavis A, Dawson M, Doble P, Soper R, Uren RF, Stretch JR, Sharma R, McCarthy SW. Antimony concentrations in nodal tissue can confirm sentinel node identity. *Mod Pathol*. 2004 Oct;17(10):1191-7. PMID: 15372052
631. Tse GM, Lui PC, Lee CS, Kung FY, **Scolyer RA**, Law BK, Lau TS, Karim R, Putti TC. Stromal expression of vascular endothelial growth factor correlates with tumor grade and microvessel density in mammary phyllodes tumors: A multicenter study of 185 cases. *Hum Pathol*. 2004 Sep;35(9):1053-7. PMID: 15343505
632. Doubrovsky A, de Wilt JH, **Scolyer RA**, McCarthy WH, Thompson JF. Sentinel node biopsy provides more accurate staging than elective lymph node dissection in patients with cutaneous melanoma. *Ann Surg Oncol*. 2004 Sep;11(9):829-36. Epub 2004 Aug 16. PMID: 15313732
633. Thompson JF, **Scolyer RA**. Cooperation between surgical oncologists and pathologists: a key element of multidisciplinary care for patients with cancer. *Pathology*. 2004 Oct;36(5):496-503. PMID: 15370122
634. Dahlstrom JE, **Scolyer RA**, Thompson JF, Jain S. Spitz naevus: diagnostic problems and their management implications. *Pathology* 2004 Oct;36(5):452-7. PMID: 15370115
635. McCarthy SW, **Scolyer RA**, Palmer AA. Desmoplastic melanoma: a diagnostic trap for the unwary. *Pathology*. 2004 Oct;36(5):445-51. PMID: 15370114
636. **Scolyer RA**, Zhuang L, Palmer AA, Thompson JF, McCarthy SW. Combined naevus: a benign lesion frequently misdiagnosed both clinically and pathologically as melanoma. *Pathology*. 2004 Oct;36(5):419-27. PMID: 15370111
637. **Scolyer RA**, McCarthy SW, Elder DE. Frontiers in melanocytic pathology. *Pathology*. 2004 Oct;36(5):385-6. PMID: 15370106
638. Li W, Thompson CH, Cossart YE, O'Brien CJ, Liu J, **Scolyer RA**, Carter J, Dalrymple C, Rose BR. The site of infection and ethnicity of the patient influence the biological pathways to HPV-induced mucosal cancer. *Mod Pathol*. 2004 Sep;17(9):1031-7. PMID: 15143339
639. Lee VK, McCaughan BC, **Scolyer RA**. Polymorphous low-grade adenocarcinoma in the lung: a case report. *Int J Surg Pathol*. 2004 Jul;12(3):287-92. PMID: 15306944
640. **Scolyer RA**, Li L-XL, McCarthy SW, Shaw HM, Stretch JR, Sharma R, Thompson JF. Immunohistochemical stains fail to increase the detection rate of micrometastatic melanoma in completion regional lymph node dissection specimens. *Melanoma Res*. 2004 Aug;14(4):263-8. PMID: 15305156
641. **Scolyer RA**, Thompson JF, Warnke K, McCarthy SW. Pigmented epithelioid melanocytoma. *Am J Surg Pathol*. 2004 Aug;28(8):1114-5; author reply 1115-6. PMID: 15252326

642. Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, Scurry J, **Scoflyer RA**, Davies MJ, Heinzelmann M, Kalish LH, Bali A, Kench JG, Edwards LS, Vanden Bergh PM, Hacker N, Sutherland RL, O'Brien PM. Overexpression of the cell adhesion molecules DDR1, Claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer. *Clin Cancer Res*. 2004 Jul 1;10(13):4427-36. PMID: 15240533
643. Zborowska B, Ell J, McGee-Collett M, **Scoflyer R**, McCluskey PJ. Progressive visual loss in a patient with presumed temporal arteritis despite treatment: how to make the diagnosis. *Clin Experiment Ophthalmol* 2004 Jun;32(3):335-6. PMID: 15180851
644. Thompson JF, Shaw HM, Hersey P, **Scoflyer RA**. The history and future of melanoma staging. *J Surg Oncol*. 2004 Jul 1;86(4):224-35. Review. PMID: 15221929
645. **Scoflyer RA**, Thompson JF, Stretch JR, Sharma R, McCarthy SW. Pathology of melanocytic lesions: new, controversial, and clinically important issues. *J Surg Oncol* 2004; 86: 200-211. PMID: 15221927
646. Tse GM, Putti TC, Lui PC, Lo AWI, **Scoflyer RA**, Law BK, Karim RZ, Lee CS. Increased c-kit (CD117) expression in malignant mammary phyllodes tumors. *Mod Pathol*. 2004 Jul;17(7):827-31. PMID: 15044924
647. Karim RZ, Tse GM, Putti T, **Scoflyer RA**, Lee S. The significance of the Wnt pathway in the pathology of human cancers. *Pathology* 2004 Apr;36(2):120-8. PMID: 15203747
648. Francken AB, Shaw HM, Thompson JF, Soon SJ, Accortt NA, Azzola MF, **Scoflyer RA**, Milton GW, McCarthy WH, Colman MH, McGovern VJ. The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up. *Ann Surg Oncol*. 2004 Apr;11(4):426-33. Epub 2004 Mar 15. PMID: 15070604
649. Wells J, Kosky CA, **Scoflyer RA**, Lee S, Bye PT, Young GA, Davies L. Unusual case of subcutaneous panniculitis-like T-cell lymphoma. *Australas J Dermatol*. 2004 May;45(2):114-8. PMID: 15068459
650. Li LX, **Scoflyer RA**, Crotty KA, Palmer AA, Kril JJ, Thompson JF, McCarthy SW. AgNOR count and morphometry in benign and malignant melanocytic lesions. Reply to Tuccar G, et al. (letter) *Am J Dermatopathol* 2004; 26: 172-3. *Original manuscript PMID: 12775980*
651. **Scoflyer RA**, Thompson JF, Li LX, Beavis A, Dawson M, Doble P, Ka VS, McKinnon JG, Soper R, Uren RF, Shaw HM, Stretch JR, McCarthy SW. Failure to remove true sentinel nodes can cause failure of the sentinel node biopsy technique: evidence from antimony concentrations in false-negative sentinel nodes from melanoma patients. *Ann Surg Oncol*. 2004 Mar;11(3 Suppl):174S-8S. PMID: 15023747
652. de Wilt JHW, Thompson JF, Uren RF, Ka VSK, **Scoflyer RA**, McCarthy WH, O'Brien CJ, Quinn MJ, Shannon KF. Correlation between preoperative lymphoscintigraphy and metastatic nodal disease sites in 362 patients with cutaneous melanomas of the head and neck. *Ann Surg*. 2004 Apr;239(4):544-52. PMID: 15024316
653. Thompson JF, Stretch JR, Uren RF, Ka VS, **Scoflyer RA**. Sentinel node biopsy for melanoma: where have we been and where are we going? *Ann Surg Oncol*. 2004 Mar;11(3 Suppl):147S-51S. PMID: 15023742
654. **Scoflyer RA**, Bonar SF, Palmer AA, Barr EM, Wills EJ, Stalley P, Schatz J, Soper J, Li L-XL, McCarthy SW. Parachordoma is not distinguishable from axial chordoma using immunohistochemistry. *Pathol Int*. 2004 May;54(5):364-70. PMID: 15086843
655. Sarris M, **Scoflyer RA**, Konopka M, Thompson J, Harper CG, Lee CS. Cytoplasmic expression of nm23 predicts the potential for cerebral metastasis in patients with primary cutaneous melanoma. *Melanoma Res*. 2004 Feb;14(1):23-7. Erratum in: *Melanoma Res*. 2004 Jun;14(3):239. Lee, Soon C [corrected to Lee, C Soon]. PMID: 15091190
656. Karim RZ, MaWyatt J, Cox M, **Scoflyer RA**. Myoid angioendothelioma of the spleen. *Int J Surg Pathol*. 2004 Jan;12(1):51-6. PMID: 14765275
657. Bonar SF, McCarthy S, Stalley P, Schatz J, Soper J, **Scoflyer R**, Barrett I. Epiphyseal osteoblastoma-like osteosarcoma. *Skeletal Radiol*. 2004 Jan;33(1):46-50. Epub 2003 Nov 20. PMID: 14628101
658. Li W, Thompson CH, Cossart YE, O'Brien CJ, McNeil EB, **Scoflyer RA**, Rose BR. The expression of key cell cycle markers and presence of human papillomavirus in squamous cell carcinoma of the tonsil. *Head Neck*. 2004 Jan;26(1):1-9. PMID: 14724900
659. **Scoflyer RA**, Shaw HM, Thompson JF, Li LX, Colman MH, Lo SK, McCarthy SW, Palmer AA, Nicoll KD, Dutta B, Slobedman E, Watson GF, Stretch JR. Interobserver reproducibility of histopathologic prognostic variables in primary cutaneous melanomas. *Am J Surg Pathol*. 2003 Dec;27(12):1571-6. PMID: 14657718
660. Li LX, Crotty KA, **Scoflyer RA**, Thompson JF, Kril JJ, Palmer AA, McCarthy SW. Use of multiple cytometric markers improves discrimination between benign and malignant melanocytic lesions: a study of DNA microdensitometry, karyometry, argyrophilic staining of nucleolar organizer regions and MIB1-Ki67 immunoreactivity. *Melanoma Res*. 2003 Dec;13(6):581-6. PMID: 14646621
661. Li W, Thompson CH, Xin D, Cossart YE, O'Brien CJ, McNeil EB, Gao K, **Scoflyer RA**, Rose BR. Absence of human papillomavirus in tonsillar squamous cell carcinomas from Chinese patients. *Am J Pathol*. 2003 Dec;163(6):2185-9. PMID: 14633593
662. Tse GMK, Lui PCW, **Scoflyer RA**, Putti TC, Kung FYL, Law BKB, Lau T-S, Lee CS. Tumor angiogenesis and p53 protein expression in mammary phyllodes tumors. *Mod Pathol*. 2003 Oct;16(10):1007-13. PMID: 14559983
663. Nelson AE, Bligh RC, Mirams M, Gill A, Au A, Clarkson A, Juppner H, Ruff S, Stalley P, **Scoflyer RA**, Robinson BG, Mason RS, Bligh PC. Clinical case seminar: Fibroblast Growth Factor 23: A New Clinical Marker for Oncogenic Osteomalacia. *J Clin Endocrinol Metab*. 2003 Sep;88(9):4088-94. PMID: 12970268
664. Dawson M, Doble P, Beavis A, Li LX, Soper R, **Scoflyer RA**, Uren RF, Thompson JF. Antimony by ICP-MS as a marker for sentinel lymph nodes in melanoma patients. *Analyst*. 2003 Mar;128(3):217-9. PMID: 12705377
665. Li LX, Crotty KA, Palmer AA, Kril JJ, **Scoflyer RA**, Thompson JF, McCarthy SW. Argyrophilic staining of nucleolar organizer region count and morphometry in benign and malignant melanocytic lesions. *Am J Dermatopathol*. 2003 Jun;25(3):190-7. DOI: 10.1097/00000372-200306000-00002. PMID: 12775980
666. Lean CL, Bourne R, Thompson JF, **Scoflyer RA**, Stretch J, Li LX, Russell P, Mountford C. Rapid detection of metastatic melanoma in lymph nodes using proton magnetic resonance spectroscopy of fine needle aspiration biopsy specimens. *Melanoma Res*. 2003 Jun;13(3):259-61. PMID: 12777980
667. Li W, Thompson CH, O'Brien CJ, McNeil EB, **Scoflyer RA**, Cossart YE, Veness MJ, Walker DM, Morgan GJ, Rose BR. Human papillomavirus positivity predicts favourable outcome for squamous carcinoma of the tonsil. *Int J Cancer*. 2003 Sep 10;106(4):553-8. PMID: 12845651
668. Li LX, **Scoflyer RA**, Ka VS, McKinnon JG, Shaw HM, McCarthy SW, Thompson JF. Pathologic review of negative sentinel lymph nodes in melanoma patients with regional recurrence: a clinicopathologic study of 1152 patients undergoing sentinel lymph node biopsy. *Am J Surg Pathol*. 2003 Sep;27(9):1197-202. PMID: 12960803

669. Slater M, **Scoflyer RA**, Gidley-Baird A, Thompson JF, Barden JA. Increased expression of apoptotic markers in melanoma. *Melanoma Res.* 2003 Apr;13(2):137-45. PMID: 12690296
670. Karim RZ, McCarthy SW, Palmer AA, **Scoflyer RA**. Intramuscular dendritic fibromyxolipoma: myxoid variant of spindle cell lipoma? *Pathol Int.* 2003 Apr;53(4):252-8. PMID: 12675771
671. Azzola MF, Shaw HM, Thompson JF, Soong S-J, **Scoflyer RA**, Watson GF, Colman MH, Zhang Y. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. *Cancer.* 2003 Mar 15;97(6):1488-98. PMID: 12627514
672. **Scoflyer RA**, Russell P. Reply to Zardawi I (letter). Aggressive endometriosis. *Int J Gynecol Cancer* 2000; 13: 100. *Original manuscript PMID: 11240684*
673. Featherstone C, **Scoflyer R**, Hruby G, Tin M, Wills E, Hendel PN. Challenging and unusual cases: Case 4. Malignant mesothelioma presenting as an anterior mediastinal mass. *J Clin Oncol.* 2003 Apr 1;21(7):1420-1. PMID: 12663739
674. **Scoflyer RA**, Crotty KA, Palmer AA, McCarthy SW. Reply to Somers G (letter). Pagetoid melanocytosis in Spitz naevi. *Pathology* 2002; 34: 592. *Original manuscript PMID: 11902448*
675. Tse GMK, Lee CS, Kung FYL, **Scoflyer RA**, Law BKB, Lau TS, Putti TC. Hormonal receptors expression in epithelial cells of mammary phyllodes tumors correlates with pathological grade of the tumor: a multicenter study of 143 cases. *Am J Clin Pathol.* 2002 Oct;118(4):522-6. PMID: 12375638
676. Li LX, Crotty KA, Palmer AA, Kril JJ, Stankovic R, **Scoflyer RA**, McCarthy SW. Differentiating benign nevi from malignant melanoma using DNA microdensitometry and caryometry and maturation: a zonal comparison, correlation and multivariate analysis. *Anal Quant Cytol Histol.* 2002 Aug;24(4):234-43. PMID: 12199325
677. Tse GM, Putti TC, Kung FY, **Scoflyer RA**, Law BK, Lau TS, Lee CS. Increased p53 protein expression in malignant mammary phyllodes tumors. *Mod Pathol.* 2002 Jul;15(7):734-40. PMID: 12118111
678. Karim R, **Scoflyer RA**. A subcutaneous nodule: another variant of a pseudotumour? Part 1. *Pathology* 34.5 (2002): 466–470. DOI: 10.1080/0031302021000009423 (Not in PubMed) Available via USyd Library.
679. Li LX, Crotty KA, Palmer AA, Kril JJ, **Scoflyer RA**, McCarthy SW. Melanin bleaching in argyrophilic staining of AgNORs in pigmented lesions: a morphometric evaluation. *Anal Quant Cytol Histol* 2002 Jun; 24(3):166-72. PMID: 12102129
680. Cooper WA, **Scoflyer RA**. An unusual pleural spindle cell tumour. Part 1. *Pathology* 2002 Aug;34(4):370-4. PMID: 12190298
681. Karim R, **Scoflyer RA**. Test and teach. Diagnosis: Subcutaneous Rosai-Dorfman disease. *Pathology* 2002 Oct;34(5): 466-70. PMID: 12408348
682. Shaw HM, McCarthy WH, **Scoflyer RA**. Clinical and histologic features of level 2 cutaneous malignant melanoma associated with metastases. *Cancer.* 2002 Aug 1;95(3):671-2; author reply 672-3. PMID: 12209764
683. Crotty KA, **Scoflyer RA**, Li L, Palmer AA, Wang L, McCarthy SW. Spitz naevus versus spitzoid melanoma: when and how can they be distinguished? *Pathology* 2002; 34: 6-12. PMID: 11902448
684. Shaw HM, **Scoflyer RA**, Thompson JF. (Letter) Sentinel lymph node metastasis in patients with spindle cell melanomas. *J Am Acad Dermatol* 2002; 47: E10. Doi:10.1067/mjd.2002.120588 (Not in PubMed)
685. **Scoflyer RA**, McKenzie PR, Achmed D, Lee CS. Can phyllodes tumours of the breast be distinguished from fibroadenomas using fine needle aspiration cytology? *Pathology* 2001 Nov;33(4):437-43. PMID: 11827409
686. Buckland ME, **Scoflyer RA**, Donnellan M, Brew S, McGee-Collette M, Harper CG. Spinal chloroma presenting with triplegia in an aleukaemic patient. *Pathology* 2001 Aug;33(3):386-9. PMID: 11523946
687. **Scoflyer RA**, McCarthy SW, Wills EJ, Palmer AA. Hyalinising spindle cell tumour with giant rosettes: report of a case with unusual features including original histological and ultrastructural observations. *Pathology* 2001; 33: 101-7. PMID: 11280598
688. Herdson PB, **Scoflyer RA**, McGregor AR. Defining moments in medicine: *Pathology.* *Med J Aust* 2001 Jan 1;174(1):11-2. PMID: 11219779
689. **Scoflyer RA**, Carter J, Russell P. Aggressive endometriosis: report of a case. *Int J Gynecol Cancer* 2000 May;10(3): 257-62. PMID: 11240684
690. **Scoflyer RA**, Brun M, D'Rozario J, Webb M. Acute basophilic leukaemia presenting with abnormal liver function tests and the absence of blast cells in the peripheral blood. *Pathology* 2000 Feb;32(1):52-5. PMID: 10740808
691. **Scoflyer RA**, Rose B, Painter DM. Test and Teach No. 96: Test and teach. Number ninety six: Part 1. Inverted duct papilloma of minor salivary gland origin. *Pathology* 1999 Nov;31(4):372, 423-4. PMID: 10643008
692. **Scoflyer RA**, Painter DM, Harper CG, Lee CS. Hepatocellular carcinoma metastasizing to the orbit diagnosed by fine needle aspiration cytology. *Pathology* 1999;31(4):350-3. PMID: 10643005
693. Desai AV, **Scoflyer RA**, McCaughan B, Torzillo PJ. Middle lobe syndrome due to obstructing solitary bronchial papilloma. *Aust NZ J Med* 1999 Oct;29(5):745-7. PMID: 10630661
694. **Scoflyer RA**. Test and teach. Number ninety-four: Part 1. Churg-Strauss syndrome. *Pathology* 1999; 31: 217-8, 275-7. PMID: 10503265

PUBLICATIONS as part of GROUP COLLABORATIONS/CONSORTIA

1. Caroline Watts, Andrew Spillane, Michael A Henderson and Anne Cust, Australian Melanoma Centre of Research Excellence Study Group. Sentinel lymph node biopsy rates in Victoria, 2018 and 2019. *Med J Aust* 14 Mar 2022 doi: 10.5694/mja2.51424. PMID: TBC
2. Smith AL, Watts CG, Robinson S, Schmid H, Goumas C, Mar VJ, Thompson JF, Rapport F; Australian Melanoma Centre of Research Excellence Study Group, Cust AE.. Knowledge and attitudes of Australian dermatologists towards sentinel lymph node biopsy for melanoma: a mixed methods study. *Australas J Dermatol.* 2021 May;62(2):168-176. doi: 10.1111/ajd.13518. Epub 2020 Dec 5. PMID: 33277693
3. Bailey MH, Meyerson WU, Dursi LJ, Wang LB, Dong G, Liang WW, Weerasinghe A, Li S, Li Y, Kelso S; MC3 Working Group; PCAWG novel somatic mutation calling methods working group, Saksena G, Ellrott K, Wendl MC, Wheeler DA, Getz G, Simpson JT, Gerstein MB, Ding L; PCAWG Consortium. Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples. *Nat Commun.* 2020 Sep 21;11(1):4748. doi: 10.1038/s41467-020-17815-1. Author correction: *Nat Commun.* 2020 Nov 30;11(1):6232. doi: 10.1038/s41467-020-20128-w. PMID: 32958763 & 33257764

4. Sex differences in oncogenic mutational processes. Li CH, Prokopec SD, Sun RX, Yousif F, Schmitz N; PCAWG Tumour Subtypes and Clinical Translation, Boutros PC; PCAWG Consortium. *Nat Commun.* 2020 Aug 28;11(1):4330. doi: 10.1038/s41467-020-17359-2. PMID: 32859912
5. GPs' involvement in diagnosing, treating, and referring patients with suspected or confirmed primary cutaneous melanoma: a qualitative study. Smith AL, Watts CG, Robinson S, Schmid H, Chang C, Thompson JF, Rapport F, Australian Melanoma Centre of Research Excellence Study Group*, Cust AE, *Australian Melanoma Centre of Research Excellence Study Group: Braithwaite J, Gyorki DE, Henderson M, Hong AM, Kelly JW, Long GV, Mar VJ, Morton RL, Saw RPM, Scolyer RA, Spillane AJ, Mann GJ. *BJGP Open* 2020 April 16. DOI:10.3399/bjgpopen20X101028 PMID: 32295791
6. Pan-cancer analysis of whole genomes. ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. *Nature.* 2020 Feb;578(7793):82-93. doi: 10.1038/s41586-020-1969-6. Epub 2020 Feb 5. PMID: 32025007.
7. Erratum: Comprehensive Characterization of Cancer Driver Genes and Mutations. Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, Colaprico A, Wendl MC, Kim J, Reardon B, Kwok-Shing Ng P, Jeong KJ, Cao S, Wang Z, Gao J, Gao Q, Wang F, Liu EM, Mularoni L, Rubio-Perez C, Nagarajan N, Cortés-Ciriano I, Zhou DC, Liang WW, Hess JM, Yellapantula VD, Tamborero D, Gonzalez-Perez A, Suphavitai C, Ko JY, Khurana E, Park PJ, Van Allen EM, Liang H; MC3 Working Group; Cancer Genome Atlas Research Network, Lawrence MS, Godzik A, Lopez-Bigas N, Stuart J, Wheeler D, Getz G, Chen K, Lazar AJ, Mills GB, Karchin R, Ding L. *Cell.* 2018 Aug 9;174(4):1034-1035. doi: 10.1016/j.cell.2018.07.034. PMID: 30096302
8. The Immune Landscape of Cancer. Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, Sivakumar IKA, Gentles AJ, Malhotra R, Farshidfar F, Colaprico A, Parker JS, Mose LE, Vo NS, Liu J, Liu Y, Rader J, Dhankani V, Reynolds SM, Bowlby R, Califano A, Cherniack AD, Anastassiou D, Bedognetti D, Mokrab Y, Newman AM, Rao A, Chen K, Krasnitz A, Hu H, Malta TM, Noushmehr H, Pedamallu CS, Bullman S, Ojesina AI, Lamb A, Zhou W, Shen H, Choueiri TK, Weinstein JN, Guinney J, Saltz J, Holt RA, Rabkin CS; Cancer Genome Atlas Research Network, Lazar AJ, Serody JS, Demicco EG, Disis ML, Vincent BG, Shmulevich I. *Immunity.* 2019 Aug 20;51(2):411-412. doi: 10.1016/j.immuni.2019.08.004. PMID: 31433971
9. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhi R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Haake S, Hakimi AA, Henske EP, Hsieh JJ, Ho TH, Kanchi RS, Krishnan B, Kwiatkowski DJ, Lui W, Merino MJ, Mills GB, Myers J, Nickerson ML, Reuter VE, Schmidt LS, Shelley CS, Shen H, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Vincent BG, Vocke CD, Wheeler DA, Yang L, Kim WY, Robertson AG; Cancer Genome Atlas Research Network, Spellman PT, Rathmell WK, Linehan WM. *Cell Rep.* 2018 Apr 3; Erratum in: *Cell Rep.* 2018 Jun 19 PMID: 29925010
10. Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients. Kahles A, Lehmann KV, Toussaint NC, Huser M, Stark SG, Sachsenberg T, Stegle O, Kohlbacher O, Sander C, Cancer Genome Atlas Research N, Ratsch G. *Cancer Cell.* 2018;34(2):211-24 e6. PMID: 30078747
11. Oncogenic Signaling Pathways in The Cancer Genome Atlas. Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadou S, Liu DL, Kantheti HS, Saghafeina S, Chakravarty D, Daian F, Gao Q, Bailey MH, Liang WW, Foltz SM, Shmulevich I, Ding L, Heins Z, Ochoa A, Gross B, Gao J, Zhang H, Kundra R, Kandath C, Bahceci I, Dervishi L, Dogrusoz U, Zhou W, Shen H, Laird PW, Way GP, Greene CS, Liang H, Xiao Y, Wang C, Iavarone A, Berger AH, Bivona TG, Lazar AJ, Hammer GD, Giordano T, Kwong LN, McArthur G, Huang C, Tward AD, Frederick MJ, McCormick F, Meyerson M; Cancer Genome Atlas Research Network, Van Allen EM, Cherniack AD, Ciriello G, Sander C, Schultz N. *Cell.* 2018 Apr 5;173(2):321-337.e10. doi: 10.1016/j.cell.2018.03.035. PMID: 29625050
12. Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer. Wang Y, Xu X, Maglic D, Dill MT, Mojumdar K, Ng PK, Jeong KJ, Tsang YH, Moreno D, Bhavana VH, Peng X, Ge Z, Chen H, Li J, Chen Z, Zhang H, Han L, Du D, Creighton CJ, Mills GB, Cancer Genome Atlas Research N, Camargo F, Liang H. *Cell Rep.* 2018 Oct 30;25(5):1304-1317.e5. doi: 10.1016/j.celrep.2018.10.001. PMID: 30380420
13. Alterations in Mediators of Signaling by the TGF- β A Pan-Cancer Analysis Reveals High-Frequency Genetic Superfamily. Korkut A, Zaidi S, Kanchi RS, Rao S, Gough NR, Schultz A, Li X, Lorenzi PL, Berger AC, Robertson G, Kwong LN, Datto M, Roszik J, Ling S, Ravikumar V, Manyam G, Rao A, Shelley S, Liu Y, Ju Z, Hansel D, de Velasco G, Pennathur A, Andersen JB, O'Rourke CJ, Ohshiro K, Jogunoori W, Nguyen BN, Li S, Osmanbeyoglu HU, Ajani JA, Mani SA, Houseman A, Wiznerowicz M, Chen J, Gu S, Ma W, Zhang J, Tong P, Cherniack AD, Deng C, Resar L; Cancer Genome Atlas Research Network, Weinstein JN, Mishra L, Akbani R. *Cell Syst.* 2018 Oct 24;7(4):422-437.e7. doi: 10.1016/j.cels.2018.08.010. Epub 2018 Sep 26. PMID: 30268436
14. Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. Ellrott K, Bailey MH, Saksena G, Covington KR, Kandath C, Stewart C, Hess J, Ma S, Chiotti KE, McLellan M, Sofia HJ, Hutter C, Getz G, Wheeler D, Ding L; MC3 Working Group; Cancer Genome Atlas Research Network. *Cell Syst.* 2018 Mar 28;6(3):271-281.e7. doi: 10.1016/j.cels.2018.03.002 PMID: 29596782
15. Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. Schaub FX, Dhankani V, Berger AC, Trivedi M, Richardson AB, Shaw R, Zhao W, Zhang X, Ventura A, Liu Y, Ayer DE, Hurlin PJ, Cherniack AD, Eisenman RN, Bernard B, Grandori C; Cancer Genome Atlas Network. *Cell Syst.* 2018 Mar 28;6(3):282-300.e2. doi: 10.1016/j.cels.2018.03.003 PMID: 29596783
16. Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas. Way GP, Sanchez-Vega F, La K, Armenia J, Chatila WK, Luna A, Sander C, Cherniack AD, Mina M, Ciriello G, Schultz N; Cancer Genome Atlas Research Network, Sanchez Y, Greene CS *Cell Rep.* 2018 Apr 3 PMID: 29617658
17. Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. Saltz J, Gupta R, Hou L, Kurc T, Singh P, Nguyen V, Samaras D, Shroyer KR, Zhao T, Batiste R, Van Arnam J, Cancer Genome Atlas Research Network, Shmulevich I, Rao AUK, Lazar AJ, Sharma A, Thorsson V. *Cell Rep.* 2018 Apr 3 PMID: 29617659
18. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Campbell JD, Yau C, Bowlby R, Liu Y, Brennan K, Fan H, Taylor AM, Wang C, Walter V, Akbani R, Byers LA, Creighton CJ, Coarfa C, Shih J, Cherniack AD, Gevaert O, Prunello M, Shen H, Anur P, Chen J, Cheng H, Hayes DN, Bullman S, Pedamallu CS, Ojesina AI, Sadeghi S, Mungall KL, Robertson AG, Benz C, Schultz A, Kanchi RS, Gay CM, Hegde A, Diao L, Wang J, Ma W, Sumazin P, Chiu HS, Chen TW, Gunaratne P, Donehower L, Rader JS, Zuna R, Al-Ahmadie H, Lazar AJ, Flores ER, Tsai KY, Zhou JH, Rustgi AK, Drill E, Shen R, Wong CK; Cancer Genome Atlas Research Network, Stuart JM, Laird PW, Hoadley KA, Weinstein JN, Peto M, Pickering CR, Chen Z, Van Waes C. *Cell Rep.* 2018 Apr 3 PMID: 29617660

19. Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types. Ge Z, Leighton JS, Wang Y, Peng X, Chen Z, Chen H, Sun Y, Yao F, Li J, Zhang H, Liu J, Shriver CD, Hu H; Cancer Genome Atlas Research Network, Piwnicka-Worms H, Ma L, Liang H. *Cell Rep.* 2018 Apr 3. DOI: 10.1016/j.celrep.2018.03.050. PMID: 29617661
20. Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. Gao Q, Liang WW, Foltz SM, Mutharasu G, Jayasinghe RG, Cao S, Liao WW, Reynolds SM, Wyczalkowski MA, Yao L, Yu L, Sun SQ; Fusion Analysis Working Group; Cancer Genome Atlas Research Network, Chen K, Lazar AJ, Fields RC, Wendl MC, Van Tine BA, Vij R, Chen F, Nykter M, Shmulevich I, Ding L. *Cell Rep.* 2018 Apr 3 PMID: 29617662
21. Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. Knijnenburg TA, Wang L, Zimmermann MT, Chambwe N, Gao GF, Cherniack AD, Fan H, Shen H, Way GP, Greene CS, Liu Y, Akbani R, Feng B, Donehower LA, Miller C, Shen Y, Karimi M, Chen H, Kim P, Jia P, Shinbrot E, Zhang S, Liu J, Hu H, Bailey MH, Yau C, Wolf D, Zhao Z, Weinstein JN, Li L, Ding L, Mills GB, Laird PW, Wheeler DA, Shmulevich I; Cancer Genome Atlas Research Network, Monnat RJ Jr., Xiao Y, Wang C. *Cell Rep.* 2018 Apr 3 PMID: 29617664
22. Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers. Peng X, Chen Z, Farshidfar F, Xu X, Lorenzi PL, Wang Y, Cheng F, Tan L, Mojumdar K, Du D, Ge Z, Li J, Thomas GV, Birsoy K, Liu L, Zhang H, Zhao Z, Marchand C, Weinstein JN; Cancer Genome Atlas Research Network, Bathe OF, Liang H. *Cell Rep.* 2018 Apr 3 PMID: 29617665
23. Systematic Analysis of Splice-Site-Creating Mutations in Cancer. Jayasinghe RG, Cao S, Gao Q, Wendl MC, Vo NS, Reynolds SM, Zhao Y, Clemente-González H, Chai S, Wang F, Varghese R, Huang M, Liang WW, Wyczalkowski MA, Sengupta S, Li Z, Payne SH, Fenyő D, Miner JH, Walter MJ; Cancer Genome Atlas Research Network, Vincent B, Eyraas E, Chen K, Shmulevich I, Chen F, Ding L. *Cell Rep.* 2018 Apr 3 PMID: 29617666
24. Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. Seiler M, Peng S, Agrawal AA, Palacino J, Teng T, Zhu P, Smith PG; Cancer Genome Atlas Research Network, Buonamici S, Yu L. *Cell Rep.* 2018 Apr 3 PMID: 29617667
25. Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context. Chiu HS, Somvanshi S, Patel E, Chen TW, Singh VP, Zorman B, Patil SL, Pan Y, Chatterjee SS; Cancer Genome Atlas Research Network, Sood AK, Gunaratne PH, Sumazin P. *Cell Rep.* 2018 Apr 3. PMID: 29617668
26. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukheim R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Haake S, Hakimi AA, Henske EP, Hsieh JJ, Ho TH, Kanchi RS, Krishnan B, Kwiatkowski DJ, Lui W, Merino MJ, Mills GB, Myers J, Nickerson ML, Reuter VE, Schmidt LS, Shelley CS, Shen H, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Vincent BG, Vocke CD, Wheeler DA, Yang L, Kim WT, Robertson AG; Cancer Genome Atlas Research Network, Spellman PT, Rathmell WK, Linehan WM. *Cell Rep.* 2018 Apr 3;23(1):313-326.e5. doi: 10.1016/j.celrep.2018.03.075. PMID: 29617669
27. Genomic and Functional Approaches to Understanding Cancer Aneuploidy. Taylor AM, Shih J, Ha G, Gao GF, Zhang X, Berger AC, Schumacher SE, Wang C, Hu H, Liu J, Lazar AJ; Cancer Genome Atlas Research Network, Cherniack AD, Beroukheim R, Meyerson M. *Cancer Cell.* 2018 Apr 9;33(4):676-689.e3. doi: 10.1016/j.ccell.2018.03.007. Epub 2018 Apr 2. PMID: 29622463
28. A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu W, Liu Y, Fan H, Shen H, Ravikumar V, Rao A, Schultz A, Li X, Sumazin P, Williams C, Mestdagh P, Gunaratne PH, Yau C, Bowlby R, Robertson AG, Tiezzi DG, Wang C, Cherniack AD, Godwin AK, Kuderer NM, Rader JS, Zuna RE, Sood AK, Lazar AJ, Ojesina AI, Adebamowo C, Adebamowo SN, Baggerly KA, Chen TW, Chiu HS, Lefever S, Liu L, MacKenzie K, Orsulic S, Roszik J, Shelley CS, Song Q, Vellano CP, Wentzensen N; Cancer Genome Atlas Research Network, Weinstein JN, Mills GB, Levine DA, Akbani R. *Cancer Cell.* 2018 Apr 9;33(4):690-705.e9. doi: 10.1016/j.ccell.2018.03.014. Epub 2018 Apr 2. PMID: 29622464
29. lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. Wang Z, Yang B, Zhang M, Guo W, Wu Z, Wang Y, Jia L, Li S; Cancer Genome Atlas Research Network, Xie W, Yang D. *Cancer Cell.* 2018 Apr 9;33(4):706-720.e9. doi: 10.1016/j.ccell.2018.03.006. Epub 2018 Apr 2. PMID: 29622465
30. Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. Liu Y, Sethi NS, Hinoue T, Schneider BG, Cherniack AD, Sanchez-Vega F, Seoane JA, Farshidfar F, Bowlby R, Islam M, Kim J, Chatila W, Akbani R, Kanchi RS, Rabkin CS, Willis JE, Wang KK, McCall SJ, Mishra L, Ojesina AI, Bullman S, Peadarallu CS, Lazar AJ, Sakai R; Cancer Genome Atlas Research Network, Thorsson V, Bass AJ, Laird PW. *Cancer Cell.* 2018 Apr 9;33(4):721-735.e8. doi: 10.1016/j.ccell.2018.03.010. Epub 2018 Apr 2. PMID 29622466
31. Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E, Shen R, Taylor AM, Cherniack AD, Thorsson V, Akbani R, Bowlby R, Wong CK, Wiznerowicz M, Sanchez-Vega F, Robertson AG, Schneider BG, Lawrence MS, Noushmeh H, Malta TM; Cancer Genome Atlas Network, Stuart JM, Benz CC, Laird PW. *Cell.* 2018 Apr 5. DOI: 10.1016/j.cell.2018.03.022. PMID: 29625048
32. Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Ding L, Bailey MH, Porta-Pardo E, Thorsson V, Colaprico A, Bertrand D, Gibbs DL, Weerasinghe A, Huang KL, Tokheim C, Cortés-Ciriano I, Jayasinghe R, Chen F, Yu L, Sun S, Olsen C, Kim J, Taylor AM, Cherniack AD, Akbani R, Suphailai C, Nagarajan N, Stuart JM, Mills GB, Wyczalkowski MA, Vincent BG, Hutter CM, Zenklusen JC, Hoadley KA, Wendl MC, Shmulevich L, Lazar AJ, Wheeler DA, Getz G; Cancer Genome Atlas Research Network. *Cell.* 2018 Apr 5 PMID: 29625049
33. Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Malta TM, Sokolov A, Gentles AJ, Burzykowski T, Poisson L, Weinstein JN, Kamińska B, Huelsken J, Omberg L, Gevaert O, Colaprico A, Czerwińska P, Mazurek S, Mishra L, Heyn H, Krasnitz A, Godwin AK, Lazar AJ; Cancer Genome Atlas Research Network, Stuart JM, Hoadley KA, Laird PW, Noushmeh H, Wiznerowicz M. *Cell.* 2018 Apr 5;173(2):338-354.e15. doi: 10.1016/j.cell.2018.03.034. PMID: 29625051
34. Pathogenic Germline Variants in 10,389 Adult Cancers. Huang KL, Mashl RJ, Wu Y, Ritter DI, Wang J, Oh C, Paczkowska M, Reynolds S, Wyczalkowski MA, Oak N, Scott AD, Krassowski M, Cherniack AD, Houlihan KE, Jayasinghe R, Wang LB, Zhou DC, Liu D, Cao S, Kim YW, Koire A, McMichael JF, Huchtagowder V, Kim TB, Hahn A, Wang C, McLellan MD, Al-Mulla F, Johnson KJ; Cancer Genome Atlas Research Network, Lichtarge O, Boutros PC, Raphael B, Lazar AJ, Zhang W, Wendl MC, Govindan R, Jain S, Wheeler D, Kulkarni S, Dipersio JF, Reimand J, Meric-Bernstam F, Chen K, Shmulevich I, Plon SE, Chen F, Ding L. *Cell.* 2018 Apr PMID: 29625052
35. Comprehensive Characterization of Cancer Driver Genes and Mutations. Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, Colaprico A, Wendl MC, Kim J, Reardon B, Ng PK, Jeong KJ, Cao S, Wang Z, Gao J, Gao Q, Wang F, Liu EM, Mularoni L, Rubio-Perez C, Nagarajan N, Cortés-Ciriano I, Zhou DC, Liang WW, Hess JM, Yellapantula VD, Tamborero D, Gonzalez-Perez A, Suphailai C, Ko JY, Khurana E, Park PJ, Van Allen EM, Liang H; MC3 Working Group; Cancer Genome Atlas Research Network,

- Lawrence MS, Godzik A, Lopez-Bigas N, Stuart J, Wheeler D, Getz G, Chen K, Lazar AJ, Mills GB, Karchin R, Ding L. Cell. 2018 Apr 5. DOI: 10.1016/j.cell.2018.02.060. PMID:29625053
36. A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. Chen H, Li C, Peng X, Zhou Z, Weinstein JN; Cancer Genome Atlas Research Network, Liang H. Cell. 2018 Apr PMID:29625054
37. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee AV, Omberg L, Wolf DM, Shriver CD, Thorsson V. Cancer Genome Atlas Research Network, Hu H. Cell. 2018 Apr 5. PMID: 29625055
38. The Immune Landscape of Cancer. Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, Sivakumar IKA, Gentles AJ, Malhotra R, Farshidfar F, Colaprico A, Parker JS, Mose LE, Vo NS, Liu J, Liu Y, Rader J, Dhankani V, Reynolds SM, Bowlby R, Califano A, Cherniack AD, Anastassiou D, Bedognetti D, Rao A, Chen K, Krasnitz A, Hu H, Malta TM, Noushmehr H, Peadarallu CS, Bullman S, Ojesina AI, Lamb A, Zhou W, Shen H, Choueiri TK, Weinstein JN, Guinney J, Saltz J, Holt RA, Rabkin CE; Cancer Genome Atlas Research Network, Lazar AJ, Serody JS, Demicco EG, Disis ML, Vincent BG, Shmulevich L. Immunity. 2018 Apr 4. PMID: 29628290
39. Genomic classification of cutaneous melanoma. The Cancer Genome Atlas Network (Corporate Author). Cell. 2015 Jun 18;161(7):1681-96. DOI: 10.1016/j.cell.2015.05.044. PMID: 26091043

EDITOR OF TEXTBOOKS

1. WHO Classification of Tumours - Skin tumours 5th edition.
2. WHO Classification of Tumours - Skin tumours 4th edition.
3. Pathology of Melanocytic Tumors. Editors: Klaus Busan, German, Richard A. Scolyer.
4. AFIP Tumor 4th edition Fascicle.

ABSTRACT PUBLICATIONS

1. Serigne Lo, Mary-Ann El Sharouni, Karijn Suijkerbuijk, Tasnia Ahmed, Witkamp Arjen, Anne E. Cust, Vigfús Sigurdsson, Paul J. van Diest, Richard A. Scolyer, Carla Van Gils, John F. Thompson. Quantifying the additional prognostic value of sentinel lymph node status over established clinicopathologic primary tumor features for predicting survival outcomes in melanoma patients. Abstract – ASCO 2020 (Accepted to be published on line).
2. A. Lepletier de Oliveira1, J. Madore, JS O'donnell, RL Johnston, M Eastgate D Mallardo, P Ascierto, D Massi, B Merelli, M Mandala, JS Wilmott, T Bald, J Stagg, B Routy, GV Long, RA Scolyer, N Waddell1, WC Dougall, MWL Teng, M Smyth. Resistance to immunotherapy is associated with high parenchymal PD1+CD8+/CD8+ T cells(PD1tR) driven by tumor CD155. Proffered paper at ESMO Immuno-Oncology Congress 2019, Geneva. 13 December 2019.
3. Tuba N. Gide, Ines P. Silva, Camelia Quek, Tasnia Ahmed, Alexander M. Menzies, Matteo S. Carlino, Robyn P.M. Saw, John F. Thompson, Marcel Batten, Georgina V. Long, **Richard A. Scolyer**, James S. Wilmott. Close Proximity of Immune and Tumor Cells Underlies Response to Anti-PD-1 Based Therapies in Metastatic Melanoma Patients. SMR 2019.
4. Grace H. Attrill*, Carina Owen* (*Co-authors), Tasnia Ahmed, Serigne Lo, Andrew Colebatch, Jordan W. Conway, Inês Pires da Silva, Matteo S. Carlino, Alexander M. Menzies, Mainthan Palendira, **Richard A. Scolyer**, Georgina V. Long, James S. Wilmott. SMR 2019.
5. Gerald B. Fogarty, Janette L. Vardy, Haryana M. Dhillon, Kari Dolven-Jacobsen, Rachael L. Morton, George Hruby, Anna K. Nowak, Katharine J. Drummond, Catherine Mandell, **Richard A. Scolyer**, Brindha Shivalingam, Mark R. Middleton, Bryan H. Burmeister, Daniel E. Roos, Serigne N. Lo, Claudius H. Reisse, Elizabeth J. Paton, Narelle C. Williams, John F. Thompson, Angela M. Hong. 'Neurocognitive outcomes in a phase 3 randomised trial comparing adjuvant whole brain radiotherapy with observation after local treatment of brain metastases in patients with melanoma'. COSA Annual Scientific Meeting Adelaide 12-14 Nov 2019.
6. Pires Da Silva, Ines Esteves Domingues. Ahmed, Tasnia. Lo, Serigne; Rai, Rajat; Smith, Jessica Louise; Park, John J; Nabhan, Caroline; **Scolyer, Richard A**; Carlino, Matteo S; Mcquade, Jennifer Leigh; Johnson, Douglas Buckner; Long, Georgina V; Menzies, Alexander M. Clinical models to predict response and survival in metastatic melanoma (MM) patients (pts) treated with anti-PD-1 alone (PD1) or combined with ipilimumab (IPI+PD1). Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019) 9542-9542. DOI: http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.9542.
7. Minocha R, Martin AJ, Chen AC, **Scolyer RA**, Lyons G, McKenzie CA, Madore J, Halliday GM, Damian DL. Nicotinamide for skin cancer chemoprevention. Effects on tumour cell infiltrates and melanoma biology. 58(S1): 24. Australasian Journal of Dermatology 2018.
8. Minocha R, Chen AC, **Scolyer RA**, Lyons G, McKenzie CA, Madore J, Halliday GM, Damian DL. Nicotinamide chemoprevention and immunomodulation in melanoma and non-melanoma skin cancer. 57(S1): 64-25. Australasian Journal of Dermatology. 2016
9. Jason Madore, Hansol Lee, Nur Gide T, Edwards J, Alexander M. Menzies, John F. Thompson, Georgina V. Long, James S. Wilmott, **Richard A. Scolyer**. Costimulatory Immune Receptor Expression by T-lymphocytes in Metastatic Melanoma
10. Su Yin Lim, Sarah Welsh, Matteo S. Carlino, Alexander M. Menzies, Richard F. Kefford, **Richard A. Scolyer**, Georgina V. Long and Helen Rizos. Identification Of Plasma Biomarkers To Predict Response To Combined Immunotherapy In Melanoma May 2016
11. Micevic G, Muthusamy V, **Scolyer RA**, Bosenberg M. Multigene epigenetic signature is a prognostic marker in melanoma. J Invest Dermatol 2015;135, S106–S113.
12. Holtkamp LHJ, Wang S, Wilmott JS, Madore J, Vilain R, Thompson JF, Nieweg OE, **Scolyer RA**. Patient outcome and detailed pathologic examination of negative completion lymph node dissection specimens in melanoma patients with minimal (<0.1mm) sentinel node metastases. SSO 68th Annual Cancer Symposium March 2015.
13. Burns WR, Watson I, Wu T, **Scolyer RA**, Chin L, Gershenwald J. Molecular Characterization of Cutaneous Melanoma for the Surgical Oncologist: Insights from the Cancer Genome Atlas Program. SSO 68th Annual Cancer Symposium March 2015.
14. Gatt, Annalisa; Crainic, Oana; Thompson, John; **Scolyer, Richard**; McCarthy, S.; Gupta, R. 17 Peritoneal epithelioid mesothelioma in a patient with metastatic melanoma - an association seen in bap1 mutations. Pathology February 2014;(46). doi: 10.1097/01.PAT.0000443707.58189.83
15. Bonenkamp J, In't Hout F, Haydu L, Murali R, Thompson JF, **Scolyer RA**. Prognostic importance of the extent of ulceration of clinically localized cutaneous melanoma. Eur J Surg Oncol 2010 September; 36(9): 908.

16. Murali R, Morey AL, Desilva C, McCarthy SW, **Scoflyer RA**. Fluorescence in situ hybridization in the evaluation of melanocytic tumors. *Melanoma 2010 Congress. Pigment Cell & Melanoma Research*, 23: 874–1004. doi: 10.1111/j.1755-148X.2010.00767.x
17. Carter C, De Silva C, Synnott M, Thompson JF, Stretch JR, Spillane A, Quinn MJ, Saw RP, Shannon K, Murali R, Kefford R, Hersey P, Shivalingam B, Hughes M, Howle J, Long G, Mann GJ, **Scoflyer RA**. Bio-specimen Banking: Melanoma Institute Australia. *Melanoma 2010 Congress. Pigment Cell Melanoma Res* 2010 December 23(6): 946-947. doi: 10.1111/j.1755-148X.2010.00767.x
18. **R.A. Scoflyer**, D. Ellis, C. James, J. Kelly, S. McCarthy, G. Stevens, S. Swain, J. Thompson. The Royal College of Pathologists of Australasia's structured pathology reporting protocol for cutaneous melanoma. *Melanoma 2010 Congress. Pigment Cell & Melanoma Research*, 23: 874–1004. doi: 10.1111/j.1755-148X.2010.00767.x
19. James Wilmott, **Richard A. Scoflyer**, Xu Dong Zhang, Peter Hersey. The role of p53, microRNA-149*, GSK-3 and MCL-1 in melanoma. *Melanoma 2010 Congress. Pigment Cell & Melanoma Research*, 23: 874–1004. doi: 10.1111/j.1755-148X.2010.00767.x
20. Sandro Pasquali, Lauren Haydu, **Richard A. Scoflyer**, Julie Winstanley, John F. Thompson. Towards achieving loco-regional control for primary melanoma ≥ 4 mm thick: histopathologic margins and sentinel node biopsy. *Melanoma 2010 Congress. Pigment Cell & Melanoma Research*, 23: 874–1004. doi: 10.1111/j.1755-148X.2010.00767.x
21. GJ Mann, GM Pupo, AE Campain, CA Carter, S Pianova, M Synnott, S-J Schramm, C De Silva, J Wilmott, K Lai, V Tembe, JF Thompson, YH Yang, **RA Scoflyer**. BRAF mutation, NRAS mutation and absence of an immune-related expressed gene profile predict poor outcome in surgically resected stage III melanoma. *Melanoma 2010 Congress. Pigment Cell & Melanoma Research*, 23: 874–1004. doi: 10.1111/j.1755-148X.2010.00767.x
22. SK Sutton, GM Marshall, **RA Scoflyer**, BB Cheung. Characterization of TRIM16 as a novel tumour suppressor in melanoma. *Melanoma 2010 Congress. Pigment Cell & Melanoma Research*, 23: 874–1004. doi: 10.1111/j.1755-148X.2010.00767.x
23. C. Madronio, B. Armstrong, J. Thompson, R. Morton, P. Kearey, A. Curtin, G. Mann, **R. Scoflyer**, R. Karim, P. Holt, M. Barton, S. Redman. Lymph node management of patients diagnosed with invasive melanoma in New South Wales. *Melanoma 2010 Congress. Pigment Cell & Melanoma Research*, 23: 874–1004. doi: 10.1111/j.1755-148X.2010.00767.x
24. **R. Scoflyer**. The Pathology report: components of the report and how they impact management and prognosis; what's new and evolving. *Melanoma 2010 Congress. Pigment Cell & Melanoma Research*, 23: 874–1004. doi: 10.1111/j.1755-148X.2010.00767.x
25. Cebon JS, Svobodová S, Browning J, Davis ID, **Scoflyer RA**, Murali R, Thompson JF, Deb S, Azad A, MacGregor D. Prognostic impact of cancer-testis antigen expression in primary cutaneous melanoma. *J Clin Oncol* 2009 May; 27(15S): 9004
26. Mandal RV, Murali R, Lundqvist KF, Ragsdale BD, Heenan P, Mihm MJ, **Scoflyer RA**, Zembowicz A. Long term follow-up in patients with pigmented epithelioid melanocytoma. *Lab Invest; Mod Pathol* 2009 Jan; 89(1s): 106A-107A; 22(1s): 106A-107A.
27. Salim AA, Stanford D, McCaughan B, Cooper WA, **Scoflyer RA**. Localised malignant mesothelioma. *Pathology International* 2008; 58: Suppl. A1.
28. Tan KL, Gzell CE, Carroll SL, Suchowerska N, Beith J, **Scoflyer RA**. Radiation recall dermatitis (RRD) after pre-sensitisation with pegylated liposomal doxorubicin (PLD): a case report. *Pathology International* 2008; 58: Suppl. A10.
29. Haydu L, Holt P, **Scoflyer R**, Karim R, Madronio C, Thompson J, Armstrong B. Quality of histopathological reporting on melanoma in NSW. *Asia-Pacific J Clin Oncol* 2008; 4; S2: A144.
30. Zhuang L, **Scoflyer RA**, McCarthy SW, Zhang XD, Lee CS, Thompson JF, Hersey P. Lactate dehydrogenase 5 (LDH5) expression in human melanoma relates to its progression. *Asia-Pacific J Clin Oncol* 2008; 4; S2: A56.
31. Spillane AJ, Cheung B, Stretch JR, **Scoflyer R**, Thompson JF. Quality benchmarks for regional lymph node dissections in melanoma. *Asia-Pacific J Clin Oncol* 2008; 4; S2: A71.
32. Murali R, Hughes TM, Thompson JF, **Scoflyer RA**. Pathological staging of primary cutaneous melanoma is affected by interobserver variation in the histopathological reporting of key prognostic parameters. *Histopathology* 2008 October; 53 (Suppl 1): 396.
33. Madronio C, Armstrong B, Thompson J, Beard J, Curtin A, Redman S, **Scoflyer R**, Karim R, Morton R, Holt, P, Mann G, Barton M, Kearney P. Melanoma ins-situ: a patterns-of-care study in New South Wales. *Asia-Pacific J Clin Oncol* 2008; 4; S2: A55.
34. Gzell C., Carroll S., Suchowerska N., Beith J., Tan K., **Scoflyer R.**, Radiation Recall Dermatitis after pre-sensitisation with pegylated liposomal doxorubicin, *Journal of Medical Imaging and Radiation Oncology*, 52(Supp. 2): A124- E08 (abstract and poster presentation RANZCR 59th Annual Scientific Meeting), 2008.
35. Oble D, **Scoflyer R**, Spatz A, Mihm M. Prognostic significance of melanoma sentinel lymph node T-regulatory cells. *J Cut Pathol* 2008; 35: 140.
36. Rossi CR, Pasquali S, Mocellin S, Pilati PL, Nitti D, Saw RP, **Scoflyer RA**, Stretch JR, Thompson JF. Efficiency of different models predicting sentinel node status in 1,104 melanoma patients. *Ann Surg Oncol* 2008; 15: S2: 64.
37. Howman-Giles R, Shaw H, Uren R, **Scoflyer R**, Thompson J. Sentinel lymph node biopsy in paediatric and adolescent melanoma patients. *Ann Surg Oncol* 2008; 15: S1: 3-4.
38. Murali R, Cochran A, Cook M, Karim R, Starz H, Moncrieff M, Thompson JF, **Scoflyer RA**. Interobserver reproducibility of micromorphometric features of sentinel lymph nodes containing metastatic melanoma. *Ann Surg Oncol* 2008; 15: S1: 29-30.
39. **Scoflyer RA**. Controversies in the histopathological assessment of sentinel lymph nodes from melanoma patients. *Ann Surg Oncol* 2008; 15: S1: 32.
40. Murali R, Loughman NT, Shaw HM, McKenzie PR, Watson GF, Thompson JF, **Scoflyer RA**. Cytological features of metastatic/recurrent lesions in patients with histologically-confirmed primary cutaneous desmoplastic melanoma. *Pathol Int* 2007 November; 57(11): A48-49.
41. Jabbour J, Cumming R, **Scoflyer RA**, Hruby G, Thompson JF, Lee S. Merkel cell carcinoma: assessing the effect of wide local excision, lymph node dissection, and radiotherapy on recurrence and survival in early-stage disease--results from a review of 82 consecutive cases diagnosed between 1992 and 2004. *Ann Surg Oncol*. 2007 Jun;14(6):1943-52.
42. Murali R, Sharma RN, Thompson JF, Stretch JR, Lee CS, McCarthy SW, **Scoflyer RA**. Sentinel lymph node biopsy aids in the management of so-called "atypical Spitzoid tumours". *Pathol Int* 2007 November; 57(11): A48.
43. Murali R, Loughman NT, McKenzie PR, Watson GF, Thompson JF, **Scoflyer RA**. Cytological features of melanoma in fluid specimens. *Histopathology* 2008 October; 53 (Suppl 1): 87-88.
44. Morey AL, McCarthy SW, **Scoflyer RA**. Diagnosis of melanoma by 4-colour FISH. *Australasian Society for Dermatology Research Conference* May 2008 Sydney.
45. Murali R, Loughman NT, Shaw HM, McKenzie PR, Watson GF, Thompson JF, **Scoflyer RA**. Cytological features of metastatic/recurrent lesions in patients with histologically-confirmed primary cutaneous desmoplastic melanoma. *Acta Cytol* 2007 Mar-Apr; 51(2 Suppl): 340.
46. Liqing Zhuang, C Soon Lee, **Richard A Scoflyer**, Stanley W McCarthy, Xu Dong Zhang, John F Thompson and Peter Hersey. Progression of melanoma is associated with increased expression of Mcl-1 and Bcl-XL but decreased expression of Bcl-2. 31st Annual Scientific

- Meeting of the Australasian Division of the International Academy of Pathology, Sydney, Australia, 2-4 June 2006. Abstract was published in: *Pathology International* 2006; 56:Suppl. A10
47. Tan KB, Moncrieff M, Thompson JF, McCarthy SW, Shaw HM, Quinn MJ, Li L-XL, Crotty KA, Stretch JR, **Scolyer RA**. Subungual melanoma: a clinicopathologic study of 124 cases. *Pathol Int* 2007 November; 57(11): A47.
 48. **Scolyer RA**, Elliott B, Suci S, Eggermont AMM, MacKie R, Robert C, Cook MG, Thompson JF, Angevin E, Spatz A; on behalf of the EORTC Melanoma Group. Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma. American Society of Clinical Oncology Annual Scientific Meeting 2007.
 49. Liqing Zhuang, C Soon Lee, Richard A **Scolyer**, Stanley W McCarthy, Xu Dong Zhang, John F Thompson and Peter Hersey. Increased expression of Mcl-1 and Bcl-XL and decreased expression of Bcl-2 is associated with melanoma progression and transcription factors. *Melanoma Research* 2006; 16(Suppl.1):S10-11
 50. Murali R, Doubrovsky A, Watson GF, McKenzie PR, Lee CS, McLeod DJ, Uren RF, Stretch JR, Saw RP, Thompson JF, **Scolyer RA**. Diagnosis of metastatic melanoma by fine needle biopsy: clinicopathologic analysis of 2204 cases. *Pathologica* 2006 October; 98(5): 327-328.
 51. Zhuang L, Lee CS, **Scolyer RA**, McCarthy SW, Palmer AA, Zhang X, Hersey P. Progression of melanoma is associated with increased expression of mcl-1 and bcl-xl but decreased expression of bcl-2. *Pathol Int* (in press).
 52. Liqing Zhuang, C Soon Lee, **Richard A Scolyer**, Stanley W McCarthy, Xu Dong Zhang, John F Thompson, Gavin Screaton and Peter Hersey. "Examination of death receptors (DR4 and DR5) for tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in human melanoma". *Pathology International* 2005; 55:Suppl. A2.
 53. Jabbour J, **Scolyer R**, Hruby G, Lee S. The management of merkel cell carcinoma: the impact of surgical margins and adjuvant radiotherapy on survival and recurrence. *J Invest Dermatol* 2005; 125: A10.
 54. Sanki A, Tran K, Shaw HM, **Scolyer RA**, Uren RF, Thompson JF. The role of preoperative ultrasound examination of sentinel lymph nodes in patients with primary cutaneous melanoma. *ANZ J Surg* (in press).
 55. Sanki A, Li W, **Scolyer RA**, Thompson JF. From mole to melanoma: reduced expression of the cyclin dependent kinase inhibitors p16 and p27 correlates with tumour progression. *ANZ J Surg* (in press).
 56. Chae J, Stanwell P, Lean C, Stretch J, **Scolyer R**, Thompson J, Malycha P, Moore K, Ramadan S, Shibli S, Gillett D, Wald L, Mountford C. Metastatic lymph nodes identified preoperatively in vivo by spectroscopy at 3T. *ISMRM* 2006.
 57. **Scolyer R**, Thompson JF, Quinn MJ: Desmoplastic melanoma and sentinel node biopsy. *ANZ J Surg* 2005.
 58. Kim Y, **Scolyer RA**, Chia E-M, Steven D, Ghabrial R. Eccrine porocarcinoma of the upper eyelid. *Aust J Dermatol* (in press).
 59. Doubrovsky A, De Wilt JH, **Scolyer RA**, McCarthy WH, Thompson JF. Sentinel node biopsy is more accurate than elective lymph node dissection in determining the regional node status of patients with cutaneous melanoma. *Ann Surg Oncol* 2004; 11:S122-3.
 60. Stretch JR, Somorjai R, Bourne R, Hsiao E, **Scolyer RA**, Dolenko B, Thompson JF, Mountford CE, Lean CL. Melanoma metastases in regional lymph nodes accurately detected by proton magnetic resonance spectroscopy of fine needle aspiration biopsies. *Ann Surg Oncol* 2004; 11:S60.
 61. Ka VSK, Thompson JF, McKinnon JG, **Scolyer RA**, Li LX-L, Uren RF. Outcome in 846 cutaneous melanoma patients from a single center after negative sentinel node biopsy. *Ann Surg Oncol* 2004;11:S60.
 62. Karim RZ, Rose B, Wills EJ, **Scolyer RA**. Condyloma Acuminata of the Urinary Bladder with PCR Confirmed HPV 11. *Pathol Int* 2004; S2: A145.
 63. Gardiner-Garden M, Henshall SM, **Scolyer RA**, Leung K-C, Scurry J, Smith AN, Sutherland RL, O'Brien PM, Hacker NF. Reduced expression of SOCS 3 predicts poor outcome in epithelial ovarian cancer. *Int J Gynecol Cancer* 2004;14 (Suppl 1),2
 64. Liqing Zhuang, C Soon Lee, **Richard A Scolyer**, Stanley W McCarthy, Allan A Palmer, Xu Dong Zhang and Peter Hersey. "Expression of extracellular-signal related kinase (ERK) and its activation (phosphorylated ERK) in melanoma". *Pathology International* 2004; 54:Suppl. A25
 65. Zhuang L, Lee CS, **Scolyer RA**, McCarthy SW, Palmer AA, Zhang X, Hersey P. Immunohistochemical detection of Akt kinase and activation of Akt (phosphorylated Akt Ser473) in melanoma. *Pathol Int* 2004; S2: A103.
 66. Heinzelmann-Schwarz V, **Scolyer R**, Scurry J, Gardiner-Garden M, Smith A, Hacker N, Sutherland R, O'Brien P. Galectin4 and Meprin alpha are biomarkers for mucinous ovarian tumors. *Pathol Int* 2004; S2: A67-8.
 67. Karim RZ, Wills EJ, McCarthy SW, **Scolyer RA**. Myxoid Adrenocortical Carcinoma- An Unusual Variant. *Pathol Int* 2004; S2: A64.
 68. Heinzelmann-Schwarz V, Gardiner-Garden M, Henshall SM, **Scolyer RA**, Leung K-C, Scurry J, Smith AN, Sutherland RL, O'Brien PM, Hacker NF. (2004). Reduced expression of SOCS3 predicts poor outcome in epithelial ovarian cancer. *International Journal of Gynecological Cancer* 14 (Suppl. 1), 2
 69. Heinzelmann-Schwarz V, Gardiner-Garden M, Henshall S, Scurry J, **Scolyer R**, Gish K, Hacker N, O'Brien P, Sutherland R. Over expression of genes involved in cellular adhesion (DDR1, claudin 3 and Ep-CAM) is an early event in the development of epithelial ovarian cancer. *Proceeding of American Association for Cancer Research*. (in press).
 70. Tse GMK, Lui PCW, **Scolyer RA**, Putti PC, Kung FYL, Lee CS. Correlation of stromal microvessel density and histological grade of mammary phyllodes tumors. *Lab Invest* 2003; 83: 49A.
 71. **Scolyer RA**. Fibrosarcomas: past and present concepts. *Pathol Int* 2004; S1: 593-6.
 72. Li LX, Crotty KA, **Scolyer RA**, Thompson JF, Kril JJ, Palmer AA, McCarthy SW. 'Use of multiple cytometric markers improves discrimination between benign and malignant melanocytic lesions: a study of DNA microdensitometry, karyometry, argyrophilic staining of nucleolar organizer regions and MIB1-Ki67 immunoreactivity.' *Melanoma Res*. 2003 Dec;13(6):581-6.
 73. Heinzelmann-Schwarz V, Gardiner-Garden M, Henshall S, Gish K, Scurry J, **Scolyer R**, Hacker N, O'Brien P, Sutherland R. Interstudy validation of gene expression profiles identifies candidate biomarkers of epithelial ovarian cancer. *Pathol Int* 2003; 53: A9.
 74. **Scolyer RA**, Lawrence L-XL, Soper R, Dawson M, Doble P, Beavis A, Uren RF, McCarthy SW, Thompson JF. Antimony quantitation in nodal tissue can validate the sentinel lymph node biopsy technique. A quality assurance tool? *Pathol Int* 2003; 53: A2.
 75. **Scolyer RA**, Shaw HM, McCarthy SW, Thompson JF. Can pathological features of the primary cutaneous lesions in melanoma patients predict the frequency of non-sentinel lymph node metastases? *Pathol Int* 2003; 53: A2-3.
 76. Beavis AD, Dawson M, Doble PA, Li LL, Soper R, **Scolyer RA**, Uren RF, Thompson JF. Detection of antimony in tissue sections as a marker for sentinel lymph nodes. *Pathol Int* 2003; 53: A1.
 77. Zhuang L, Ooi T, Halliday G, Barnetson R, **Scolyer R**. Inflammatory reaction in actinic keratosis- an immunohistochemical analysis. *Pathol Int* 2003; 53: A2.

78. Sarris M, **Scoflyer R**, Konopka M, Thompson J, Harper CG, Lee CS. Nm23 cytoplasmic expression is reduced in primary cutaneous melanomas with cerebral metastases. *J Histotechnology* 2002; 25(3); 169-170.
79. Sarris M, **Scoflyer R**, Konopka M, Thompson J, Harper CH, Lee CS. Nm23 cytoplasmic expression is reduced in primary cutaneous melanomas with cerebral metastases. *Pathol Int* 2002; 52: A10.
80. Karim RZ, Ma Wyatt J, **Scoflyer RA**. Myoid Angioendothelioma of the spleen. *Pathol Int* 2002; 52: A4-5.
81. Zhuang L, McCarthy SW, Palmer AA, **Scoflyer RA**. Combined naevi- benign lesions frequently misdiagnosed clinically and pathologically as melanomas. Clinicopathological review of 182 cases. *Pathol Int* 2002; 52: A2-3.
82. Li, **Scoflyer RA**, Ka V, McKinnon G, McCarthy SW, Thompson JF. Pathological review of negative sentinel lymph nodes (SLNs) in patients with regional recurrence of malignant melanoma: a clinicopathological review of 1400 cutaneous melanoma patients with SLN biopsies. *Pathol Int* 2002; 52: A1-2.
83. Li L, Crotty KA, Palmer AA, Kril JJ, **Scoflyer RA**, Thompson JF, McCarthy SW. Melanin can be effectively bleached for argyrophilic staining of nucleolar organizer regions (AgNORs) of pigmented lesions: a morphometric evaluation. *Pathol Int* 2002; 52: A1.
84. Nicoll KD, McCarthy SW, Palmer AA, Bonar SF, Taylor GB, Wood B, Scurry JF, **Scoflyer RA**. Inflammatory Myxohyaline Tumour: a report of 6 cases. *Pathol Int* 2002; 52: A5.
85. Buckland M, Davies S, **Scoflyer R**, Harper C. Expression of the oligodendrocyte-specific antigen CNPase in human gliomas. *Pathol Int* 2001; 51: A9.
86. Cooper WA, Nicoll KD, Wills EJ, McKenzie PR, **Scoflyer RA**. Extrapleural solitary fibrous tumours- a report of two cases. *Pathol Int* 2001; 51: A3.
87. **Scoflyer RA**, McKenzie PR, Achmed D, Lee CS. Can breast fine needle aspiration cytology be used to distinguish phyllodes tumours from fibroadenomas? *Pathol Int* 2001; 51: A2.
88. **Scoflyer RA**, McCarthy SW, Wills EJ, Palmer AA. Low-grade Fibrosarcoma with Palisaded Granuloma-like Bodies (Giant Rosettes). *Pathol Int* 2000; 50: A1.
89. **Scoflyer RA**, Painter DM, Harper CG, Lee CS. Diagnosis of Hepatocellular Carcinoma Metastasizing to the Orbit by Fine Needle Aspiration Cytology. *Pathol Int* 1999; 49: A2.

AUTHORSHIP OF CLINICAL PRACTICE GUIDELINES, CLASSIFICATIONS AND REPORTING PROTOCOLS FOR PROFESSIONAL AND LEARNED BODIES AND GOVERNMENT

1. International Collaboration on Cancer Reporting Melanoma dataset (RS chaired the international multidisciplinary expert working group and drafted the report).
2. The RCPA Structured reporting protocol for melanoma x3 (RS chaired the expert panel and drafted the report).
3. The College of American Pathologists Melanoma Protocol (RS co-lead author).
4. Australian Clinical Practice Guidelines for Melanoma Guidelines- RS member of the advisory panel, working group and author of multiple chapters (2008 and 2015- onwards).
5. Australian Clinical Practice Guidelines for Non-melanoma Skin Cancer Guidelines- RS contributor and author.
6. International Collaboration on Cancer merkel cell carcinoma reporting protocol (RS member of international multidisciplinary expert working group).
7. WHO Classifications- Editor of fourth edition of WHO Classification of Skin Tumours (responsible editor for three of the six sections and author of more than 40 chapters. Also an author on multiple volumes within their fifth addition WHO Classification Series including soft tissue tumours, female genital tract tumours and gastrointestinal tumours.
8. EORTC Sentinel node guidelines.
9. International Collaboration on Cancer Reporting Invasive Melanoma Histopathology Reporting Guide 2nd Edition Version 2.0 published Oct 2019. ISBN: 978-1-925687-32-3.
10. College of American Pathologists: Protocol for the Examination of Biopsy Specimens From Patients with Melanoma of the Skin (Version Melanoma Biopsy 4.1.0.0 – August 2019).
11. Busam K, Bichakjian C, Coit D, Kutzner H, Requena L, Scoflyer R, Stefanato C, Walsh N, Wood B. (2019) Merkel Cell Carcinoma, Histopathology Reporting Guide, 1st Edition. International Collaboration on Cancer Reporting; Sydney, Australia. ISBN: 978-1-925687-33-0.

BOOK REVIEWS

1. Kilpatrick SE, Renner JB. Diagnostic Musculoskeletal Surgical Pathology. Philadelphia: Saunders, 2004. Published in Pathology 2005; 37: 329.
2. Weedon D. Skin Pathology 2nd Ed. Churchill Livingstone, 2002. Published in Pathology 2003; 35: 360.
3. Weiss SW, Goldblum JR. Enzinger and Weiss's Soft Tissue Tumours 4th Ed. Mosby, 2001. Published in Pathology 2002; 34: 384.
4. Carter D, Patchefsky AS. Tumors and Tumor-like Lesions of the Lung. Philadelphia: Saunders, 1998. Published in Pathology 1999; 31: 175-6.
5. Centano BA, Bishop Pitman M. Fine Needle Aspiration Biopsy of the Pancreas. Boston: Butterworth-Heinemann, 1999. Published in Pathology 2000; 32: 159.

MEDIA AND COMMUNITY ENGAGEMENT

1. 23.06.2022: Live television interview with Greg Jennett of [ABC TV Afternoon Briefing](#) program discussing the launch of Melanoma Institute Australia's Immunotherapy Response Prediction Tool – the world's first online calculator to predict a patient's response to immunotherapy.
2. 21.06.2022: Representing Melanoma Institute Australia (as Co-Medical Director) at merger announcement of Melanoma Institute Australia and Skin Cancer Tasmania. Also in attendance was Minister Jacquie Petrusma MP, representing the Premier and Health Minister and the Honorable Jeremy Rockliff MP, together with the Founder, Vice Chair, Secretary and Board Member of Skin Cancer Tasmania, with media coverage by Chanel 9.

3. 10.6.2022: podcast via Melanoma Institute Australia's education portal ([link](#)) "Melanoma Insights for Professionals" - suitable for GPs, Dermatologists, Surgeons, Oncologists, Pathologists and other healthcare professionals, discussing the role of pathologist in the diagnosis and treatment of melanoma is pivotal to optimal patient care. With so many disciplines relying on the pathologist for accurate diagnoses and critical pathological information, we decided to reach out to our clinical melanoma community to ask them for their critical pathology questions. In this podcast, Prof John Thompson AO and Prof Feral Moloney pick at the brain of the world's leading melanoma Pathologist, Prof Richard Scolyer AO, as they discuss:
 - i. The clinical information needed to aid diagnosis
 - ii. The role of artificial intelligence and computing in pathology
 - iii. Overdiagnosis of melanoma
 - iv. The problem of partial biopsies
 - v. Diagnosing borderline lesions
 - vi. What is a melanocytoma and how should it be managed
 - vii. What is an irritated naevus
 - viii. Dysplastic naevi and appropriate management
4. 11.04.2022: Derm Club Podcast interview – RAS with Dr Hannah Kopelman – to discuss expertise in melanoma. Dr Kopelman, an aspiring dermatologist, dual fellowship trained in cutaneous oncology from Boston University and hair loss from Columbia University, interviewing leading experts in dermatology globally to educate the general public and other dermatologists. ([link to follow](#))
5. 24.03.2022: Riverina Melanoma Ride – the Riverine Melanoma Ride is a 1000km 8 day ride centred around raising the awareness of Melanoma Cancer as well as raising funds. RS took part on Day 1 - 130km bike ride from Albury to Wagga Wagga.
6. 20.03.2022: Melanoma Institute Australia's Melanoma March 2022 in Hobart – annual event to raise funds for lifesaving melanoma research. Participant in this event as representative of Melanoma Institute Australia in capacity as Co-Medical Director.
7. 13.03.2022: Melanoma Institute Australia's Melanoma March 2022 in Canberra – annual event to raise funds for lifesaving melanoma research. Participant in this event as representative of Melanoma Institute Australia in capacity as Co-Medical Director.
8. 04.03.2022: interview with Candace Scanlan of The Royal College of Pathologists of Australasia as part of PathUpdate2022 conference in Sydney.
9. 02.03.2022: interview with The Examiner Newspaper in Tasmania re: Melanoma March.
10. 01.03.2022: live program interview in studio with Ray Hadley on [2GB Morning Show](#) – re: Melanoma March and Personalised Immunotherapy Clinical Trial, broadcast across the following stations:-

i. 2GB Radio	ii. 5CC	iii. Magic 105.9
iv. 2CC Talking Canberra	v. 5CS Classic Hits	vi. Magic 89.9
vii. 4BC 1116 News Talk	viii. 5MU	ix. Magic 92.1
x. 990 AM 4RO	xi. 5RM	xii. Mix 104.9
xiii. ABC New England North West AM	xiv. 981 2NM	xv. Power FM 98.7
xvi. Forever Classic 2GN	xvii. Eagle FM 93.5 2 SNO	xviii. Power FM Began Bay
xix. 2UE	xx. Five aa	xxi. Power FM Nowra
xxii. 3AW 693 News Talk	xxiii. Gold Central Victoria	xxiv. Radio 2ST Coast
xxv. 5AU Classic Hits	xxvi. Hot 100FM	xxvii. River 1467
11. 28.2.2022 – Interview with Darragh Cormac O'Carroll MD who is producing a documentary on Climate Change and Melanoma (currently in pre-production mode).
12. 12.2.2022 Participated in the Erik Mather 2, 4, 6km swim (2km), an event run by The Balmoral Beach Club Events and the Mather Family, fundraising to support Melanoma Institute Australia held on Saturday 12th February 2022.
13. 11.2.2022: podcast by Professors Richard A. Scolyer and Georgina V. Long via Melanoma Institute Australia's education portal ([link: https://melanomaeducation.org.au/courses/melanoma133/](https://melanomaeducation.org.au/courses/melanoma133/)). Title: The evolving paradigm shift in melanoma. This podcast is suitable for oncologists, surgeons, dermatologists, skin cancer GPs, GPs, nurses and other healthcare professionals. Discussed in the podcast:
 - i. how melanoma management has transformed in the last decade
 - ii. the challenge of diagnosing melanoma for clinicians and pathologists, and practical ways to help make accurate assessments
 - iii. the importance of staging
 - iv. why sentinel node biopsies are important
 - v. how multidisciplinary care enhances patient outcomes
 - vi. emerging evidence on neoadjuvant treatment and how this will change the way melanoma is managed
 - vii. the challenge of supportive care and where to find help.
14. 11.2.2022: RAS featured in a live Zoom interview with Eloise Le Gros of Prime 7 to discuss the presentation to Parliament of the Melanoma State of the Nation Report - [link](#).
15. 9.2.2022: RAS conducted a live program interview with ABC Radio Illawarra Drive with Lindsay McDougall to discuss the presentation to Parliament of the Melanoma State of the Nation Report. [ABC Illawarra](#) (national viewership 28,800)
16. 9.2.2022: RAS conducted (together with Anne Gately – Melanoma patient) a live TV interview with ABC TV live IV with Greg Jennett – to discuss the presentation to Parliament of the Melanoma State of the Nation Report. Watch on iview (interview commences at 48:22) <https://iview.abc.net.au/video/NU2222V008S00>.
17. 9.2.2022: RAS conducted a live radio interview with ABC Radio Sydney Drive with Richard Glover to discuss the presentation to Parliament of the Melanoma State of the Nation Report. [702 ABC Sydney](#) (national viewership 68,000).
18. 9.2.2022: State of the Nation on Melanoma Report presented to Parliament via webinar by Executive at Melanoma Institute Australia, including Richard Scolyer - [link to YouTube recording](#). The media coverage around the State of the Nation on Melanoma Report was widely reported across various TV, radio and social media platforms including Prime7 News Canberra. Channel 9 News, Health Industry Hub, 10 Brisbane, 10 Gold Coast, 10 Perth, 123 ABC Newcastle, 3AW 693 News Talk, 702 ABC Sydney, 891 ABC Adelaide, ABC 1 Sydney, ABC Broken Hill AM, ABC Canberra, ABC Coffs Coast FM, ABC Hobart, ABC Illawarra, ABC Mid North Coast NSW Radio, ABC New England North West AM, ABC News, ABC NewsRadio, ANC North and West SA, ABC North Coast, ABC Radio National, ABC Riverina, ABC Riverland, ABC South East NSW< ABC South Ease SA, ABC Upper Hunter AM, ABC West Coast SA AM, ABC Western Plains, Five aa, SBS, Imparja Bull, NBN Coffs Harbour, NBN Gold Coast, NBN Gosford, NBMN

- Lismore, NBN Newcastle, NBN Port Macquarie, NBN Tamworth, Nine Brisbane, Nine Bunbury, Nine Cairns, Nine Canberra, Nine Central Queensland, Nine Central West, Nine Darwin, Nine Gold Coast, Nine Illawarra, Nine McKay, Nine Orange, Nine Perth, Nine Riverina, Nine Sunshine Coast, Nine Sydney, Nine Toowoomba, Nine Townsville, Nine Wide Bay, Prime 7, SBS One, Ten Cairns, Ten Central Digital TV, Ten Central Queensland, Ten McKay, Ten Sunshine Coast, Ten Toowoomba, Ten Townsville, Ten Wide Bay, WIN TV Canberra, Twitter, Facebook, x99news.com, azerbaijan.kivazen.com, thenewsverse.com, and many more.
19. 11.12.2021: contributed to [A Current Affair story](#) "Aussie sporting legends share skin cancer warning" on Jackie Byrnes fighting melanoma and MIA's "Game on Mole" campaign. This was also shared on various platforms including Imparj Bull, NBN Gold Coast, Nine Brisbane, Nine Bunbury, Nine Cairns, Nine Central Queensland, Nine Darwin, Nine Gold Coast, Nine Mackay, Nine Mount Gambier, Nine Perth, Nine Sunshine Coast, Nine Toowoomba, Nine Townsville, Nine Wide Bay.
 20. 05.11.2021: RAS conducted live interview with [ABC TV News Channel](#) with Nick Hose discussing COVID impact on new patient numbers and our early launch of Game On Mole. This was broadcast across various ABC news and radio platforms including, ABC 1 Perth, ABC 24, ABC Evening News, ABC Illawarra and ABC NewsRadio.
 21. 5.11.2021: Pandemic Melanoma Crisis. Interview by Richard Scolyer published in My Weekly Review ([print version](#)).
 22. 01.11.2021: "[Fears of post-pandemic skin cancer crisis in Australia](#)" on-line article to Times News Express, Australia Online News, Head Topics. SBS.
 23. 01.11.2021: "[Fears of an increase in undiagnosed melanoma cases](#)" via SBS News in depth (PlayerFM).
 24. 31.10.2021: article by Jessica McSweeney of The Sunday Mail titled "[Fear skin checks put off in lockdown](#)" (on-line and in print)
 25. 31.10.2021: article by John Kidman of AAP titled "[Fears of post-pandemic melanoma crisis](#)" - circulated nationally and internationally both on-line and in print:-

i. Sydney News Today	ii. Beaudesert Times	iii. Jimboomba Times
iv. Sound Telegraph	v. 7NEWS.com.au	vi. Northern Rivers Review
vii. Blue Mountains Gazette	viii. The Young Witness	ix. Wellington Times
x. Goondiwindi Argus	xi. Newcastle Herald	xii. The Canberra Times
xiii. The Northern Daily Leader	xiv. St George & Sutherland Shire Leader	xv. Gloucester Advocate
xvi. Whyalla News	xvii. Liverpool City Champion	xviii. SBS
xix. Seymour Telegraph	xx. The Corowa Free Press	xxi. Redland City Bulletin
xxii. Daily Mail	xxiii. The West Australian	xxiv. Perth Now
xxv. Moree Champion	xxvi. Port Lincoln Times	xxvii. The Islander
xxviii. Bay Post	xxix. Camden Haven Courier	xxx. Bendigo Advertiser
xxxi. Tenterfield Star	xxxii. Southern Cross	xxxiii. Inverell Times
xxxiv. The Advocate	xxxv. Bunbury Mail	xxxvi. Blayney Chronicle (Licensed by Copyright Agency)
xxxvii. The Macleay Argus	xxxviii. Coastal Leader	
 26. 28.9.2021: "Sydney Spotlight Series" by The University of Sydney (<https://communications.sydney.edu.au/link/id/zzzz615270f8f08f9772Pzzzz5ce1eae4ec447206/page.html>)
 27. 27.9.2021: interview with Medical Republic re: ESMO Stage II drug therapy study.
 28. 19.9.2021: Articles "Australian researchers breakthrough in melanoma treatment" and/or "New Hope for Early Melanoma Patients" – circulated both nationally and internationally via Australian Associated Press (AAP) both on-line and in print:-

i. The Singapore Times	ii. The Bharat Express News	iii. Albert Forbes
iv. News Chant	v. PressFrom Germany	vi. Sydney News Today
vii. The Canberra Times	viii. Shepparton News	ix. Seymour Telegraph
x. MSN - Australia	xi. The McIvor Times	xii. Jimboomba Times
xiii. The Corowa Free Press	xiv. Daily Mail	xv. Sound Telegraph
xvi. The West Australian	xvii. Perth Now	xviii. Western Magazine
xix. Southern Highland News	xx. Yass Tribune	xxi. Northern Beaches Review
xxii. The Examiner	xxiii. The Daily Advertiser	xxiv. Whyalla News
xxv. Milton Ulladulla Times	xxvi. Illawarra Mercury	xxvii. Redland City Bulletin
xxviii. Newcastle Herald	xxix.	
 29. 18.9.2021: an article relating to a research paper presented at ESMO Congress 2021 "Adjuvant immunotherapy prolongs recurrence-free survival in resected stage II B/C melanoma" on which RAS is a co-author – has been circulated to various national and international on-line websites including:-

i. Bioengineer.org	ii. ScienMag
iii. EurekAlert!	iv. Mirage News
 30. 25.8.2021: Podcast: Prof. Richard Scolyer with Prof. George Netto, Editor in Chief of Modern Pathology – [link](#)
 31. 16.6.2021: Sydney Local Health District – "Queen's Birthday Honours" RPA's Professor Richard Scolyer among honour recipients – [SLHD website media](#)
 32. 16.6.2021: The University of Sydney's on-line News – "Queen's Birthday Honours celebrates University community" – [link](#)
 33. 15.6.2021: An email message circulated to all members by Clinical Oncology Society of Australia (COSA) – "2021 Queen's Birthday Honours" – [link to on-line message](#)
 34. 14.6.2021: [ABC Radio National](#) – on RN Breakfast with Hamish MacDonald - "Melanoma researcher Richard Scolyer awarded Queen's Birthday Honour"
 35. 14.6.2021: Social medial comments of congratulations relating to Order of Australia award via Twitter, ABC Radio, Melanoma Institute Australia, The University of Sydney, #Queens Birthday Honours; MIA melanomaWA; UQ Dermatology Research Centre; Charles Perkins Centre The University of Sydney, SoM Public Health, MIA Amie St Clair; Public Pathology Australia; AAHMS.
 36. 14.6.2021: [Campus Morning Mail](#): "Achievements: the Queen's Birthday Honours List"
 37. 14.6.2021: [The Examiner](#) by Jessica Willard – "Experts in their fields awarded top honours"

38. 14.6.2021: Article by Jessica Willard - "Launceston-born melanoma expert Richard Scolyer appointed Officer of the Order of Australia" – circulated via Australian Associated Press (on-line and/or in print) to:-
- | | | |
|--|--|---|
| i. PressFrom: Germany | ii. PressFrom: France | iii. Seymour Telegraph |
| iv. The Mclvor Times | v. Jimboomba Times | vi. The Riverine Herald |
| vii. Vietnam Explorer News Channel | viii. MSN - Australia | ix. Daily Mail |
| x. Thisismoney.co.uk | xi. The West Australian (on-line & in print) | xii. Sound Telegraph |
| xiii. Perth Now | xiv. The Examiner (on-line & in print) | xv. Bega District News |
| xvi. Deniliquin Pastoral Times | xvii. Port Macquarie News | |
39. 13.6.2021: "Queen's Birthday Honours – Prof. Richard Scolyer awarded Order of Australia" broadcast via:-
- | | | |
|--|--|---|
| i. Channel 7 Adelaide | ii. Channel 7 Cairns | iii. Channel 7 Darwin |
| iv. Channel 7 Mackay | v. Channel 7 Perth | vi. Channel 7 Sunshine Coast |
| vii. Channel 7 Sydney | viii. Channel 7 Toowoomba | ix. Channel 7 Townsville |
| x. Channel 7 Wide Bay | xi. GWN7 Television | xii. Nine Canberra |
| xiii. Nine Central West | xiv. Nine Illawarra | xv. Nine Riverina |
| xvi. Nine Sydney | xvii. Prime7 Canberra | xviii. Prime7 Port Macquarie |
| xix. Prime7 Tamworth | xx. Prime7 Wagga Wagga | xxi. Southern Cross Alice Springs |
| xxii. Southern Cross GTS/BKN | xxiii. Southern Cross Hobart | xxiv. Southern Cross Launceston |
| xxv. Southern Cross Mt Isa | xxvi. Southern Cross Newcastle | |
40. 12.06.2021: Media (radio and television) broadcasts re: "Researchers in the US have discovered monoamine oxidase inhibitors may help the immune system attack cancer" – comments by Prof. Richard Scolyer:-
- | | | |
|----------------------|------------------------------------|---|
| i. 1053 2CA Canberra | ii. 2BS 95.1 FM | iii. 2CC Talking Canberra |
| iv. 2GB Radio | v. Radio 2ST Coast | vi. Radio 2ST Highlands |
41. Podcast: RAS with Dr Michael Dray, President of Royal College of Pathologists (RCPA) re: Melanoma. Recorded via Zoom on Thursday 3rd June 2021 - [link](#)
42. A story by Sam Cucchiara on "The dangerous side-hustle hiding in a backyard exposed" with comments on the dangers of solariums from Professor Richard Scolyer, Professor Georgina Long and patient, Anne Gately aired on Wednesday 12th May 2021 on Chanel 9 – A Current Affair - [link](#) and subsequently aired on each of the following stations:-
- | | | |
|---|--|--|
| i. Imparja Bull on Wednesday - link | ii. NBN Gold Coast on Wednesday - link | iii. NBN Gosford - link |
| iv. NBN Lismore - link | v. Nine Adelaide - link | vi. Nine Brisbane - link |
| vii. Nine Cairns - link | viii. Nine Central Queensland - link | ix. Nine Darwin - link |
| x. Nine Gold Coast - link | xi. Nine Mackay - link | xii. Nine Perth - link |
| xiii. Nine Sunshine Coast - link | xiv. Nine Toowoomba - link | xv. Nine Townsville - link |
| xvi. Nine Wide Bay - link | | |
43. Article by Jackie Sinnerton, Health Reporter, The Courier Mail in March 2021, published on-line and in print at:-
- i. Townsville Bulletin (on-line - Mar 30, 2021) "Hayden Price, 8, diagnosed with rare melanoma" - [link](#)
 - ii. The Chronicle (on-line - Mar 30, 2021) "Hayden Price, 8, diagnosed with rare melanoma" - [link](#)
 - iii. The Advertiser (on-line - Mar 30, 2021) "Hayden Price, 8, diagnosed with rare melanoma" - [link](#)
 - iv. The Courier-Mail (on-line - Mar 30, 2021) "Hayden Price, 8, diagnosed with rare melanoma" - [link](#)
 - v. Geelong Advertiser (on-line - Mar 30, 2021) "Hayden Price, 8, diagnosed with rare melanoma" - [link](#)
 - vi. Ntnews.com.au (on-line - Mar 30, 2021) "Hayden Price, 8, diagnosed with rare melanoma" - [link](#)
 - vii. Herald Sun (on-line - Mar 30, 2021) "Hayden Price, 8, diagnosed with rare melanoma" - [link](#)
 - viii. The Courier-Mail (in print - Mar 30, 2021) "Rare childhood skin cancer rocks family" - [link](#)
 - ix. Tweed Daily News (on-line - Mar 30, 2021) "Every parent must read: Boy's shock melanoma diagnosis" - [link](#)
 - x. Gladstone Observer (on-line - Mar 30, 2021) "Every parent must read: Boy's shock melanoma diagnosis" - [link](#)
 - xi. The Morning Bulletin (on-line - Mar 30, 2021) "Every parent must read: Boy's shock melanoma diagnosis" - [link](#)
 - xii. Chinchilla News (on-line - Mar 30, 2021) "Every parent must read: Boy's shock melanoma diagnosis" - [link](#)
 - xiii. News Mail (on-line - Mar 30, 2021) "Every parent must read: Boy's shock melanoma diagnosis" - [link](#)
 - xiv. The Queensland Times (on-line - Mar 30, 2021) "Every parent must read: Boy's shock melanoma diagnosis" - [link](#)
 - xv. Sunshine Coast Daily (on-line - Mar 30, 2021) "Every parent must read: Boy's shock melanoma diagnosis" - [link](#)
 - xvi. Byron Shire News (on-line - Mar 30, 2021) "Every parent must read: Boy's shock melanoma diagnosis" - [link](#)
 - xvii. Charleville Western Times (on-line - Mar 30, 2021) "Every parent must read: Boy's shock melanoma diagnosis" - [link](#)
 - xviii. South Burnett Times (on-line - Mar 30, 2021) "Every parent must read: Boy's shock melanoma diagnosis" - [link](#)
 - xix. Central Queensland News (on-line - Mar 30, 2021) "Every parent must read: Boy's shock melanoma diagnosis" - [link](#)
 - xx. Northern Star (on-line - Mar 30, 2021) "Every parent must read: Boy's shock melanoma diagnosis" - [link](#)
 - xxi. Gatton Star (on-line - Mar 30, 2021) "Every parent must read: Boy's shock melanoma diagnosis" - [link](#)
 - xxii. Central & North Burnett Times (on-line - Mar 30, 2021) "Every parent must read: Boy's shock melanoma diagnosis" - [link](#)
 - xxiii. Whitsunday Times (on-line - Mar 30, 2021) "Every parent must read: Boy's shock melanoma diagnosis" - [link](#)
 - xxiv. Warwick Daily News (on-line - Mar 30, 2021) "Every parent must read: Boy's shock melanoma diagnosis" - [link](#)
 - xxv. The Gympie Times (on-line - Mar 30, 2021) "Every parent must read: Boy's shock melanoma diagnosis" - [link](#)
 - xxvi. Ballina Shire Adocate (on-line - Mar 30, 2021) "Every parent must read: Boy's shock melanoma diagnosis" - [link](#)
 - xxvii. Stanthorpe Border Post (on-line - Mar 30, 2021) "Every parent must read: Boy's shock melanoma diagnosis" - [link](#)
 - xxviii. Daily Mail UK (on-line - Mar 30, 2021) "How a young boy's skin tag on his head turned out to be a deadly melanoma despite him never been allowed in the sun without a hat - and the warning signs his parents say every family should know" - [link](#)

- xxix. This is Money UK (on-line – Mar 30, 2021) “How a young boy’s skin tag on his head turned out to be a deadly melanoma despite him never been allowed in the sun without a hat - and the warning signs his parents say every family should know” – [link](#)
- xxx. Mail on Sunday UK (on-line – Mar 30, 2021) “How a young boy’s skin tag on his head turned out to be a deadly melanoma despite him never been allowed in the sun without a hat - and the warning signs his parents say every family should know” – [link](#)
- xxxi. Amed Post UK (on-line – Mar 30, 2021) “Skin tag on little boy’s head turned out to be a deadly melanoma” – [link](#)
- xxxii. MSN (Mar 31, 2021) “Skin tag on little boy’s head turned out to be a deadly melanoma” – [link](#)
- xxxiii. Brinkwire (Mar 31, 2021) “Skin tag on little boy’s head turned out to be a deadly melanoma” – [link](#)
44. Chanel 9 news story – RAS was interviewed as part of a Chanel 9 news story on Hayden Price following MIA’s media release “Family of 8-year-old with melanoma calls on all Australian to step up to help save lives from the disease” – [link](#).
45. Participated in the Erik Mather 2, 4, 6km swim (2km), an event run by The Balmoral Beach Club Events and the Mather Family, fundraising to support Melanoma Institute Australia on Saturday 13th February 2021.
46. Article by Samantha Selinger-Morris “What exactly does the sun do to your skin?” quoting Richard Scolyer, available via:-
- i. Meltwater Outside Insight (16.1.2021) – [link to article](#)
 - ii. Yerepouni News (14.01.2021) – [link to article](#)
 - iii. Sydney Morning Herald (5.1.2021) – [link to article](#)
 - iv. WA today (5.1.2021) – [link to article](#)
 - v. Brisbane Times (5.1.2021) – [link to article](#)
 - vi. The Age (5.1.2021) – [link to article](#)
 - vii. Internewscast (5.1.2021) – [link to article](#)
 - viii.
47. ABC’s 7:30 Report – RAS interviewed as part of a story on Stuart Taylor’s journey with an aggressive form of melanoma ([ABC link](#)). Aired on Monday 14 December 2020 @ 8:22pm and further broadcast to:-
- i. ABC 24 (15.12.20)
 - ii. ABC 1 Adelaide (15.12.20)
 - iii. ABC 1 Brisbane (15.12.20)
 - iv. ABC 1 Sydney (15.12.20)
 - v. ABC1 Melbourne (15.12.20)
 - vi. ABC 1 Darwin (15.12.20)
 - vii. ABC 1 Perth (14.12.20)
 - viii. ABC 1 Canberra (15.12.20)
48. 2GB national radio interview (live) - Healthy Living on Sunday 29th November 2020 at 7:20pm re: CINSW Outstanding Researcher Award, sun safety and early detection. This interview was broadcast to 150000 listeners across 2GB Sydney, 2AW Melbourne, 4BC Brisbane and 6PR Perth, including:-
- i. 2CC Talking Canberra
 - ii. 2GB Radio
 - iii. 2AW 693 News Talk
 - iv. 4BC 1116 News Talk
 - v. 6PR 88 News Talk
 - vi. 7AD 900AM
 - vii. 7BU 558 AM
 - viii. FIVEaa
 - ix. Sea FM 101.7
 - x. ABC 1 Hobart (15.12.20)
 - xi. Planet America
 - xii. Sea FM 107.7
49. ABC 702 LIVE program interview with Sarah McDonald re: Melanoma Institute Australia’s Game on Mode campaign on Thursday 19th November 2020. This interview was broadcast across NSW and ACT, including:-
- i. 1233 ABC Newcastle
 - ii. 666 ABC Canberra
 - iii. ABC Sydney
 - iv. ABC Central Coast NSW
 - v. ABC Central West NSW AM
 - vi. ABC Coffs Coast FM
 - vii. ABC Illawarra
 - viii. ABC Mid North Coast NSW
 - ix. ABC New England North West
 - x. ABC North Coast NSW
 - xi. ABC Riverina FM
 - xii. ABC South East NSW
 - xiii. ABC Upper Hunter AM
 - xiv. ABC Western Plains
50. Richard Scolyer was quoted in an article within the Greek Tribune, Adelaide on 1 November 2020 “During the corona crisis – do not neglect cancer tests” – [link to article](#).
51. Televised interview with Chanel 9 on Friday 16th October 2020 re: Melanoma cancer kills one Australian every five hours ([link: https://twitter.com/9NewsSyd/status/1317010087131611136?s=20](https://twitter.com/9NewsSyd/status/1317010087131611136?s=20)), with the story being run across Australian Community Media digital sites nationally on Saturday 17th and Sunday 18th October 2020, including:-
- i. 1053 2CA Canberra
 - ii. 2BS 95.1 FM
 - iii. 2EC East coast Radio
 - iv. 2GB Radio
 - v. 3AW 693 News Talk
 - vi. 3BA FM
 - vii. 4BC 1116 News Talk
 - viii. 5AU Classic Hits
 - ix. 5CC
 - x. 5CS Classic Hits
 - xi. 5MU
 - xii. 5R
 - xiii. 6PR 882 News Talk
 - xiv. 7AD 900AM
 - xv. 7BU 558 AM
 - xvi. 7 HO FM
 - xvii. 7XS West Coast Radio Tasmania
 - xviii. 89.3 LAFM
 - xix. 93.9 Bay FM
 - xx. 96.5 Wave FM
 - xxi. ABC Coffs Coast FM
 - xxii. Chillii 99.7 FM
 - xxiii. FIVEaa
 - xxiv. Forever Classic 2GN
 - xxv. Gold Central Victoria
 - xxvi. Hot 100 FM
 - xxvii. I98FM Illawarra
 - xxviii. K-Rock 95.5
 - xxix. Magic 105.9
 - xxx. Magic 89.9
 - xxxi. Magic 93.1
 - xxxii. Mix 104.9
 - xxxiii. Perth’s 6iX
 - xxxiv. Power FM 98.7
 - xxxv. Power FM Bega Bay
 - xxxvi. Power FM Nowra
 - xxxvii. Radio 7SD 540AM
 - xxxviii. River 1467
 - xxxix. Sea FM 107.7
52. 15.10.2020 – In-depth interview with Sydney Morning Herald for the ‘Explainer’ series on sun and melanoma.
53. Interview with SBS World News - Speedweek - Monday 28th September 2020 regarding delays in skin checks due to pandemic and the importance of early detection ([link: https://transition.meltwater.com/cus/follow/20200929.q7N1qFnJ8L0](https://transition.meltwater.com/cus/follow/20200929.q7N1qFnJ8L0)).
54. Publicity generated 26,000 uses of the risk prediction tools following its first week of being launched.
55. Live radio interview with ABC Radio Newcastle on Friday 28th August 2020 in relation to Melanoma Institute Australia’s Melanoma “calculator” for skin cancer risk.

56. Interviews with national TV networks on Friday 28th August 2020 in relation to Melanoma Institute Australia's Melanoma "calculator" for skin cancer risk ([link to 7News report](#)), including:-

i. 10 Adelaide	ii. Nine Brisbane	iii. Nine Riverina
iv. 10 Brisbane	v. Nine Cairns	vi. Nine Sunshine Coast
vii. 10 Broken Hill	viii. Nine Canberra	ix. Nine Sydney
x. 10 Darwin	xi. Nine Central West	xii. Nine Toowoomba
xiii. 10 Gold Coast	xiv. Nine Central West	xv. Nine Townsville
xvi. 10 News First	xvii. Nine Gold Coast	xviii. Nine Wide Bay
xix. 10 Perth	xx. Nine Illawarra	xxi. Nine Perth
xxii. 10 Sydney	xxiii. Nine Mackay	xxiv. Nine Adelaide

57. Interview with AAP on Thursday 27th August 2020 in relation to Melanoma Institute Australia's Melanoma "calculator" for skin cancer risk, with the story being run across Australian Community Media digital sites nationally, including:-

Radio platforms

i. 2GB radio network;	ii. 4KQ 693AM	iii. 97.3 FM	iv. Classic Hits 104.3
v. Eagle FM 93.5	vi. Forever Classic 2GN	vii. Five aa	viii. i98FM Illawarra
ix. KIIS 101.1	x. KIIS 1065	xi. Magic 89.9	xii. Magic 93.1
xiii. Magic 105.9	xiv. Power FN Mowra	xv. Power FM Bega Bay	xvi. Power FM 98.7
xvii. Perth's 6iX	xviii. Radio 2ST	xix. Radio 2ST Coast	xx. River 1467
xxi. River 94.9	xxii. The Edge 96.1	xxiii. 990 AM 4RO	xxiv. 981 2NM
xxv. 96.5 Wave FM	xxvi. 7HO FM	xxvii. 5RM	xxviii. 5CS Classic Hits
xxix. 5CC	xxx. 5AU Classic Hits	xxxi. 4BC 1116 News	xxxii. 2UE
xxxiii. 2EC East Coast	xxxiv. 2BS 95.1 FM	xxxv. 1233 ABC	xxxvi. ABC Upper Hunter
xxxvii. Eagle FM 93.5	xxviii. Forever Classic 2GN	xxxix. Hot 100 FM	xl. Impargja Bull
xli. Mix 102.3	xlii. Ix 104.9	xliii.	xliv.

On-line platforms

i. The Advocate	ii. The Hawkesbury Gazette	iii. The Western Advocate	iv. The Leader;
v. Urall News.com	vi. Yarrwonga Chronicle	vii. Southern Riverina News	viii. Riverine Herald
ix. Campaspe News	x. Kyabram Free Press	xi. The Corowa Free Press	xii. The McIvor Times
xiii. Seymour Times	xiv. Seymour Telegraph	xv. Cobram Courier	xvi. Shepparton News
xvii. In Queensland	xviii. Daily Mail Online	xix. Thisismoney.co.uk	xx. Harden Murrumburrah Express
xxi. Inverell Times	xxii. Campbelltown Macarthur Advertiser	xxiii. Jimboomba Times	xxiv. The Rural
xxv. Boorowa News	xxvi. The Queanbeyan Age	xxvii. Goulburn Post	xxviii. Guardian News
xxix. Bega District News	xxx. Southern Highland News	xxxi. The Border Mail	xxxii. The Flinders News
xxxiii. Narooma News	xxxiv. Bombala Times	xxxv. The Times - On The Coast	xxxvi. The Advocate - Hepburn
xxxvii. Busselton-Dunsborough Mail	xxxviii. The Riverina Leader	xxxix. The Advocate	xl. Bendigo Advertiser
xli. Collie Mail	xlii. Blayney Chronicle	xliii. Tenterfield Star	

In print: Sunraysia Daily (29.08.2020)

58. Radio interview – ABC Radio North Tasmania Breakfast with Belinda King re: Melanoma March (Devonport and Launceston) – Thursday 5th March 2020.
59. Daily Advertiser Wagga Wagga – "Cancer professors join forces with Wagga melanoma charity", 28 February 2020, interviewed and quoted - <https://www.dailytelegraph.com.au/newslocal/thewagga/news/amie-st-clair-melanoma-trust-and-melanoma-institute-australia-merge-to-benefit-riverina/news-story/449ee3c5206d619839c0773496878d00?btr=02154542435889dd115d6e5e5e179a7d>
60. Radio interview – ABC Riverina with Sally Bryant on Friday 28th February 2020 – Profs. Richard Scolyer, Georgina Long and John Thompson in Wagga Wagga re: MIA-Amie St Clair Melanoma Trust merger.
61. Public launch of merger between Melanoma Institute Australia and Amie St Clair Melanoma Trust in Wagga Wagga on Thursday 27th February 2020.
62. The Project – Monday 9th December 2019 with MP Jason Clare.
63. Sky News live interview with Jacinta Tynan on Saturday 7th December 2019 "Game on Mole" campaign and sun-safe behaviours - <https://www.skynews.com.au/details/6113876345001>.
64. Radio interview – ABC Radio Evenings with Chris Bath – Monday 2nd December 2019.

65. Radio interview – Uni of Qld re: blood test for ocular melanoma – run nationally on 130 regional stations. Power FM Hunter Valley Friday 15 November 2019 – link: <http://my.tvey.es/At85E>.
66. Interviewed for article in NSW Health Pathology's Compass Magazine – September 2019.
67. ABC Nightlife LIVE Interview – Monday 9th September 2019
68. The Pathologist's 2019 "Trailblazers" Power List 2019 - a power list of top 100 Pathologists worldwide with RS listed in top 10 and the only Australian in the top 100.
69. Northshore Living – 01.10.2019. Article – On the medical frontier - <https://www.thinklocal.com.au/thmagazines/north-shore-living-october-2019> - Pages 32 and 33.
70. The limbic - Genomic studies get beneath the surface of mucosal melanoma <https://thelimbic.com/dermatology/genomic-studies-get-beneath-the-surface-of-mucosal-melanoma/> 26 July 2019
71. Melanoma Institution Australia Education Portal <https://melanomaeducation.org.au>
72. ABC 7.30 Report Breakthrough in skin cancer diagnosis <https://www.abc.net.au/7.30/breakthrough-in-skin-cancer-diagnosis/10894510> 13 March 2019
73. Southern Cross TV Launceston Sunday, March 03, 2019 <http://my.tvey.es/d7ZE>
74. Examiner News March 2019 <https://www.examiner.com.au/story/5933435/melanoma-march-raising-vital-funds-for-life-saving-research/>
75. Examiner News February 2019 - <https://www.examiner.com.au/story/5917470/launceston-student-turned-world-melanoma-expert/?cs=95>
76. ABC 7.30 Report - The melanoma problem in Australia, and MIA's view about the benefits/possibilities associated with an early detection blood test.
77. Cate Campbell - MIA's new National Ambassador - coverage Ch7, Ch10, Ch9, Daily Telegraph, 2GB – February 2019
78. Back Chat Sydney Morning Herald *Good Weekend* – December 2018
79. 3AW Breakfast Program (Melbourne) GSK Award for Research Excellence - Research Australia's Health and Medical Research Awards, NSW Premier's Awards for Outstanding Cancer Research, NSW Premier's Awards for Outstanding Cancer Research, November 2018
80. DermNet NZ <https://www.dermnetnz.org/topics/germline-bap1-mutation/> 2018
81. Remember to be sun smart this summer - RCPA ePathway Magazine 2018
82. Emma Betts and her legacy – ABC's Australia Story April 2018
83. Interview/Article RCPA 2018, research related to targeted therapy to block the BRAF gene for ePathWay "Australian researchers put melanoma on the back foot"
84. 2018 Interviewed by Australian and international media regarding acral and mucosal melanoma research published in Nature journal, and adjuvant therapy trials detailed at ESMO and published in New England Journal of Medicine. Media interviews conducted included all Australian television news networks (ABC TV, SBS World News and Channels 10, 9, 7 nightly news bulletins); live ABC Television News 24 in studio interview; more than 20 metropolitan radio and print interviews; live interviews on BBC World News Today; and live BBC Radio interviews.
85. ABC TV News 24 – September 2017
86. ABC 702 Sydney Breakfast – May 2017
87. ePathway article September 2015 – Dysplastic nevus – Joining the dots between a dysplastic nevus and atypical mole is tricky
88. ePathway article December 2011/January 2012 – Skin cancer – Australia and New Zealand still top skin cancer list
89. ePathway article November 2011 – Sunburn – Be on 'red alert' this summer to avoid the trauma of sunburn
90. Interview 'Joining the dots between dysplastic naevus and atypical mole is tricky.' Published in September edition of ePathway, online magazine from the Royal College of Pathologists of Australasia. <http://epathway.rcpa.edu.au>

SUPERVISORY TEACHING – FELLOWS AND SPECIALIST TRAINEES

1. Supervisor: Pathology Fellow at Tissue Pathology and Diagnostic Oncology Department, Royal Prince Alfred Hospital in conjunction with Melanoma Institute Australia:-
 - (i) Dr Nigel Maher – 1 February 2022 – current.
 - (ii) Dr Elizabeth Paver – 1 February 2021 – 10 June 2022.
 - (iii) Dr Alison Potter – 1 February 2021 – 31 March 2022.
 Nb: Dr Alison Potter was awarded the "Physician-in-Training Award for the Best Resident/Fellow Poster Abstract Presentation" relating to abstract titled: 'Driver Mutation Status of Cutaneous Scalp Melanoma' at The American Society of Dermatopathology (ASDP) 58th Virtual Annual Meeting (20-24 October 2021) and was also awarded the "People's Choice – presentation, poster, and best Early Career Researcher (ECR) presentation" at NSW Health Pathology's Inaugural Research Forum for 2021.
 - (iv) Dr Karina Aivazian - July 2019 to February 2021.
 Nb: Dr Karina Aivazian was awarded the "Physician-in-Training Award for the Best Fellow Study Presentation" for her study titled: 'Regression in Primary Cutaneous Melanoma: Impact on Sentinel Lymph Node Status and Survival' at the 57th Annual Meeting of The American Society of Dermatopathology (ADSP) (October 2020). This major international award is a huge honour and recognition of her excellent research and presentation of the findings at this event.
 - (v) Dr Andrew Colebatch - February 2019 to March 2020;
 - (vi) Dr Peter Ferguson – February 2017 to February 2018.
 - (vii) Dr Robert Rawson "Cameron Pathology Fellow" sponsored – February 2016 to February 2017.
 - (viii) Dr Louise Jackett – 2016-2017.
 - (ix) Dr Ricardo Vilain – 2014-2015.
 - (x) Dr Oana Crainic.
 - (xi) Raghwa Sharma – 2006.
2. Supervisor: Specialist Training program "Laboratory Training in Dermatopathology" through The Royal College of Pathologists of Australia at Royal Prince Alfred Hospital, Australia:-

- (i) Dr Leili Moyaed Alaei, Anatomical Pathology registrar, 8 August 2022 to January 2023.
 - (ii) Dr Emily Heffernan Anatomical Pathology registrar (3rd year), February 2022 to 29 July 2022.
 - (iii) Dr Fiona Ray, Anatomical Pathology registrar, July 2021 to January 2022.
 - (iv) Dr Timothy Fielder, Anatomical Pathology (Melanoma) registrar, February 2021 to July 2021.
 - (v) Dr Donya Tohidi-Esfahani, Anatomical Pathology registrar, July 2020 to January 2021.
 - (vi) Dr Natasha Prosser, Anatomical Pathology registrar- July 2019 to July 2020;
 - (vii) Dr Fran Watts, Anatomical Pathology registrar – January to July 2019;
 - (viii) Dr Sameera Ansar, 4th year Anatomical Pathology registrar – July to December 2018;
 - (ix) Dr Maryam Massaeli, Anatomical Pathology registrar – January to July 2018;
 - (x) Dr Edward Roper, Anatomical Pathology registrar – August 2016 to February 2017;
 - (xi) Dr Chandra Adhikari.
 - (xii) Dr Tom Bringkorg.
 - (xiii) Dr Carolyn Shaw.
 - (xiv) Dr Ricardo Vilain.
 - (xv) Dr Tristan Dodds.
 - (xvi) Dr Peter Ferguson.
 - (xvii) Dr Oana Cramie.
 - (xviii) Dr Robert Rawson.
 - (xix) Dr Louise Jackett.
3. Laboratory Training in Dermatopathology at Royal Prince Alfred Hospital - visiting national and international Pathologists:-
- (i) Dr Sandy Darling, Pathologist, Melbourne, Victoria – 6-24 June 2022.
 - (ii) Carolyn J. Shiau, Toronto, Canada.
 - (iii) Duncan Lambie, Head of Department at Princess Alexander Hospital, Brisbane.
 - (iv) Edwin Tan, Rockhampton - 3-7 June 2019.

PHD & POSTGRADUATE STUDENT SUPERVISION

Current

1. Eva Shteinman – PhD student, The University of Sydney, Australia. Thesis title: Characterising the Genomic and Immune Landscape of Melanoma Subtypes. Role: Co-supervisor. PhD commenced 1 March 2022 (*current*).
2. Anna McLean – PhD student, The University of Sydney, Australia. Thesis title: The role of the microbiome as a biomarker in lung cancer and mesothelioma. RAS lead supervisor. PhD commenced 1 March 2021 (*current*).
3. Xinyu Bai – PhD student, The University of Sydney, Australia. Thesis title: tbc. RAS role: “Co-Supervisor”, Primary Supervisor: Dr Camelia Quek, Other Supervisor: JS Wilmott. PhD commenced in 2021 – Feb 2024 (*current*).
4. Jorja Braden – PhD student, The University of Sydney, Australia. Thesis title: tbc. RAS role: “Mentor”, Primary Supervisor: Dr James Wilmott, Other Supervisors: Long, Da Silva. PhD commenced in 2021 – Feb 2024 (*current*).
5. Andrew Li – PhD student, The University of Sydney, Australia. Thesis title: Clinicopathologic and Molecular Characterisation of Cutaneous Head and Neck Melanoma. RAS role: Co-supervisor with John F Thompson – Primary Supervisor: Sydney Ch’ng. PhD commenced in 2020 (*current*).
6. Rebecca Simpson – PhD student, The University of Sydney, Australia. Thesis title: Assessing the mechanistic links between the intestinal microbiota and the immune system during cancer immunotherapy. RAS role: “Mentor”, Primary Supervisor: Dr James Wilmott, Other Supervisors: Long, Shanahan, Tiffen. PhD commenced in January 2020 – Feb 2023 (*current*).
7. Grace Attrill - PhD student, The University of Sydney, Australia. Thesis title: “Assessing the function of tumour specific and bystander T-cells in relation to clinical outcomes of melanoma patients”. RAS role: “Co-Supervisor”. Others supervisors: JS Wilmott, M Palendira. PhD commenced in July 2019 – December 2022 (*current*).
8. Dr Robert Rawson – PhD student, The University of Sydney, Australia. Thesis title: TBC. RAS role: “Primary-Supervisor” – Other Supervisor: Dr James Wilmott. PhD - commenced 2019 – Feb 2025 (*current*).
9. Dr Jordan Conway, PhD student, The University of Sydney, Australia. RAS role: Mentor. Supervisors: Silva, Long, Wilmott. Thesis title: TBC. PhD commenced in January 2019 – Dec 2022 (*current*).
10. Dr Louise Jackett – PhD student, The University of Sydney, Australia. Thesis title: “Clinical and histopathological associations of melanocytic lesions in the molecular era”. RAS role: Primary Supervisor. PhD commenced 2017 (*current*).

Former

11. Dr Jarem Edwards – PhD student, The University of Sydney, Australia. Thesis title: Mechanisms of response and resistance to anti-PD-1 immunotherapy. RAS role: “Other Co-supervisor, together with Georgina Long” – Primary Supervisor: Dr Mainthan Palendira. PhD commenced in March 2018 (*current*) – Thesis submitted 21.2.22 – accepted 28.4.22 (subject to minor corrections).
12. Dr Kazi Nahar, PhD student, The University of Sydney, Australia. Thesis title: Mechanisms of immune checkpoint inhibitor-induced gastrointestinal toxicities. RAS role “Mentor” – Primary Supervisors: Mainthan Palendira and Alex Menzies. PhD commenced in February 2018 – December 2021.
13. Hansol Lee – PhD student, The University of Sydney, Australia. Thesis title: NK cells in the microenvironment of anti-PD1 treated melanoma. Co-supervisor. PhD commenced in 2016 - awarded in 2021.
14. Xinyu Catherine Bai – Honours student, The University of Sydney, Australia. Honours thesis title: Immunogenomic features of adolescent and young adult melanoma and their implications for response to checkpoint inhibitor immunotherapy. First Class Honours (score of 89) and a high distinction from The University of Sydney. Bachelor of Medical Science (Honours), completed 2020. She also won Best Rapid Fire Oral Presentation at The Kids Cancer Alliance Early Career Research Symposium 2020 – this is a big achievement, it’s rare for an Honours student to be awarded best oral presentation. Catherine has been accepted to undertake her PhD continuing on from this work, looking at Defining the immunogenomic landscape of cancer immunotherapy. RAS a co-supervisor. Commenced in January 2020 to November 2020.

15. Aubrey Wood – Honours student, The University of Sydney, Australia. Honours thesis title: Investigating immunotherapy drug targets for metastatic melanoma. Bachelor of Medical Science (honours), double-majoring in Anatomy and Histology, and Pathology, with first class honours in Immunology. RAS a co-supervisor. From January to November 2020.
16. Dr Rajat Rai – PhD student. Thesis title: “Selection and sequencing of combination immunotherapies for advanced melanoma”. Phoebe Star - Australasian College of Dermatology Training Programme: Research Proposal 2018-2020
17. Rebecca Simpson – Post Graduate Student, The University of Sydney, Australia. RAS role: Co-Supervisor. Primary Supervisor: Dr Marcel Batten. January to December 2019.
18. Grace Attrill – Post Graduate Student, The University of Sydney, Australia. RAS role: Primary Supervisor. 2018.
19. Rashi Minocha – Master of Philosophy student, The University of Sydney. Title: “Nicotinamide for Skin Cancer Chemoprevention: Effects On Tumour Immune Cell Infiltrates and Melanoma Biology”. RAS role: Supervisor. 2017
20. Tuba Nur Gide – PhD student, The University of Sydney, Australia (co-supervisor). Thesis: Biomarkers of response and resistance to anti-PD1 immunotherapy in melanoma. Commenced 2015. Completed PhD in 2019.
21. Dr Matteo Carlino - PhD student, The University of Sydney, Australia. Completed and awarded PhD in 2015 (co-supervisor). Thesis: Determining the Molecular mechanisms of BRAF/MEK inhibitor resistance in Melanoma.
22. Dr Alexander Menzies – PhD student, The University of Sydney, Australia. Completed and awarded PhD in 2015 (co-supervisor). Thesis: The biology of BRAF mutant melanoma and biomarkers of response to targeted therapy. In the capacity of Co-supervisor at The University of Sydney.
23. Dr Megan Lyle – PhD student, The University of Sydney, Australia. Commenced Masters 2013 (co-supervisor). Thesis: Somatic Mutations in Metastatic Melanoma in a large cohort of Australian patients. In the capacity of Co-supervisor at The University of Sydney.
24. Dr Hojabr Kakavand - PhD student, The University of Sydney, Australia. Co-supervisor. Thesis title: Molecular determinants of melanoma progression and susceptibility to current treatment. PhD commenced in 2013 and awarded in 2017.
25. Dr James Wilmott - PhD student, The University of Sydney, Australia. Thesis title: Biomarkers and biology of BRAF inhibitor treated metastatic melanoma. RAS role: Primary Supervisor. PhD awarded in 2013.
26. Dr Caroline Cooper, Cancer Institute of NSW Senior Registrar recipient. 2007-2008
27. Dr Meena Shingde, Cancer Institute of NSW Senior Registrar recipient 2007-2008
28. Dr Colin Arnold, Cancer Institute of NSW Clinical Fellowship recipient 2007
29. Nicolas Urriol, Honours medical student, The University of Sydney, Australia. Thesis: The significance of regression in primary cutaneous melanomas. RAS role: Co-Supervisor. 2005-2006.
30. Dr Rajmohan Murali: Cancer Institute of NSW Clinical Fellowship recipient 2006
31. Dr Rooshdiya Karim: Cancer Institute of NSW Clinical Fellowship recipient 2006
32. Dr Karen Van Den Berg: Visiting medical student (Netherlands)- pathology reporting of cutaneous melanomas Nov 2005- Feb 2006.
33. Associate Supervisor of Dr Amira Sanki (full-time candidate for degree of Master of Surgery in the Faculty of Medicine of the University of Sydney) in 2005. 3 oral presentations.
34. Dr James Jarbour, Merkel Cell Carcinomas 2004-2005.
35. Dr Wei Li, Melanoma & Skin Cancer Research Institute, University of Sydney, Postdoctoral Research Scientist 2005.
36. Dr Warnke. Animal Type Melanomas- are they all malignant? Visiting Medical Student from University of Southern California. Feb to March 2004. (1 publication)
37. Ms Alison Beavis, PhD candidate, University of Technology of Sydney (co supervision with Prof Michael Dawson and Prof John Thompson). 2002-4. Antimony analysis of sentinel lymph nodes. (3 publications)
38. Co-supervisor of Dr Liqing (Lily) Zhuang. Doctor of Philosophy, Department of Pathology, University of Sydney. June 2003-ongoing. Project: Examination of apoptotic and antiapoptotic factors in tissue sections of melanomas. (multiple publications)
39. Dr Anna Doubrovsky. Postgraduate Fellow, Melanoma & Skin Cancer Research Institute, University of Sydney, 2003-2004. Diagnostic accuracy of fine needle aspiration biopsy in metastatic melanoma. 3 publications.
40. Dr Lawrence Li. Postdoctoral Fellow, Melanoma & Skin Cancer Research Institute, University of Sydney, 2001-2004. Sentinel lymph node evaluation in melanoma patients. (numerous publications including in *Am J Surg Pathol*)
41. Dr Luc Bron. Postgraduate Fellow. January 2002- December 2003. Project: Expression of apoptotic markers in melanomas. (publication in *Pathology*)
42. Emma Dean. Visiting medical student (University of Aberdeen). Project: Incidence of positive sentinel lymph nodes in patients with desmoplastic melanomas. Sydney Melanoma Unit, July 2003- September 2003
43. J.H.M.J. Vestjens. Honours medical student. Project: Prognostic factors in melanoma: The relationship between patient age and tumour mitotic rate. Sydney Melanoma Unit, June 2003 – August 2003.
44. S. Sassen. Honours medical student. Project: The relationship between patient age and sentinel lymph node metastasis in primary cutaneous melanoma. Sydney Melanoma Unit, June 2003 – August 2003.
45. Dr Viola Heinzlmann-Schwarz. Co supervision- Project: Gene expression profiles identifies tumour markers of epithelial ovarian cancer. Masters in Medicine, University of New South Wales & Garvan Institute of Medical Research. 2001-2004. Multiple publications including Clin Cancer Research. Prizes: 2nd Prize for Poster presentations at Annual Scientific Meeting of the Australasian Division of the International Academy of Pathology 2003. Winner of the Swiss Society of Gynecologists and Obstetricians prize in research excellence 2004 at Annual Meeting of the SGGG, Interlaken/Switzerland (Award: SFR 20000). Winner Travel Award Australian Society for Medical Research, 42nd National Scientific Conference, Adelaide/Australia.
46. Dr Anne-Brecht Franken. Co supervision- Project: Assessment of the prognostic importance of tumour mitotic rate as determined by the late Prof Vince McGovern. Sydney Melanoma Unit, September 2002- April 2003. (Publication in *Ann Surg Oncol*)
47. Dr Manuela Azzola. Co supervision- Project: The prognostic importance of tumour mitotic rate in primary cutaneous melanoma. Sydney Melanoma Unit, July 2001- December 2001. (Publication in *Cancer*)

48. Co supervision of Emma Bomford & Edwina Berman. Year 3 Postgraduate medical students. Honours project: Impact of postmortem neuropathology microscopic findings in comparison with macroscopic findings. July to December 2000 (Chief supervisor: Dr Roger Pamphlett, Neuropathology Department, University of Sydney).

TEACHING EXPERIENCE

- “Zero Deaths from Melanoma” – lecture objectives: (i) understand the melanoma pathways defined in the WHO classification and their implications for diagnosis and management, (ii) understand the concept of borderline melanocytic tumors and how they have been incorporated into the WHO classification and (iii) recognize the pitfalls in the diagnosis of melanocytic tumors and know strategies on how to avoid them. Invited lecture at Wake Forest Baptist Health Department of Dermatology’s Virtual Quarterly Meeting on 1 December 2021.
- Microscope Sessions A&B “Challenging Pigmented Lesions”, together with Dr Elizabeth Paver at the Harvard CME course Dermatopathology Update on Friday 10 September 2021 (AEST) – live/virtual (9-11 September 2021).
- Recordings from the GP Education Evening “Melanoma diagnosis and staging: A survival guide for GPs | RACGP” 2019
- Examiner Anatomical Pathology RCPA (The Royal College of Pathologist of Australia) 2002 – 2019
- (TBL) Team based Learning I must be getting old’ (topic: Skin Cancer) The University Of Sydney - March 2018
- Invited guest lecturer and faculty member, Harvard Medical School Dermatopathology Update, Boston USA September 2014
- Regular Presenter at Clinicopathological Meetings at Royal Prince Alfred Hospital
- Regular presenter at the Australasian Division of the International Society of Gynaecological Pathologists meetings
- Running a regular weekly Surgical Pathology teaching session for Specialist Trainees (registrars) in the Department of Anatomical Pathology, Royal Prince Alfred Hospital
- Presenting at numerous scientific meetings
- Participation in the teaching activities for medical students enrolled at the University of Sydney postgraduate medical course including:
 - a) Tutoring in the problem-based learning blocks in 2000, 2001, 2002 and 2007.
 - b) Participating in “Scorpio” teaching sessions in 1999 and 2000.
 - c) Co-authoring the online Skin Cancer Course/Tutorial for the University of Sydney year 4 medical students (www.skincancer.med.usyd.edu.au).
 - d) Assisting two year 3 postgraduate medical students of the University of Sydney with their honours project (‘Impact of postmortem neuropathology microscopic findings in comparison with macroscopic findings.’) from July to December 2000.
 - e) Contributor with Professor John Thompson and Clinical Associate Professor Rogen Uren to the University of Sydney medical student interactive session titled “Effective teams: lessons from PBL” (coordinated by Dr Greg Ryan) on 5/5/04.
 - f) Adhoc tutorials for medical students at the Central Sydney Clinical School since 1998
- Presentation at Conference Week 2007, to Final Year University of Sydney Medical Students: “A Career in Pathology”
- Invited guest lecturer, Memorial Sloan Kettering Cancer Center, New York USA, September 2005
- Invited guest lecturer, Mayo Clinic, Rochester USA, September 2005
- Invited guest lecturer and faculty member, Harvard Medical School Dermatopathology Update September 2005 Boston USA
- Lecturer in Royal Australasian College of Radiation Oncologists NSW Training Programme for Trainees 2004
- Convenor, Lecturer, Chairman and Facilitator in RCPA Postgraduate Diagnostic Histopathology Interactive Courses in 2001, 2002, 2003 and 2004
- Contributor with Profs John Thompson and Rogen Uren to University of Sydney medical students- interactive session with Dr Greg Ryan: “Effective teams: lessons from PBL” on 5th May 2004
- Lecturing to and performing tutorial sessions with medical students in the Graduate Medical Program of the University of Sydney including Problem Based Learning tutorials and “Scorpio” sessions, 1999 to 2002
- Lecturer in Royal Australasian College of Surgeons NSW Training Programme for General Surgical Trainees - from 2002
- Tutorials with Radiology Registrars at Royal Prince Alfred Hospital 1999 - 2001
- Running a trial phase II exam for Part I Anatomical Pathology trainees in NSW, August 2000
- Presenter at Grand Rounds at Royal Prince Alfred Hospital 1999 & 2000
- Lectures to Pathology Staff at RPAH 1999
- 35 Lectures to Pathology Staff at ACT Pathology 1995 - 1998:
 - a) Pathology Registrar Scientific Sessions
 - b) Presentations at Anatomical Pathology QAP Meetings
 - c) Presentations at Haematology QAP Meetings
- Regular Presenter at Grand Rounds at The Canberra Hospital 1995 – 1998
- Regular presenter at the Prince of Wales Surgical Pathology Meetings for Specialist Anatomical Pathologists
- Informal Teaching to Scientific Staff at ACT Pathology
- Regular Presenter at Clinicopathological Meetings at ACT Pathology